##################################################################################
# Document Properties Section

SET DOCUMENT Name = "BEL Framework Small Corpus Document"
SET DOCUMENT Description = "Approximately 2000 hand curated statements drawn from 57 PubMeds."
SET DOCUMENT Version = "1.6"
SET DOCUMENT Copyright = "Copyright (c) 2011-2012, Selventa. All Rights Reserved."
SET DOCUMENT Authors = "Selventa"
SET DOCUMENT Licenses = "Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported License"
SET DOCUMENT ContactInfo = "support@belframework.org"

##################################################################################
# Definitions Section

DEFINE NAMESPACE SDIS AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-diseases.belns"
DEFINE NAMESPACE PFR AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-protein-families.belns"
DEFINE NAMESPACE MGI AS URL "http://resource.belframework.org/belframework/1.0/namespace/mgi-approved-symbols.belns"
DEFINE NAMESPACE PFM AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-protein-families.belns"
DEFINE NAMESPACE MESHPP AS URL "http://resource.belframework.org/belframework/1.0/namespace/mesh-biological-processes.belns"
DEFINE NAMESPACE MESHCL AS URL "http://resource.belframework.org/belframework/1.0/namespace/mesh-cellular-locations.belns"
DEFINE NAMESPACE NCH AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-complexes.belns"
DEFINE NAMESPACE CHEBI AS URL "http://resource.belframework.org/belframework/1.0/namespace/chebi-names.belns"
DEFINE NAMESPACE NCR AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-complexes.belns"
DEFINE NAMESPACE HGNC AS URL "http://resource.belframework.org/belframework/1.0/namespace/hgnc-approved-symbols.belns"
DEFINE NAMESPACE SPAC AS URL "http://resource.belframework.org/belframework/1.0/namespace/swissprot-accession-numbers.belns"
DEFINE NAMESPACE PFH AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-protein-families.belns"
DEFINE NAMESPACE NCM AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-complexes.belns"
DEFINE NAMESPACE CHEBIID AS URL "http://resource.belframework.org/belframework/1.0/namespace/chebi-ids.belns"
DEFINE NAMESPACE RGD AS URL "http://resource.belframework.org/belframework/1.0/namespace/rgd-approved-symbols.belns"
DEFINE NAMESPACE MESHD AS URL "http://resource.belframework.org/belframework/1.0/namespace/mesh-diseases.belns"
DEFINE NAMESPACE GO AS URL "http://resource.belframework.org/belframework/1.0/namespace/go-biological-processes-names.belns"
DEFINE NAMESPACE SCHEM AS URL "http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names.belns"
DEFINE NAMESPACE EGID AS URL "http://resource.belframework.org/belframework/1.0/namespace/entrez-gene-ids-hmr.belns"

DEFINE ANNOTATION HemicAndImmuneSystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-hemic-and-immune-system.belanno"
DEFINE ANNOTATION UrogenitalSystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-urogenital-system.belanno"
DEFINE ANNOTATION FluidAndSecretion AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-fluid-and-secretion.belanno"
DEFINE ANNOTATION CellStructure AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-cell-structure.belanno"
DEFINE ANNOTATION CellLine AS  URL "http://resource.belframework.org/belframework/1.0/annotation/atcc-cell-line.belanno"
DEFINE ANNOTATION TextLocation AS  LIST {"Abstract","Results","Legend","Review"}
DEFINE ANNOTATION IntegumentarySystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-integumentary-system.belanno"
DEFINE ANNOTATION DigestiveSystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-digestive-system.belanno"
DEFINE ANNOTATION MuskuloskeletalSystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-musculoskeletal-system.belanno"
DEFINE ANNOTATION Tissue AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-tissue.belanno"
DEFINE ANNOTATION BodyRegion AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-body-region.belanno"
DEFINE ANNOTATION Cell AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-cell.belanno"
DEFINE ANNOTATION NervousSystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-nervous-system.belanno"
DEFINE ANNOTATION SenseOrgan AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-sense-organ.belanno"
DEFINE ANNOTATION Disease AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-disease.belanno"
DEFINE ANNOTATION RespiratorySystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-respiratory-system.belanno"
DEFINE ANNOTATION Species AS  URL "http://resource.belframework.org/belframework/1.0/annotation/species-taxonomy-id.belanno"
DEFINE ANNOTATION CardiovascularSystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-cardiovascular-system.belanno"
DEFINE ANNOTATION EndocrineSystem AS  URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-endocrine-system.belanno"

##################################################################################
# Statements Section

SET STATEMENT_GROUP = "Group 1"

SET Disease = "Atherosclerosis"
SET CardiovascularSystem = "Arteries"
SET TextLocation = "Review"
SET Evidence = "Oxidation and nitration of macromolecules, such as proteins, DNA and lipids, are prominent
in atherosclerotic arteries."
SET Citation = {"PubMed","Trends in molecular medicine","12928037","","de Nigris F|Lerman A|Ignarro LJ|Williams-Ignarro S|Sica V|Baker AH|Lerman LO|Geng YJ|Napoli C",""}

pathology(MESHD:Atherosclerosis) positiveCorrelation biologicalProcess(GO:"lipid oxidation")
pathology(MESHD:Atherosclerosis) positiveCorrelation biologicalProcess(GO:"protein oxidation")

SET Evidence = "Arterial cells are highly susceptible to oxidative stress, which can induce both necrosis
and apoptosis (programmed cell death) [1,2]"

biologicalProcess(GO:"response to oxidative stress") increases biologicalProcess(GO:"apoptotic process")
biologicalProcess(GO:"response to oxidative stress") increases biologicalProcess(GO:necrosis)

SET Cell = "Endothelial Cells"
SET Evidence = "One such risk factor is oxLDL, which exert pro-apoptotic effects on a variety of cell
lineages, including endothelial cells and VSMCs, both in cultured cells and
in arteries [19–26]. Increased formation of oxygen radicals (and other radical
species) facilitates LDL oxidation and influences oxidation-sensitive mechanisms
[15]."

abundance(SCHEM:"Oxidized Low Density Lipoprotein") increases biologicalProcess(GO:"apoptotic process")

SET MuskuloskeletalSystem = "Muscle, Smooth, Vascular"

abundance(SCHEM:"Oxidized Low Density Lipoprotein") increases biologicalProcess(GO:"apoptotic process")
abundance(CHEBI:"oxygen radical") increases abundance(SCHEM:"Oxidized Low Density Lipoprotein")

SET Evidence = "Not surprisingly, high concentrations of exogenous reactive oxygen species (ROS),
generated by enzymatic reactions or by radiation, also stimulate the apoptosis
of endothelial cells in vitro [29–31]."

abundance(CHEBI:"reactive oxygen species") increases biologicalProcess(GO:"apoptotic process")

SET Evidence = "The peptide hormone angiotensin II and pro-inflammatory cytokines also trigger the
apoptotic program in endothelial cells [33,34]."

abundance(CHEBI:"angiotensin II") increases biologicalProcess(GO:"apoptotic process")

SET Evidence = "Aging, one of the major predictors for atherosclerotic lesion formation, increases
the sensitivity of endothelial cells to apoptosis induced by in vitro and in vivo
stimuli [35–37]."

biologicalProcess(GO:aging) positiveCorrelation pathology(MESHD:"Plaque, Atherosclerotic")
biologicalProcess(GO:aging) increases biologicalProcess(GO:"apoptotic process")

SET Evidence = "Shear stress enhances expression of the gene encoding the endothelial nitric oxide
synthase (eNOS) and further stimulates its enzymatic activity, leading to physiologic
low concentrations of nitric oxide (NO) within endothelial cells [44–46].
This continuous generation of NO prevents the apoptosis of endothelial cells,
thereby protecting the endothelial monolayer from injury [47,48]."

biologicalProcess(GO:"response to fluid shear stress") increases rnaAbundance(HGNC:NOS3)
biologicalProcess(GO:"response to fluid shear stress") increases catalyticActivity(proteinAbundance(HGNC:NOS3))
catalyticActivity(proteinAbundance(HGNC:NOS3)) directlyIncreases abundance(CHEBI:"nitric oxide")
abundance(CHEBI:"nitric oxide") decreases biologicalProcess(GO:"apoptotic process")

SET Evidence = "More importantly, intervention with L-arginine has induced beneficial effects on atherosclerosis
in experimental and human studies [46,49]."

abundance(CHEBI:"L-arginine") decreases pathology(MESHD:Atherosclerosis)

SET Tissue = "Endothelium, Vascular"
SET Evidence = "OxLDL induces the generation of ROS in different vascular cell types [15,58], and
might also promote a rise in ROS levels through a decrease in ROS degradation,
because oxLDL induces a reduction in the antioxidant enzymes Cu/Zn superoxide dismutase
[59] and glutathione peroxidase [60]."

abundance(SCHEM:"Oxidized Low Density Lipoprotein") increases abundance(CHEBI:"reactive oxygen species")
abundance(SCHEM:"Oxidized Low Density Lipoprotein") decreases proteinAbundance(HGNC:SOD1)
abundance(SCHEM:"Oxidized Low Density Lipoprotein") decreases proteinAbundance(PFH:"GPX Family")

SET CellLine = "U-937"
SET Evidence = "For instance, during 7-ketocholesterol-induced apoptosis of U937 cells, the cellular
antioxidant content falls rapidly [64], but administration of two potent antioxidants,
the aminothiols glutathione and N-acetylcysteine, can protect themonocytic
cells from 7-ketocholesterol-induced apoptotic cell death [64]."

abundance(SCHEM:"7-Ketocholesterol") increases biologicalProcess(GO:"apoptotic process")
abundance(SCHEM:"7-Ketocholesterol") negativeCorrelation abundance(CHEBI:antioxidant)
abundance(CHEBI:antioxidant) decreases (abundance(SCHEM:"7-Ketocholesterol") increases biologicalProcess(GO:"apoptotic process"))

SET Tissue = "Muscle, Smooth, Vascular"
SET Evidence = "In addition, another oxygen-radical scavenger enzyme, catalase, can prevent VSMC apoptosis
triggered by hydrogen peroxide [27,65]."

abundance(CHEBI:"hydrogen peroxide") increases biologicalProcess(GO:"apoptotic process")
proteinAbundance(HGNC:CAT) decreases (abundance(CHEBI:"hydrogen peroxide") increases biologicalProcess(GO:"apoptotic process"))

SET Evidence = "The proto-oncogene c-myc can promote cell death (probably mediated through p53) or
cell proliferation, depending on its expression level. It functions as a nuclear
phosphoprotein with particular properties of a transcription factor [68,69].
In serum deprived cultures, cells overexpressing c-myc readily undergo apoptosis.
In addition, deregulation of c-myc causes apoptosis of VSMCs deprived of growth
factors or treated with cytokines such as interferon-g [70]."

proteinAbundance(HGNC:MYC) increases biologicalProcess(GO:"apoptotic process")
proteinAbundance(HGNC:MYC) increases biologicalProcess(GO:"cell proliferation")

SET Evidence = "Tissue factor (TF) is a 47 kDa transmembrane glycoprotein that initiates blood coagulation
by binding coagulation factor VII and its activated form (factor VIIa),
to produce a high-affinity complex [72] that proteolytically activates factors
IX and X, leading to thrombin generation."

peptidaseActivity(complexAbundance(proteinAbundance(HGNC:F3),proteinAbundance(HGNC:F7))) directlyIncreases peptidaseActivity(proteinAbundance(HGNC:F9))
peptidaseActivity(complexAbundance(proteinAbundance(HGNC:F3),proteinAbundance(HGNC:F7))) directlyIncreases peptidaseActivity(proteinAbundance(HGNC:F10))
peptidaseActivity(proteinAbundance(HGNC:F9)) increases peptidaseActivity(proteinAbundance(HGNC:F2))
peptidaseActivity(proteinAbundance(HGNC:F10)) increases peptidaseActivity(proteinAbundance(HGNC:F2))

SET CellStructure = "Cell Membrane"
SET Evidence = "TF works at the surface of cell membranes, and its activity is highly dependent on
the presence of phosphatidylserine (PS), an anionic phospholipid that is redistributed
on the cell surface during apoptotic death and confers a potent pro-coagulant
activity to the apoptotic cell [74]."

abundance(CHEBI:"phosphatidyl-L-serine") increases peptidaseActivity(proteinAbundance(HGNC:F3))
biologicalProcess(GO:"apoptotic process") increases abundance(CHEBI:"phosphatidyl-L-serine")
abundance(CHEBI:"phosphatidyl-L-serine") increases biologicalProcess(GO:coagulation)

SET Evidence = "TIMP-3 can be anti-angiogenic by direct binding to vascular endothelial growth factor
(VEGF) receptor 2 in a matrix-metalloproteinase- independent manner [94]."

proteinAbundance(HGNC:TIMP3) decreases biologicalProcess(GO:angiogenesis)
complexAbundance(proteinAbundance(HGNC:TIMP3),proteinAbundance(HGNC:KDR)) decreases biologicalProcess(GO:angiogenesis)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 2"

SET TextLocation = "Abstract"
SET Evidence = "Phosphorylation at Ser473, along with Thr308 of its activation loop, is deemed necessary
for Akt function, although the regulatory mechanisms and physiological importance
of each phosphorylation site remain to be fully understood."
SET Citation = {"PubMed","Cell","16962653","2006-10-07","Jacinto E|Facchinetti V|Liu D|Soto N|Wei S|Jung SY|Huang Q|Qin J|Su B",""}
SET Species = "9606"

proteinAbundance(HGNC:AKT1,proteinModification(P,T,308)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:AKT1))
proteinAbundance(HGNC:AKT1,proteinModification(P,S,473)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:AKT1))

SET Evidence = "Genetic ablation of sin1 abolished Akt-Ser473 phosphorylation and disrupted rictor-mTOR
interaction but maintained Thr308 phosphorylation."

proteinAbundance(HGNC:MAPKAP1) increases proteinAbundance(HGNC:AKT1,proteinModification(P,S,473)) //sin1 = MAPKAP1

SET Cell = "Fibroblasts"
SET TextLocation = "Results"
SET Evidence = "We next examined the Akt T-loop Thr308 phosphorylation in wild-type and SIN1−/− cells.
We found that although Ser473 phosphorylation was completely abolished in
the SIN1−/− cells, Thr308 phosphorylation of Akt was not blocked (Figure 3A)."
SET Species = "10090"

proteinAbundance(MGI:Mapkap1) increases proteinAbundance(MGI:Akt1,proteinModification(P,S,473))
proteinAbundance(MGI:Mapkap1) causesNoChange proteinAbundance(MGI:Akt1,proteinModification(P,S,308))

SET Evidence = "We also examined phosphorylation of TSC2, another Akt target (Manning et al., 2002),
at the Akt target sites Ser939 and Thr1462 and found no significant difference
between wild-type and SIN1−/− cells upon serum and insulin stimulation (Figure
3C)."

kinaseActivity(proteinAbundance(MGI:Akt1)) directlyIncreases proteinAbundance(MGI:Tsc2,proteinModification(P,S,939))
kinaseActivity(proteinAbundance(MGI:Akt1)) directlyIncreases proteinAbundance(MGI:Tsc2,proteinModification(P,T,1462)) //Human T1462 = Mouse T1465

SET Evidence = "To identify a function that could be linked specifically to Akt-Ser473 phosphorylation,
we further examined known Akt substrates that may have defective phosphorylation
in SIN1−/− cells. We found that phosphorylation of FoxO1/3a (also called
FKHR/FKHRL1) (Greer and Brunet, 2005), was affected in SIN1−/− cells. In particular,
phosphorylation of FoxO1/3a at Thr24/Thr32 was significantly decreased in
the absence of SIN1 under normal growing and restimulated conditions (Figure 4A)."

proteinAbundance(MGI:Mapkap1) increases proteinAbundance(MGI:Foxo1,proteinModification(P,T,24))
proteinAbundance(MGI:Mapkap1) increases proteinAbundance(MGI:Foxo3,proteinModification(P,T,32))
kinaseActivity(proteinAbundance(MGI:Akt1)) directlyIncreases proteinAbundance(MGI:Foxo1,proteinModification(P,T,24))
kinaseActivity(proteinAbundance(MGI:Akt1)) directlyIncreases proteinAbundance(MGI:Foxo3,proteinModification(P,T,32))

SET Evidence = "We also found that the recombinant FoxO1 could not be phosphorylated at Thr24/32 in
vitro by an Akt mutant harboring an alanine mutation in either Thr308 or Ser473,
whereas a Ser473 to Ala mutated Akt could still phosphorylate recombinant GSK3
(Figure S2). These results indicate that Akt-Ser473 phosphorylation is required
for FoxO1/3a phosphorylation at Thr24/32."

proteinAbundance(MGI:Akt1,proteinModification(P,S,473)) directlyIncreases proteinAbundance(MGI:Foxo1,proteinModification(P,T,24))
proteinAbundance(MGI:Akt1,proteinModification(P,S,473)) directlyIncreases proteinAbundance(MGI:Foxo3,proteinModification(P,T,32))
kinaseActivity(proteinAbundance(MGI:Akt1)) directlyIncreases proteinAbundance(MGI:Foxo1,proteinModification(P,T,24))
kinaseActivity(proteinAbundance(MGI:Akt1)) directlyIncreases proteinAbundance(MGI:Foxo3,proteinModification(P,T,32))
proteinAbundance(MGI:Akt1,proteinModification(P,S,473)) directlyIncreases kinaseActivity(proteinAbundance(MGI:Akt1))

SET Evidence = "In etoposide-treated cells, there was a 2-fold increase in the number of cells that
underwent apoptosis after 48 hr in SIN1 knockouts (Figure 4D). Thus, we find
that the SIN1−/− cells were more sensitive to stress-induced apoptosis, suggesting
that Akt-Ser473 phosphorylation plays an important role in cell survival (Figures
4C and 4D)."

proteinAbundance(MGI:Mapkap1) decreases biologicalProcess(GO:"apoptotic process")

SET Evidence = "The phosphorylation of S6K at Thr389, which is the TORC1-mediated site, was not inhibited
in the SIN1-/- cells (Figure 5A)."

kinaseActivity(complexAbundance(NCM:"TORC1 Complex")) directlyIncreases proteinAbundance(MGI:Rps6kb1,proteinModification(P,T,412))

SET Evidence = "Likewise, phosphorylation of another translational regulator, 4E-BP1, at the mTOR
target site Thr37/46 (Gingras et al., 1999), was also not impaired in SIN1−/− cells
(Figure 5A)."

kinaseActivity(complexAbundance(NCM:"TORC2 Complex")) directlyIncreases proteinAbundance(MGI:Eif4ebp1,proteinModification(P,T,36))
kinaseActivity(complexAbundance(NCM:"TORC2 Complex")) directlyIncreases proteinAbundance(MGI:Eif4ebp1,proteinModification(P,T,45))
kinaseActivity(proteinAbundance(MGI:Mtor)) directlyIncreases proteinAbundance(MGI:Eif4ebp1,proteinModification(P,T,36))
kinaseActivity(proteinAbundance(MGI:Mtor)) directlyIncreases proteinAbundance(MGI:Eif4ebp1,proteinModification(P,T,45))

SET Evidence = "Akt Ser473 was strongly induced in wild-type cells by different growth factors such
as the platelet-derived growth factor, epidermal growth factor, and insulin,
even in the absence of amino acids and glucose (Figure 5B). In SIN1−/− cells, Akt-Ser473
phosphorylation was not induced by any type of stimulus."

proteinAbundance(MGI:Mapkap1) increases proteinAbundance(MGI:Akt1,proteinModification(P,S,473))
proteinAbundance(PFM:"Pdgf Family") increases proteinAbundance(MGI:Akt1,proteinModification(P,S,473))
proteinAbundance(MGI:Egf) increases proteinAbundance(MGI:Akt1,proteinModification(P,S,473))
proteinAbundance(PFM:"Ins Family") increases proteinAbundance(MGI:Akt1,proteinModification(P,S,473))

SET Evidence = "As shown in Figures 5E and 5F, SIN1 was able to associate with Akt under normal growth,
starvation, or restimulated conditions. Although SIN1 and Akt interacted
under starved condition, the SIN1 bound Akt was not phosphorylated on Ser473 (Figure
5E)."

complexAbundance(proteinAbundance(MGI:Akt1),proteinAbundance(MGI:Mapkap1))

SET Evidence = "Akt has been well characterized as a prosurvival molecule, and part of this function
is mediated through its suppression of the activity of the FoxO proteins (Greer
and Brunet, 2005)."

kinaseActivity(proteinAbundance(MGI:Akt1)) directlyDecreases transcriptionalActivity(proteinAbundance(PFM:"Foxo Family"))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 3"

SET TextLocation = "Review"
SET Evidence = "For example, the inactivation of VHL has been demonstrated in 70–80% of all sporadic
clear cell RCC, the major form of RCC, which accounts for ~2% of all cancer
deaths worldwide [8]."
SET Citation = {"PubMed","Trends in molecular medicine","15350900","","Barry RE|Krek W",""}
SET Species = "9606"

proteinAbundance(HGNC:VHL) negativeCorrelation pathology(MESHD:"Carcinoma, Renal Cell") //curating to protein, since inactivation of gene may be via mutation, deletion, or hypermethylation and will affect protein levels

SET Evidence = "The best-established function of pVHL to date has been as a substrate recognition
component of an E3 ubiquitinprotein ligase complex, comprising pVHL, Elongin C,
Elongin B, Cullin 2 and the RING finger protein, Rbx1, and this is referred to
as the VCB–Cul2 complex [17]."

complexAbundance(proteinAbundance(HGNC:VHL),proteinAbundance(HGNC:TCEB1),proteinAbundance(HGNC:TCEB2),proteinAbundance(HGNC:CUL2),proteinAbundance(HGNC:RBX1))

SET Evidence = "In this setting, pVHL targets the α-subunits of hypoxiainducible factor (HIF) for
ubiquitin-mediated proteolysis under normal oxygen conditions [18]."

molecularActivity(proteinAbundance(HGNC:VHL)) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A))
molecularActivity(proteinAbundance(HGNC:VHL)) directlyIncreases degradation(proteinAbundance(HGNC:EPAS1))
molecularActivity(proteinAbundance(HGNC:VHL)) directlyIncreases degradation(proteinAbundance(HGNC:HIF3A))

SET Evidence = "The stabilization of HIF in response to hypoxia involves the inactivation of prolylhydroxylases
that modify HIF at specific proline residues in an oxygendependent
manner. Proline hydroxylation marks HIF for degradation by the VCB–Cul2 E3 ligase
complex (Figure 3 and Box 1)."

abundance(CHEBI:dioxygen) increases proteinAbundance(HGNC:HIF1A,proteinModification(H,P))
proteinAbundance(HGNC:HIF1A,proteinModification(H,P)) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:HIF1A,proteinModification(P,H)) directlyIncreases (catalyticActivity(complexAbundance(proteinAbundance(HGNC:VHL),proteinAbundance(HGNC:TCEB1),proteinAbundance(HGNC:TCEB2),proteinAbundance(HGNC:RBX1),proteinAbundance(HGNC:CUL2))) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A)))

SET Evidence = "The VHL-mediated proteolytic degradation of HIF suppresses a transcription programme
that is normally engaged by HIF as part of the adaptive response of the cell
to hypoxia, such as the activation of vascular endothelial growth factor (VEGF),
which is a potent angiogenic factor that is involved in the formation and differentiation
of blood vessels."

transcriptionalActivity(proteinAbundance(HGNC:HIF1A)) increases rnaAbundance(HGNC:VEGFA)
biologicalProcess(GO:"response to hypoxia") increases rnaAbundance(HGNC:VEGFA)
proteinAbundance(HGNC:VEGFA) increases biologicalProcess(GO:angiogenesis)

SET TextLocation = "Legend"
SET Evidence = "Transcriptional control is also maintained by a specific acetylation (Ac) event at
lysine 532 and an additional asparagine hydroxylation (OH) event at position 863,
both of which act as negative regulators of the transcriptional activity of
HIF."

proteinAbundance(HGNC:HIF1A,proteinModification(A,K,532)) directlyDecreases transcriptionalActivity(proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:HIF1A,proteinModification(H,N,863)) directlyDecreases transcriptionalActivity(proteinAbundance(HGNC:HIF1A))

SET Disease = "Neoplasms"
SET TextLocation = "Review"
SET Evidence = "highly vascular phenotype of VHL-null tumours."

proteinAbundance(HGNC:VHL) negativeCorrelation biologicalProcess(GO:vasculogenesis)

SET Disease = "Carcinoma, Renal Cell"
SET Evidence = "The inhibition of HIF-2α expression by siRNA inhibits the growth of VHL-negative tumours
[20]. Furthermore, the re-introduction of a degradation-resistant mutant
of HIF-2α into RCC cells ectopically expressing pVHL abolishes the ability of VHL
to suppress the growth of these cell lines [21]."

proteinAbundance(HGNC:EPAS1) increases biologicalProcess(GO:"cell growth") //HIF2-alpha = EPAS1

SET TextLocation = "Legend"
SET Evidence = "Hydroxylation at two proline residues on the HIF polypeptide mediates interactions
between the b-domain of the von Hippel–Lindau protein (pVHL) and HIF [60]. Each
site can interact independently with pVHL, potentially contributing to the extremely
rapid proteolysis of HIF-a that is observed under normoxic conditions. These
sites contain a conserved LxxLAP motif and are targeted by proline hydroxylases
(PHD) that, in mammalian cells, are provided by three isoforms termed PHD 1–3
[61]."

proteinAbundance(HGNC:HIF1A,proteinModification(H,P)) directlyIncreases complexAbundance(proteinAbundance(HGNC:VHL),proteinAbundance(HGNC:HIF1A))
catalyticActivity(proteinAbundance(HGNC:EGLN1)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P)) //PHD1-3 = EGLN1 -3
catalyticActivity(proteinAbundance(HGNC:EGLN2)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P))
catalyticActivity(proteinAbundance(HGNC:EGLN3)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P))
abundance(CHEBI:dioxygen) increases degradation(proteinAbundance(HGNC:HIF1A))

SET Evidence = "In a second hydroxylation-dependent control, b-hydroxylation of an asparaginyl residue
in the C-terminal activation domain of HIF-a (N803 in human HIF-1a) is regulated
by a HIF asparaginyl hydroxylase called FIH (factor inhibiting HIF) [62,63].
Hydroxylation at this site prevents the binding of the transcriptional co-activators
p300/CBP (CREB binding protein). Under normoxic conditions, these hydroxylation
reactions provide a dual mechanism for HIF inactivation that involves proteolytic
destruction and the inhibition of transcriptional activity [64]."

proteinAbundance(HGNC:HIF1A,proteinModification(H,N,803)) directlyDecreases complexAbundance(proteinAbundance(HGNC:HIF1A),proteinAbundance(HGNC:CREBBP))
proteinAbundance(HGNC:HIF1A,proteinModification(H,N,803)) directlyDecreases complexAbundance(proteinAbundance(HGNC:HIF1A),proteinAbundance(HGNC:EP300))
catalyticActivity(proteinAbundance(HGNC:HIF1AN)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,N,803)) //FIH = HIF1AN
complexAbundance(proteinAbundance(HGNC:HIF1A),proteinAbundance(HGNC:CREBBP)) directlyIncreases transcriptionalActivity(proteinAbundance(HGNC:HIF1A))
complexAbundance(proteinAbundance(HGNC:HIF1A),proteinAbundance(HGNC:EP300)) directlyIncreases transcriptionalActivity(proteinAbundance(HGNC:HIF1A))

SET Evidence = "These hydroxylases are all Fe(II)- and 2-oxoglutarate-dependent dioxygenases that
require molecular oxygen. Therefore, HIFa becomes stabilized under hypoxic conditions
in which oxygen availability is low."

abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN1))
abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN2))
abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN3))
abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:HIF1AN)) //FIH = HIF1AN
abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN1))
abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN2))
abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN3))
abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:HIF1AN))
abundance(CHEBIID:16810) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN1))
abundance(CHEBIID:16810) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN2))
abundance(CHEBIID:16810) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN3))
abundance(CHEBIID:16810) directlyIncreases catalyticActivity(proteinAbundance(HGNC:HIF1AN)) //FIH = HIF1AN
biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:HIF1A)

SET Evidence = "Furthermore, an acetyltransferase, ARD1, acetylates K532, a residue previously shown
to result in HIFa stability, thereby negatively regulating it [65]. Jab1, a
transcriptional co-activator, has been shown to positively regulate HIFa [66]."

catalyticActivity(proteinAbundance(HGNC:NAA10)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(A,K,532)) //AARD1 = NAA10
catalyticActivity(proteinAbundance(HGNC:NAA10)) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:HIF1A,proteinModification(A,K,532)) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A))
transcriptionalActivity(proteinAbundance(HGNC:COPS5)) increases proteinAbundance(HGNC:HIF1A)

SET TextLocation = "Review"
SET Evidence = "RCC cells lacking functional pVHL overexpress various growth factors, including platelet-derived
growth factor b (PDGFb), VEGF and transforming growth factor (TGF)-a
[25]. The latter is a bona fide renal-cell mitogen that activates the Ras–Raf–MAP
kinase signalling cascade through its cognate epidermal growth factor (EGF)
cell-surface receptor [26]."

proteinAbundance(HGNC:VHL) negativeCorrelation proteinAbundance(HGNC:PDGFB)
proteinAbundance(HGNC:VHL) negativeCorrelation proteinAbundance(HGNC:VEGFA)
proteinAbundance(HGNC:VHL) negativeCorrelation proteinAbundance(HGNC:TGFA)
proteinAbundance(HGNC:TGFA) directlyIncreases kinaseActivity(proteinAbundance(HGNC:EGFR))
proteinAbundance(HGNC:TGFA) increases gtpBoundActivity(proteinAbundance(PFH:"RAS Family"))
kinaseActivity(proteinAbundance(HGNC:EGFR)) increases gtpBoundActivity(proteinAbundance(PFH:"RAS Family"))

SET Evidence = "The overproduction of TGF-a in RCC cells is, at least in part, HIF-dependent and a
major contributory event that confers a growth advantage to these cells [25,27]."

transcriptionalActivity(proteinAbundance(HGNC:HIF1A)) increases proteinAbundance(HGNC:TGFA)
proteinAbundance(HGNC:TGFA) increases biologicalProcess(GO:"cell growth")

SET Evidence = "tumour necrosis factor (TNF)-a has been shown to promote HIF-1a accumulation, and
this might involve a VHL-dependent step [33,34]."

proteinAbundance(HGNC:TNF) increases proteinAbundance(HGNC:HIF1A)

SET Evidence = "In particular, it has been reported that RCC cells can be sensitized to TNF-a-induced
cytotoxicity by re-introducing wild-type VHL [38]. The authors highlight the
fact that TNFreceptor engagement by TNF-a triggers the activation of atypical
protein kinase C (aPKC), which, through IKKb phosphorylation, liberates NFkB, thereby
initiating the transcription of genes that are involved in apoptosis"

proteinAbundance(HGNC:VHL) increases (proteinAbundance(HGNC:TNF) increases biologicalProcess(GO:"cell death"))
molecularActivity(proteinAbundance(HGNC:TNFRSF1A)) increases kinaseActivity(proteinAbundance(PFH:"PRKC Family"))
kinaseActivity(proteinAbundance(PFH:"PRKC Family")) directlyIncreases proteinAbundance(HGNC:IKBKB,proteinModification(P))
proteinAbundance(HGNC:TNF) directlyIncreases molecularActivity(proteinAbundance(HGNC:TNFRSF1A))
proteinAbundance(HGNC:IKBKB,proteinModification(P)) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))

SET Evidence = "pVHL has been shown to bind directly to various aPKC isoforms and to target aPKCl
for ubiquitin-mediated degradation [39,40]."

proteinAbundance(HGNC:VHL) directlyIncreases degradation(proteinAbundance(HGNC:PRKCI)) //PKC lambda = PKC iota

SET Disease = "Neoplasms"
SET Evidence = "pVHL has also been implicated in tumour invasion and metastasis, which represent complex
multi-step processes that require the proteolytic degradation of the basement
membrane and tissue matrix, changes in cell polarity and motility, and the
attachment and detachment of cells to and from the extracellular matrix (ECM) [41]."

proteinAbundance(HGNC:VHL) association pathology(MESHD:"Neoplasm Invasiveness")
proteinAbundance(HGNC:VHL) association pathology(MESHD:"Neoplasm Metastasis")

SET Evidence = "Nevertheless, the restored ability of pVHL-positive transfectants to assemble extracellular
fibronectin was mediated by b1 integrins, implying that pVHL controls
ECM assembly, at least in part, through integrin signalling [46]. A recent development
has demonstrated that an ubiquitin-like molecule, NEDD8, covalently modifies
pVHL and that a neddylation- defective pVHL mutant, despite retaining its ability
to degrade HIF, fails to promote the assembly of a fibronectin matrix [47]."

proteinAbundance(HGNC:VHL) increases biologicalProcess(GO:"extracellular matrix assembly")
proteinAbundance(HGNC:VHL) increases (biologicalProcess(GO:"integrin-mediated signaling pathway") increases biologicalProcess(GO:"extracellular matrix assembly"))

SET Evidence = "The regulation of insulin growth factor (IGF)-I-mediated cell invasion of RCC cells
appears to be dependent upon PKCd inhibition by pVHL. This inhibition is mediated
through a protein–protein interaction involving a domain of pVHL that shows
similarity to protein kinase inhibitor (PKI), a natural inhibitor of cAMP-dependent
protein kinase (PKA) [48]"

proteinAbundance(HGNC:VHL) directlyDecreases kinaseActivity(proteinAbundance(HGNC:PRKCD))

SET Disease = "Carcinoma, Renal Cell"

proteinAbundance(HGNC:IGF1) increases pathology(MESHD:"Neoplasm Invasiveness")

SET Evidence = "In contrast to protein-binding inhibition, evidence has shown that pVHL binds to both
atypical PKC isoforms (l and z) through its b-domain, and in the case of activated
aPKCl, mediates its turnover as part of the E3-ligase function of pVHL [39,40].
Although the functional significance of this inhibition remains elusive,
given the central role for atypical PKCs (especially aPKCz) in establishing cell
polarity in conjunction with PAR6 and the GTPase CDC42 [49], one could envisage
a scenario whereby the loss of pVHL leads to altered cell polarity and, by extension,
aberrant cell migration."

complexAbundance(proteinAbundance(HGNC:VHL),proteinAbundance(HGNC:PRKCZ))
complexAbundance(proteinAbundance(HGNC:VHL),proteinAbundance(HGNC:PRKCI)) //PKC lambda = PKC iota (PRKCI)
catalyticActivity(proteinAbundance(HGNC:VHL)) directlyIncreases degradation(proteinAbundance(HGNC:PRKCI))
kinaseActivity(proteinAbundance(HGNC:PRKCZ)) increases biologicalProcess(GO:"establishment of cell polarity")

SET Evidence = "Consistent with this, pVHL30 has been shown to co-localize with the microtubule network
in vivo and to promote microtubule stabilization [12]. Because microtubule
dynamics have been intimately linked to the process of directed cell migration
[49],"

proteinAbundance(HGNC:VHL) increases biologicalProcess(GO:"negative regulation of microtubule depolymerization") //microtubule stabilization" synonym = "negative regulation of microtubule depolymerization

SET Evidence = "This same study demonstrated that the loss of VHL function negatively regulates tissue
inhibitor of metalloproteinase 2 (TIMP-2), resulting in the upregulation of
matrix metalloproteinase 2 (MMP2) and MMP9, thereby implicating pVHL in the control
of these molecules."

proteinAbundance(HGNC:VHL) increases peptidaseActivity(proteinAbundance(HGNC:TIMP2))
peptidaseActivity(proteinAbundance(HGNC:TIMP2)) decreases proteinAbundance(HGNC:MMP2)
peptidaseActivity(proteinAbundance(HGNC:TIMP2)) decreases proteinAbundance(HGNC:MMP9)

SET Evidence = "Importantly, it has been demonstrated that hypoxia promotes tumour cell invasion by
inducing the expression of the Met receptor [54]. This establishes a mechanism
whereby transformed cells can be spurred to exit a hypoxic microenvironment and
invade the surrounding tissues, which provide more favourable growth conditions.
Because HIF-1a is involved in Met gene expression, the constitutive activation
of HIF-1a as a consequence of pVHL deregulation provides a mechanism explaining
the observation that the expression of HGF and Met receptor is associated with
genetic alterations of VHL in primary RCC."

biologicalProcess(GO:"response to hypoxia") increases rnaAbundance(HGNC:MET)
transcriptionalActivity(proteinAbundance(HGNC:HIF1A)) increases rnaAbundance(HGNC:MET)
geneAbundance(HGNC:VHL) association rnaAbundance(HGNC:MET)
geneAbundance(HGNC:VHL) association rnaAbundance(HGNC:HGF)

SET Evidence = "The gene encoding the chemokine receptor CXCR4 has been discovered as a novel HIF
target based on a microarray comparison of genetic profiles derived from VHL-null
RCC cells and their isogenic wild-type VHLexpressing counterparts [52]."

proteinAbundance(HGNC:VHL) decreases rnaAbundance(HGNC:CXCR4)

SET Evidence = "The fact that CXCR4 is a hypoxia-inducible gene provided a potential mechanistic explanation
for CXCR4 upregulation during tumour cell evolution. CXCR4- induced
cell-surface expression due to the loss of VHL function confers enhanced migratory
potential to RCC cells in response to its cognate ligand stromal-derived factor
1 (SDF1)."

biologicalProcess(GO:"response to hypoxia") increases rnaAbundance(HGNC:CXCR4)
proteinAbundance(HGNC:VHL) decreases cellSurfaceExpression(proteinAbundance(HGNC:CXCR4))
proteinAbundance(HGNC:CXCL12) directlyIncreases molecularActivity(proteinAbundance(HGNC:CXCR4)) //SDF1 = CXCL12
molecularActivity(proteinAbundance(HGNC:CXCR4)) increases biologicalProcess(GO:"cell migration")

SET TextLocation = "Legend"
SET Evidence = "Figure 4. The role of hypoxia-inducible factor (HIF) in conferring tumour growth potential.
In solid tumours, HIFa is stabilised under conditions of low oxygen due
to a lack of vascularisation and the subsequent evolution of a hypoxic microenvironment.
In a VHL-null tumour, HIFa is constitutively active, and can initiate
genetic programmes within the entire population of cells that would normally be
activated only under hypoxic conditions."

biologicalProcess(GO:"response to hypoxia") decreases degradation(proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:VHL) decreases transcriptionalActivity(proteinAbundance(HGNC:HIF1A))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 4"

SET TextLocation = "Review"
SET Evidence = "These modifications render Ras functional and capable of localizing to the lipid-rich
inner surface of the cell membrane. The first and most critical modification,
farnesylation, which is principally catalyzed by protein FTase, adds a 15-carbon
hydrobobic farnesyl isoprenyl tail to the carboxyl terminus of Ras."
SET Citation = {"PubMed","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","16170185","","Beeram M|Patnaik A|Rowinsky EK",""}

catalyticActivity(complexAbundance(proteinAbundance(HGNC:FNTA),proteinAbundance(HGNC:FNTB))) directlyIncreases proteinAbundance(PFH:"RAS Family",proteinModification(F))
proteinAbundance(PFH:"RAS Family",proteinModification(F)) directlyIncreases translocation(proteinAbundance(PFH:"RAS Family"),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane")

SET Evidence = "The considerable attention paid to targeting Ras as a therapeutic strategy is based
on the high incidence of activating ras mutations in human malignancies, including
approximately 22% of non–small-cell lung, 50% of colorectal, and 90% of pancreatic
cancers. 53,60,61"
SET Species = "9606"

gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) positiveCorrelation pathology(MESHD:"Carcinoma, Non-Small-Cell Lung")
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) positiveCorrelation pathology(MESHD:"Colorectal Neoplasms")
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) positiveCorrelation pathology(MESHD:"Pancreatic Neoplasms")

SET Evidence = "Localization of GTP-bound Ras to the inner surface of the cell membrane activates
several downstream effectors, most notably the serine/threonine kinase Raf, which
is the first signaling element in the MAPK pathway. 2,67,68 As shown in Figure
1, other downstream effectors of Ras include the PI3K cell survival pathway, the
small GTP-binding proteins Rac and Rho, and the stress-activated protein kinase
pathway (also referred to as the c-jun N-terminal kinase [JNK] pathway). 69-71
In addition, in response to cellular stress and cytokine stimulation mediated
through Ras, the dual-specificity p38MAPK kinases (MKK3 and MKK6) and the JNK kinases
(MKK4 and MKK7) phosphorylate p38MAPK and JNK, respectively. 72-76"

gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases gtpBoundActivity(proteinAbundance(PFH:"RAC Family"))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases gtpBoundActivity(proteinAbundance(PFH:"RHO Family"))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(HGNC:MAP2K3))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(HGNC:MAP2K6))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(HGNC:MAP2K4))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(HGNC:MAP2K7))
biologicalProcess(GO:"cellular response to stress") increases gtpBoundActivity(proteinAbundance(PFH:"RAS Family"))
biologicalProcess(GO:"cellular response to cytokine stimulus") increases gtpBoundActivity(proteinAbundance(PFH:"RAS Family"))

SET CellStructure = "Cell Membrane"
SET Evidence = "GTP-bound Ras interacts directly with Raf and mobilizes the inactive protein from
the cytoplasm (Figs 1 and 2). Once the Ras-Raf complex is translocated to the cell
membrane, Ras activates the serine/threonine kinase function of Raf through
an association between its Ras-binding domain (RBD) in the amino-terminal regulatory
region and Ras-GTP."

gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) directlyIncreases kinaseActivity(proteinAbundance(PFH:"RAF Family"))

SET Evidence = "Raf is also activated by Ras-independent activators, including the soluble non-RTK
Src and Janus kinase 1, which are involved in cytokine signaling.86 Other Ras-independent
activators of Raf include interferon beta, protein kinase C (PKC) alpha,
antiapoptotic proteins (eg, Bcl-2), scaffolding proteins (eg, ceramide-activated
protein kinase), ultraviolet light, ionizing radiation, retinoids, erythropoietin,
and dimerization between Raf isoforms 86-94 (Fig 3)."

kinaseActivity(proteinAbundance(HGNC:JAK1)) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
kinaseActivity(proteinAbundance(HGNC:SRC)) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
proteinAbundance(HGNC:IFNB1) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
kinaseActivity(proteinAbundance(HGNC:PRKCA)) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
proteinAbundance(HGNC:BCL2) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
biologicalProcess(GO:"response to UV") increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
biologicalProcess(GO:"response to ionizing radiation") increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
abundance(CHEBI:retinoid) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
proteinAbundance(HGNC:EPO) increases kinaseActivity(proteinAbundance(PFH:"RAF Family"))

SET Evidence = "Furthermore, the kinase activity of Raf is inhibited by its interactions with cholesterol-rich
lipid rafts in the cell membrane and phosphorylation by protein kinases
A (PKA) and B (PKB/Akt), as shown in Figure 2.95-98"

abundance(MESHCL:"Membrane Microdomains") directlyDecreases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
kinaseActivity(proteinAbundance(PFH:"PRKA Family")) decreases kinaseActivity(proteinAbundance(PFH:"RAF Family"))
kinaseActivity(proteinAbundance(PFH:"AKT Family")) decreases kinaseActivity(proteinAbundance(PFH:"RAF Family"))

SET Evidence = "The mammalian raf family consists of the following three genes: A-raf, B-raf, and
C-raf, which are located on chromosomes Xp11, 7q32, and 3p25, respectively."

proteinAbundance(PFH:"RAF Family") hasMembers list(proteinAbundance(HGNC:ARAF),proteinAbundance(HGNC:BRAF),proteinAbundance(HGNC:RAF1))

SET Evidence = "Additional support for the diverse functionality of Raf family members is provided
by the disparate responses of B-Raf and C-Raf to identical stimuli, as well as
the distinct messages that each isoform relays downstream to Rap1, which is a small
GTPase that functions as both an activator and repressor of Raf.115  Rap1-mediated
stimulation of B-Raf by cyclic adenosine monophosphate (cAMP) phosphorylates
ERK, whereas stimulation of C-Raf inhibits ERK phosphorylation.115"

abundance(CHEBI:"3',5'-cyclic AMP") increases gtpBoundActivity(proteinAbundance(HGNC:RAP1A))
gtpBoundActivity(proteinAbundance(HGNC:RAP1A)) increases (kinaseActivity(proteinAbundance(HGNC:BRAF)) increases proteinAbundance(PFH:"MAPK Erk1/3 Family",proteinModification(P)))
gtpBoundActivity(proteinAbundance(HGNC:RAP1A)) decreases kinaseActivity(proteinAbundance(HGNC:RAF1)) //The effect of RAP1A on RAF1 (c-RAF) does not appear to be stimulating

SET Evidence = "With regard to differences in signaling between the Raf isoforms, A-Raf is a weaker
activator of MEK than B-Raf or C-Raf. Furthermore, A-Raf can activate MEK1 only,
whereas C-Raf activates both MEK1 and MEK2.123-125"

kinaseActivity(proteinAbundance(HGNC:ARAF)) causesNoChange kinaseActivity(proteinAbundance(HGNC:MAP2K2))
kinaseActivity(proteinAbundance(HGNC:ARAF)) increases kinaseActivity(proteinAbundance(HGNC:MAP2K1))
kinaseActivity(proteinAbundance(HGNC:RAF1)) increases kinaseActivity(proteinAbundance(HGNC:MAP2K1))
kinaseActivity(proteinAbundance(HGNC:RAF1)) increases kinaseActivity(proteinAbundance(HGNC:MAP2K2))

SET CellStructure = "Cytoplasm"
SET Evidence = "C-Raf exists in the cytoplasm as a 300- to 500-kd protein complex. The complex consists
of C-Raf, heat shock protein 90 (Hsp90), and the dimeric protein cofactor
14-3-3. 14-3-3 binds to two specific phosphoserine residues of C-Raf, which masks
its kinase domain and inactivates the protein. The binding of Ras to C-Raf displaces
the 14-3-3 dimer, rendering C-Raf accessible to dephosphorylation by protein
phosphatase 2A.126"

complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:HSP90AA1),proteinAbundance(PFH:"14-3-3 Family"))
complexAbundance(proteinAbundance(PFH:"RAS Family"),proteinAbundance(HGNC:RAF1)) directlyDecreases complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(PFH:"14-3-3 Family"))
proteinAbundance(PFH:"14-3-3 Family") directlyDecreases kinaseActivity(proteinAbundance(HGNC:RAF1))
phosphataseActivity(complexAbundance(NCH:"PP2A Complex")) directlyDecreases proteinAbundance(HGNC:RAF1,proteinModification(P,S))

SET Evidence = "The effector domain of GTP-bound Ras binds to C-Raf through the RBD and CRD in the
CR1. Although binding to both sites is required for Raf activation, the most critical
interaction is between Ras-GTP and the RBD.127  All Ras isoforms are capable
of interacting with Raf, but K-Ras is the most potent activator, whereas N-Ras
is much more efficient than H-Ras.128  The interaction between Ras and C-Raf
alone is insufficient to activate C-Raf, but it serves to translocate C-Raf to
the cell membrane where it can be activated."

gtpBoundActivity(proteinAbundance(HGNC:HRAS)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:RAF1))
gtpBoundActivity(proteinAbundance(HGNC:NRAS)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:RAF1))
gtpBoundActivity(proteinAbundance(HGNC:KRAS)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:RAF1))

SET Evidence = "The activation of B-Raf by Ras has been less well studied; however, the interacting
amino acids in the Ras-Raf interface are identical for B-Raf and C-Raf.129,130
 The association of Ras with B-Raf also translocates B-Raf to the cell membrane
where it is activated.124  Interestingly, a membrane-free complex of B-Raf and
14-3-3 can be activated in vitro by recombinant Ras. This is in stark contrast
to A-Raf and C-Raf, which must undergo a series of phosphorylation reactions on
serine and tyrosine residues in the cell membrane and cannot be activated by Ras
alone.124,130  Of the Raf isoforms, B-Raf is activated first, and on stimulation
by Ras, it heterodimerizes with C-Raf, the significance of which is not known.94"

gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) directlyIncreases kinaseActivity(proteinAbundance(HGNC:BRAF))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) directlyIncreases translocation(proteinAbundance(HGNC:BRAF),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane")
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:BRAF))

SET Evidence = "Both B-Raf and C-Raf can bind to other small GTPases, most notably Rap1.115,131,132
 The effector domains of Rap1 and Ras are nearly identical, but activation of
these proteins produces vastly different downstream effects. Furthermore, Rap1
mediates distinct effects after binding to various Raf isoforms. The B-Raf–Rap1
complex activates B-Raf, whereas the C-Raf–Rap1 interaction does not activate C-Raf
and, in fact, may be inhibitory.115,132,133  This occurs because Rap1 binds
to the CRD of C-Raf with higher affinity than Ras and excludes Ras from binding."

gtpBoundActivity(proteinAbundance(HGNC:RAP1A)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:BRAF))
gtpBoundActivity(proteinAbundance(HGNC:RAP1A)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:RAF1))

SET Evidence = "The Rho family of small GTPases, consisting of Rho, Rac, and cyclin-dependent kinase
(Cdc) 42, regulate cytoskeletal organization during the cell cycle and also
mediate Ras-induced activation of Raf, especially C-Raf.134-136  These GTPases do
not directly bind to Raf but, instead, signal by activating downstream kinases.
Rho signals by activating the serine/threonine protein kinases N1 and N2 and Rho-associated
kinase 1, whereas Rac and Cdc42 signal through p21-activated kinase
(PAK).134-136"

gtpBoundActivity(proteinAbundance(PFH:"RHO Family")) increases biologicalProcess(GO:"regulation of cytoskeleton organization")
gtpBoundActivity(proteinAbundance(PFH:"RHO Family")) increases (gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) directlyIncreases kinaseActivity(proteinAbundance(HGNC:RAF1)))
gtpBoundActivity(proteinAbundance(PFH:"RHO Family")) increases kinaseActivity(proteinAbundance(HGNC:PKN1))
gtpBoundActivity(proteinAbundance(PFH:"RHO Family")) increases kinaseActivity(proteinAbundance(HGNC:PKN2))
gtpBoundActivity(proteinAbundance(PFH:"RAC Family")) increases kinaseActivity(proteinAbundance(PFH:"PAK Family"))
gtpBoundActivity(proteinAbundance(HGNC:CDC42)) increases kinaseActivity(proteinAbundance(PFH:"PAK Family"))
gtpBoundActivity(proteinAbundance(PFH:"RHO Family")) increases kinaseActivity(proteinAbundance(HGNC:ROCK1))

SET Evidence = "Phosphorylation.  Raf is principally activated by phosphorylation of specific amino
acid residues as shown for each isoform in Figure 4. From an evolutionary standpoint,
the Raf activation sites are highly conserved from yeast to humans. Several
amino acids in Raf, particularly serine (S) 259 and S621, which bind 14-3-3
and maintain C-Raf in a closed auto-inhibited conformation, are phosphorylated
in the basal state.137  On stimulation, Ras-GTP displaces 14-3-3 from S259, and
C-Raf is translocated to the cell membrane, where it can be dephosphorylated at
S259 by protein phosphatase 2A or other phosphatases.126  S259 also represents the
site of inhibitory phosphorylation by PKB/Akt, PKA, and serum glucocorticoid-inducible
kinase.121,138,139  Phosphorylation at S621 seems to have greater significance
because mutations at this site inactivate Raf's kinase activity. Hence,
a balance of phosphorylation and dephosphorylation is required to prime Raf in
the basal state before stimulation by Ras or mitogens.137"

proteinAbundance(HGNC:RAF1,proteinModification(P,S,259)) directlyIncreases complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(PFH:"14-3-3 Family"))
proteinAbundance(HGNC:RAF1,proteinModification(P,S,259)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:RAF1))
proteinAbundance(HGNC:RAF1,proteinModification(P,S,621)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:RAF1))
proteinAbundance(HGNC:RAF1,proteinModification(P,S,621)) directlyIncreases complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(PFH:"14-3-3 Family"))
phosphataseActivity(complexAbundance(NCH:"PP2A Complex")) directlyDecreases proteinAbundance(HGNC:RAF1,proteinModification(P,S,259))
kinaseActivity(proteinAbundance(PFH:"AKT Family")) directlyIncreases proteinAbundance(HGNC:RAF1,proteinModification(P,S,259))
kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyIncreases proteinAbundance(HGNC:RAF1,proteinModification(P,S,259))
kinaseActivity(proteinAbundance(HGNC:SGK1)) directlyIncreases proteinAbundance(HGNC:RAF1,proteinModification(P,S,259))

SET Evidence = "Raf is also phosphorylated at other serine and threonine residues, the most important
of which are S338 and tyrosine (Y) 341, which are situated adjacent to the
C-Raf kinase domain.140  Phosphorylation of these residues relieves the inhibitory
effects of the regulatory domain on the kinase domain.141  S338, which is the
evolutionarily conserved PAK phosphorylation site that resides on the amino-terminal
side of the kinase domain, is critical for Raf activation.134-136,140,142
 This site is also phosphorylated in response to stimulation by growth factors,
integrins, Ras, PAK1, and PAK3.78,136,143"

proteinAbundance(HGNC:RAF1,proteinModification(P,S,338)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:RAF1))
proteinAbundance(HGNC:RAF1,proteinModification(P,Y,341)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:RAF1))
kinaseActivity(proteinAbundance(HGNC:PAK1)) directlyIncreases proteinAbundance(HGNC:RAF1,proteinModification(P,S,338))
kinaseActivity(proteinAbundance(HGNC:PAK3)) directlyIncreases proteinAbundance(HGNC:RAF1,proteinModification(P,S,338))
biologicalProcess(GO:"integrin activation") increases proteinAbundance(HGNC:RAF1,proteinModification(P,S,338))
biologicalProcess(GO:"cellular response to growth factor stimulus") increases proteinAbundance(HGNC:RAF1,proteinModification(P,S,338))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases proteinAbundance(HGNC:RAF1,proteinModification(P,S,338))

SET Evidence = "The homologous site on B-Raf, S445, is constitutively phosphorylated, accounting for
the higher basal activity of B-Raf. Ras presumably phosphorylates this site
by activating PI3K."

proteinAbundance(HGNC:BRAF,proteinModification(P,S,445)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:BRAF))

SET Evidence = "Y341 is phosphorylated by the Src family of non-RTKs, Janus kinase, and erythropoietin.85,92"

kinaseActivity(proteinAbundance(PFH:"SRC Family")) directlyIncreases proteinAbundance(HGNC:RAF1,proteinModification(P,Y,341)) //evidence text refers to c-RAF (RAF1)
kinaseActivity(proteinAbundance(PFH:"JAK Family")) directlyIncreases proteinAbundance(HGNC:RAF1,proteinModification(P,Y,341))
proteinAbundance(HGNC:EPO) increases proteinAbundance(HGNC:RAF1,proteinModification(P,Y,341))

SET Evidence = "As shown in Figure 2, C-Raf interacts with a diverse array of scaffolding proteins
(kinase suppressor of Ras and MEK partner-1), adaptor proteins (Bcl-2–associated
athanogene-1), chaperone proteins (Hsp90 and Hsp70), substrates (retinoblastoma
protein [Rb]), lipids (phosphatidic acid, cholesterol-rich caveolae, and cytosolic
lipid rafts), and cellular constituents, many of which, in turn, modulate
its kinase activity.95"

complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:KSR1)) //kinase suppressor of RAF = KSR1
complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:LAMTOR3)) //MEK partner 1 = LAMTOR3
complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:BAG1)) //Bcl-2–associated athanogene-1 = BAG1
complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:HSP90AA1))
complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(PFH:"HSPA Family"))
complexAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:RB1))
complexAbundance(proteinAbundance(HGNC:RAF1),abundance(CHEBI:"phosphatidic acid"))

SET Evidence = "The Raf isoforms are the best characterized MEK1 and MEK2 activators, and all Raf
isoforms activate MEK1, whereas only B-Raf and C-Raf activate MEK2. MEK1 and MEK2
contain a proline-rich sequence that enables recognition and activation by Raf.125,146-153."

kinaseActivity(proteinAbundance(HGNC:RAF1)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAP2K1))
kinaseActivity(proteinAbundance(HGNC:BRAF)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAP2K1))
kinaseActivity(proteinAbundance(HGNC:ARAF)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAP2K1))
kinaseActivity(proteinAbundance(HGNC:BRAF)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAP2K2))
kinaseActivity(proteinAbundance(HGNC:RAF1)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAP2K2))

SET Evidence = "the dual-specificity p38MAPK kinases (MKK3 and MKK6) and JNK kinases (MKK4 and MKK7)
phosphorylate p38MAPK  and JNK, respectively.72-76"

kinaseActivity(proteinAbundance(HGNC:MAP2K3)) directlyIncreases kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family"))
kinaseActivity(proteinAbundance(HGNC:MAP2K6)) directlyIncreases kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family"))
kinaseActivity(proteinAbundance(HGNC:MAP2K4)) directlyIncreases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
kinaseActivity(proteinAbundance(HGNC:MAP2K7)) directlyIncreases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET Evidence = "Although both A-Raf and C-Raf are capable of activating other signaling elements independent
of MAPK pathway activation, such as nuclear factor-kappa B (NF-κB),
Rb, and Bcl-2, MEK1 and MEK2 are the only known substrates for B-Raf.154-157"

kinaseActivity(proteinAbundance(HGNC:ARAF)) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
kinaseActivity(proteinAbundance(HGNC:RAF1)) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))

SET Evidence = "Cell survival signaling is also regulated by C-Raf, which induces phosphorylation
of Iκ B in the NF-κB–Iκ B complex. This action releases activated NF-κB, which
is then translocated to the nucleus where it mediates transcription of antiapoptotic
factors.155,166"

kinaseActivity(proteinAbundance(HGNC:RAF1)) increases proteinAbundance(HGNC:NFKBIA,proteinModification(P))
proteinAbundance(HGNC:NFKBIA,proteinModification(P)) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))

SET Evidence = "Other antiapoptotic effects of C-Raf are mediated by a mitochondrial pool of the protein,
which, on stimulation, localizes to the mitochondrial membrane where the
protein interacts with and phosphorylates Bcl-2, Bcl-2–associated athanogene,
and other pro-apoptotic regulators, abrogating their pro-apoptotic effects.157,167
The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat
protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169"

kinaseActivity(proteinAbundance(HGNC:RAF1)) decreases biologicalProcess(GO:"apoptotic process")
kinaseActivity(proteinAbundance(HGNC:RAF1)) directlyIncreases proteinAbundance(HGNC:BCL2,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:RAF1)) directlyIncreases proteinAbundance(HGNC:BAG1,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:RAF1)) directlyIncreases (molecularActivity(proteinAbundance(HGNC:BCL2)) decreases biologicalProcess(GO:"apoptotic process")) //evidence line is unclear; BCL2 and BAG1 should be anti-apoptotic
kinaseActivity(proteinAbundance(HGNC:RAF1)) directlyIncreases (molecularActivity(proteinAbundance(HGNC:BAG1)) decreases biologicalProcess(GO:"apoptotic process")) //evidence line is unclear; BCL2 and BAG1 should be anti-apoptotic
kinaseActivity(proteinAbundance(HGNC:RAF1)) decreases (kinaseActivity(proteinAbundance(HGNC:MAP3K5)) increases biologicalProcess(GO:"apoptotic process")) //ASK1 = MAP3K5

SET Evidence = "In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory
proteins in metaphase.156,170,171  Lastly, C-Raf induces transcription of the multidrug
resistance gene mdr-1,  and its activation has been associated with multidrug
resistance.172"

kinaseActivity(proteinAbundance(HGNC:RAF1)) increases proteinAbundance(HGNC:RB1,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:RAF1)) increases proteinAbundance(HGNC:TP53,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:RAF1)) increases proteinAbundance(PFH:"CDC25 Family",proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:RAF1)) increases rnaAbundance(HGNC:ABCB1) //MDR-1 = ABCB1

SET Evidence = "Somatic B-raf mutations were demonstrated in 60% to 70% of malignant melanomas and
in moderate to high rates in carcinomas of the colon, ovary, and thyroid (papillary),
implicating activating oncogenic B-raf mutations as critical promoters of
these malignancies.9,14-17"

kinaseActivity(proteinAbundance(HGNC:BRAF)) positiveCorrelation pathology(MESHD:Melanoma)
kinaseActivity(proteinAbundance(HGNC:BRAF)) positiveCorrelation pathology(MESHD:"Colorectal Neoplasms")
kinaseActivity(proteinAbundance(HGNC:BRAF)) positiveCorrelation pathology(MESHD:"Ovarian Neoplasms")
kinaseActivity(proteinAbundance(HGNC:BRAF)) positiveCorrelation pathology(MESHD:"Thyroid Neoplasms")

SET Evidence = "V599EB-Raf possesses the hallmarks of a conventional oncogene because the kinase activity
of its encoded protein is greatly elevated; it constitutively stimulates
ERK in vivo in the absence of Ras activation; and it transforms NIH3T3 cells.144"

proteinAbundance(HGNC:BRAF,substitution(V,599,E)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:BRAF))

SET Evidence = "Originally identified by high-throughput screening of small molecules against C-Raf
kinase, sorafenib was found to be a potent competitive inhibitor of ATP binding
in the catalytic domains of C-Raf, wild-type B-Raf, and V599EB-Raf mutant."

abundance(CHEBI:sorafenib) directlyDecreases kinaseActivity(proteinAbundance(HGNC:RAF1))
abundance(CHEBI:sorafenib) directlyDecreases kinaseActivity(proteinAbundance(HGNC:BRAF))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 5"

SET TextLocation = "Review"
SET Evidence = "Originally identified by high-throughput screening of small molecules against C-Raf
kinase, sorafenib was found to be a potent competitive inhibitor of ATP binding
in the catalytic domains of C-Raf, wild-type B-Raf, and V599EB-Raf mutant."
SET Citation = {"PubMed","The Biochemical journal","12444918","","Houslay MD|Adams DR",""}

molecularActivity(proteinAbundance(HGNC:ADRB2)) directlyIncreases complexAbundance(proteinAbundance(HGNC:ADRB2),proteinAbundance(PFH:"PDE4 Family"),proteinAbundance(PFH:"ARRB Family"))

SET Evidence = "Long PDE4 isoforms from all four subfamilies can be activated through PKA phosphorylation
[50,54–57] of a single serine residue[50,56,58–61] found at the extreme
N-terminal end of UCR1, within the PKA consensus, RRESF."

kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyIncreases catalyticActivity(proteinAbundance(PFH:"PDE4 Long Family"))
kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyIncreases proteinAbundance(PFH:"PDE4 Long Family",proteinModification(P,S))

SET Evidence = "Once cAMP is generated, the only way to inactivate it is to degrade it to 5'-AMP,
through PDE action"

catalyticActivity(proteinAbundance(PFH:"PDE Family")) directlyIncreases reaction(reactants(abundance(CHEBI:"3',5'-cyclic AMP")),products(abundance(CHEBI:AMP)))

SET CellStructure = "Cell Membrane"
SET Evidence = "cAMP is of pivotal importance in determining many aspects of cellular function [1,2].
It is generated at the cytosol surface of the plasma membrane through the action
of adenylate cyclases, of which there is a large family. Increased levels
of cAMP are translated into cellular responses through the action of cAMP-dependent
protein kinase (PKA)"

catalyticActivity(proteinAbundance(PFH:"ADCY Family")) directlyIncreases abundance(CHEBI:"3',5'-cyclic AMP")
abundance(CHEBI:"3',5'-cyclic AMP") directlyIncreases kinaseActivity(proteinAbundance(PFH:"PRKA Family"))

SET Evidence = "Consistent with this, gene knockout studies have shown that PDE4B(-/-)  mice exhibit
a profound attenuation in the ability of lipopolysaccharide ('LPS') to generate
tumour necrosis factor-α ('TNF-α') [18]."
SET Species = "10090"

proteinAbundance(MGI:Pde4b) increases (abundance(SCHEM:Lipopolysaccharide) increases proteinAbundance(MGI:Tnf))

SET Evidence = "The third subdomain of the catalytic unit of all PDE4 subfamilies, but not that of
PDE4A, contains a single, ERK consensus motif (Pro-Xaa-Ser-Pro). The serine residue
in this site can be phosphorylated, both in vitro and in vivo , by ERK [49,70,71]."

kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) directlyIncreases proteinAbundance(HGNC:PDE4B,proteinModification(P,S))
kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) directlyIncreases proteinAbundance(HGNC:PDE4C,proteinModification(P,S))
kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) directlyIncreases proteinAbundance(HGNC:PDE4D,proteinModification(P,S))

SET Evidence = "ERK phosphorylation of PDE4 long isoforms leads to inhibition under conditions where
the serine target is the sole residue phosphorylated [49,70,71]."

kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) directlyDecreases catalyticActivity(proteinAbundance(PFH:"PDE4 Long No A Family"))

SET CardiovascularSystem = "Aorta"
SET Tissue = "Muscle, Smooth"
SET Evidence = "In these cells ERK causes the autocrine generation of prostaglandin E2  (PGE2) through
activation of PKA2 and the production of arachidonic acid. Thus the rapidly
generated PGE2 stimulates adenylate cyclase, increasing cAMP levels,"
SET Species = "9606"

kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) increases abundance(CHEBI:"prostaglandin E2")
kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) increases catalyticActivity(proteinAbundance(PFH:"PLA2 Family"))
catalyticActivity(proteinAbundance(PFH:"PLA2 Family")) increases abundance(CHEBI:"arachidonic acid")
abundance(CHEBI:"prostaglandin E2") increases catalyticActivity(proteinAbundance(PFH:"ADCY Family"))

SET Cell = "Myeloid Cells"
SET Evidence = "Whether a similar mechanism underpins the ability of interleukin 3 (IL-3) and IL-4
to increase PDE4 activity in myeloid cells through an ERK-mediated process [75],
or because ERK-activated short forms predominate in such cells (see above), remains
to be seen."

proteinAbundance(HGNC:IL3) increases catalyticActivity(proteinAbundance(PFH:"PDE4 Family"))
proteinAbundance(HGNC:IL4) increases catalyticActivity(proteinAbundance(PFH:"PDE4 Family"))
kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) directlyIncreases catalyticActivity(proteinAbundance(PFH:"PDE4 Short Family"))

SET Evidence = "PA causes a marked (0.7-3-fold) activation of various long PDE4 isoforms, but fails
to affect short and super-short isoforms [87,91]. Similar activation was seen
with the acidic phospholipid phosphatidylserine (PS), but not with neutral phospholipids."

abundance(CHEBI:"phosphatidic acid") increases catalyticActivity(proteinAbundance(PFH:"PDE4 Long Family"))
abundance(CHEBI:"phosphatidyl-L-serine") increases catalyticActivity(proteinAbundance(PFH:"PDE4 Long Family"))

SET Evidence = "All 3 categories of PDE4 isoforms from all four subfamilies can interact with β-arrestin1/2,
implying that a common region in the PDE4 catalytic unit provides a
binding site for β-arrestins [65]. Thus challenge of cells with a β-agonist has
been shown to cause recruitment of a PDE4–arrestin complex to the β2- AR."

complexAbundance(proteinAbundance(PFH:"PDE4 Family"),proteinAbundance(PFH:"ARRB Family"))
molecularActivity(proteinAbundance(HGNC:ADRB2)) directlyIncreases complexAbundance(proteinAbundance(HGNC:ADRB2),proteinAbundance(PFH:"PDE4 Family"),proteinAbundance(PFH:"ARRB Family"))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 6"

SET CellLine = "T-47D"
SET TextLocation = "Abstract"
SET BodyRegion = "Mammary Glands, Human"
SET Evidence = "Like progesterone receptors (PR), Stat5a and 5b are required for normal mammary gland
growth and differentiation. These two proteins are up-regulated during pregnancy,
a period dominated by high levels of progesterone."
SET Citation = {"PubMed","The Journal of biological chemistry","9813040","","Richer JK|Lange CA|Manning NG|Owen G|Powell R|Horwitz KB",""}
SET Species = "9606"

proteinAbundance(HGNC:STAT5A) increases biologicalProcess(MESHPP:"Cell Differentiation")
proteinAbundance(HGNC:STAT5B) increases biologicalProcess(MESHPP:"Cell Differentiation")
proteinAbundance(HGNC:PGR) increases biologicalProcess(MESHPP:"Cell Differentiation")
biologicalProcess(MESHPP:Pregnancy) positiveCorrelation proteinAbundance(HGNC:STAT5A)
biologicalProcess(MESHPP:Pregnancy) positiveCorrelation proteinAbundance(HGNC:STAT5B)

SET Disease = "Breast Neoplasms"
SET Evidence = "In addition, progestin treatment induces translocation of Stat5 into the nucleus,
possibly mediated by the association of PR and Stat5. Last, progesterone pretreatment
enhances the phosphorylation of Stat5 on tyrosine 694 induced by epidermal
growth factor."

abundance(CHEBIID:59826) increases translocation(proteinAbundance(PFH:"STAT5 Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")
abundance(CHEBIID:59826) increases (proteinAbundance(HGNC:EGF) increases proteinAbundance(PFH:"STAT5 Family",proteinModification(P,Y,694)))

SET Evidence = "Functional data show that progestin pretreatment of breast cancer cells enhances the
ability of prolactin to stimulate the transcriptional activity of Stat5 on a
β-casein promoter. Progesterone and epidermal growth factor synergize to control
transcription from p21WAF1 and c-fos promoters."

compositeAbundance(abundance(CHEBIID:59826),proteinAbundance(HGNC:PRL)) increases (transcriptionalActivity(proteinAbundance(PFH:"STAT5 Family")) directlyIncreases rnaAbundance(HGNC:CSN2))
compositeAbundance(abundance(CHEBI:progesterone),proteinAbundance(HGNC:EGF)) increases (transcriptionalActivity(proteinAbundance(PFH:"STAT5 Family")) directlyIncreases rnaAbundance(HGNC:FOS))
compositeAbundance(abundance(CHEBI:progesterone),proteinAbundance(HGNC:EGF)) increases (transcriptionalActivity(proteinAbundance(PFH:"STAT5 Family")) directlyIncreases rnaAbundance(HGNC:CDKN1A))

SET TextLocation = "Results"
SET Evidence = "Stat5 protein levels were elevated by 8 h and remained elevated until 72 h after R5020
treatment with increases of 4–7-fold (Fig. 1A). To test the PR dependence
of this effect, the experiment was repeated using PR-negative T47D-Y cells (28)
(Fig. 1B). In the absence of PR, R5020 did not up-regulate Stat5."

abundance(CHEBIID:59826) increases proteinAbundance(PFH:"STAT5 Family") //R5020 is a synthetic progestin
proteinAbundance(HGNC:PGR) increases proteinAbundance(PFH:"STAT5 Family")

SET Evidence = "This study shows that both the longer (95 kDa) Stat5a and the shorter (92 kDa) Stat5b
isoform are up-regulated by progestin treatment."

abundance(CHEBIID:59826) increases proteinAbundance(HGNC:STAT5A)
abundance(CHEBIID:59826) increases proteinAbundance(HGNC:STAT5B)

SET Evidence = "Similar studies using anti-Stat3 (Fig. 2B) and anti-Stat1 (Fig. 2C) antibodies show
that these STAT family members are also progestin regulated. While Stat3 is clearly
up-regulated by progestin treatment, Stat1 is slightly down-regulated."

abundance(CHEBIID:59826) increases proteinAbundance(HGNC:STAT3)
abundance(CHEBIID:59826) decreases proteinAbundance(HGNC:STAT1)

SET Evidence = "Northern blot analysis demonstrates hormone-dependent induction of Stat5a message
at 12 and 24 h following progestin treatment (Fig. 3)."

abundance(CHEBIID:59826) increases rnaAbundance(HGNC:STAT5A)

SET Evidence = "In contrast, the same Northern blot hybridized with cDNA for two genes known to be
PR regulated, fatty acid synthetase (30,38) or cyclin D1 (18,39), shows equal
induction of these genes by the two PR isoforms."

transcriptionalActivity(proteinAbundance(HGNC:PGR)) increases rnaAbundance(HGNC:FASN) //fatty acid synthase = FASN
transcriptionalActivity(proteinAbundance(HGNC:PGR)) increases rnaAbundance(HGNC:CCND1)

SET Evidence = "T47Dco cells were treated for 24 h with 10 nm R5020 or vehicle, then with 10 nm EGF
or vehicle for 5 min. Nuclear and cytosolic extracts were prepared and equal
amounts of protein were probed with antibody recognizing total Stat5 (Fig. 4A).
In untreated cells, Stat5 was exclusively cytoplasmic (lane 1); no Stat5 was found
in the nucleus (lane 2). As expected, EGF treatment promoted nuclear translocation
of a portion of Stat5 (lanes 5 and 6). Surprisingly, R5020 not only increased
total Stat5 levels (lanes 3  and 4; 7and 8), but also promoted extensive nuclear
translocation of Stat5 (compare lanes 2 and 4) independent of EGF treatment."

abundance(CHEBIID:59826) increases proteinAbundance(PFH:"STAT5 Family")
abundance(CHEBIID:59826) increases translocation(proteinAbundance(PFH:"STAT5 Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")
proteinAbundance(HGNC:EGF) increases translocation(proteinAbundance(PFH:"STAT5 Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")

SET CellLine = "HeLa"
SET Evidence = "These reciprocal studies show that PR and Stat5 are associated, either directly or
in a multiprotein complex."

complexAbundance(proteinAbundance(HGNC:PGR),proteinAbundance(PFH:"STAT5 Family"))

SET CellLine = "T-47D"
SET Evidence = "In the absence of R5020 pretreatment, JAK2 is immunoprecipitated with the anti-phosphotyrosine
antibody only following EGF treatment (lane 2). Note that JAK2 is
not present in phosphotyrosine immunoprecipitates after 1 h of R5020 treatment (lane
1). However, JAK2 is immunoprecipitated with the anti-phosphotyrosine antibody
as efficiently after 48 h of R5020 treatment (lane 4) as with EGF treatment
(lane 5)."

abundance(CHEBIID:59826) increases proteinAbundance(HGNC:JAK2,proteinModification(P,Y))
proteinAbundance(HGNC:EGF) increases proteinAbundance(HGNC:JAK2,proteinModification(P,Y))

SET Evidence = "However, Stat5 remained unphosphorylated (P-Stat5, lanes 1–5), except in the cells
that were pretreated with R5020 for 48 h, prior to the 10-min prolactin treatment
(P-Stat5, lane 6). Prolactin alone had no effect (lane 3) nor did transient
(1 h) or chronic (48 h) R5020 treatment (lane 2). Thus, in T47Dco cells, Stat5 phosphorylation
by prolactin requires progesterone pretreatment."

compositeAbundance(proteinAbundance(HGNC:PRL),abundance(CHEBIID:59826)) increases proteinAbundance(PFH:"STAT5 Family",proteinModification(P))

SET Evidence = "The β-casein promoter, known to be induced by Stat5 when activated by prolactin via
prolactin receptors and JAK2, was next used to test the function of the phosphorylated
Stat5. T47D-YB cells were pretreated with either R5020 or ethanol vehicle
for 48 h. Cells were then washed, transfected with a β-casein promoter-luciferase
reporter, treated with either R5020 or prolactin, and harvested for luciferase
assay 24 h after hormone treatment. We found that in T47D-YB breast cancer
cells, prolactin alone has minimal to no significant effect on the β-casein luciferase
promoter. However, after R5020 pretreatment, a 6–7-fold induction of the
β-casein luciferase promoter was observed (Fig.7B). Thus R5020 sensitized these
breast cancer cells to the transcriptional effects of prolactin mediated through
Stat5."

compositeAbundance(proteinAbundance(HGNC:PRL),abundance(CHEBIID:59826)) increases transcriptionalActivity(proteinAbundance(PFH:"STAT5 Family"))
compositeAbundance(proteinAbundance(HGNC:PRL),abundance(CHEBIID:59826)) increases rnaAbundance(HGNC:CSN2) //beta casein = CSN2

SET Evidence = "Fig. 8A shows that the p21WAF1 promoter is induced 4.5-fold by progesterone, 2.4-fold
by EGF, and 13.2-fold by both hormones together. The average increase in five
experiments was progesterone, 3.5-fold; EGF, 2.2-fold; both hormones, 11-fold.
Fig. 8B demonstrates the corresponding increases in endogenous p21 levels when
T47D-YB cells are treated for 24 h with ethanol, progesterone, EGF, or both hormones.
Whole cell lysates were probed by immunoblotting with antibody to p21."

compositeAbundance(proteinAbundance(HGNC:EGF),abundance(CHEBI:progesterone)) increases rnaAbundance(HGNC:CDKN1A)
abundance(CHEBI:progesterone) increases rnaAbundance(HGNC:CDKN1A)
proteinAbundance(HGNC:EGF) increases rnaAbundance(HGNC:CDKN1A)

SET Evidence = "Fig. 8C shows that the c-fos promoter is induced 19.3-fold by R5020 and 6.2-fold by
EGF. Remarkably, together the two hormones produced a 145-fold increase in luciferase
activity."

compositeAbundance(proteinAbundance(HGNC:EGF),abundance(CHEBIID:59826)) increases rnaAbundance(HGNC:FOS)
proteinAbundance(HGNC:EGF) increases rnaAbundance(HGNC:FOS)
abundance(CHEBIID:59826) increases rnaAbundance(HGNC:FOS)

SET TextLocation = "Legend"
SET Evidence = "Progesterone enhances the ability of EGF to phosphorylate Stat5 on tyrosine 694."

compositeAbundance(proteinAbundance(HGNC:EGF),abundance(CHEBI:progesterone)) increases proteinAbundance(PFH:"STAT5 Family",proteinModification(P,Y,694))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 7"

SET TextLocation = "Abstract"
SET Evidence = "Mitochondrial dysfunction is a major mechanism whereby drugs can induce liver injury
and other serious side effects such as lactic acidosis and rhabdomyolysis in
some patients."
SET Citation = {"PubMed","Fundamental & clinical pharmacology","18705745","","Labbe G|Pessayre D|Fromenty B",""}
SET Species = "9606"

pathology(SDIS:"mitochondrial damage") increases pathology(MESHD:"Drug-Induced Liver Injury")

SET TextLocation = "Review"

pathology(SDIS:"mitochondrial damage") increases pathology(MESHD:"Acidosis, Lactic")
pathology(SDIS:"mitochondrial damage") increases pathology(MESHD:Rhabdomyolysis)

SET TextLocation = "Abstract"
SET Evidence = "drugs can induce microvesicular steatosis, a potentially severe lesion that can be
associated with profound hypoglycaemia and encephalopathy"

pathology(SDIS:Steatosis) positiveCorrelation pathology(MESHD:Hypoglycemia)
pathology(SDIS:Steatosis) positiveCorrelation pathology(MESHD:"Hepatic Encephalopathy")

SET TextLocation = "Review"

pathology(SDIS:Steatosis) positiveCorrelation pathology(MESHD:"Fatty Liver")

SET TextLocation = "Abstract"
SET DigestiveSystem = "Liver"
SET Evidence = "They can also trigger hepatic necrosis and/or apoptosis, causing cytolytic hepatitis,
which can evolve into liver failure."

biologicalProcess(GO:necrosis) increases pathology(MESHD:Hepatitis)
biologicalProcess(GO:"apoptotic process") increases pathology(MESHD:Hepatitis)

SET TextLocation = "Review"
SET Evidence = "During the fasting state, fatty acid oxidation (FAO) in the liver is incomplete; the
acetyl-CoA that is generated is not oxidized in the liver, but condenses into
ketone bodies (mainly acetoacetate and β-hydroxybutyrate) (Figure 1), which are
released into the plasma for subsequent oxidation in extrahepatic tissues."

biologicalProcess(GO:"fatty acid oxidation") increases abundance(CHEBI:"acetyl-CoA")
reaction(reactants(abundance(CHEBI:"acetyl-CoA")),products(abundance(CHEBI:acetoacetate),abundance(CHEBI:"3-hydroxybutyrate")))
cellSecretion(abundance(CHEBI:acetoacetate))
cellSecretion(abundance(CHEBI:"3-hydroxybutyrate"))

SET TextLocation = "Legend"
SET CellStructure = "Mitochondrial Membranes"
SET Evidence = "LCFAs are activated into LCFA-coenzyme A (acyl- CoA) thioesters by long-chain acyl-CoA
synthetases (ACS) located in the outer mitochondrial membrane, microsomes
and peroxisomes"

catalyticActivity(proteinAbundance(PFH:"ACSL Family")) directlyIncreases reaction(reactants(abundance(SCHEM:"Long-chain fatty acid")),products(abundance(SCHEM:"Long-chain fatty acyl CoA")))

SET CellStructure = "Microsomes"

catalyticActivity(proteinAbundance(PFH:"ACSL Family")) directlyIncreases reaction(reactants(abundance(SCHEM:"Long-chain fatty acid")),products(abundance(SCHEM:"Long-chain fatty acyl CoA")))

SET CellStructure = "Peroxisomes"

catalyticActivity(proteinAbundance(PFH:"ACSL Family")) directlyIncreases reaction(reactants(abundance(SCHEM:"Long-chain fatty acid")),products(abundance(SCHEM:"Long-chain fatty acyl CoA")))

SET CellStructure = "Mitochondrial Membranes"
SET Evidence = "The long-chain acyl-CoA is converted into an acyl-carnitine by carnitine palmitoyltransferase-I
(CPT-I) in the outer mitochondrial membrane."

catalyticActivity(proteinAbundance(HGNC:CPT1A)) directlyIncreases reaction(reactants(abundance(SCHEM:"Long-chain fatty acyl CoA")),products(abundance(SCHEM:"O-Acylcarnitine")))

SET CellStructure = "Mitochondria"
SET Evidence = "LCFA-CoA thioesters are then oxidized into acetyl-CoA moieties via the β-oxidation
process."

biologicalProcess(GO:"fatty acid beta-oxidation") increases reaction(reactants(abundance(SCHEM:"Long-chain fatty acyl CoA")),products(abundance(CHEBI:"acetyl-CoA")))

SET Evidence = "Acetyl-CoA moieties can then generate ketone bodies (mainly acetoacetate and β-hydroxybutyrate)
via ketogenesis, which is stimulated during fasting."

biologicalProcess(MESHPP:Eating) decreases reaction(reactants(abundance(SCHEM:"Acetyl-CoA")),products(abundance(SCHEM:acetoacetate),abundance(CHEBI:"3-hydroxybutyrate")))
abundance(SCHEM:acetoacetate) isA abundance(SCHEM:"Ketone Body")
abundance(CHEBI:"3-hydroxybutyrate") isA abundance(SCHEM:"Ketone Body")

SET CellStructure = "Mitochondria, Liver"
SET Evidence = "Ketone bodies are liberated into the plasma to be used by extrahepatic tissues for
energy production."

cellSecretion(abundance(SCHEM:"Ketone Body")) increases biologicalProcess(GO:"energy derivation by oxidation of organic compounds")

SET Evidence = "After a meal, however, the acetyl-CoA moieties are mainly generated in the liver by
the glycolysis of glucose into pyruvate and the oxidative decarboxylation of
pyruvate."

biologicalProcess(MESHPP:Eating) increases reaction(reactants(abundance(CHEBI:glucose)),products(abundance(CHEBI:pyruvate)))
reaction(reactants(abundance(CHEBI:glucose)),products(abundance(CHEBI:pyruvate))) subProcessOf biologicalProcess(MESHPP:Glycolysis)

SET Evidence = "The formed acetyl-CoA enters the tricarboxylic acid (TCA) cycle (not shown), to be
fully oxidized or to form citrate, which can leave mitochondria and regenerate
acetyl-CoA in the cytosol for subsequent de novo lipogenesis."

reaction(reactants(abundance(CHEBI:"acetyl-CoA")),products(abundance(SCHEM:Citrate))) subProcessOf biologicalProcess(GO:"tricarboxylic acid cycle")

SET Evidence = "Mitochondrial fatty acid β-oxidation (FAO) and the TCA cycle generate NADH and FADH2,
which transfer their electrons (e-) to the mitochondrial respiratory chain
(MRC), regenerating NAD+ and FAD used for other β-oxidation (or TCA) cycles"

biologicalProcess(GO:"fatty acid beta-oxidation") increases abundance(CHEBI:NADH)
biologicalProcess(GO:"fatty acid beta-oxidation") increases abundance(CHEBI:FADH2)
biologicalProcess(GO:"tricarboxylic acid cycle") increases abundance(CHEBI:NADH)
biologicalProcess(GO:"tricarboxylic acid cycle") increases abundance(CHEBI:FADH2)

SET Evidence = "When energy is needed (i.e. when ATP levels are low), these protons re-enter the matrix
through ATP synthase (also referred to as complex V), thus liberating energy
that is used to phosphorylate ADP into ATP."

catalyticActivity(complexAbundance(NCH:"Proton Transporting ATP Synthase Complex")) directlyIncreases biologicalProcess(GO:"ATP synthesis coupled proton transport")
abundance(CHEBI:ATP) decreases catalyticActivity(complexAbundance(NCH:"Proton Transporting ATP Synthase Complex"))

SET Evidence = "Cytochrome c release induces caspase activation and cell death via apoptosis or necrosis."

translocation(proteinAbundance(HGNC:CYCS),MESHCL:Mitochondria,MESHCL:Cytoplasm) increases biologicalProcess(GO:"apoptotic process")
translocation(proteinAbundance(HGNC:CYCS),MESHCL:Mitochondria,MESHCL:Cytoplasm) increases biologicalProcess(GO:necrosis)
translocation(proteinAbundance(HGNC:CYCS),MESHCL:Mitochondria,MESHCL:Cytoplasm) increases biologicalProcess(GO:"activation of cysteine-type endopeptidase activity")

SET TextLocation = "Review"
SET Evidence = "When cells need energy, the rise in ADP levels within the mitochondria induces the
re-entry of protons into the mitochondrial matrix through the membranespanning
F0 portion of the ATP synthase complex (also referred to as the 'complex V of the
MRC')."

abundance(CHEBI:ADP) increases catalyticActivity(complexAbundance(NCH:"Proton Transporting ATP Synthase Complex"))

SET Evidence = "Classically, it is considered that the number of normal mtDNA copies must fall below
20–40% of basal levels to induce mitochondrial dysfunction and adverse events
[6]. Below this threshold, hepatic mtDNA depletion can impair the MRC. This impairment
can hamper the regeneration of NAD+ and FAD, thus leading to a secondary
inhibition of the oxidation of fatty acids and pyruvate."

biologicalProcess(SDIS:"mitochondrial DNA damage") decreases biologicalProcess(GO:"mitochondrial respiratory chain complex assembly")
biologicalProcess(GO:"mitochondrial respiratory chain complex assembly") increases abundance(CHEBI:FAD)
abundance(CHEBI:NAD) increases biologicalProcess(GO:"fatty acid beta-oxidation")
abundance(CHEBI:FAD) increases biologicalProcess(GO:"fatty acid beta-oxidation")
abundance(CHEBI:NAD) increases biologicalProcess(GO:"pyruvate oxidation")
abundance(CHEBI:FAD) increases biologicalProcess(GO:"pyruvate oxidation")

SET Evidence = "a key feature of the mitochondrial genome is its high sensitivity to oxidative damage,
because of its proximity to the inner membrane (the main cellular source of
ROS)"

biologicalProcess(GO:"response to oxidative stress") increases pathology(SDIS:"mitochondrial DNA damage")
abundance(CHEBI:"reactive oxygen species") increases pathology(SDIS:"mitochondrial DNA damage")

SET Evidence = "However, at several upstream sites of the MRC (most probably complexes I and III),
a small fraction of these electrons can directly react with oxygen, to generate
the superoxide anion radical."

biologicalProcess(GO:"mitochondrial respiratory chain complex assembly") increases reaction(reactants(abundance(CHEBI:electron),abundance(CHEBI:dioxygen)),products(abundance(CHEBI:superoxide)))

SET Evidence = "to generate the superoxide anion radical. This radical is then dismutated by the mitochondrial
manganese superoxide dismutase (MnSOD) into hydrogen peroxide (H2O2),
which is detoxified into water by the mitochondrial glutathione peroxidase."

catalyticActivity(proteinAbundance(HGNC:SOD2)) increases reaction(reactants(abundance(CHEBI:superoxide)),products(abundance(CHEBI:"hydrogen peroxide")))
catalyticActivity(proteinAbundance(HGNC:GPX1)) increases reaction(reactants(abundance(CHEBI:"hydrogen peroxide")),products(abundance(CHEBI:water)))

SET Evidence = "Hence, in the normal (non-diseased) state, most of the ROS generated by the MRC is
detoxified by the mitochondrial antioxidant defences."

biologicalProcess(GO:"mitochondrial respiratory chain complex assembly") increases abundance(CHEBI:"reactive oxygen species")

SET CellStructure = {"Mitochondria, Liver","Mitochondria, Liver"}
SET Evidence = "However, glutathione peroxidase needs adequate amounts of reduced glutathione in the
mitochondrial matrix to detoxify H2O2."

abundance(CHEBI:glutathione) increases catalyticActivity(proteinAbundance(HGNC:GPX1))

SET CellStructure = "Mitochondria, Liver"
SET Evidence = "The depletion of mitochondrial glutathione below a critical threshold can impair mitochondrial
H2O2 detoxification, which can trigger mitochondrial dysfunction,
mitochondrial permeability transition (MPT) and cell death [22]."

abundance(CHEBI:glutathione) decreases pathology(SDIS:"mitochondrial DNA damage")
abundance(CHEBI:glutathione) decreases biologicalProcess(GO:"positive regulation of mitochondrial membrane permeability")
abundance(CHEBI:glutathione) decreases biologicalProcess(GO:"cell death")

SET Evidence = "rupture of the outer membrane and the release of pro-apoptotic proteins from the intermembrane
space into the cytosol. The release of apoptosis-inducing factor (AIF)
triggers the fragmentation of largesized nuclear DNA."

translocation(proteinAbundance(HGNC:AIFM1),MESHCL:Mitochondria,MESHCL:Cytoplasm) increases biologicalProcess(GO:"DNA fragmentation involved in apoptotic nuclear change")

SET Evidence = "The release of a protein called 'second mitochondria-derived activator of caspase/
direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO)' inactivates
the inhibitor of apoptosis proteins (IAPs)."

translocation(proteinAbundance(HGNC:DIABLO),MESHCL:Mitochondria,MESHCL:Cytoplasm) increases biologicalProcess(GO:"apoptotic process")

SET CellStructure = "Cytoplasm"
SET Evidence = "the released cytochrome c binds in the cytosol to Apaf-1 in an ATP-dependent manner
to activate caspase-9."

abundance(CHEBI:ATP) increases complexAbundance(proteinAbundance(HGNC:CYCS),proteinAbundance(HGNC:APAF1))
complexAbundance(proteinAbundance(HGNC:CYCS),proteinAbundance(HGNC:APAF1)) increases peptidaseActivity(proteinAbundance(HGNC:CASP9))

SET CellStructure = "Mitochondria, Liver"
SET Evidence = "Mitochondrial permeability transition can cause either apoptosis or necrosis."

biologicalProcess(GO:"positive regulation of mitochondrial membrane permeability") increases biologicalProcess(GO:"apoptotic process")
biologicalProcess(GO:"positive regulation of mitochondrial membrane permeability") increases biologicalProcess(GO:necrosis)

SET Evidence = "In contrast, when MPT occurs in most mitochondria in a single cell, ATP generation
is compromised because of the collapse of the Δψm, and the resulting ATP depletion
triggers cell necrosis [2,24]."

biologicalProcess(GO:"regulation of mitochondrial membrane permeability") decreases abundance(CHEBI:ATP)

SET Evidence = "Mitochondrial permeability transition pore opening, which is calcium-dependent, can
be triggered by a variety of endogenous compounds such as iron, ROS, nitric oxide,
free fatty acids (and acyl-CoA derivatives), ceramide and bile salts [25,26]."

abundance(CHEBI:"calcium ion") increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")
abundance(CHEBIID:24875) increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")
abundance(CHEBI:"nitric oxide") increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")
abundance(CHEBI:"fatty acid") increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")
abundance(CHEBI:ceramide) increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")
abundance(CHEBI:"bile salt") increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")

SET Evidence = "MPT can also be triggered by extracellular cytokines such as tumour necrosis factor-a
(TNF-α) and Fas ligand (Fas-L) acting through their plasma membrane receptors
[27,28]."

proteinAbundance(HGNC:TNF) increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")
proteinAbundance(HGNC:FASLG) increases biologicalProcess(GO:"regulation of mitochondrial membrane permeability")

SET Cell = "Hepatocytes"
SET Evidence = "troglitazone and acetaminophen activate c-Jun N-terminal protein kinase (JNK), thus
inducing the cleavage of Bid, the translocation of this pro-apoptotic protein
to the outer mitochondrial membranes and the release of cytochrome c from mitochondria
[32,33]."

abundance(CHEBI:troglitazone) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
abundance(CHEBI:paracetamol) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")) increases translocation(proteinAbundance(HGNC:CYCS),MESHCL:"Mitochondrial Membranes",MESHCL:Cytoplasm)

SET Evidence = "Severe inhibition of mitochondrial β-oxidation can lead to microvesicular steatosis
characterized by the presence of many tiny lipid droplets within the cytoplasm
of hepatocytes."

biologicalProcess(GO:"fatty acid beta-oxidation") decreases pathology(SDIS:Steatosis)

SET CellStructure = "Cytoplasm"

pathology(SDIS:Steatosis) association biologicalProcess(SDIS:"Lipid Droplet")

SET Evidence = "ROS overproduction may be a key event in the pathogenesis of drug-induced steatohepatitis
by inducing lipid peroxidation (favoured by lipid accumulation), and possibly
by triggering the generation of proapoptotic (TNF-α) and pro-fibrotic (TGF-β)
cytokines by Kupffer cells and other inflammatory cells [2,4,40]."

abundance(CHEBI:"reactive oxygen species") increases biologicalProcess(SDIS:"lipid peroxidation")

SET Cell = "Kupffer Cells"

abundance(CHEBI:"reactive oxygen species") increases proteinAbundance(HGNC:TNF)
abundance(CHEBI:"reactive oxygen species") increases proteinAbundance(HGNC:TGFB1)
proteinAbundance(HGNC:TNF) increases biologicalProcess(GO:"apoptotic process")
proteinAbundance(HGNC:TGFB1) increases biologicalProcess(SDIS:fibrosis)

SET CellStructure = "Mitochondria, Liver"
SET Evidence = "tamoxifen directly inhibits the transfer of electrons within the MRC, and also progressively
depletes hepatic mtDNA through a mechanism that may involve the inhibition
of mitochondrial topoisomerases and the impairment of mtDNA replication by
this DNA-intercalating drug [41,42]."

abundance(CHEBI:tamoxifen) decreases biologicalProcess(GO:"respiratory electron transport chain")
abundance(CHEBI:tamoxifen) increases pathology(SDIS:"mitochondrial DNA damage")
abundance(CHEBI:tamoxifen) decreases biologicalProcess(GO:"mitochondrial DNA replication")

SET Evidence = "some drugs (e.g. amiodarone, amineptine, pirprofen) also inhibit microsomal triglyceride
transfer protein (MTP), an enzyme playing a major role in the formation
of very-low-density-lipoprotein (VLDL) particles [43]. Such drugs therefore inhibit
the two main pathways removing fat from the liver, namely FAO and hepatic VLDL
secretion."

abundance(CHEBI:amiodarone) decreases molecularActivity(proteinAbundance(HGNC:MTTP))
abundance(CHEBI:amineptine) decreases molecularActivity(proteinAbundance(HGNC:MTTP))
abundance(CHEBI:amiodarone) decreases biologicalProcess(GO:"fatty acid beta-oxidation")
abundance(CHEBI:amiodarone) decreases biologicalProcess(SDIS:"VLDL secretion")
abundance(CHEBI:amineptine) decreases biologicalProcess(GO:"fatty acid beta-oxidation")
abundance(CHEBI:amineptine) decreases biologicalProcess(SDIS:"VLDL secretion")

SET Evidence = "Cationic amphiphilic drugs such as amiodarone, perhexiline, diethylaminoethoxyhexestrol
(DEAEH) and tamoxifen can be first protonated in the intermembrane space
of mitochondria, and then electrophoretically transported into the mitochondrial
matrix thanks to the Δψm [3,4,40,42], as discussed in greater detail below. This
transfer across the inner mitochondrial membrane dissipates Δψm (Figure 1) and
increases the basal (state 4) mitochondrial respiration. This phenomenon, which
is called 'OXPHOS uncoupling', can also be observed in the case of some mitochondrial
poisons such as the protonophores 2,4-dinitrophenol (DNP) and carbonylcyanide
p-trifluoromethoxyphenylhydrazone (FCCP)."

abundance(CHEBI:amiodarone) increases biologicalProcess(GO:"regulation of oxidative phosphorylation uncoupler activity")
abundance(CHEBI:perhexiline) increases biologicalProcess(GO:"regulation of oxidative phosphorylation uncoupler activity")
abundance(CHEBI:tamoxifen) increases biologicalProcess(GO:"regulation of oxidative phosphorylation uncoupler activity")
abundance(CHEBI:"2,4-dinitrophenol") increases biologicalProcess(GO:"regulation of oxidative phosphorylation uncoupler activity")

SET Evidence = "Finally, it must be pointed out that another important consequence of drug-induced
OXPHOS uncoupling is the reduction of ATP synthesis, as the re-entry of protons
within the mitochondrial matrix bypasses ATP synthase [3,40]."

biologicalProcess(GO:"regulation of oxidative phosphorylation uncoupler activity") decreases biologicalProcess(GO:"ATP synthesis coupled proton transport")

SET Evidence = "valproic acid inhibits mitochondrial FAO through the sequestration of coenzyme A (a
cofactor mandatory for FAO),"

abundance(CHEBI:"valproic acid") decreases biologicalProcess(GO:"fatty acid beta-oxidation")

SET Evidence = "this antiepileptic drug can induce MPT (Figure 1) [29], which may explain why valproateinduced
microvesicular steatosis can be associated with liver cell death [2]."

abundance(CHEBI:"valproic acid") increases biologicalProcess(GO:"positive regulation of mitochondrial membrane permeability")

SET Evidence = "ethanol intoxication also increases cytochrome P450 2E1 (CYP2E1) levels, not only
in the endoplasmic reticulum but also in mitochondria [77]."

abundance(CHEBI:ethanol) increases proteinAbundance(HGNC:CYP2E1)

SET CellStructure = "Endoplasmic Reticulum"

abundance(CHEBI:ethanol) increases proteinAbundance(HGNC:CYP2E1)

SET CellStructure = "Mitochondria, Liver"
SET Evidence = "The ectopic localization of CYP2E1 may enhance the mitochondrial generation of N-acetyl-p-benzoquinone
imine (NAPQI), the toxic metabolite of acetaminophen."

proteinAbundance(HGNC:CYP2E1) increases abundance(CHEBI:"N-acetyl-1,4-benzoquinone imine")

SET Evidence = "As the reactive NAPQI has a direct toxicity effect on mitochondria, in particular
by triggering MPT [78,79]"

abundance(CHEBI:"N-acetyl-1,4-benzoquinone imine") increases biologicalProcess(GO:"positive regulation of mitochondrial membrane permeability")

SET Evidence = "An example is the combined role of aspirin and viral infections in the occurrence
of Reye’s syndrome, a severe post-infectious metabolic disease characterized by
extensive microvesicular steatosis of the liver, severe hypoglycaemia and a non-inflammatory
encephalopathy [3,83]."

pathology(MESHD:"Reye Syndrome") association pathology(SDIS:Steatosis)
pathology(MESHD:"Reye Syndrome") association pathology(SDIS:hypoglycemia)
pathology(MESHD:"Reye Syndrome") association pathology(SDIS:Encephalopathy)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 8"

SET TextLocation = "Abstract"
SET Evidence = "In support of a role for PRP4K in pre-mRNA splicing, we identified PRP6, SWAP, and
pinin as interacting proteins and demonstrated that PRP4K is a U5 snRNP-associated
kinase."
SET Citation = {"PubMed","Molecular and cellular biology","12077342","","Dellaire G|Makarov EM|Cowger JJ|Longman D|Sutherland HG|Lührmann R|Torchia J|Bickmore WA",""}

complexAbundance(proteinAbundance(HGNC:PRPF4B),proteinAbundance(HGNC:PRPF6)) //disambiguation PRP4K = PRPF4B
complexAbundance(proteinAbundance(HGNC:PRPF4B),proteinAbundance(HGNC:SFSWAP))
complexAbundance(proteinAbundance(HGNC:PRPF4B),proteinAbundance(HGNC:PNN))

SET CellLine = "HT-1080"
SET TextLocation = "Results"
SET CellStructure = "Cell Nucleus"
SET Evidence = "The subcellular distribution of endogenous PRP4K in human and mouse cells was analyzed
by indirect immunofluorescence (Fig. 2D). PRP4K is distributed throughout
the nucleus, excluding the nucleolus, but is enriched in multiple speckles. In addition,
some endogenous PRP4K is associated with unfixed mitotic chromosomes (Fig.
2D; F9 and HT1080)."
SET Species = "9606"

proteinAbundance(HGNC:PRPF4B)

SET TextLocation = "Abstract"
SET Evidence = "In addition, BRG1 and N-CoR, components of nuclear hormone coactivator and corepressor
complexes, also interact with PRP4K."

complexAbundance(proteinAbundance(HGNC:PRPF4B),proteinAbundance(HGNC:SMARCA4)) //BRG1 = SMARCA4
complexAbundance(proteinAbundance(HGNC:PRPF4B),proteinAbundance(HGNC:NCOR1))

SET CellLine = "HeLa"
SET TextLocation = "Results"
SET Evidence = "The differentially migrating forms of PRP4K detected by Western blot analysis (Fig.
2C) suggest that it is posttranslationally modified. Phosphatase treatment of
nuclear extracts reduces most PRP4K to the 147-kDa fast-migrating form (Fig. 5D).
Thus, the slower-migrating forms of PRP4K are phosphorylated, and it is only
the hypophosphorylated (147 kDa) form that is coimmunoprecipitated by BRG1 and PRP6
antibodies (Fig. 5B and C)."

proteinAbundance(HGNC:PRPF4B,proteinModification(P)) directlyDecreases complexAbundance(proteinAbundance(HGNC:PRPF4B),proteinAbundance(HGNC:SMARCA4))
proteinAbundance(HGNC:PRPF4B,proteinModification(P)) directlyDecreases complexAbundance(proteinAbundance(HGNC:PRPF4B),proteinAbundance(HGNC:PRPF6))

SET Evidence = "A strongly labeled doublet (Fig. 6, band B) corresponds to the relative position of
PRP4K, a finding consistent with the reported ability of mammalian PRP4K homologues
to autophosphorylate (19, 27). Two other prominently labeled proteins correspond
in size to BRG1 and PRP6 (Fig. 6, bands A and C, respectively). To confirm
that these proteins were indeed BRG1 and PRP6, we carried out kinase assays with
BRG1 and PRP6 IP complexes, which also contain coimmunoprecipitated PRP4K (Fig.
5). These immunoprecipitates do exhibit kinase activity, and both phosphorylated
PRP6 and BRG1 are much more intense in their respective IP reactions, reflecting
the relative increase in each substrate for PRP4K."

kinaseActivity(proteinAbundance(HGNC:PRPF4B)) directlyIncreases proteinAbundance(HGNC:PRPF4B,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:PRPF4B)) directlyIncreases proteinAbundance(HGNC:PRPF6,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:PRPF4B)) directlyIncreases proteinAbundance(HGNC:SMARCA4,proteinModification(P))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 9"

SET Disease = "Breast Neoplasms"
SET TextLocation = "Abstract"
SET BodyRegion = "Breast"
SET Evidence = "Residual breast carcinomas that had been surgically removed within 48 days after first
surgery showed a significant increase in proliferation if they were HER2-positive.
Wound drainage fluid and postsurgical serum samples from patients stimulated
in-vitro growth of HER2-overexpressing breast carcinoma cells. Removal of
HER2 from the cell membrane led to a striking reduction of the induced proliferation."
SET Citation = {"PubMed","Lancet","12932384","","Tagliabue E|Agresti R|Carcangiu ML|Ghirelli C|Morelli D|Campiglio M|Martel M|Giovanazzi R|Greco M|Balsari A|Ménard S",""}
SET Species = "9606"

pathology(SDIS:"tissue damage") increases biologicalProcess(GO:"cell proliferation")
proteinAbundance(HGNC:ERBB2) increases (pathology(SDIS:"tissue damage") increases biologicalProcess(GO:"cell proliferation"))

SET CellLine = "MDA-MB-453"
SET TextLocation = "Results"
SET Evidence = "To determine the potential role of these growth factors in cell growth induced by
drainage fluid, MDAMB453 cells were treated with drainage fluids in the presence
of neutralising antibodies against HB-EGF or TGFα. Cell proliferation induced
by all drainage fluids was found to decrease by about 50% and 30%, respectively,
and no further decrease was noted in the presence of both antibodies together,
as shown by selected data shown for two drainage fluids in figure 3."

proteinAbundance(HGNC:TGFA) increases biologicalProcess(GO:"cell proliferation")
proteinAbundance(HGNC:HBEGF) increases biologicalProcess(GO:"cell proliferation")

SET Evidence = "In the other five cases, the concentrations of EGF-like factors were below the detection
limits in both presurgical and postsurgical serum samples. A highly significant
direct correlation (r=0.77, 95% CI 0.49–0.92, p=0.002) was found between
EGF in postsurgical serum and cellular damage induced by surgery, measured on the
basis of creatine phosphokinase concentration in drainage fluids obtained 1 day
after surgery (figure 4). The degree of drainage-fluid-induced MDAMB453 cell
proliferation also directly correlated with creatine phosphokinase concentration
(r=0.69, 95% CI 0.25–0·91, p=0.009; figure 4)."

proteinAbundance(PFH:"EGFR Ligand Family") positiveCorrelation pathology(SDIS:"tissue damage")
biologicalProcess(GO:"cell proliferation") positiveCorrelation pathology(SDIS:"tissue damage")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 10"

SET Disease = "Multiple Myeloma"
SET TextLocation = "Abstract"
SET Evidence = "We show that protein kinase C (PKC) alpha is translocated to the plasma membrane and
activated by adhesion of MM cells to fibronectin and VEGF. We identify beta(1)
integrin modulating VEGF-triggered MM cell migration on fibronectin. We show
that transient enhancement of MM cell adhesion to fibronectin triggered by VEGF
is dependent on the activity of both PKC and beta(1) integrin. Moreover, we demonstrate
that PKC alpha is constitutively associated with beta(1) integrin."
SET Citation = {"PubMed","The Journal of biological chemistry","11751905","2002-01-20","Podar K|Tai YT|Lin BK|Narsimhan RP|Sattler M|Kijima T|Salgia R|Gupta D|Chauhan D|Anderson KC",""}
SET Species = "9606"

biologicalProcess(GO:"cell-matrix adhesion") increases translocation(proteinAbundance(HGNC:PRKCA),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane")
compositeAbundance(proteinAbundance(HGNC:FN1),proteinAbundance(HGNC:VEGFA)) increases translocation(proteinAbundance(HGNC:PRKCA),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane")
biologicalProcess(GO:"cell-matrix adhesion") increases kinaseActivity(proteinAbundance(HGNC:PRKCA))
compositeAbundance(proteinAbundance(HGNC:FN1),proteinAbundance(HGNC:VEGFA)) increases kinaseActivity(proteinAbundance(HGNC:PRKCA))
proteinAbundance(HGNC:VEGFA) increases (proteinAbundance(HGNC:ITGB1) increases biologicalProcess(GO:"cell migration"))
proteinAbundance(HGNC:VEGFA) increases (compositeAbundance(molecularActivity(proteinAbundance(HGNC:ITGB1)),kinaseActivity(proteinAbundance(HGNC:PRKCA))) increases biologicalProcess(GO:"cell-matrix adhesion"))
complexAbundance(proteinAbundance(HGNC:PRKCA),proteinAbundance(HGNC:ITGB1))

SET Evidence = "These data are consistent with PKC alpha-dependent exocytosis of activated beta(1)
integrin to the plasma membrane, where its increased surface expression mediates
binding to fibronectin; conversely, catalytically active PKC alpha-driven internalization
of beta(1) integrin results in MM cell de-adhesion."

kinaseActivity(proteinAbundance(HGNC:PRKCA)) decreases cellSurfaceExpression(proteinAbundance(HGNC:ITGB1))
kinaseActivity(proteinAbundance(HGNC:PRKCA)) increases cellSurfaceExpression(proteinAbundance(HGNC:ITGB1))
cellSurfaceExpression(proteinAbundance(HGNC:ITGB1)) increases biologicalProcess(GO:"cell-matrix adhesion")

SET Evidence = "We show that the regulatory subunit of phosphatidylinositol (PI) 3-kinase (p85) is
constitutively associated with FMS-like tyrosine kinase-1 (Flt-1). VEGF stimulates
activation of PI 3-kinase, and both MM cell adhesion and migration are PI 3-kinase-dependent.
Moreover, both VEGF-induced PI 3-kinase activation and beta(1)
integrin-mediated binding to fibronectin are required for the recruitment and
activation of PKC alpha."

complexAbundance(proteinAbundance(HGNC:FLT1),proteinAbundance(PFH:"PIK3R Class IA Family"))
proteinAbundance(HGNC:VEGFA) increases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases biologicalProcess(GO:"cell-matrix adhesion")
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases biologicalProcess(GO:"cell migration")
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases kinaseActivity(proteinAbundance(HGNC:PRKCA))
biologicalProcess(GO:"cell-matrix adhesion") increases kinaseActivity(proteinAbundance(HGNC:PRKCA))
molecularActivity(proteinAbundance(HGNC:ITGB1)) increases kinaseActivity(proteinAbundance(HGNC:PRKCA))

SET TextLocation = "Results"
SET Evidence = "After VEGF stimulation of cells seeded on fibronectin, PKCα translocated into the
membrane fraction after 30 min (Fig. 2a), whereas no significant changes in distribution
of PKC isoforms as PKCγ, PKCε, and PKCξ were observed."

compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) increases cellSurfaceExpression(proteinAbundance(HGNC:PRKCA))
compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) causesNoChange cellSurfaceExpression(proteinAbundance(HGNC:PRKCG))
compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) causesNoChange cellSurfaceExpression(proteinAbundance(HGNC:PRKCE))
compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) causesNoChange cellSurfaceExpression(proteinAbundance(HGNC:PRKCZ))

SET Evidence = "The activation of PKCα after VEGF treatment of cells attached to fibronectin was further
supported by a 2-fold increase in PKCα-IP kinase activity;"

compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) increases kinaseActivity(proteinAbundance(HGNC:PRKCA))

SET Evidence = "As shown previously, MM cells spontaneously adhered to fibronectin, and this adhesion
was increased upon stimulation with VEGF (Fig.3a)."

proteinAbundance(HGNC:VEGFA) increases biologicalProcess(GO:"cell-matrix adhesion")

SET Evidence = "As shown in Fig. 3,d–e, incubation with the PKC inhibitor BIM I (as well as with the
β1-neutralizing mAb) blocked dose-dependent VEGF-induced cell adhesion to fibronectin.
This involvement of PKC in MM cell adhesion to fibronectin was further
confirmed by a dose-dependent increment of adhesion triggered by PMA stimulation
(Fig. 3d) similar to that induced by VEGF. Taken together, our results show that
VEGF transiently enhances MM cell adhesion to fibronectin, dependent on both
PKC and β1 integrin activity."

abundance(CHEBI:"phorbol 13-acetate 12-myristate") increases biologicalProcess(GO:"cell-matrix adhesion")
proteinAbundance(HGNC:ITGB1) increases (proteinAbundance(HGNC:VEGFA) increases biologicalProcess(GO:"cell-matrix adhesion"))
kinaseActivity(proteinAbundance(HGNC:PRKCA)) increases (proteinAbundance(HGNC:VEGFA) increases biologicalProcess(GO:"cell-matrix adhesion"))

SET Evidence = "These data confirm that β1 integrin (CD29) is the integrin primarily associated with
VEGF-triggered MM cell migration on fibronectin."

proteinAbundance(HGNC:ITGB1) increases biologicalProcess(GO:"cell migration")
proteinAbundance(HGNC:ITGB1) increases (compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) increases biologicalProcess(GO:"cell migration"))

SET TextLocation = "Legend"
SET Evidence = "Figure 4.  VEGFR-1/Flt-1 associates with β1-integrin and CADTK and enhances CADTK-phosphorylation,
dependent on PKC- and β1-integrin activation."

complexAbundance(proteinAbundance(HGNC:FLT1),proteinAbundance(HGNC:ITGB1),proteinAbundance(HGNC:PTK2B))
kinaseActivity(proteinAbundance(HGNC:FLT1)) increases proteinAbundance(HGNC:PTK2B,proteinModification(P))
kinaseActivity(proteinAbundance(PFH:"PRKC Family")) increases proteinAbundance(HGNC:PTK2B,proteinModification(P))
molecularActivity(proteinAbundance(HGNC:ITGB1)) increases proteinAbundance(HGNC:PTK2B,proteinModification(P))

SET Evidence = "(a) Co-immunoprecipitation of CADTK and β1-integrin with PKCα. (b) constitutive association
of Flt-1 and CADTK. (c) activation of CADTK upon treatment with PMA (300nM),
20 min. (d) Additional increase of CADTK-phosphorylation in the presence
of VEGF (100ng/mL). (e) Dependency of VEGF-induced CADTK activation on PKC and
β1-integrin. β1, β1-integrin; pY, phosphotyrosine; C, IP control"

complexAbundance(proteinAbundance(HGNC:FLT1),proteinAbundance(HGNC:PTK2B))
abundance(CHEBI:"phorbol 13-acetate 12-myristate") increases kinaseActivity(proteinAbundance(HGNC:PTK2B))
proteinAbundance(HGNC:VEGFA) increases proteinAbundance(HGNC:PTK2B,proteinModification(P))
proteinAbundance(HGNC:ITGB1) increases (proteinAbundance(HGNC:VEGFA) increases kinaseActivity(proteinAbundance(HGNC:PTK2B)))
kinaseActivity(proteinAbundance(PFH:"PRKC Family")) increases (proteinAbundance(HGNC:VEGFA) increases kinaseActivity(proteinAbundance(HGNC:PTK2B)))
complexAbundance(proteinAbundance(HGNC:PTK2B),proteinAbundance(HGNC:ITGB1),proteinAbundance(PFH:"PRKC Family"))

SET TextLocation = "Results"
SET Evidence = "we have previously shown that CADTK is activated upon dex-treatment,suggesting its
role in dex-induced apoptosis (47)."

abundance(CHEBI:dexamethasone) increases kinaseActivity(proteinAbundance(HGNC:PTK2B))

SET Evidence = "Our results show that VEGF induces the association of CADTK with the β1  integrin/PKCα
protein complex (Fig. 4a)."

proteinAbundance(HGNC:VEGFA) increases complexAbundance(proteinAbundance(HGNC:ITGB1),proteinAbundance(HGNC:PRKCA),proteinAbundance(HGNC:PTK2B))

SET Evidence = "We have shown recently that Flt-1 VEGFR is expressed in the human MM cell line and
patient MM cells and is tyrosine-phosphorylated upon VEGF stimulation (12). Because
Flt-1 and the p85 subunit of PI 3-kinase were associated when overexpressed
in yeast cells (54), we next determined whether this interaction is biologically
significant in MM cells. Flt-1 was immunoprecipitated from VEGF treated and non-treated
MM.1S cells followed by immunoblotting with anti-p85 Ab. As illustrated
in Fig.5a, p85 is constitutively associated with Flt-1, suggesting that PI 3-kinase
participates in Flt-1-mediated VEGF signal transduction."

proteinAbundance(HGNC:VEGFA) increases proteinAbundance(HGNC:FLT1,proteinModification(P,Y))
complexAbundance(proteinAbundance(HGNC:FLT1),proteinAbundance(PFH:"PIK3R Class IA Family"))

SET Evidence = "VEGF induced tyrosine phosphorylation of the regulatory p85 subunit of PI 3-kinase,
evidenced by immunoblotting of anti-p85 immunoprecipitates with an anti-pY mAb
(Fig. 5b). Moreover, immunoblotting of anti-pY immunoprecipitates with specific
p85 mAb showed an increased association of p85 with tyrosine-phosphorylated proteins,
which was maximal after 5 min of VEGF treatment (Fig. 5c). To determine
whether VEGF-induced p85 phosphorylation regulates p110, the catalytic counterpart
of PI 3-kinase, we performed in vitrokinase assays using PI 4,5-bisphosphate
as a substrate. As shown in Fig. 5d, VEGF induced peak activation (6-fold) of PI
3-kinase activity at 5 min."

proteinAbundance(HGNC:VEGFA) increases proteinAbundance(PFH:"PIK3R Class IA Family",proteinModification(P,Y))
proteinAbundance(HGNC:VEGFA) increases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))

SET Evidence = "When PI 3-kinase activation in MM cells seeded on fibronectin was inhibited by LY294002,
PKCα recruitment to the plasma membrane was also abrogated (Fig. 6). These
results indicate that VEGF-induced PI 3-kinase activation along with β1 integrin
binding to fibronectin activate PKCα."

abundance(SCHEM:"LY 294002") decreases translocation(proteinAbundance(HGNC:PRKCA),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane")
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases kinaseActivity(proteinAbundance(HGNC:PRKCA))
complexAbundance(proteinAbundance(HGNC:ITGB1),proteinAbundance(HGNC:FN1)) increases kinaseActivity(proteinAbundance(HGNC:PRKCA))

SET Evidence = "As seen in Fig. 7a, VEGF added to the conditioned medium in the lower chamber induced
a dose-dependent migration of growth-factor-deprived MM.1S cells seeded on
fibronectin in the upper chamber, which was totally inhibited by the PKC inhibitor
BIM I. Pre-incubation with the PI3-kinase inhibitor LY294002 (20μM) at 37°C for
45min prior to VEGF stimulation similarly inhibited MM cell migration."

compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) increases biologicalProcess(GO:"cell migration")
abundance(SCHEM:"LY 294002") decreases (compositeAbundance(proteinAbundance(HGNC:VEGFA),proteinAbundance(HGNC:FN1)) increases biologicalProcess(GO:"cell migration"))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 11"

SET Tissue = "Muscle Fibers, Slow-Twitch"
SET TextLocation = "Abstract"
SET Evidence = "Here, we show that repetitive slow fiber type electrical stimulation, but not fast
fiber type stimulation, caused HDAC4-GFP, but not HDAC5-GFP, to translocate from
the nucleus to the cytoplasm in cultured adult skeletal muscle fibers. HDAC4-GFP
translocation was blocked by calmodulin-dependent protein kinase (CaMK) inhibitor
KN-62."
SET Citation = {"PubMed","The Journal of cell biology","15767461","","Liu Y|Randall WR|Schneider MF",""}
SET Species = "10090"

biologicalProcess(GO:"cellular response to electrical stimulus") increases translocation(proteinAbundance(MGI:Hdac4),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)
biologicalProcess(GO:"cellular response to electrical stimulus") causesNoChange translocation(proteinAbundance(MGI:Hdac5),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)
abundance(SCHEM:"KN 62") directlyDecreases kinaseActivity(proteinAbundance(PFM:"Camk Family"))
abundance(SCHEM:"KN 62") decreases (biologicalProcess(GO:"cellular response to electrical stimulus") increases translocation(proteinAbundance(MGI:Hdac4),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm))

SET CellStructure = "Cell Nucleus"
SET Evidence = "Slow fiber type stimulation increased MEF2 transcriptional activity, nuclear Ca2+
concentration, and nuclear levels of activated CaMKII, but not total nuclear CaMKII
or CaM-YFP. Thus, calcium transients for slow, but not fast, fiber stimulation
patterns appear to provide sufficient Ca2+-dependent activation of nuclear CaMKII
to result in net nuclear efflux of HDAC4."

biologicalProcess(GO:"cellular response to electrical stimulus") increases transcriptionalActivity(proteinAbundance(PFM:"Mef2 Family"))
biologicalProcess(GO:"cellular response to electrical stimulus") increases abundance(CHEBI:"calcium(2+)")
biologicalProcess(GO:"cellular response to electrical stimulus") increases kinaseActivity(proteinAbundance(PFM:"Camk2 Family"))
abundance(CHEBI:"calcium(2+)") directlyIncreases kinaseActivity(proteinAbundance(PFM:"Camk2 Family"))

SET TextLocation = "Results"
SET Evidence = "It is known that CaMK can phosphorylate class II HDACs (Grozinger and Schreiber, 2000;
Wang et al., 2000). Phosphorylated intranuclear HDACs bind to 14-3-3 proteins
(McKinsey et al., 2001), exposing a nuclear export signal at the HDAC COOH terminus
and thus allowing HDAC translocation to the cytoplasm."

kinaseActivity(proteinAbundance(PFM:"Camk2 Family")) directlyIncreases proteinAbundance(PFM:"Hdac Class II Family",proteinModification(P))
proteinAbundance(PFM:"Hdac Class II Family",proteinModification(P)) directlyIncreases complexAbundance(proteinAbundance(PFM:"Hdac Class II Family"),proteinAbundance(PFM:"14-3-3 Family"))
complexAbundance(proteinAbundance(PFM:"Hdac Class II Family"),proteinAbundance(PFM:"14-3-3 Family")) directlyIncreases translocation(proteinAbundance(PFM:"Hdac Class II Family"),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)

SET Evidence = "In the presence of 5 μM KN-62, there was no change in either nuclear or cytoplasmic
fluorescence either at rest or in response to 10-Hz train stimulation (Fig. 2
C; nine nuclei from four fibers). The results in Fig. 2 (A and C) strongly suggest
that electrical stimulation resulted in HDAC4-GFP phosphorylation by CaMK before
translocation."

biologicalProcess(GO:"cellular response to electrical stimulus") increases (kinaseActivity(proteinAbundance(PFM:"Camk Family")) increases proteinAbundance(MGI:Hdac4,proteinModification(P)))

SET Evidence = "1 h of 10-Hz train stimulation significantly increased (P < 0.01) the mean nuclear
stain of activated CaMKII compared with unstimulated fibers, and KN-62 (5 μM)
blocked the increase in activated CaMKII staining after stimulation (Fig. 3 A).
In parallel experiments, in which the fibers were stained with antibody directed
against total CaMKII, there was no difference in mean nuclear antibody stain between
stimulated and unstimulated fibers (P > 0.05; Fig. 3 A). These results are
consistent with activation of nuclear CaMKII by fiber electrical stimulation without
any appreciable translocation of CaMKII from the cytoplasm to the nucleus."

biologicalProcess(GO:"cellular response to electrical stimulus") increases kinaseActivity(proteinAbundance(PFM:"Camk2 Family"))

SET Evidence = "The same stimulation (5 h, followed by 19 h without stimulation) in the presence of
the CaMK inhibitor KN-62 gave the same luciferase activity as control. Thus,
KN-62 completely blocked the stimulation-dependent increase in MEF2 reporter activity,
just as KN-62 completely blocked the stimulation-dependent efflux of HDAC4
from the nucleus (Fig. 2)."

kinaseActivity(proteinAbundance(PFM:"Camk Family")) increases transcriptionalActivity(proteinAbundance(PFM:"Mef2 Family"))
abundance(SCHEM:"KN 62") decreases transcriptionalActivity(proteinAbundance(PFM:"Mef2 Family"))

SET Evidence = "In contrast to the lack of effect of electrical stimulation on the distribution of
CaM, prolonged continuous elevation of Ca2+ concentration by addition of ionomycin
(2 μM) to the bathing solution (presumably elevating both cytosolic and nuclear
Ca2+ concentration) did give rise to a delayed redistribution of CaM from the
cytoplasm to the nucleus,"

abundance(SCHEM:Ionomycin) increases abundance(CHEBI:"calcium(2+)")
abundance(SCHEM:Ionomycin) increases translocation(proteinAbundance(PFM:"Calm Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")

SET Evidence = "Nuclear and cytoplasmic calcium is elevated during electrical stimulation"

biologicalProcess(GO:"cellular response to electrical stimulus") increases abundance(CHEBI:"calcium(2+)")

SET Evidence = "Leptomycin B binds to the nuclear export mediator protein CRM1, thereby blocking the
binding of CRM1 to proteins containing the nuclear export signal (Fukuda et
al., 1997) and preventing their nuclear export. During exposure to leptomycin B
(40 nM), nuclear HDAC4-GFP continuously increased over a 60-min experimental period,
whereas the cytoplasmic fluorescence signal was stable (Fig. 8 A)."

abundance(CHEBIID:52646) directlyDecreases transportActivity(proteinAbundance(MGI:Xpo1))
abundance(CHEBIID:52646) increases translocation(proteinAbundance(MGI:Hdac4),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")

SET Evidence = "Over a 60-min period of treatment with 1 μM calyculin A (a PP1 and PP2A phosphatase
inhibitor that does not affect PP2B; Ishihara et al., 1989), the nuclear HDAC4-GFP
fluorescence decreased linearly with a mean net export rate of -0.71 ± 0.07%/min
(Fig. 9 A, 13 nuclei from 5 fibers)."

abundance(SCHEM:"Calyculin A") directlyDecreases phosphataseActivity(proteinAbundance(PFM:"Ppp1c Family"))
abundance(SCHEM:"Calyculin A") directlyDecreases phosphataseActivity(complexAbundance(NCM:"PP2A Complex"))
abundance(SCHEM:"Calyculin A") increases translocation(proteinAbundance(MGI:Hdac4),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)
abundance(SCHEM:"Calyculin A") causesNoChange phosphataseActivity(proteinAbundance(PFM:"Ppp3 Family"))

SET Evidence = "Interestingly, calyculin A also caused a similar rate of efflux of HDAC5-GFP (-0.62
± 0.05, nine nuclei from six fibers) from nuclei as observed for HDAC4, establishing
the ability of HDAC5 to move out of the nucleus even though it did not translocate
in response to electrical stimulation."

abundance(SCHEM:"Calyculin A") increases translocation(proteinAbundance(MGI:Hdac5),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)
biologicalProcess(GO:"cellular response to electrical stimulus") causesNoChange translocation(proteinAbundance(MGI:Hdac5),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 12"

SET Tissue = "Endothelium"
SET TextLocation = "Abstract"
SET Evidence = "LPS + IFNγ caused an increase in monolayer permeability, induction of iNOS and NADPH
oxidase type 1 (Nox1) proteins, formation of superoxide, nitric oxide and 3-nitrotyrosine,
and increase in PP2A activity in endothelial cells. These effects
of LPS + IFNγ were diminished by tripterine (50-200 nM)."
SET Citation = {"PubMed","British journal of pharmacology","19508391","2009-07-05","Wu F|Han M|Wilson JX",""}
SET Species = "10090"

compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases biologicalProcess(MESHPP:"Capillary Permeability")
compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases proteinAbundance(MGI:Nos2)
compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases proteinAbundance(MGI:Nox1)
compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:superoxide)
compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:"nitric oxide")
compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:"3-nitro-L-tyrosine")
compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases phosphataseActivity(complexAbundance(NCM:"PP2A Complex"))
abundance(SCHEM:Tripterine) decreases (compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases biologicalProcess(MESHPP:"Capillary Permeability"))
abundance(SCHEM:Tripterine) decreases (compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases proteinAbundance(MGI:Nos2))
abundance(SCHEM:Tripterine) decreases (compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases proteinAbundance(MGI:Nox1))
abundance(SCHEM:Tripterine) decreases (compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:superoxide))
abundance(SCHEM:Tripterine) decreases (compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:"nitric oxide"))
abundance(SCHEM:Tripterine) decreases (compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:"3-nitro-L-tyrosine"))
abundance(SCHEM:Tripterine) decreases (compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases phosphataseActivity(complexAbundance(NCM:"PP2A Complex")))

SET Evidence = "Further, LPS + IFNγ -induced expression of iNOS and Nox1 was attenuated by the mitogen-activated
protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor
SP600125, the Jak2 inhibitor AG490 and the NFκB inhibitor MG132, but not
by the p38 mitogen-activated protein kinase inhibitor SB203580. LPS + IFNγ stimulated
phosphorylation of ERK, JNK and Jak2, and degradation of IκB, but only Jak2
phosphorylation was sensitive to tripterine (50-200 nM). Further, tripterine
diminished the increased vascular permeability in inflamed air pouches."

abundance(SCHEM:"PD 98,059") decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nos2))
abundance(SCHEM:"PD 98,059") decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nox1))
abundance(SCHEM:"PD 98,059") directlyDecreases kinaseActivity(proteinAbundance(MGI:Map2k1))
abundance(SCHEM:"PD 98,059") directlyDecreases kinaseActivity(proteinAbundance(MGI:Map2k2))
abundance(SCHEM:SP600125) directlyDecreases kinaseActivity(proteinAbundance(PFM:"Mapk JNK Family"))
abundance(SCHEM:SP600125) decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nos2))
abundance(SCHEM:SP600125) decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nox1))
abundance(SCHEM:"AG-490") directlyDecreases kinaseActivity(proteinAbundance(MGI:Jak2))
abundance(SCHEM:"AG-490") decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nos2))
abundance(SCHEM:"AG-490") decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nox1))
abundance(SCHEM:"Benzyloxycarbonylleucyl-leucyl-leucine aldehyde") decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nos2)) //MG132 = "Benzyloxycarbonylleucyl-leucyl-leucine aldehyde"
abundance(SCHEM:"Benzyloxycarbonylleucyl-leucyl-leucine aldehyde") decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Nox1))
abundance(SCHEM:"SB-203580") directlyDecreases kinaseActivity(proteinAbundance(PFM:"Mapk p38 Family"))
abundance(SCHEM:Tripterine) decreases proteinAbundance(MGI:Jak2,proteinModification(P))
compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(PFM:"MAPK Erk1/3 Family",proteinModification(P))
compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(PFM:"Mapk JNK Family",proteinModification(P))
compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases proteinAbundance(MGI:Jak2,proteinModification(P))
compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases degradation(proteinAbundance(MGI:Nfkbia))
abundance(SCHEM:"Benzyloxycarbonylleucyl-leucyl-leucine aldehyde") decreases transcriptionalActivity(complexAbundance(NCM:"Nfkb Complex"))

SET Evidence = "Our results indicate that, by preventing Jak2-dependent induction of iNOS and Nox1,
tripterine inhibits peroxynitrite precursor synthesis, attenuates the increased
activity of PP2A and consequently protects endothelial barrier function."

abundance(SCHEM:Tripterine) decreases abundance(CHEBI:peroxynitrite)

SET TextLocation = "Results"
SET Evidence = "The increased endothelial permeability induced by LPS + IFNγ was attenuated by the
NADPH oxidase inhibitor apocynin (250 µM; based on Coyle and Kader, 2007), iNOS
inhibitor 1400W (50 µM; based on Hortelano et al., 2000), and tripterine (50 nM
and 200 nM; based on Allison et al., 2001) (Figure 1B). Neither apocynin, 1400W
nor tripterine (50 nM and 200 nM) altered the endothelial permeability in the
absence of a pro-inflammatory stimulus (Figure 1B)."

abundance(CHEBI:apocynin) directlyDecreases catalyticActivity(complexAbundance(NCM:"NADPH Oxidase Complex"))
abundance(CHEBI:apocynin) decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases biologicalProcess(MESHPP:"Capillary Permeability"))
catalyticActivity(proteinAbundance(MGI:Nos2)) increases biologicalProcess(MESHPP:"Capillary Permeability") //No term for 1400W
abundance(SCHEM:Tripterine) decreases (compositeAbundance(proteinAbundance(MGI:Ifng),abundance(SCHEM:Lipopolysaccharide)) increases biologicalProcess(MESHPP:"Capillary Permeability"))

SET Evidence = "However, tripterine at a concentration of 1 µM (based on Allison et al., 2001), either
alone or together with LPS + IFNγ, significantly decreased cell viability,
which may have caused the permeability increase observed for this high dose (Figure
1B,C)."

abundance(SCHEM:Tripterine) increases biologicalProcess(GO:"cell death")

SET Evidence = "LPS + IFNγ induces NO and superoxide production in microvascular endothelial cells
(Wu et al., 2001; 2002; 2008)."

compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:"nitric oxide")
compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases abundance(CHEBI:superoxide)

SET Evidence = "Our previous study identified NADPH oxidase activity as the principal source of superoxide
in LPS + IFNγ-stimulated microvascular endothelial cells (Wu et al., 2007;
2008)."

compositeAbundance(abundance(SCHEM:Lipopolysaccharide),proteinAbundance(MGI:Ifng)) increases catalyticActivity(complexAbundance(NCM:"NADPH Oxidase Complex"))
catalyticActivity(complexAbundance(NCM:"NADPH Oxidase Complex")) directlyIncreases abundance(CHEBI:superoxide)

SET Cell = "Endothelial Cells"
SET Evidence = "Nox1 is a catalytic subunit of NADPH oxidase that is expressed in endothelial cells
(Sorescu et al., 2004; Wu et al., 2008)."

complexAbundance(NCM:"NADPH Oxidase Complex") hasComponent proteinAbundance(MGI:Nox1)

SET Evidence = "Tripterine alone also decreased the basal production of NO in endothelial cells, in
the absence of LPS + IFNγ stimulation (Figure 4D)."

abundance(SCHEM:Tripterine) decreases abundance(CHEBI:"nitric oxide")

SET Evidence = "iNOS-derived NO and NADPH oxidase-derived superoxide react to form peroxynitrite that
can nitrate the tyrosine residues of target proteins, leading to the formation
of 3-nitrotyrosine."

catalyticActivity(proteinAbundance(MGI:Nos2)) directlyIncreases abundance(CHEBI:"nitric oxide")
catalyticActivity(complexAbundance(NCM:"NADPH Oxidase Complex")) directlyIncreases abundance(CHEBI:superoxide)
reaction(reactants(abundance(CHEBI:superoxide),abundance(CHEBI:"nitric oxide")),products(abundance(CHEBI:peroxynitrite)))
abundance(CHEBI:peroxynitrite) increases abundance(CHEBI:"3-nitro-L-tyrosine")

SET Evidence = "Increased production of peroxynitrite is associated with the activation of PP2A; this
causes an increase in the permeability of the endothelial cell monolayer (Wu
and Wilson, 2009)."

abundance(CHEBI:peroxynitrite) increases phosphataseActivity(complexAbundance(NCM:"PP2A Complex"))
phosphataseActivity(complexAbundance(NCM:"PP2A Complex")) increases biologicalProcess(MESHPP:"Capillary Permeability")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 13"

SET Disease = "Carcinoma, Non-Small-Cell Lung"
SET TextLocation = "Abstract"
SET Evidence = "Constitutive Akt/protein kinase B (PKB) activity was demonstrated in 16 of 17 cell
lines by maintenance of S473 phosphorylation with serum deprivation. Additional
analysis of five of 2these NSCLC lines revealed that phosphorylation of S473 and
T308 correlated with in vitro kinase activity."
SET Citation = {"PubMed","Cancer research","11358816","","Brognard J|Clark AS|Ni Y|Dennis PA",""}
SET Species = "9606"

kinaseActivity(proteinAbundance(PFH:"AKT Family")) positiveCorrelation pathology(MESHD:"Carcinoma, Non-Small-Cell Lung")
proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473)) positiveCorrelation pathology(MESHD:"Carcinoma, Non-Small-Cell Lung")
proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473)) positiveCorrelation kinaseActivity(proteinAbundance(PFH:"AKT Family"))
proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308)) positiveCorrelation pathology(MESHD:"Carcinoma, Non-Small-Cell Lung")
proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308)) positiveCorrelation kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET Evidence = "Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival
because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited
Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells
with active Akt/PKB."

kinaseActivity(proteinAbundance(PFH:"AKT Family")) increases biologicalProcess(MESHPP:"Cell Survival")
abundance(SCHEM:"LY 294002") decreases proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))
abundance(CHEBIID:52289) decreases proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))
abundance(SCHEM:"LY 294002") decreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
abundance(CHEBIID:52289) decreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
abundance(CHEBIID:52289) decreases (kinaseActivity(proteinAbundance(PFH:"AKT Family")) decreases biologicalProcess(GO:"apoptotic process"))
abundance(SCHEM:"LY 294002") decreases (kinaseActivity(proteinAbundance(PFH:"AKT Family")) decreases biologicalProcess(GO:"apoptotic process"))

SET TextLocation = "Results"
SET Evidence = "Table 1  shows that under normal growth conditions, 17 of 19 NSCLC cell lines (89%)
exhibit phosphorylation of S473. Phosphorylation of S473 was maintained in 16
of 17 positive cell lines (94%) when cells were deprived of serum."

proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473)) positiveCorrelation pathology(MESHD:"Carcinoma, Non-Small-Cell Lung")

SET Evidence = "In all 10 cell lines tested, IGF-I increased S473 phosphorylation irrespective of
endogenous levels, indicating that NSCLC cell lines phosphorylate Akt/PKB in response
to IGF-I, and that the IGF-IR signaling pathway that leads to Akt/PKB activation
is intact, even in cells that exhibit no Akt/PKB phosphorylation (H1355)."

proteinAbundance(HGNC:IGF1) increases proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))

SET CellLine = "NCI-H1155"
SET Evidence = "Fig. 1A shows that the H1155, H157, and H1703 cells exhibit S473 phosphorylation under
normal growth conditions and serum deprivation, but A549 and H1355 cells show
little S473 phosphorylation in low-serum conditions. Levels of phosphorylated
S473 were greatest in the H1155 cells. Regulation of S473 phosphorylation by serum
withdrawal was only observed with the A549 cells."

proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))

SET CellLine = "NCI-H1703"

proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))

SET CellLine = "A549"

biologicalProcess(GO:"cellular response to starvation") decreases proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))

SET Evidence = "Phosphorylation patterns for T308, the PDK1 site (Fig. 1B), generally correlated with
the S473 pattern; only the H1155, H157, and H1703 cells displayed phosphorylation
of Akt/PKB at T308."

proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473)) positiveCorrelation proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))
kinaseActivity(proteinAbundance(HGNC:PDPK1)) directlyIncreases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))

SET CellLine = "NCI-H1155"

proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))

SET CellLine = "NCI-H1703"

proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))

SET Evidence = "Interestingly, both H1703 and H1155 cells increased T308 phosphorylation when transitioned
from normal growth conditions to serum deprivation, indicating that increased
T308 phosphorylation might be an adaptive response to the stress of serum
deprivation in these cells."

biologicalProcess(GO:"cellular response to starvation") increases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))

SET CellLine = "NCI-H1155"

biologicalProcess(GO:"cellular response to starvation") increases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))

SET Evidence = "In contrast to the low or absent PTEN in cells with phosphorylated Akt/PKB, the cell
lines with the lowest levels of phosphorylated Akt had the highest level of
PTEN protein expression (A549 and H1355). Both A549 and H1355 cells have wild-type
PTEN (Ref. 69  and data not shown, respectively). Taken together, these data
show that Akt/PKB phosphorylation and mutations in PTEN are inversely correlated
in four of five NSCLC cell lines."

proteinAbundance(HGNC:PTEN) negativeCorrelation proteinAbundance(PFH:"AKT Family",proteinModification(P))

SET Evidence = "we tested the ability of two PI3-K inhibitors, LY294002 and wortmannin, to inhibit
Akt/PKB phosphorylation. Fig. 2A shows that both LY294002 and wortmannin completely
inhibited phosphorylation of S473 in the three NSCLC cell lines that maintain
S473 phosphorylation under serum deprivation. Native Akt/PKB levels did not
change. Similar results were obtained for T308 phosphorylation (Fig. 2B)."

abundance(SCHEM:"LY 294002") decreases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))
abundance(SCHEM:"LY 294002") decreases proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))
abundance(CHEBI:wortmannin) decreases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))
abundance(CHEBI:wortmannin) decreases proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))
abundance(CHEBI:wortmannin) directlyDecreases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))
abundance(SCHEM:"LY 294002") directlyDecreases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))

SET Evidence = "These data demonstrate that Akt/PKB phosphorylation in the three positive cell lines
is PI3-K-dependent, making it unlikely that other kinases are directly involved
in activating Akt/PKB."

kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases proteinAbundance(PFH:"AKT Family",proteinModification(P))

SET Evidence = "Fig. 5A shows that in the three cell lines with high Akt/PKB activity, basal levels
of apoptosis were potentiated 6–16-fold by LY294002 (Lanes 1)."

abundance(SCHEM:"LY 294002") increases biologicalProcess(GO:"apoptotic process")

SET Evidence = "we transiently cotransfected NSCLC cell lines with HA-tagged dominant negative Akt/PKB
(K179M Akt/PKB) and GFP and assessed apoptosis in the GFP-positive cells.
Fig. 6 shows that in the cell lines with high Akt/PKB activity, transfection of
K179M Akt/PKB resulted in a 2–5-fold increase in basal apoptosis."

proteinAbundance(PFH:"AKT Family",substitution(K,179,M)) directlyDecreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
proteinAbundance(PFH:"AKT Family",substitution(K,179,M)) increases biologicalProcess(GO:"apoptotic process")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 14"

SET Cell = "Blood Platelets"
SET TextLocation = "Abstract"
SET Evidence = "platelet adhesion is an essential function in response to vascular injury and is generally
viewed as the first step during which single platelets bind through specific
membrane receptors to cellular and extracellular matrix constituents of the
vessel wall and tissues. This response initiates thrombus formation that arrests
hemorrhage and permits wound healing"
SET Citation = {"PubMed","Circulation research","17585075","","Ruggeri ZM|Mendolicchio GL",""}

biologicalProcess(MESHPP:"Platelet Adhesiveness") decreases pathology(SDIS:hemorrhage)
biologicalProcess(MESHPP:"Platelet Adhesiveness") increases biologicalProcess(MESHPP:"Wound Healing")

SET Disease = "Atherosclerosis"
SET TextLocation = "Review"
SET Evidence = "In pathological conditions, platelets are a major contributor to arterial thrombosis,
which typically occurs at sites of atherosclerosis with stenosis of the vessel
lumen, where shear-stress values are considerably higher than in the normal
circulation.11–13"

biologicalProcess(GO:"response to fluid shear stress") increases pathology(MESHD:Thrombosis)

SET Cell = "Leukocytes"
SET Evidence = "Shear stress, in contrast, influences the lifetime of an adhesive bond once formed,
thus the off-rate of the interaction, and the consequence is decreased efficiency
caused by detachment of adherent cells with increasing shear stress. The point
has been well documented for leukocyte adhesion.14"

biologicalProcess(GO:"response to fluid shear stress") decreases biologicalProcess(GO:"leukocyte cell-cell adhesion")

SET Cell = "Blood Platelets"
SET TextLocation = "Legend"
SET Evidence = "The results demonstrate that the adhesive function of GPIbα is as necessary as that
of αIIbβ3 to sustain platelet aggregation at the edge of a growing thrombus"

molecularActivity(proteinAbundance(HGNC:GP1BA)) increases biologicalProcess(GO:"platelet aggregation")
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3))) increases biologicalProcess(GO:"platelet aggregation")

SET TextLocation = "Review"
SET Evidence = "Among the substrates required for normal thrombus formation, VWF is unique for its
role in initiating platelet adhesion and sustaining platelet aggregation under
conditions of elevated shear stress.16,18"

proteinAbundance(HGNC:VWF) increases biologicalProcess(GO:"platelet aggregation")
proteinAbundance(HGNC:VWF) increases biologicalProcess(MESHPP:"Platelet Adhesiveness")

SET Evidence = "Platelets have 2 main binding sites for VWF,57,58 GPIbα in the GPIβ-IX-V complex26
and the integrin αIIbβ3.59"

complexAbundance(proteinAbundance(HGNC:VWF),proteinAbundance(HGNC:GP1BA))
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:VWF))

SET Evidence = "The integrin αIIbβ3, on the other hand, binds several ligands, in addition to VWF,
that are key to the process of platelet adhesion and aggregation, primarily fibrinogen,64
fibronectin, 65 and CD40 ligand.66"

complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:VWF)) increases biologicalProcess(MESHPP:"Platelet Adhesiveness")
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:VWF)) increases biologicalProcess(GO:"platelet aggregation")
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),abundance(SCHEM:Fibrinogen)) increases biologicalProcess(MESHPP:"Platelet Adhesiveness")
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),abundance(SCHEM:Fibrinogen)) increases biologicalProcess(GO:"platelet aggregation")
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:FN1)) increases biologicalProcess(MESHPP:"Platelet Adhesiveness")
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:FN1)) increases biologicalProcess(GO:"platelet aggregation")
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:CD40LG)) increases biologicalProcess(MESHPP:"Platelet Adhesiveness")
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:CD40LG)) increases biologicalProcess(GO:"platelet aggregation")

SET Evidence = "ADAMTS-13 can cleave circulating VWF multimers while they mediate activationindependent
interplatelet cohesion under high shear stress, thus dispersing the aggregates.73"

peptidaseActivity(proteinAbundance(HGNC:ADAMTS13)) increases degradation(proteinAbundance(HGNC:VWF))

SET Evidence = "In contrast, blocking the other receptor, GPVI, impairs thrombus formation on all
types of collagen fibers.77,78"

molecularActivity(proteinAbundance(HGNC:GP6)) increases pathology(MESHD:Thrombosis)

SET Evidence = "The expression of alpha2beta1 on normal platelets varies by as much as 1 order of
magnitude,92 and may positively correlate to the rapidity of the initial phase
of platelet adhesion to collagen"

cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1))) positiveCorrelation biologicalProcess(GO:"regulation of collagen binding")

SET Evidence = "In the latter study, with blood perfused over fibrillar collagen type I at shear rates
between 400 and 1300 sec-1, the isolated deficiency of α2β1 or GPVI-Fc receptor
-chain (FcR-g) complex caused an equivalent partial defect of platelet thrombus
formation, whereas the combined deficiency caused complete inhibition.97"
SET Species = "10090"

complexAbundance(proteinAbundance(MGI:Itga2),proteinAbundance(MGI:Itgb1)) increases pathology(MESHD:Thrombosis)
complexAbundance(proteinAbundance(MGI:Gp6),complexAbundance(NCM:"FcR Gamma Chain Complex")) increases pathology(MESHD:Thrombosis)

SET Evidence = "Fibronectin is an essential adhesive substrate in many fundamental biological processes.24
Platelets possess 2 main receptors for this protein, α5β1 and αIIbβ3,114
the latter of which requires activation to function.65"

complexAbundance(proteinAbundance(HGNC:ITGA5),proteinAbundance(HGNC:ITGB1),proteinAbundance(HGNC:FN1))
complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3),proteinAbundance(HGNC:FN1))
proteinAbundance(HGNC:FN1) directlyIncreases molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA5),proteinAbundance(HGNC:ITGB1)))
proteinAbundance(HGNC:FN1) directlyIncreases molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3)))

SET Evidence = "α5β1 supports platelet adhesion to endothelial extracellular matrix"

complexAbundance(proteinAbundance(HGNC:ITGA5),proteinAbundance(HGNC:ITGB1)) increases biologicalProcess(MESHPP:"Platelet Adhesiveness")

SET CellStructure = "Cell Membrane"
SET Evidence = "thrombospondin-1 binds to the platelet membrane and mediates adhesion"

proteinAbundance(HGNC:THBS1) increases biologicalProcess(MESHPP:"Platelet Adhesiveness")

SET Disease = "Plaque, Atherosclerotic"
SET Evidence = "The significance of thrombospondin-1 in platelet thrombus formation is still unclear,
although it is intriguing to note that this glycoprotein is abundant in atherosclerotic
plaques"

proteinAbundance(HGNC:THBS1) positiveCorrelation pathology(MESHD:"Plaque, Atherosclerotic")

SET Evidence = "These findings delineate a synergistic role for α5β1 and GPVI as laminin receptors,
coupled to distinct activation pathways convergent on the function of the Syk
tyrosine kinase"

complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB1)) increases kinaseActivity(proteinAbundance(HGNC:SYK))
proteinAbundance(HGNC:GP6) increases kinaseActivity(proteinAbundance(HGNC:SYK))

SET CardiovascularSystem = "Blood Vessels"
SET Evidence = "The main substrate capable of binding VWF is collagen,36 particularly types I and
III in deeper layers of the vessel wall and microfibrillar collagen type VI in
the subendothelial matrix,30,37–39 with heparin, sulfatides, and fibrin providing
additional interaction sites (see the online data supplement)."

complexAbundance(proteinAbundance(HGNC:VWF),proteinAbundance(PFH:"COL1 Family"))

SET Evidence = "The platelet membrane is endowed with several collagen receptors, including the integrin
α2β1,79–81 GPVI,82,83 GPIV (CD-36),84–86 and the 65-kDa protein (p65) reportedly
specific specific for type I collagen.87"

complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1),proteinAbundance(PFH:"COL1 Family"))
complexAbundance(proteinAbundance(HGNC:GP6),proteinAbundance(PFH:"COL1 Family"))
complexAbundance(proteinAbundance(HGNC:CD36),proteinAbundance(PFH:"COL1 Family"))
proteinAbundance(PFH:"COL1 Family") directlyIncreases molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1)))
proteinAbundance(PFH:"COL1 Family") directlyIncreases molecularActivity(proteinAbundance(HGNC:GP6))
proteinAbundance(PFH:"COL1 Family") directlyIncreases molecularActivity(proteinAbundance(HGNC:CD36))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 15"

SET Cell = {"Cells, Cultured","Endothelial Cells"}
SET CardiovascularSystem = "Umbilical Veins"
SET TextLocation = "Abstract"
SET Evidence = "In human umbilical vein endothelial cells (HUVECs), cigarette smoke extracts (CSE)
inhibited VEGF induced tube formation in the matrigel assay. CSE did not affect
HUVECs proliferation, but significantly reduced cellular migration in response
to VEGF."
SET Citation = {"PubMed","Journal of molecular and cellular cardiology","16806264","2006-07-27","Michaud SE|Dussault S|Groleau J|Haddad P|Rivard A",""}

abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell migration"))
abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"blood vessel endothelial cell migration"))
abundance(SCHEM:"Smoke extract, cigarette") causesNoChange (proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell proliferation"))
abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"epithelial tube formation"))
abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell migration"))

SET TextLocation = "Results"

abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases catalyticActivity(proteinAbundance(HGNC:NOS3)))

SET Evidence = "We studied the effect of CSE exposure on tube formation in vitro. As determined using
the Matrigel assay, VEGF significantly increased capillary-like tube formation
in HUVECs. However, the induction of tube formation by VEGF was almost completely
abolished when HUVECs were exposed to 10% CSE (Fig. 1 and Table 1)."

abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"blood vessel endothelial cell migration"))

SET Evidence = "As expected, VEGF treatment significantly induced both migration and proliferation
in HUVECs (Figs. 2A–B and Table 1). Interestingly, CSE exposure was associated
with a selective inhibition of VEGF-induced HUVEC migration, whereas cellular proliferation
was not significantly affected (Figs. 2A– B and Table 1)."

proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell migration")
proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell proliferation")
abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell migration"))

SET Evidence = "Surface integrins have been shown to be critical regulators of endothelial cell migration
in response to VEGF and NO. Here we found that VEGF-stimulated HUVECs exposed
to CSE had a significant reduction in the expression of several surface integrins
including αvβ3, αvβ5, α5β1 and α2β1 (Fig. 2C). Moreover, the adhesion of
VEGF-stimulated HUVECs was significantly reduced following exposure to 10% CSE,
suggesting an impairment of integrin activity/function (Fig. 2D)."

abundance(SCHEM:"Smoke extract, cigarette") decreases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)))
abundance(SCHEM:"Smoke extract, cigarette") decreases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB5)))
abundance(SCHEM:"Smoke extract, cigarette") decreases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGA5),proteinAbundance(HGNC:ITGB1)))
abundance(SCHEM:"Smoke extract, cigarette") decreases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1)))
abundance(SCHEM:"Smoke extract, cigarette") decreases biologicalProcess(GO:"cell adhesion")

SET Evidence = "CSE show an important increase of intracellular ROS, as assessed by 2',7'-dichlorofluorescin
diacetate (DCFH-DA) (Fig. 3). Importantly, antioxidants such as NAC
and vitamin C can significantly reduce the generation of ROS in HUVECs exposed to
CSE (Fig. 3)."

abundance(SCHEM:"Smoke extract, cigarette") increases abundance(CHEBI:"reactive oxygen species")
abundance(CHEBI:"vitamin C") decreases (abundance(SCHEM:"Smoke extract, cigarette") increases abundance(CHEBI:"reactive oxygen species"))
abundance(CHEBI:"N-acetyl-L-cysteine") decreases (abundance(SCHEM:"Smoke extract, cigarette") increases abundance(CHEBI:"reactive oxygen species"))

SET CellLine = "HUV-EC-C"
SET Evidence = "Because NO is an essential mediator of endothelial cell migration and VEGF-induced
angiogenesis, we investigated the effect of CSE exposure on VEGF-dependent Akt/eNOS/NO
pathway. VEGF-stimulated HUVECs exposed to CSE show a dose-dependent inhibition
of phosphorylated Akt and eNOS (Fig. 4A). Importantly, the activation of
Akt and eNOS by VEGF can be rescued following treatment with the antioxidants
NAC and vitamin C (Fig. 4B). Similarly, we found that the induction of NO by VEGF
in endothelial cell cultures was severely compromised in the presence of CSE,
but that NO levels could be normalized with antioxidants (Fig. 4C). Globally, these
data suggest that ROS are involved in the impairment of VEGF-induced Akt/eNOS/NO
pathway by CSE."

abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases kinaseActivity(proteinAbundance(PFH:"AKT Family")))
abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases catalyticActivity(proteinAbundance(HGNC:NOS3)))

SET Evidence = "Similarly, we found that the induction of NO by VEGF in endothelial cell cultures
was severely compromised in the presence of CSE, but that NO levels could be normalized
with antioxidants (Fig. 4C). Globally, these data suggest that ROS are
involved in the impairment of VEGF-induced Akt/eNOS/NO pathway by CSE."

abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases abundance(CHEBI:"nitric oxide"))
abundance(CHEBI:"reactive oxygen species") decreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
abundance(SCHEM:"Smoke extract, cigarette") decreases catalyticActivity(proteinAbundance(HGNC:NOS3))

SET Evidence = "Because NO is an essential mediator of endothelial cell migration and VEGF-induced
angiogenesis, we investigated the effect of CSE exposure on VEGF-dependent Akt/eNOS/NO
pathway. VEGF-stimulated HUVECs exposed to CSE show a dose-dependent inhibition
of phosphorylated Akt and eNOS (Fig. 4A). Importantly, the activation of
Akt and eNOS by VEGF can be rescued following treatment with the antioxidants
NAC and vitamin C (Fig. 4B)."

abundance(CHEBI:"nitric oxide") increases biologicalProcess(GO:"cell migration")
proteinAbundance(PFH:"VEGF Family") increases abundance(CHEBI:"nitric oxide")
abundance(CHEBI:"nitric oxide") increases biologicalProcess(GO:angiogenesis)
abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases kinaseActivity(proteinAbundance(PFH:"AKT Family")))
abundance(SCHEM:"Smoke extract, cigarette") decreases (proteinAbundance(PFH:"VEGF Family") increases catalyticActivity(proteinAbundance(HGNC:NOS3)))

SET Evidence = "These data suggest that CSE prevents VEGF-induced endothelial cell migration and tube
formation by increasing oxidative stress. The importance of NO in that physiopathology
was demonstrated by showing that NO donors (SNAP 75 μM, SNP 0.1 mM)
or a cGMP analog (8-Br-cGMP 2 mM) rescued integrin expression (Fig. 5A), cellular
migration (Fig. 5B) and tube formation (Fig. 5C) in endothelial cells exposed
to CSE."

abundance(CHEBI:"nitric oxide") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)))
abundance(CHEBI:"nitric oxide") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB5)))
abundance(CHEBI:"nitric oxide") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGA5),proteinAbundance(HGNC:ITGB1)))
abundance(CHEBI:"nitric oxide") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1)))
abundance(CHEBI:"3',5'-cyclic GMP") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)))
abundance(CHEBI:"3',5'-cyclic GMP") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB5)))
abundance(CHEBI:"3',5'-cyclic GMP") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGA5),proteinAbundance(HGNC:ITGB1)))
abundance(CHEBI:"3',5'-cyclic GMP") increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1)))
abundance(CHEBI:"nitric oxide") increases biologicalProcess(GO:"cell migration")
abundance(CHEBI:"nitric oxide") increases biologicalProcess(GO:"blood vessel endothelial cell migration")
abundance(CHEBI:"3',5'-cyclic GMP") increases biologicalProcess(GO:"cell migration") //Making the inference here that 8-Br-cGMP acts as cGMP. c-Br-cGMP is extensively characterized and a very specific cGMP mimetic.
abundance(CHEBI:"3',5'-cyclic GMP") increases biologicalProcess(GO:"blood vessel endothelial cell migration")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 16"

SET TextLocation = "Abstract"
SET Evidence = "Here we examine the nature of the physical interaction between the αvβ3 integrin and
two receptor tyrosine kinases (RTKs), the platelet-derived growth factor receptor
β (PDGF-Rβ) and the vascular endothelial growth factor receptor 2 (VEGF-R2,
also known as KDR and flk-1). Both of these RTKs associate with the αvβ3 integrin
but do not associate with β1 integrins. Furthermore, growth factor stimulation
of these RTKs promotes increased cell proliferation and migration when cells
are attached to the αvβ3 ligand, vitronectin."
SET Citation = {"PubMed","The Journal of biological chemistry","10964931","","Borges E|Jan Y|Ruoslahti E",""}
SET Species = "9606"

proteinAbundance(HGNC:VTN) directlyIncreases molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)))
complexAbundance(proteinAbundance(HGNC:PDGFRB),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))
complexAbundance(proteinAbundance(HGNC:KDR),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))
complexAbundance(proteinAbundance(HGNC:VTN),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)) increases (kinaseActivity(proteinAbundance(HGNC:PDGFRB)) increases biologicalProcess(GO:"cell proliferation"))
complexAbundance(proteinAbundance(HGNC:VTN),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)) increases (kinaseActivity(proteinAbundance(HGNC:PDGFRB)) increases biologicalProcess(GO:"cell migration"))
complexAbundance(proteinAbundance(HGNC:VTN),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)) increases (kinaseActivity(proteinAbundance(HGNC:KDR)) increases biologicalProcess(GO:"cell proliferation"))
complexAbundance(proteinAbundance(HGNC:VTN),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3)) increases (kinaseActivity(proteinAbundance(HGNC:KDR)) increases biologicalProcess(GO:"cell migration"))

SET TextLocation = "Review"
SET Evidence = "Previous studies have shown that PDGF-Rβ (9,10) and VEGF-R2 (12) associate with the
αvβ3 integrin but not with β1 integrins. The association was detected after cells
were stimulated with the respective growth factor."

proteinAbundance(PFH:"PDGF Family") directlyIncreases complexAbundance(proteinAbundance(HGNC:PDGFRB),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))
proteinAbundance(PFH:"VEGF Family") directlyIncreases complexAbundance(proteinAbundance(HGNC:KDR),proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))

SET Evidence = "To study the role of αv in the formation of the RTK-integrin complex, we transfected
PDGF-Rβ into CHO cells that overexpress the platelet integrin αIIbβ3. As shown
in Fig. 5A, equal amounts of PDGF-Rb were coprecipitated with both anti-αIIb
and anti-β3 antibodies."

complexAbundance(proteinAbundance(HGNC:PDGFRB),proteinAbundance(HGNC:ITGA2B),proteinAbundance(HGNC:ITGB3))

SET Evidence = "We have previously shown that the attachment of cells to a substrate through the αvβ3
integrin enhances the ability of insulin and PDGF to stimulate cell proliferation
and migration (9,11)."

molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))) increases (proteinAbundance(PFH:"PDGF Family") increases biologicalProcess(GO:"cell proliferation"))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))) increases (proteinAbundance(HGNC:INS) increases biologicalProcess(GO:"cell proliferation"))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))) increases (proteinAbundance(PFH:"PDGF Family") increases biologicalProcess(GO:"cell migration"))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGAV),proteinAbundance(HGNC:ITGB3))) increases (proteinAbundance(HGNC:INS) increases biologicalProcess(GO:"cell migration"))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 17"

SET Cell = "Keratinocytes"
SET TextLocation = "Abstract"
SET Evidence = "Ligation of α6β4  in primary human keratinocytes caused tyrosine phosphorylation of
Shc, recruitment of Grb2, activation of Ras and stimulation of the MAP kinases
Erk and Jnk."
SET Citation = {"PubMed","The EMBO journal","9171350","","Mainiero F|Murgia C|Wary KK|Curatola AM|Pepe A|Blumemberg M|Westwick JK|Der CJ|Giancotti FG",""}
SET Species = "9606"

molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases proteinAbundance(HGNC:SHC1,proteinModification(P,Y))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases complexAbundance(proteinAbundance(HGNC:SHC1),proteinAbundance(HGNC:GRB2))
complexAbundance(proteinAbundance(HGNC:SHC1),proteinAbundance(HGNC:GRB2)) increases gtpBoundActivity(proteinAbundance(PFH:"RAS Family"))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family"))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases gtpBoundActivity(proteinAbundance(PFH:"RAS Family"))

SET Evidence = "Ligation of α6β4 in primary human keratinocytes caused tyrosine phosphorylation of
Shc, recruitment of Grb2, activation of Ras and stimulation of the MAP kinases
Erk and Jnk. In contrast, ligation of the laminin- and collagen-binding integrins
α3β1  and α2β1  did not cause these events."

molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA3),proteinAbundance(HGNC:ITGB1))) causesNoChange complexAbundance(proteinAbundance(HGNC:SHC1),proteinAbundance(HGNC:GRB2))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1))) causesNoChange complexAbundance(proteinAbundance(HGNC:SHC1),proteinAbundance(HGNC:GRB2))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA3),proteinAbundance(HGNC:ITGB1))) causesNoChange proteinAbundance(HGNC:SHC1,proteinModification(P,Y))
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1))) increases proteinAbundance(HGNC:SHC1,proteinModification(P,Y))

SET CellLine = "HeLa"
SET Evidence = "While the stimulation of Erk by α6β4 was suppressed by dominant-negative Shc, Ras
and RhoA, the activation of Jnk was inhibited by dominant-negative Ras and Rac1
and by the phosphoinositide 3-kinase inhibitor Wortmannin."

molecularActivity(proteinAbundance(HGNC:SHC1)) increases (molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases (molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")))
gtpBoundActivity(proteinAbundance(HGNC:RHOA)) increases (molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")))
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases (molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")))
gtpBoundActivity(proteinAbundance(HGNC:RAC1)) increases (molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")))
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases (molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")))
abundance(SCHEM:Wortmannin) directlyDecreases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))

SET Evidence = "Adhesion mediated by α6β4 induced transcription from the Fos serum response element
and promoted cell cycle progression in response to mitogens."

molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases biologicalProcess(GO:"cell-matrix adhesion")
molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA6),proteinAbundance(HGNC:ITGB4))) increases rnaAbundance(HGNC:FOS)

SET Cell = "Cells, Cultured"
SET TextLocation = {"Results","Results"}
SET UrogenitalSystem = "Urinary Bladder"
SET Evidence = "These results are consistent with the hypothesis that the recruitment of Shc to activated
α6β4 is mediated by tyrosine phosphorylation of the cytoplasmic domain
of β4."
SET Species = "10116"

proteinAbundance(RGD:Itgb4,proteinModification(P,Y)) directlyIncreases complexAbundance(proteinAbundance(RGD:Itga6),proteinAbundance(RGD:Itgb4),proteinAbundance(RGD:Shc1))

SET TextLocation = "Results"
SET Evidence = "This suggests that ligation of α6β4, but not α2β1, is sufficient to promote transcription
from the Fos SRE in the absence of mitogens."
SET Species = "9606"

molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGA2),proteinAbundance(HGNC:ITGB1))) causesNoChange rnaAbundance(HGNC:FOS)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 18"

SET TextLocation = "Review"
SET Evidence = "secreted proteins such as Norrin and R-Spondin were shown to be activators of the
canonical Wnt pathway owing to their interaction with Frizzled–LRP receptors79,80"
SET Citation = {"PubMed","Nature reviews. Cancer","18432252","","Klaus A|Birchmeier W",""}

proteinAbundance(HGNC:NDP) increases biologicalProcess(GO:"Wnt receptor signaling pathway")
proteinAbundance(HGNC:RSPO1) increases biologicalProcess(GO:"Wnt receptor signaling pathway")

SET TextLocation = "Results"
SET Evidence = "Following phosphorylation, β-catenin is targeted for proteasome-dependent degradation
involving interaction with β-TrCP (β-transducin repeat-containing protein),
a component of the E3 ubiquitin ligase complex89–92"

proteinAbundance(HGNC:CTNNB1,proteinModification(P)) directlyIncreases degradation(proteinAbundance(HGNC:CTNNB1))
proteinAbundance(HGNC:CTNNB1,proteinModification(P)) directlyIncreases complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:BTRC))
complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:BTRC)) directlyIncreases degradation(proteinAbundance(HGNC:CTNNB1))

SET Disease = "Fibrosis"
SET RespiratorySystem = "Lung"
SET Evidence = "Moreover, uncontrolled Wnt-β-catenin signalling that is associated with elevated β-catenin
levels is also linked to aggressive fibromatosis and pulmonary fibrosis140,141"

proteinAbundance(HGNC:CTNNB1) positiveCorrelation pathology(MESHD:"Pulmonary Fibrosis")

SET Cell = "Stem Cells"
SET TextLocation = "Review"
SET BodyRegion = "Breast"
SET Evidence = "It was shown that the frequency of CD29+CD24+ stem cells in the mammary gland increases
by a factor of 6.4 following activation of WNT1 (REF. 201)."

molecularActivity(proteinAbundance(HGNC:WNT1)) increases biologicalProcess(GO:"stem cell development")
molecularActivity(proteinAbundance(HGNC:WNT1)) increases cellSurfaceExpression(proteinAbundance(HGNC:ITGB1))
molecularActivity(proteinAbundance(HGNC:WNT1)) increases cellSurfaceExpression(proteinAbundance(HGNC:CD24))

SET Disease = "Neoplasms"
SET Evidence = "In recent years, other mechanisms of activation of the canonical Wnt pathway in tumours
have been discovered; for example, silencing of the genes that encode the
inhibitory Wnt ligands SFRPs and DKKs by hypermethylation, or by overexpression
of Wnt proteins (WNT2B for example), Frizzleds (FZD10 for example) or Dishevelled142-149"

proteinAbundance(HGNC:WNT2B) increases biologicalProcess(GO:"Wnt receptor signaling pathway")
proteinAbundance(HGNC:FZD10) increases biologicalProcess(GO:"Wnt receptor signaling pathway")
proteinAbundance(PFH:"DVL Family") increases biologicalProcess(GO:"Wnt receptor signaling pathway")

SET HemicAndImmuneSystem = "Hematopoietic Stem Cells"
SET Evidence = "Wnt-β-catenin signalling has been proposed to increase haematopoietic stem cell renewal58,185-187"

molecularActivity(proteinAbundance(PFH:"WNT Family")) increases biologicalProcess(GO:"stem cell division")
transcriptionalActivity(proteinAbundance(HGNC:CTNNB1)) increases biologicalProcess(GO:"stem cell division")

SET BodyRegion = "Head"
SET Evidence = "DKK1 antagonizes Wnt signalling during head formation in mice77. An additional DKK-receptor,
Kremen, was shown to inhibit the Wnt signalling pathway by internalization
of LRP"
SET Species = "10090"

proteinAbundance(MGI:Dkk1) decreases biologicalProcess(GO:"Wnt receptor signaling pathway")
complexAbundance(proteinAbundance(MGI:Kremen1),proteinAbundance(MGI:Dkk1))
proteinAbundance(MGI:Kremen1) decreases biologicalProcess(GO:"Wnt receptor signaling pathway")

SET DigestiveSystem = "Colon"
SET Evidence = "axin1 and axin2 loss-of-function mutations have also been detected in rare cases of
colorectal cancer124,125."
SET Species = "9606"

proteinAbundance(HGNC:AXIN1) negativeCorrelation pathology(MESHD:Neoplasms)
proteinAbundance(HGNC:AXIN2) negativeCorrelation pathology(MESHD:Neoplasms)

SET Evidence = "loss of Indian hedgehog, also contribute to the progression of colorectal cancer157"

proteinAbundance(HGNC:IHH) negativeCorrelation pathology(MESHD:Neoplasms)

SET Evidence = "In the presence of canonical Wnt ligands (FIG. 1b), LRP5-LRP6 is phosphorylated by
CK1γ and GSK3β96,97 (and possibly other protein kinases yet to be identified),
and Dishevelled is recruited to the plasma membrane, where it interacts with Frizzled
receptors and polymerizes with other Dishevelled molecules98,99."

proteinAbundance(PFH:"WNT Family") increases (kinaseActivity(proteinAbundance(HGNC:CSNK1G2)) directlyIncreases proteinAbundance(HGNC:LRP5,proteinModification(P)))
proteinAbundance(PFH:"WNT Family") increases (kinaseActivity(proteinAbundance(HGNC:GSK3B)) directlyIncreases proteinAbundance(HGNC:LRP5,proteinModification(P)))
proteinAbundance(PFH:"WNT Family") increases (kinaseActivity(proteinAbundance(HGNC:CSNK1G2)) directlyIncreases proteinAbundance(HGNC:LRP6,proteinModification(P)))
proteinAbundance(PFH:"WNT Family") increases (kinaseActivity(proteinAbundance(HGNC:GSK3B)) directlyIncreases proteinAbundance(HGNC:LRP6,proteinModification(P)))
proteinAbundance(HGNC:LRP6,proteinModification(P)) increases translocation(proteinAbundance(PFH:"DVL Family"),MESHCL:Cytoplasm,MESHCL:"Cell Membrane")

SET CellStructure = "Cell Membrane"

translocation(proteinAbundance(PFH:"DVL Family"),MESHCL:Cytoplasm,MESHCL:"Cell Membrane") increases complexAbundance(proteinAbundance(PFH:"DVL Family"),proteinAbundance(PFH:"FZD Family"))
translocation(proteinAbundance(PFH:"DVL Family"),MESHCL:Cytoplasm,MESHCL:"Cell Membrane") increases complexAbundance(proteinAbundance(PFH:"DVL Family"),proteinAbundance(PFH:"DVL Family"))

SET Evidence = "Surplus β-catenin then translocates to the nucleus, interacts with the LEF and TCF
transcription factors, and persistently transactivates genes associated with the
regulation of cell proliferation, such as MYC and cyclin D1 (Refs 30,32,106,135-137)."

translocation(proteinAbundance(HGNC:CTNNB1),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus") increases complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:LEF1))
complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:LEF1)) directlyIncreases transcriptionalActivity(proteinAbundance(HGNC:CTNNB1))
transcriptionalActivity(proteinAbundance(HGNC:CTNNB1)) directlyIncreases rnaAbundance(HGNC:CCND1)
transcriptionalActivity(proteinAbundance(HGNC:CTNNB1)) directlyIncreases rnaAbundance(HGNC:MYC)

SET Evidence = "N-terminal phosphorylation of β-catenin by the kinases CK1α (casein kinase 1α) and
GSK3β (glycogen synthase kinase 3β), and subsequent ubiquitylation by β-TrCP (β
-transducin repeat-containing protein, an E3 ubiquitin ligase), β -catenin is
proteasomally degraded"

kinaseActivity(proteinAbundance(HGNC:CSNK1A1)) directlyIncreases proteinAbundance(HGNC:CTNNB1,proteinModification(P))

SET TextLocation = {"Review","Review"}
SET Evidence = "In the nucleus, β-catenin forms a transcriptionally active complex with LEF and TCF
transcription factors30–32 by displacing Grouchos and interacting with other
co-activators such as BCL9, Pygopus, CBP (CREB-binding protein) or Hyrax47–51,101–105
(TIMELINE)."

complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:LEF1))
complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:BCL9))
complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:CREBBP))
translocation(proteinAbundance(HGNC:CTNNB1),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus") increases complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:BCL9))
translocation(proteinAbundance(HGNC:CTNNB1),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus") increases complexAbundance(proteinAbundance(HGNC:CTNNB1),proteinAbundance(HGNC:CREBBP))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 19"

SET TextLocation = "Abstract"
SET Evidence = "Here, we show that Wnt/β-catenin signaling regulates proximal-distal differentiation
of airway epithelium. Inhibition of Wnt/β-catenin signaling, either by expression
of Dkk1 or by tissue-specific deletion of β-catenin, results in disruption
of distal airway development and expansion of proximal airways."
SET Citation = {"PubMed","Developmental biology","15907834","","Shu W|Guttentag S|Wang Z|Andl T|Ballard P|Lu MM|Piccolo S|Birchmeier W|Whitsett JA|Millar SE|Morrisey EE",""}
SET Species = "10090"

proteinAbundance(PFM:"Wnt Family") increases biologicalProcess(GO:"lung pattern specification process")
proteinAbundance(MGI:Ctnnb1) increases biologicalProcess(GO:"lung pattern specification process")

SET Evidence = "Moreover, we show that β-catenin and LEF/TCF activate the promoters of BMP4 and N-myc."

transcriptionalActivity(proteinAbundance(MGI:Ctnnb1)) directlyIncreases rnaAbundance(MGI:Bmp4)
transcriptionalActivity(proteinAbundance(PFM:"Tcf/Lef Family")) directlyIncreases rnaAbundance(MGI:Bmp4)
transcriptionalActivity(proteinAbundance(MGI:Ctnnb1)) directlyIncreases rnaAbundance(MGI:Mycn)
transcriptionalActivity(proteinAbundance(PFM:"Tcf/Lef Family")) directlyIncreases rnaAbundance(MGI:Mycn)

SET RespiratorySystem = "Lung"
SET TextLocation = "Results"
SET Evidence = "This pattern of activity and expression overlaps extensively with that of Wnt7b, which
is known to play a key role in lung epithelial differentiation (Shu et al.,
2002)."

proteinAbundance(MGI:Wnt7b) increases biologicalProcess(GO:"lung epithelium development")

SET Evidence = "These data suggest that, along with airway epithelium, the proximal– distal expression
of smooth muscle in lung mesoderm is disrupted in SP-C/rtTA X tetO-Dkk1 double
transgenic embryos and that Wnt signaling lies upstream of signals regulating
proximal–distal patterning of both endodermal (airway epithelium) and mesodermal
(airway smooth muscle) cell lineages."

proteinAbundance(MGI:Dkk1) decreases biologicalProcess(GO:"lung epithelium development")
proteinAbundance(MGI:Dkk1) decreases biologicalProcess(GO:"lung smooth muscle development")
proteinAbundance(PFM:"Wnt Family") increases biologicalProcess(GO:"lung smooth muscle development")
proteinAbundance(PFM:"Wnt Family") increases biologicalProcess(GO:"lung epithelium development")

SET Evidence = "Wnt signaling has been directly associated with cell proliferation in a multitude
of tissues and cell types including colon epithelium and in stem cell self renewal
(Pinto et al., 2003; Reya et al., 2003; van de Wetering et al., 2002)."

proteinAbundance(PFM:"Wnt Family") increases biologicalProcess(GO:"cell proliferation")

SET Evidence = "Loss of N-myc function has been shown to result in defective branching morphogenesis
in the lung (Moens et al., 1993; Okubo et al., 2005; Sawai et al., 1993; Stanton
et al., 1992). Furthermore, N-myc has been recently implicated in the regulation
of distal airway progenitor development (Okubo et al., 2005). c-myc, a highly
related myc gene, is a well-established down-stream target of Wnt/β-catenin
signaling in several tissues including intestinal epithelium (Anna et al., 2003;
Cong et al., 2003; Pinto et al., 2003)."

proteinAbundance(MGI:Mycn) increases biologicalProcess(GO:"lung proximal/distal axis specification")
proteinAbundance(PFM:"Wnt Family") increases rnaAbundance(MGI:Myc)
transcriptionalActivity(proteinAbundance(MGI:Ctnnb1)) increases rnaAbundance(MGI:Myc)

SET Evidence = "As expected, N-myc is expressed at high levels in distal airway epithelium in wild-type
lung tissue at E12.5 and E16.5 (Figs. 5A and C). However, N-myc expression
in E12.5 SP-C/rtTA:tetO-cre X β-cateninflox and E16.5 SP-C/ Dkk1 lung tissue was
severely attenuated (Figs. 5B and D).  These data indicate that N-myc is down-stream
of Wnt/β-catenin signaling in airway epithelium."

proteinAbundance(MGI:Dkk1) decreases rnaAbundance(MGI:Mycn)
proteinAbundance(MGI:Ctnnb1) increases rnaAbundance(MGI:Mycn)

SET Evidence = "Previous studies have implicated BMP signaling in the regulation of lung airway morphogenesis,
specifically proximal–distal patterning of the airways (Lu et al.,
2001; Weaver et al., 1999)."

proteinAbundance(PFM:"Bmp Family") increases biologicalProcess(GO:"lung proximal/distal axis specification")

SET Evidence = "In SP-C/Dkk1 embryos, however, BMP4 expression is significantly reduced (Fig. 5J).
As discussed above, at E12.5, the efficiency of β-catenin excision in many SP-C/rtTA:tetO-cre
X β-cateninflox embryos is less than 100% in some embryos resulting
in a mosaic pattern of β-catenin expression in the lung airway epithelium. However,
this result proves advantageous since we can determine in a precise cell
specific manner whether loss of β-catenin leads to a loss of BMP4. As expected,
BMP4 and β-catenin are expressed at high levels in distal airway epithelium in
wild-type lungs at E12.5 (Figs. 5K– M). Lungs exhibiting mosaic expression of β-catenin
also express BMP4 in a mosaic pattern that closely correlates with presence
of β-catenin (Figs. 5N–P). Complete loss of β-catenin leads to a complete loss
of BMP4 expression (Figs. 5Q–S)."

proteinAbundance(MGI:Dkk1) decreases rnaAbundance(MGI:Bmp4)
proteinAbundance(MGI:Ctnnb1) increases rnaAbundance(MGI:Bmp4)

SET Evidence = "FGF signaling is known to be a critical regulator of lung airway development. Loss
of FGF signaling in the lung, either through loss of FGF10 expression or expression
of a dominant-negative FGF receptor, results in a severe abrogation of lung
airway branching (Bellusci et al., 1997; Min et al., 1998; Peters et al., 1994;
Sekine et al., 1999)."

proteinAbundance(MGI:Fgf10) increases biologicalProcess(GO:"respiratory tube development")

SET Evidence = "In situ hybridization demonstrates that FGFR2 expression is dramatically reduced in
lung airway epithelium but not tracheal epithelium of SP-C/rtTA:tetO-cre X h-cateninflox
(Figs. 6A and B)."

proteinAbundance(MGI:Ctnnb1) increases rnaAbundance(MGI:Fgfr2)

SET Evidence = "Loss of h-catenin expression leads to a dramatic reduction in ERK1/2 activity (Figs.
6C and D)."

proteinAbundance(MGI:Ctnnb1) increases kinaseActivity(proteinAbundance(MGI:Mapk1))
proteinAbundance(MGI:Ctnnb1) increases kinaseActivity(proteinAbundance(MGI:Mapk3))

SET Evidence = "Co-transfection of luciferase reporter plasmids containing these sequences along with
expression plasmids encoding either an activated β-catenin containing mutations
in the GSK-3h phosphorylation sites (β-catenin/4145) or with a TCF3-VP16 fusion
protein demonstrated that both promoter sequences could be activated by transcriptional
mediators of Wnt signaling (Figs. 7A and B). Addition of both h-catenin/4154
and TCF3-VP16 resulted in cooperative activation of both promoters (Figs.
7A and B). Furthermore, a dominantnegative TCF3 construct repressed both BMP4
and N-myc promoters (Figs. 7C and D). Chromatin immunoprecipitation assays show
that β-catenin associates with the conserved LEF/TCF DNA binding sites located
in the BMP4 and N-myc promoters, indicating direct regulation of these promoters
by canonical Wnt signaling (Figs. 7E and F). Together, these results demonstrate
that BMP4 and Nmyc are targets of Wnt/β-catenin signaling in lung airway epithelium."

transcriptionalActivity(proteinAbundance(MGI:Ctnnb1)) directlyIncreases rnaAbundance(MGI:Bmp4)
transcriptionalActivity(proteinAbundance(MGI:Ctnnb1)) directlyIncreases rnaAbundance(MGI:Mycn)
transcriptionalActivity(proteinAbundance(MGI:Tcf3)) directlyIncreases rnaAbundance(MGI:Mycn)
transcriptionalActivity(proteinAbundance(MGI:Tcf3)) directlyIncreases rnaAbundance(MGI:Bmp4)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 20"

SET RespiratorySystem = "Lung"
SET TextLocation = "Abstract"
SET Evidence = "Exposure of rats to 80 mg/m3 tobacco smoke significantly induced apoptosis in the
lungs. Tobacco smoke resulted in inhibition of NF-κB activity, noted by suppression
of inhibitor of κB (IκB) kinase (IKK), accumulation of IκBα, decrease of NF-κB
DNA binding activity, and downregulation of NF-κB-dependent anti-apoptotic proteins,
including Bcl-2, Bcl-xl, and inhibitors of apoptosis."
SET Citation = {"PubMed","Toxicology and applied pharmacology","18355884","2008-03-15","Zhong CY|Zhou YM|Pinkerton KE",""}
SET Species = "10116"

abundance(SCHEM:"Smoke, cigarette") increases biologicalProcess(GO:"apoptotic process")
abundance(SCHEM:"Smoke, cigarette") decreases transcriptionalActivity(complexAbundance(NCR:"Nfkb Complex"))
abundance(SCHEM:"Smoke, cigarette") decreases kinaseActivity(complexAbundance(NCR:"IkappaB Kinase Complex"))
abundance(SCHEM:"Smoke, cigarette") increases proteinAbundance(RGD:Nfkbia)
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Bcl2)
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Bcl2l1)

SET Evidence = "Initiator caspases for the death receptor pathway (caspase 8) and the mitochondrial
pathway (caspase 9) as well as effector caspase 3 were activated following tobacco
smoke exposure."

abundance(SCHEM:"Smoke, cigarette") increases peptidaseActivity(proteinAbundance(RGD:Casp8))
abundance(SCHEM:"Smoke, cigarette") increases peptidaseActivity(proteinAbundance(RGD:Casp9))
abundance(SCHEM:"Smoke, cigarette") increases peptidaseActivity(proteinAbundance(RGD:Casp3))

SET Cell = "Epithelial Cells"
SET TextLocation = "Results"
SET Evidence = "In contrast, exposure of animals to 80 mg/m3 tobacco smoke resulted in a significant
decrease of NFκ-B -DNA binding activity. In addition to NF-κB –DNA binding activity,
the level of NF-κB subunits, including p65 and p50 in the nucleus, were
measure by Western blot analyses. Consistent with the EMSA results, the nuclear
protein levels of both NF-κB p65 and p50 were significantly reduced in the lungs
of rats exposed to 80 mg/m3 with respect to FA control animals (Fig. 3)."

abundance(SCHEM:"Smoke, cigarette") decreases transcriptionalActivity(complexAbundance(NCR:"Nfkb Complex"))

SET Evidence = "In order to better understand the underlying mechanisms of tobacco smoke on NF-κB
activity, the NF-κB activation pathway was examined. Fig. 4B demonstrates that
the levels of the inhibitor of NF-κB (IκB)-α in cytoplasm were significantly elevated
in rats exposed to 80 mg/m3 tobacco smoke, whereas the cytoplasmic levels
of IκB-α was not changed by tobacco smoke exposure, regardless of concentration."

abundance(SCHEM:"Smoke, cigarette") increases proteinAbundance(RGD:Nfkbia)

SET Evidence = "Examination of IκB kinases (IKK) revealed that 80 mg/m3 of tobacco smoke suppressed
the levels of IKKα and IKKβ phosphorylation (activation). No significant changes
were observed for the levels of IKKα and IKKβ activation from rats exposed to
30 mg/m3 tobacco smoke."

abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Chuk,proteinModification(P,S,176))
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Ikbkb,proteinModification(P,S,177))
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Ikbkb,proteinModification(P,S,181))
proteinAbundance(RGD:Chuk,proteinModification(P,S,180)) directlyIncreases kinaseActivity(proteinAbundance(RGD:Chuk))
proteinAbundance(RGD:Ikbkb,proteinModification(P,S,177)) directlyIncreases kinaseActivity(proteinAbundance(RGD:Ikbkb))
proteinAbundance(RGD:Ikbkb,proteinModification(P,S,181)) directlyIncreases kinaseActivity(proteinAbundance(RGD:Ikbkb))
abundance(SCHEM:"Smoke, cigarette") decreases kinaseActivity(proteinAbundance(RGD:Chuk))
abundance(SCHEM:"Smoke, cigarette") decreases kinaseActivity(proteinAbundance(RGD:Ikbkb))
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Chuk,proteinModification(P,S,180))
proteinAbundance(RGD:Chuk,proteinModification(P,S,176)) directlyIncreases kinaseActivity(proteinAbundance(RGD:Chuk))

SET Evidence = "Because of their molecular chaperone property, heat shock proteins (HSP), HSP70 in
particular, can exert an inhibitory effect on NF-κB as a partial substitute for
IκB. Therefore, the effect of tobacco smoke on HSP70 induction was examined. The
level of HSP70 was significantly greater (152%) in animals exposed to 80 mg/m3
tobacco smoke compared to animals exposed to FA (Fig. 4D)."

abundance(PFR:"Hspa Family") directlyDecreases transcriptionalActivity(complexAbundance(NCR:"Nfkb Complex"))
abundance(SCHEM:"Smoke, cigarette") increases proteinAbundance(PFR:"Hspa Family")

SET Evidence = "In line with the NF-κB activity described above, exposure to 80 mg/m3 tobacco smoke
significantly down regulated the expression levels of Bcl-2, Bcl-xl, c-IAP1,
c-IA2 and XIAP by 49.7%, 67%, 75.9%, 57.1%, and 63.2%, respectively (Fig. 5B)."

abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Bcl2)
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Bcl2l1)
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Birc3)
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Ptprn)
abundance(SCHEM:"Smoke, cigarette") decreases proteinAbundance(RGD:Xiap)

SET Evidence = "Apoptosis is executed through the activation of caspases. To further verify the effect
of tobacco smoke in the induction of apoptosis, the levels of cleaved caspases
8, 9, and 3 in rat lungs were determined. In agreement with the apoptotic results
described above, exposure of rats to 80 mg/m3 tobacco smoke resulted in significantly
increased levels of cleaved caspases 8, 9, and 3, indicating the activation
of these caspases (Fig. 7B). Compared to FA control animals, the cleaved
caspases 8, 9, and 3 were elevated by 98.1%, 113.9%, and 84.7 %, respectively."

abundance(SCHEM:"Smoke, cigarette") increases peptidaseActivity(proteinAbundance(RGD:Casp8))
abundance(SCHEM:"Smoke, cigarette") increases peptidaseActivity(proteinAbundance(RGD:Casp9))
abundance(SCHEM:"Smoke, cigarette") increases peptidaseActivity(proteinAbundance(RGD:Casp3))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 21"

SET Cell = "Cells, Cultured"
SET TextLocation = "Review"
SET Evidence = "Following the molecular characterization of several angiogenic growth factors, landmark
studies in the early 1990s showed that hypoxia could induce expression of
platelet-derived growth factor mRNA9 and vascular endothelial growth factor (VEGF)
mRNA in tissue culture10."
SET Citation = {"PubMed","Nature medicine","12778166","","Pugh CW|Ratcliffe PJ",""}

biologicalProcess(GO:"response to hypoxia") increases rnaAbundance(HGNC:VEGFA)
biologicalProcess(GO:"response to hypoxia") increases rnaAbundance(HGNC:PDGFA)

SET HemicAndImmuneSystem = "Blood"
SET Evidence = "Circulating erythropoietin increases several hundred fold within hours of hypoxic
stimulation (reviewed in ref. 13)."

biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:EPO)

SET Evidence = "Hydroxylation at two prolyl residues (Pro402 and Pro564 in human HIF-1α) mediates
interactions with the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex that
targets HIF-α for proteasomal destruction28, 29, 30, 34. Each site can interact
independently with VHL E3, potentially contributing to the extremely rapid proteolysis
of HIF-α that is observed in oxygenated cells34. These sites contain a conserved
LxxLAP motif and are targeted by a newly defined prolyl hydroxylase activity,
that in mammalian cells is provided by three isoforms termed PHD (prolyl hydroxylase
domain) 1-3 (refs. 31,32)."

proteinAbundance(HGNC:HIF1A,proteinModification(H,P,402)) directlyIncreases complexAbundance(proteinAbundance(HGNC:VHL),proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:HIF1A,proteinModification(H,P,402)) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:HIF1A,proteinModification(H,P,564)) directlyIncreases complexAbundance(proteinAbundance(HGNC:VHL),proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:HIF1A,proteinModification(H,P,564)) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A))
proteinAbundance(HGNC:VHL) directlyIncreases degradation(proteinAbundance(HGNC:HIF1A))
catalyticActivity(proteinAbundance(HGNC:EGLN1)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P,402))
catalyticActivity(proteinAbundance(HGNC:EGLN1)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P,564))
catalyticActivity(proteinAbundance(HGNC:EGLN2)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P,402))
catalyticActivity(proteinAbundance(HGNC:EGLN2)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P,564))
catalyticActivity(proteinAbundance(HGNC:EGLN3)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P,402))
catalyticActivity(proteinAbundance(HGNC:EGLN3)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,P,564))

SET Evidence = "In a second hydroxylation-dependent control, β-hydroxylation of an asparaginyl residue
in the C-terminal activation domain of HIF-α (Asn803 in human HIF-1α)35 is
regulated by a HIF asparaginyl hydroxylase33,36 termed FIH (factor inhibiting HIF)37.
Hydroxylation at this site blocks interaction of the HIF-α C-terminal activation
domain with the transcriptional coactivator p300."

catalyticActivity(proteinAbundance(HGNC:HIF1AN)) directlyIncreases proteinAbundance(HGNC:HIF1A,proteinModification(H,N,803))
proteinAbundance(HGNC:HIF1A,proteinModification(H,N,803)) directlyDecreases complexAbundance(proteinAbundance(HGNC:HIF1A),proteinAbundance(HGNC:EP300))

SET Evidence = "In oxygenated cells, these hydroxylation reactions provide a dual mechanism of HIF
inactivation that involves proteolytic destruction and inhibition of transcriptional
activity (Fig.1). The HIF hydroxylases are all Fe(II)- and 2-oxoglutarate-dependent
dioxygenases that have an absolute requirement for molecular oxygen,
allowing HIF to escape inactivation in hypoxia."

abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN1))
abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN2))
abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN3))
abundance(CHEBI:"iron(2+)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:HIF1AN))
abundance(CHEBI:"2-oxoglutarate(2-)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN1))
abundance(CHEBI:"2-oxoglutarate(2-)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN2))
abundance(CHEBI:"2-oxoglutarate(2-)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN3))
abundance(CHEBI:"2-oxoglutarate(2-)") directlyIncreases catalyticActivity(proteinAbundance(HGNC:HIF1AN))
abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN1))
abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN2))
abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:EGLN3))
abundance(CHEBI:dioxygen) directlyIncreases catalyticActivity(proteinAbundance(HGNC:HIF1AN))

SET Evidence = "In hypoxia, VEGF transcription is upregulated by HIF18, 19, mRNA stability is increased
by binding of proteins to specific sequences in the 3' UTR71, and an internal
ribosomal entry site allows preserved translation in the face of normal cellular
hypoxic shutdown72. The biological activity of secreted VEGF is further influenced
by hypoxia-inducible expression of the Flt-1 receptor49,"

transcriptionalActivity(proteinAbundance(HGNC:HIF1A)) directlyIncreases rnaAbundance(HGNC:VEGFA)
biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:VEGFA)
biologicalProcess(GO:"response to hypoxia") increases rnaAbundance(HGNC:FLT1)

SET Evidence = "In keeping with the central role of HIF in responses to hypoxia observed in tissue
culture, targeted inactivation of either Hif1a (refs. 68,70,74) or Arnt (encoding
HIF-1β)75 in the mouse results in abnormal vascular development and embryonic
lethality."
SET Species = "10090"

transcriptionalActivity(proteinAbundance(MGI:Hif1a)) increases biologicalProcess(GO:angiogenesis)
transcriptionalActivity(proteinAbundance(MGI:Arnt)) increases biologicalProcess(GO:angiogenesis)

SET Evidence = "In addition to activation by hypoxia, the HIF system is also induced or amplified
by a wide range of growth-promoting stimuli and oncogenic pathways such as the
insulin, insulin-like growth factor-1, epidermal growth factor and mutant Ras and
Src kinase pathways."

biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:HIF1A)
biologicalProcess(GO:"insulin receptor signaling pathway") increases proteinAbundance(HGNC:HIF1A)
biologicalProcess(GO:"insulin-like growth factor receptor signaling pathway") increases proteinAbundance(HGNC:HIF1A)
biologicalProcess(GO:"epidermal growth factor receptor signaling pathway") increases proteinAbundance(HGNC:HIF1A)
gtpBoundActivity(proteinAbundance(PFH:"RAS Family")) increases proteinAbundance(HGNC:HIF1A)
kinaseActivity(proteinAbundance(PFH:"SRC Family")) increases proteinAbundance(HGNC:HIF1A)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 22"

SET TextLocation = "Review"
SET Evidence = "Numerous studies have shown that the RB protein is an inhibitor of cell proliferation"
SET Citation = {"PubMed","Gene","15225871","","Yee AS|Paulson EK|McDevitt MA|Rieger-Christ K|Summerhayes I|Berasi SP|Kim J|Huang CY|Zhang X",""}

proteinAbundance(HGNC:RB1) decreases biologicalProcess(MESHPP:"Cell Proliferation")

SET Evidence = "RB and the related family members p107 and p130 can each bind E2F to repress genes
that are otherwise important for progression from G1 to S phase."

complexAbundance(proteinAbundance(HGNC:RB1),proteinAbundance(PFH:"E2F Family")) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")
complexAbundance(proteinAbundance(HGNC:RBL1),proteinAbundance(PFH:"E2F Family")) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")
complexAbundance(proteinAbundance(HGNC:RBL2),proteinAbundance(PFH:"E2F Family")) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")
proteinAbundance(HGNC:RB1) directlyDecreases transcriptionalActivity(proteinAbundance(PFH:"E2F Family"))

SET Evidence = "The binding of RB, p107, or p130 has two simultaneous consequences: (1) binding prevents
E2F from interacting with transcriptional co-activators (e.g., p300);"

complexAbundance(proteinAbundance(HGNC:RB1),proteinAbundance(PFH:"E2F Family")) directlyDecreases complexAbundance(proteinAbundance(PFH:"E2F Family"),proteinAbundance(HGNC:EP300))
complexAbundance(proteinAbundance(HGNC:RBL1),proteinAbundance(PFH:"E2F Family")) directlyDecreases complexAbundance(proteinAbundance(PFH:"E2F Family"),proteinAbundance(HGNC:EP300))
complexAbundance(proteinAbundance(HGNC:RBL2),proteinAbundance(PFH:"E2F Family")) directlyDecreases complexAbundance(proteinAbundance(PFH:"E2F Family"),proteinAbundance(HGNC:EP300))

SET Evidence = "In normal G1 progression, the Cyclin D1/CDK4 kinase phosphorylates RB, triggers disruption
of the RB/ E2F complex, and frees E2F to activate genes that are necessary
for S-phase progression."

kinaseActivity(complexAbundance(proteinAbundance(HGNC:CCND1),proteinAbundance(HGNC:CDK4))) directlyIncreases proteinAbundance(HGNC:RB1,proteinModification(P))
proteinAbundance(HGNC:RB1,proteinModification(P)) directlyDecreases complexAbundance(proteinAbundance(HGNC:RB1),proteinAbundance(PFH:"E2F Family"))

SET Evidence = "The p16 protein is a CDK4 inhibitor that restrains the activity of Cyclin D1/CDK4
and thus inhibits G1 progression."

proteinAbundance(HGNC:CDKN2A) directlyDecreases kinaseActivity(complexAbundance(proteinAbundance(HGNC:CCND1),proteinAbundance(HGNC:CDK4)))
proteinAbundance(HGNC:CDKN2A) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")

SET Disease = "Neoplasms"
SET Evidence = "Cyclin D1 overexpression/amplification is associated with numerous cancers."

geneAbundance(HGNC:CCND1) positiveCorrelation pathology(MESHD:Neoplasms)

SET Evidence = "As described below, we and other groups reisolated HBP1 as an RB and p130 interacting
protein (Lavender et al., 1997; Tevosian et al., 1997"

complexAbundance(proteinAbundance(HGNC:HBP1),proteinAbundance(HGNC:RB1))
complexAbundance(proteinAbundance(HGNC:HBP1),proteinAbundance(HGNC:RBL2))

SET MuskuloskeletalSystem = "Muscles"
SET Evidence = "HBP1 is consistently up regulated in differentiation and under conditions of cell
cycle arrest in muscle, adipocyte, erythroid, and other cell types"

proteinAbundance(HGNC:HBP1) positiveCorrelation biologicalProcess(GO:"cell differentiation")

SET Cell = "Adipocytes"

proteinAbundance(HGNC:HBP1) positiveCorrelation biologicalProcess(GO:"cell differentiation")

SET Cell = "Erythroid Cells"

proteinAbundance(HGNC:HBP1) positiveCorrelation biologicalProcess(GO:"cell differentiation")
proteinAbundance(HGNC:HBP1) positiveCorrelation biologicalProcess(GO:"cell cycle arrest")

SET Cell = "Adipocytes"

proteinAbundance(HGNC:HBP1) positiveCorrelation biologicalProcess(GO:"cell cycle arrest")

SET Cell = "Erythroid Cells"

proteinAbundance(HGNC:HBP1) positiveCorrelation biologicalProcess(GO:"cell cycle arrest")

SET Evidence = "Consistent with these results, we showed that overexpression of HBP1 in cells inhibited
G1 and S-phase progression (Tevosian et al., 1997)."

proteinAbundance(HGNC:HBP1) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")

SET Evidence = "HDAC4, a Class II histone deacetylase binds within a region from amino acids 220–250,
which resides within the Ataxin homology region (see Fig. 3)."

complexAbundance(proteinAbundance(HGNC:HDAC4),proteinAbundance(HGNC:HBP1))

SET Evidence = "Our detailed investigation showed that both Cyclin D1 and c-MYC expression was extinguished
upon HBP1 expression."

proteinAbundance(HGNC:HBP1) decreases rnaAbundance(HGNC:CCND1)
proteinAbundance(HGNC:HBP1) decreases rnaAbundance(HGNC:MYC)

SET Evidence = "Specifically, HBP1 inhibited the activity of LEF/TCFs."

proteinAbundance(HGNC:HBP1) decreases transcriptionalActivity(proteinAbundance(HGNC:LEF1))

SET BodyRegion = "Breast"
SET Evidence = "A constitutive Wnt signaling pathway has been linked to breast, colon, and other cancers
(for reviews, see Bienz and Clevers, 2000; Polakis, 2000)."

biologicalProcess(GO:"Wnt receptor signaling pathway") positiveCorrelation pathology(MESHD:Neoplasms)

SET DigestiveSystem = "Colon"

biologicalProcess(GO:"Wnt receptor signaling pathway") positiveCorrelation pathology(MESHD:Neoplasms)

SET Evidence = "The accumulation of β-catenin results from the inhibition of the GSK3β kinase, which
normally would phosphorylate β-catenin as a degradation signal."

kinaseActivity(proteinAbundance(HGNC:GSK3B)) directlyIncreases proteinAbundance(HGNC:CTNNB1,proteinModification(P))
proteinAbundance(HGNC:CTNNB1,proteinModification(P)) increases degradation(proteinAbundance(HGNC:CTNNB1))

SET Evidence = "Wild-type APC and Axin trigger β-catenin degradation through recruitment of GSK3b
to the Axin- APC scaffold, which provides for potent activation of GSK3β."

complexAbundance(proteinAbundance(HGNC:APC),proteinAbundance(PFH:"AXIN Family")) directlyIncreases (kinaseActivity(proteinAbundance(HGNC:GSK3B)) increases degradation(proteinAbundance(HGNC:CTNNB1)))

SET Evidence = "high β-catenin levels correlate with poor prognosis in human breast cancer and result
from biochemical, not genetic, dysregulation (Ryo et al., 2001; Wulf et al.,
2001, 2003)."

proteinAbundance(HGNC:CTNNB1) prognosticBiomarkerFor pathology(MESHD:"Breast Neoplasms")

SET Evidence = "Cyclin D1, MYC, and Cox-2 are three clinically relevant Wnt target genes that are
overexpressed in breast and many other cancers (e.g., Weinstat-Saslow et al., 1995;
Naidu et al., 2002a,b; Singh and Luci, 2002; Spizzo et al., 2003)."

proteinAbundance(HGNC:CCND1) positiveCorrelation pathology(MESHD:"Breast Neoplasms")
proteinAbundance(HGNC:MYC) positiveCorrelation pathology(MESHD:"Breast Neoplasms")
proteinAbundance(HGNC:PTGS2) positiveCorrelation pathology(MESHD:"Breast Neoplasms")

SET Evidence = "Cyclin D1 and MYC are examples of direct Wnt target genes in proliferation and whose
activation requires the LEF/TCF sites in the respective promoters (He et al.,
1998; Tetsu and McCormick, 1999)."

transcriptionalActivity(proteinAbundance(HGNC:LEF1)) directlyIncreases rnaAbundance(HGNC:CCND1)
transcriptionalActivity(proteinAbundance(HGNC:LEF1)) directlyIncreases rnaAbundance(HGNC:MYC)

SET Evidence = "Cyclin D1 expression best correlates with breast proliferation."

proteinAbundance(HGNC:CCND1) positiveCorrelation biologicalProcess(MESHPP:"Cell Proliferation")

SET Evidence = "Increased Cyclin D1 levels in breast cancer cell lines and tumors have been correlated
with increased β-catenin accumulation and constitutive Wnt signaling (Lin
et al., 2000)."

proteinAbundance(HGNC:CCND1) positiveCorrelation proteinAbundance(HGNC:CTNNB1)
proteinAbundance(HGNC:CCND1) positiveCorrelation biologicalProcess(GO:"Wnt receptor signaling pathway")

SET Evidence = "The NADPH oxidase is the principle source of intracellular reactive oxygen species
(ROS) that is generated by mitogenic signaling."

complexAbundance(NCH:"NADPH Oxidase Complex") directlyIncreases abundance(CHEBI:"reactive oxygen species")

SET Evidence = "The importance of a functional NADPH oxidase is underscored by the observation that
mutations of the p47phox and gp91phox genes are associated with chronic granulomatosis,
in which patients have increased susceptibility to bacterial and fungal
infections (reviewed in Cheng et al., 2001)."

complexAbundance(NCH:"NADPH Oxidase Complex") hasComponents list(proteinAbundance(HGNC:NCF1),proteinAbundance(HGNC:CYBB))

SET CellLine = "NIH/3T3"
SET Evidence = "Stable transfection of NIH/3T3 fibroblasts with active Ras (H-RasV12) results in transformation
and in significant intracellular ROS generation. The importance of
intracellular ROS in RAS-mediated transformation is highlighted by the observation
that pharmacological inhibition of the NADPH oxidase reverses transformation
(Irani et al., 1997)."
SET Species = "10090"

gtpBoundActivity(proteinAbundance(MGI:Hras1,substitution(G,12,V))) increases catalyticActivity(complexAbundance(NCM:"NADPH Oxidase Complex"))
catalyticActivity(complexAbundance(NCM:"NADPH Oxidase Complex")) directlyIncreases abundance(CHEBI:"reactive oxygen species")

SET Evidence = "the expression of the Nox1/Mox1 catalytic subunit of the NADPH oxidase in NIH/3T3
fibroblasts not only triggered increased superoxide production, but also oncogenic
transformation (Suh et al., 1999; Arnold et al., 2001)."

proteinAbundance(MGI:Nox1) increases abundance(CHEBI:superoxide)

SET Evidence = "RAC itself is also an obligate subunit of the cellular NADPH oxidase"

complexAbundance(NCH:"NADPH Oxidase Complex") hasComponent proteinAbundance(HGNC:RAC1)

SET Evidence = "The expression of active Rac1 in many cell types causes increased superoxide production,
while expression of a dominant-negative Rac1 block superoxide production....superoxide
production is necessary for Rac dependent G1 progression and cellular
shape changes"

proteinAbundance(HGNC:RAC1) increases abundance(CHEBI:superoxide)
abundance(CHEBI:superoxide) increases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")
abundance(CHEBI:superoxide) increases biologicalProcess(GO:"cell morphogenesis")

SET Evidence = "The promoter of the p47phox gene contains six tandem high-affinity HBP1 DNA binding
elements at -1243 to -1318 bp from the transcriptional start site and which were
required for repression."

complexAbundance(proteinAbundance(HGNC:HBP1),geneAbundance(HGNC:NCF1))
transcriptionalActivity(proteinAbundance(HGNC:HBP1)) directlyDecreases rnaAbundance(HGNC:NCF1)

SET Disease = "Neuroblastoma"
SET Evidence = "We identified the N-MYC gene as a new HBP1 target (Tevosian et al., 1997). The expression
of NMYC is increased in neuroblastomas."

proteinAbundance(HGNC:MYCN) positiveCorrelation pathology(MESHD:Neuroblastoma)
complexAbundance(proteinAbundance(HGNC:HBP1),geneAbundance(HGNC:MYCN))

SET Evidence = "Histone H10 gene as another RB-regulated HBP1 target that is also cell cycle regulated."

complexAbundance(proteinAbundance(HGNC:HBP1),geneAbundance(HGNC:H1F0))

SET Evidence = "HBP1 was identified as a regulator of the Histone H10 gene. HBP1 appears to be an
activator for this gene."

transcriptionalActivity(proteinAbundance(HGNC:HBP1)) directlyIncreases rnaAbundance(HGNC:H1F0)

SET Evidence = "Lin et al. (2001) have shown that myeloperoxidase (MPO) gene is another HBP1 target."

complexAbundance(proteinAbundance(HGNC:HBP1),geneAbundance(HGNC:MPO))

SET Disease = "Leukemia, Myeloid"
SET Evidence = "Myeloperoxidase is a clinical prognostic marker for the progression of myeloid leukemia"

proteinAbundance(HGNC:MPO) prognosticBiomarkerFor pathology(MESHD:"Leukemia, Myeloid")

SET Evidence = "p38 MAPK activity is also linked with differentiation and recently, with senescence
and tumor suppression (reviewed in Kyriakis and Avruch, 2001 and see below)."

proteinAbundance(PFH:"MAPK p38 Family") positiveCorrelation biologicalProcess(GO:"cell differentiation")
proteinAbundance(PFH:"MAPK p38 Family") positiveCorrelation biologicalProcess(GO:"cell aging")
proteinAbundance(PFH:"MAPK p38 Family") negativeCorrelation biologicalProcess(SDIS:"tumor growth")

SET Evidence = "p21 protein levels increased by a post-transcriptional mechanism and concluded that
the SAPKs p38 MAPK and JNK were involved in stabilizing the p21 protein. A specific
site on p21 (serine 190) was defined for p38 MAPK-mediated stabilization
(Kim et al., 2002)."

kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family")) directlyIncreases proteinAbundance(HGNC:CDKN1A,proteinModification(P,S,190))
proteinAbundance(HGNC:CDKN1A,proteinModification(P,S,190)) decreases degradation(proteinAbundance(HGNC:CDKN1A))

SET Evidence = "the apparent mechanism was that p38 MAPK-mediated phosphorylation of the HBP1 led
to increased protein stability and a G1 arrest"

kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family")) directlyIncreases proteinAbundance(HGNC:HBP1,proteinModification(P))
kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family")) decreases degradation(proteinAbundance(HGNC:HBP1))

SET Evidence = "the activation of the upstream kinases MKK 6 and MKK 3 lead to a senescent phenotype
that was dependent on p38 MAPK activity"

kinaseActivity(proteinAbundance(HGNC:MAP2K6)) increases kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family"))
kinaseActivity(proteinAbundance(HGNC:MAP2K3)) increases kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family"))
kinaseActivity(proteinAbundance(PFH:"MAPK p38 Family")) increases biologicalProcess(GO:"cell aging")

SET Evidence = "A loss of both MKK6 and MKK3 resulted in cells with increased proliferation and susceptibility
to tumorigenic conversion (Brancho et al., 2003)."

proteinAbundance(HGNC:MAP2K6) decreases biologicalProcess(GO:"cell proliferation")
proteinAbundance(HGNC:MAP2K3) decreases biologicalProcess(GO:"cell proliferation")
proteinAbundance(HGNC:MAP2K6) decreases biologicalProcess(SDIS:"tumor growth")
proteinAbundance(HGNC:MAP2K3) decreases biologicalProcess(SDIS:"tumor growth")

SET Evidence = "deletion of the p38a (mapk14) isoform also resulted in cells with increased susceptibility
to tumorigenic conversion (Bulavin et al., 2002)."

proteinAbundance(HGNC:MAPK14) decreases biologicalProcess(SDIS:"tumor growth")

SET Disease = "Neoplasms"
SET Evidence = "In breast cancer, amplification of the human epidermal growth factor receptor- 2 (Her-2)
is associated with aggressively proliferating breast cancers."

geneAbundance(HGNC:ERBB2) positiveCorrelation biologicalProcess(MESHPP:"Cell Proliferation")
kinaseActivity(proteinAbundance(HGNC:EGFR)) negativeCorrelation proteinAbundance(PFH:"ESR Family")

SET Evidence = "In addition, excessive EGFR signaling is a common scenario in breast cancer, specifically
in estrogen receptor-negative subtypes"

kinaseActivity(proteinAbundance(HGNC:EGFR)) negativeCorrelation proteinAbundance(PFH:"ESR Family")

SET Evidence = "Herceptin therapy is blocking the Her-2 receptor and its resulting signaling."

abundance(SCHEM:Trastuzumab) directlyDecreases kinaseActivity(proteinAbundance(HGNC:ERBB2))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 23"

SET Cell = "Adipocytes, Brown"
SET TextLocation = "Review"
SET Evidence = "UCP-1 allows the re-entry of protons and, as a consequence, energy liberated from
substrate oxidation is dissipated as heat (Fig. 1)."
SET Citation = {"PubMed","Mini reviews in medicinal chemistry","15777261","","Valverde AM|Benito M",""}

proteinAbundance(HGNC:UCP1) increases biologicalProcess(GO:"heat dissipation")

SET Evidence = "UCP-1 allows the re-entry of protons and, as a consequence, energy liberated from
substrate oxidation is dissipated as heat (Fig. 1). This mechanism is reversible,
since it can be inhibited by purine nucleotides such as GDP [5]."

abundance(CHEBI:GDP) decreases (proteinAbundance(HGNC:UCP1) increases biologicalProcess(GO:"heat dissipation"))

SET Evidence = "Acute activation of BAT thermogenesis appears to be mediated by noradrenaline (NA)
liberated from the sympathetic nervous system"

abundance(CHEBI:noradrenaline) increases biologicalProcess(MESHPP:Thermogenesis)

SET Evidence = "By acting through β-receptors, NA increases intracellular cAMP levels, which in turn
activate lipolysis (Fig. 1)."

abundance(CHEBI:noradrenaline) directlyIncreases molecularActivity(proteinAbundance(PFH:"ADRB Family"))
molecularActivity(proteinAbundance(PFH:"ADRB Family")) increases abundance(CHEBI:"3',5'-cyclic AMP")
abundance(CHEBI:"3',5'-cyclic AMP") increases biologicalProcess(MESHPP:Lipolysis)

SET Evidence = "The resulting free fatty acids are used as substrates for mitochondrial respiration
and as activators of UCP-1 [5]."

biologicalProcess(MESHPP:Lipolysis) increases abundance(CHEBI:"fatty acid")
abundance(CHEBI:"fatty acid") increases biologicalProcess(GO:"cellular respiration")
abundance(CHEBI:"fatty acid") increases molecularActivity(proteinAbundance(HGNC:UCP1))

SET Evidence = "They found an A/C transition in the 5' untranslated region of exon 1 (112 bp upstream
of the translation initiation codon) and also a Met229/Leu variant. Interestingly,
the allele frequencies for the C variant and for the Leu229 variant were
higher in the Type 2 diabetic group than in the control group."
SET Species = "9606"

proteinAbundance(HGNC:UCP1,substitution(M,229,L)) positiveCorrelation pathology(MESHD:"Diabetes Mellitus, Type 2")
proteinAbundance(HGNC:UCP1,substitution(M,229,L)) positiveCorrelation pathology(MESHD:"Diabetes Mellitus, Type 2")

SET Evidence = "Insulin and IGF-I initiate the biological effects in target cells by binding to and
activating its endogenous tyrosine kinase receptors [23,24]. These receptors
are believed to transduce signals by phosphorylation on tyrosine residues of several
cellular substrates including IRS proteins (IRS-1,-2,- 3 and –4) [25-28]."

proteinAbundance(HGNC:INS) directlyIncreases kinaseActivity(proteinAbundance(HGNC:INSR))
proteinAbundance(HGNC:IGF1) directlyIncreases kinaseActivity(proteinAbundance(HGNC:IGF1R))
kinaseActivity(proteinAbundance(HGNC:INSR)) directlyIncreases proteinAbundance(HGNC:IRS1,proteinModification(P,Y))
kinaseActivity(proteinAbundance(HGNC:INSR)) directlyIncreases proteinAbundance(HGNC:IRS2,proteinModification(P,Y))
kinaseActivity(proteinAbundance(HGNC:INSR)) directlyIncreases proteinAbundance(HGNC:IRS4,proteinModification(P,Y))
kinaseActivity(proteinAbundance(HGNC:IGF1R)) directlyIncreases proteinAbundance(HGNC:IRS1,proteinModification(P,Y))
kinaseActivity(proteinAbundance(HGNC:IGF1R)) directlyIncreases proteinAbundance(HGNC:IRS2,proteinModification(P,Y))
kinaseActivity(proteinAbundance(HGNC:IGF1R)) directlyIncreases proteinAbundance(HGNC:IRS4,proteinModification(P,Y))

SET Evidence = "The p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase) contains
two SH2 domains that allow its binding to the IRS proteins [29]."

proteinAbundance(PFH:"IRS Family",proteinModification(P)) directlyIncreases complexAbundance(proteinAbundance(PFH:"PIK3R Class IA Family"),proteinAbundance(PFH:"IRS Family"))

SET Evidence = "PI 3-kinase is a heterodimer composed of an 85-kDa regulatory subunit and a 110-kDa
catalytic subunit, capable of phosphorylating phosphoinositides at the 3'-position
of the inositol ring, thus initiating phospholipid turnover [29]."

kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) directlyIncreases abundance(CHEBI:"phosphatidylinositol trisphosphate")

SET Evidence = "The phosphoinositides produced by PI 3-kinase activate the phosphoinositide-dependent
kinases 1 and 2. These kinases phosphorylate and activate the serine/threonine
kinase PKB/Akt [32]."

abundance(CHEBI:"phosphatidylinositol trisphosphate") increases kinaseActivity(proteinAbundance(HGNC:PDPK1))
kinaseActivity(proteinAbundance(HGNC:PDPK1)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:AKT1))

SET Evidence = "The mammalian target of rapamycin (mTOR), a 290 kDa serine/threonine kinase and aminoacid
sensor, is a direct target for Akt [33]."

kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyIncreases proteinAbundance(HGNC:MTOR,proteinModification(P))

SET Evidence = "mTOR can phosphorylate and activate the prototypical p70s6k, a process which is blocked
by rapamycin."

abundance(CHEBI:rapamycin) directlyDecreases (kinaseActivity(proteinAbundance(HGNC:MTOR)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:RPS6KB2)))

SET Evidence = "P70s6k is involved in the phosphorylation of ribosomal protein S6"

kinaseActivity(proteinAbundance(HGNC:RPS6KB2)) directlyIncreases proteinAbundance(HGNC:RPS6,proteinModification(P))

SET Evidence = "One of the well-known downstream targets of MAPK is p90 RSK (ribosomal S6 kinase)."

kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family")) directlyIncreases proteinAbundance(PFH:"RPS6KA Family",proteinModification(P))

SET Evidence = "Fetal brown adipocytes primary cultures offer an excellent cell model to study the
molecular mechanisms of insulin/IGF-I-mediated differentiation processes. In these
cells insulin and IGF-I, acting independently, up-regulate the expression of
adipogenic-related genes (fatty acid synthase, glycerol-3-phosphate dehydrogenase,
malic enzyme, glucose- 6-phosphate dehydrogenase) in a dose and time-dependent
manner at the transcriptional level, resulting in an increase of cytosolic lipid
content [20,40]."

proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:FASN)
proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:G6PD)
proteinAbundance(HGNC:IGF1) increases rnaAbundance(HGNC:FASN)
proteinAbundance(HGNC:IGF1) increases rnaAbundance(HGNC:G6PD)

SET CellStructure = "Cytoplasm"

proteinAbundance(HGNC:INS) increases abundance(CHEBI:lipid)
proteinAbundance(HGNC:IGF1) increases abundance(CHEBI:lipid)

SET Evidence = "Activation of PI 3- kinase mediates GLUT4 redistribution from an intracellular compartment
to the plasma membrane upon insulin stimulation [47]"

proteinAbundance(HGNC:INS) increases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases translocation(proteinAbundance(HGNC:SLC2A4),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane")

SET Evidence = "In primary cultures of brown adipocytes, insulin and IGF-I transactivated the GLUT4
promoter and upregulated the expression of the GLUT4 gene, producing a time-dependent
mRNA accumulation and significantly increasing the amount of protein located
in total membrane fraction."

proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:SLC2A4)
proteinAbundance(HGNC:IGF1) increases rnaAbundance(HGNC:SLC2A4)

SET CellStructure = "Cell Membrane"

proteinAbundance(HGNC:INS) increases proteinAbundance(HGNC:SLC2A4)
proteinAbundance(HGNC:IGF1) increases proteinAbundance(HGNC:SLC2A4)

SET Evidence = "insulin and IGF-I transactivated the GLUT4 promoter and upregulated the expression
of the GLUT4 gene, producing a time-dependent mRNA accumulation and significantly
increasing the amount of protein located in total membrane fraction. Consequently,
glucose uptake was augmented [49]."

transportActivity(proteinAbundance(HGNC:SLC2A4)) increases biologicalProcess(GO:"glucose import")

SET Evidence = "Inhibition of PI 3-kinase with either wortmannin or LY294002 down-regulated insulin-induced
GLUT4 mRNA accumulation or GLUT4 protein content as well as precluded
the transactivation of the GLUT4 promoter"

abundance(CHEBI:wortmannin) decreases (proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:SLC2A4))
abundance(CHEBI:wortmannin) decreases (proteinAbundance(HGNC:INS) increases proteinAbundance(HGNC:SLC2A4))
abundance(SCHEM:"LY 294002") decreases (proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:SLC2A4))
abundance(SCHEM:"LY 294002") decreases (proteinAbundance(HGNC:INS) increases proteinAbundance(HGNC:SLC2A4))

SET Evidence = "LY294002 down-regulated insulin-induced GLUT4 mRNA accumulation or GLUT4 protein content
as well as precluded the transactivation of the GLUT4 promoter. Similar
results have been obtained by transient transfection of primary brown adipocytes
with constructs encoding dominant negative p85 (Dp85)."

kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases rnaAbundance(HGNC:SLC2A4)
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases proteinAbundance(HGNC:SLC2A4)

SET Evidence = "Conversely, the use of 1-(5-Chloronaphthalene-1-sulfonyl) homopiperazine (ML-9) compound
(Fig. 5) as an inhibitor of PKB/Akt enzymatic activity (IC50=10-50 mM) [50]
has revealed that activation of PKB/Akt is necessary for the acute (GLUT4 translocation)
and chronic (GLUT4 gene expression) insulin effects that lead to glucose
uptake [51]"

abundance(SCHEM:"ML 9") directlyDecreases kinaseActivity(proteinAbundance(HGNC:AKT1))
abundance(SCHEM:"ML 9") decreases (proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:SLC2A4))
abundance(SCHEM:"ML 9") decreases (proteinAbundance(HGNC:INS) increases translocation(proteinAbundance(HGNC:SLC2A4),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane"))

SET Evidence = "Okadaic acid is an ionophore-like polyether derivate of a C38 fatty acid compound
that has tumor promoting properties (Fig. 6) [52]. It is a potent inhibitor of
protein serine/threonine phosphatase 1 (IC50=10-15 nM) and protein serine/threonine
phosphatase 2A (IC50=0.1 nM) without any inhibitory effect on the activity of
tyrosine phosphatases."

abundance(CHEBI:"okadaic acid") directlyDecreases phosphataseActivity(complexAbundance(NCH:"PP2A Complex"))

SET Evidence = "Primary brown adipocytes pretreated with this compound before insulin stimulation
showed a marked increase in IRS-1/2 serine phosphorylation with a concomitant decrease
in tyrosine phosphorylation of these molecules and a partial inhibition
of IRS-1- and IRS-2-associated PI 3-kinase activity [53]."

abundance(CHEBI:"okadaic acid") increases proteinAbundance(HGNC:IRS1,proteinModification(P,S))
abundance(CHEBI:"okadaic acid") increases proteinAbundance(HGNC:IRS2,proteinModification(P,S))
proteinAbundance(HGNC:IRS1,proteinModification(P,S)) negativeCorrelation proteinAbundance(HGNC:IRS1,proteinModification(P,Y))
proteinAbundance(HGNC:IRS2,proteinModification(P,S)) negativeCorrelation proteinAbundance(HGNC:IRS2,proteinModification(P,Y))

SET Evidence = "Downstream PI 3-kinase, okadaic acid blunted insulin induced PKCz activity, but not
PKB/Akt or p70s6k phosphorylation."

abundance(CHEBI:"okadaic acid") decreases (proteinAbundance(HGNC:INS) increases kinaseActivity(proteinAbundance(HGNC:PRKCZ)))

SET Evidence = "The metabolic consequence of PKCz inhibition is a blockade of insulin-induced glucose
uptake."

kinaseActivity(proteinAbundance(HGNC:PRKCZ)) increases (proteinAbundance(HGNC:INS) increases biologicalProcess(GO:"glucose import"))

SET Evidence = "PD098059 blocks the activity of MEK and not that of MAPK. In addition, PD098059 did
not inhibit a number of other kinase activities both in vitro and in cultured
cells. These include Raf kinase, PKC, cyclic AMP-dependent kinase, vsrc kinase,
PDGF receptor tyrosine kinase and PI 3-kinase"

abundance(SCHEM:"PD 98,059") directlyDecreases kinaseActivity(proteinAbundance(PFH:"MEK1/2 Family"))
abundance(SCHEM:"PD 98,059") causesNoChange kinaseActivity(proteinAbundance(HGNC:RAF1))
abundance(SCHEM:"PD 98,059") causesNoChange kinaseActivity(proteinAbundance(PFH:"PRKC Family"))
abundance(SCHEM:"PD 98,059") causesNoChange kinaseActivity(proteinAbundance(PFH:"PRKA Family"))
abundance(SCHEM:"PD 98,059") causesNoChange kinaseActivity(proteinAbundance(PFH:"SRC Family"))
abundance(SCHEM:"PD 98,059") causesNoChange kinaseActivity(proteinAbundance(PFH:"PDGFR Family"))
abundance(SCHEM:"PD 98,059") causesNoChange kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))

SET Evidence = "insulin and IGF-I are novel thermogenic factors through the ability to increase UCP-1
gene transcription rate and also UCP-1 mRNA accumulation [19,21]."

proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:UCP1)
proteinAbundance(HGNC:IGF1) increases rnaAbundance(HGNC:UCP1)

SET Evidence = "Inhibition of PI 3-kinase with wortmannin or LY294002, completely blocked insulin/IGF-I
induced transactivation of the UCP-1 promoter and UCP-1 mRNA accumulation
[21,41]."

abundance(CHEBI:wortmannin) decreases (proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:UCP1))
abundance(CHEBI:wortmannin) decreases (proteinAbundance(HGNC:IGF1) increases rnaAbundance(HGNC:UCP1))
abundance(SCHEM:"LY 294002") decreases (proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:UCP1))
abundance(SCHEM:"LY 294002") decreases (proteinAbundance(HGNC:IGF1) increases rnaAbundance(HGNC:UCP1))

SET Evidence = "transient transfection of primary brown adipocytes with a dominantnegative form of
p21 Ras completely abolished insulininduced UCP-1-CAT transactivation [58]."

proteinAbundance(PFH:"RAS Family") increases (proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:UCP1))

SET Evidence = "The first reported action of TNFa in brown adipocytes was the induction of insulin
resistance [62]."

proteinAbundance(HGNC:TNF) increases pathology(MESHD:"Insulin Resistance")

SET Evidence = "pretreatment of rat fetal brown adipocytes in primary culture with TNFα inhibited
insulin-induced expression of several adipogenic differentiation mRNAs markers
such as FAS and G3PD"
SET Species = "10116"

proteinAbundance(RGD:Tnf) decreases (proteinAbundance(PFR:"Ins Family") increases rnaAbundance(RGD:Fasn))

SET Evidence = "The antiadipogenic effect of TNFα was accompanied by a down-regulation of the mRNAs
for the transcription factors C/EBPα and β."

proteinAbundance(HGNC:TNF) decreases rnaAbundance(HGNC:CEBPA)
proteinAbundance(HGNC:TNF) decreases rnaAbundance(HGNC:CEBPB)

SET Evidence = "TNFα caused an insulin resistance on the insulin-induced glucose uptake in brown adipocytes."

proteinAbundance(HGNC:TNF) increases pathology(MESHD:"Insulin Resistance")

SET Evidence = "TNFα on brown adipocytes seemed to be due to the hypophosphorylation of the insulin
receptor in response to insulin as well as the hypophosphorylation of IRS-2,
resulting in an impairment of IRS-2-associated PI 3-kinase activity [62]."

proteinAbundance(HGNC:TNF) decreases (proteinAbundance(HGNC:INS) increases proteinAbundance(HGNC:INSR,proteinModification(P)))
proteinAbundance(HGNC:TNF) decreases (proteinAbundance(HGNC:INS) increases proteinAbundance(HGNC:IRS2,proteinModification(P)))
proteinAbundance(HGNC:TNF) decreases (proteinAbundance(HGNC:INS) increases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")))

SET Evidence = "TNFα mediates the production of ceramide which triggers PKB/Akt dephosphorylation
through the activation of a protein phosphatase [63]."

proteinAbundance(HGNC:TNF) increases abundance(CHEBI:ceramide)
abundance(CHEBI:ceramide) decreases proteinAbundance(HGNC:AKT1,proteinModification(P))

SET Cell = {"Adipocytes, Brown","Adipocytes, Brown"}
SET TextLocation = {"Review","Review"}
SET Evidence = "TNFα is also a direct inhibitor of adipogenic genes and UCP-1 expression acting through
mechanisms mediated by TNFα receptors, but unrelated with the induction of
insulin resistance [64,65]."

proteinAbundance(HGNC:TNF) decreases proteinAbundance(HGNC:UCP1)

SET Cell = "Adipocytes, Brown"
SET TextLocation = "Review"
SET Evidence = "IRS-1 has recently been described as an essential signaling molecule, acting through
PI 3-kinase, in the  differentiation of brown adipocytes in vitro based on protocols
developed in mouse fibroblasts [67] and in brown fat preadipocytes [56]."
SET Species = "10090"

proteinAbundance(MGI:Irs1) increases biologicalProcess(GO:"brown fat cell differentiation")

SET Evidence = "Moreover, the loss of insulin-induced PI 3- kinase activity in IRS-1-/- brown adipocytes
was accompanied by a decrease in the phosphorylation of PKB/Akt, without
changes in the phospho-70s6k content"

proteinAbundance(MGI:Irs1) increases (proteinAbundance(PFM:"Ins Family") increases kinaseActivity(complexAbundance(NCM:"p85/p110 PI3Kinase Complex")))
proteinAbundance(MGI:Irs1) increases proteinAbundance(MGI:Akt1,proteinModification(P))
proteinAbundance(MGI:Irs1) causesNoChange proteinAbundance(MGI:Rps6kb2,proteinModification(P))

SET CellStructure = "Cytoplasm"
SET Evidence = "IRS-1 diminished the cytosolic lipid content in serum-starved homozygous and heterozygous
IRS-1-deficient brown adipocytes, as compared to wild-type cells."

proteinAbundance(MGI:Irs1) increases abundance(CHEBI:lipid)

SET Evidence = "Moreover, insulin induced a significant increase in FAS mRNA in wild-type cells, but
not in IRS-1-/- cells."

proteinAbundance(MGI:Irs1) increases (proteinAbundance(PFM:"Ins Family") increases rnaAbundance(MGI:Fasn))

SET Cell = {"Adipocytes, Brown","Adipocytes, Brown"}
SET TextLocation = {"Review","Review"}
SET Evidence = "Insulin fails to induce UCP-1 expression and to transactivate the UCP-1 promoter in
IRS-1-deficient fetal brown adipocytes due to the lack of IRS-1-associated/Akt
signaling in response to insulin (Fig. 7)."

proteinAbundance(HGNC:IRS1) increases (proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:UCP1))

SET Cell = "Adipocytes, Brown"
SET TextLocation = "Review"
SET Evidence = "IRS- 2 seems to be crucial in mediating insulin-induced glucose uptake since insulin-stimulated
glucose uptake was impaired in immortalized brown adipocytes derived
from IRS-2- deficient mice [76]."

proteinAbundance(MGI:Irs2) increases (proteinAbundance(PFM:"Ins Family") increases biologicalProcess(GO:"glucose import"))

SET Evidence = "IRS-2-deficient brown adipocytes insulin-induced effect on GLUT4 translocation to
the plasma membrane was impaired [76]."

proteinAbundance(HGNC:IRS2) increases (proteinAbundance(HGNC:INS) increases translocation(proteinAbundance(HGNC:SLC2A4),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane"))

SET Evidence = "PI 3- kinase/PKCξ, but not PI 3-kinase/Akt signaling pathway, is inhibited in IRS-2-deficient
brown adipocytes upon insulin stimulation"

proteinAbundance(HGNC:IRS2) increases kinaseActivity(proteinAbundance(HGNC:PRKCZ))
proteinAbundance(HGNC:IRS2) causesNoChange kinaseActivity(proteinAbundance(HGNC:AKT1))

SET Evidence = "wild-type cells expressing a kinase inactive (KI) mutant of PKCξ lack insulin responsiveness
in induce GLUT4 translocation and glucose uptake [78]."

kinaseActivity(proteinAbundance(HGNC:PRKCZ)) increases translocation(proteinAbundance(HGNC:SLC2A4),MESHCL:"Intracellular Space",MESHCL:"Cell Membrane")
kinaseActivity(proteinAbundance(HGNC:PRKCZ)) increases biologicalProcess(GO:"glucose import")

SET Evidence = "TZD induce their diverse effects by binding to and activating the peroxisome proliferator-
activated receptor (PPAR)γ [79]."

abundance(SCHEM:Thiazolidinedione) directlyIncreases transcriptionalActivity(proteinAbundance(HGNC:PPARG))

SET Cell = "Adipocytes"
SET Evidence = "increased GLUT4 expression has been reported in adipocytes treated with TZD [82]."

abundance(SCHEM:Thiazolidinedione) increases proteinAbundance(HGNC:SLC2A4)

SET Cell = "Adipocytes, Brown"
SET Evidence = "In brown adipocytes, TZD increase UCP-1 expression [83,84]."

abundance(SCHEM:Thiazolidinedione) increases proteinAbundance(HGNC:UCP1)

SET CellLine = "3T3-L1"
SET Evidence = "IRS-2 protein expression increased after TZD treatment in murine 3T3-L1 and human
adipocytes [85]."

abundance(SCHEM:Thiazolidinedione) increases proteinAbundance(MGI:Irs2)

SET Cell = "Adipocytes"
SET Species = "9606"

abundance(SCHEM:Thiazolidinedione) increases proteinAbundance(HGNC:IRS2)

SET Cell = {"Adipocytes, Brown","Adipocytes, White"}
SET Evidence = "Previous work reported by Angel et al. [94] demonstrated that GLUT4 mRNA and protein
levels are decreased in WAT and BAT of Type 2 diabetic rats."
SET Species = "10116"

proteinAbundance(RGD:Slc2a4) negativeCorrelation pathology(MESHD:"Diabetes Mellitus, Type 2")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 24"

SET CellLine = "MCF 10A"
SET TextLocation = "Abstract"
SET Evidence = "USF1 and USF2 bound the IGF2R promoter in vitro, and both USF1 and USF2, but not c-Myc,
were present within the IGF2R promoter-associated chromatin in vivo. Overexpressed
USF2, but not USF1, transactivated the IGF2R promoter, and IGF2R mRNA
was markedly decreased by expression of a USF-specific dominant negative mutant,
identifying IGF2R as a USF2 target."
SET Citation = {"PubMed","The Journal of biological chemistry","12857727","2003-08-11","Szentirmay MN|Yang HX|Pawar SA|Vinson C|Sawadogo M",""}

complexAbundance(proteinAbundance(HGNC:USF1),geneAbundance(HGNC:IGF2R))
complexAbundance(proteinAbundance(HGNC:USF2),geneAbundance(HGNC:IGF2R))
transcriptionalActivity(proteinAbundance(HGNC:USF2)) directlyIncreases rnaAbundance(HGNC:IGF2R)
transcriptionalActivity(proteinAbundance(HGNC:USF1)) causesNoChange rnaAbundance(HGNC:IGF2R)

SET Evidence = "c-Myc was present on the CDK4 promoter to the small extent expected in nontumorigenic
cells (8). ChIP with c-Myc antibodies was repeated in the MCF-7 breast cancer
cell line, where c-Myc is more abundant (8), to rule out a problem of detection
sensitivity. This analysis clearly demonstrated the presence of c-Myc at the
CDK4 promoter."

complexAbundance(proteinAbundance(HGNC:MYC),geneAbundance(HGNC:CDK4))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 25"

SET Cell = "Keratinocytes"
SET TextLocation = "Abstract"
SET Evidence = "The epidermis develops depending on the transcription factor p63, a member of the
p53 family of transcription factors."
SET Citation = {"PubMed","Cell death and differentiation","18483491","2008-06-16","Lena AM|Shalom-Feuerstein R|Rivetti di Val Cervo P|Aberdam D|Knight RA|Melino G|Candi E",""}

transcriptionalActivity(proteinAbundance(HGNC:TP63)) increases biologicalProcess(GO:"epidermis development")

SET Cell = {"Keratinocytes","Cells, Cultured"}
SET Evidence = "Here we report that microRNA (miR)-203 is induced in vitro in primary keratinocytes
in parallel with differentiation. We found that miR-203 specifically targets
human and mouse p63 3'-UTRs and not SOCS-3, despite bioinformatics alignment between
miR-203 and SOCS-3 3'-UTR."
SET Species = "9606"

microRNAAbundance(HGNC:MIR203) positiveCorrelation biologicalProcess(GO:"keratinocyte differentiation")

SET Species = "10090"

microRNAAbundance(MGI:Mir203) positiveCorrelation biologicalProcess(GO:"keratinocyte differentiation")
microRNAAbundance(MGI:Mir203) directlyDecreases rnaAbundance(MGI:Trp63)

SET Cell = "Keratinocytes"
SET Evidence = "In addition, we demonstrate that miR-203 is downregulated during the epithelial commitment
of embryonic stem cells, and that overexpression of miR-203 in rapidly
proliferating human primary keratinocytes significantly reduces their clonogenic
capacity. The results suggest that miR-203, by regulating the ΔNp63 expression
level, is a key molecule controlling the p63-dependent proliferative potential
of epithelial precursor cells both during keratinocyte differentiation and in epithelial
development."

microRNAAbundance(MGI:Mir203) decreases biologicalProcess(GO:"cell proliferation")
microRNAAbundance(MGI:Mir203) decreases (proteinAbundance(MGI:Trp63) increases biologicalProcess(GO:"cell proliferation"))

SET Evidence = "As shown in Figure 1a and b, miR-203 was rapidly upregulated (about 12-fold in mouse
keratinocytes upon 24 h calcium treatment) when cells where induced by calcium
to differentiate in vitro. Concurrently, with miR-203 upregulation, we observed
DNp63 downregulation in differentiating cells (Figure 1a and b)."

microRNAAbundance(MGI:Mir203) positiveCorrelation biologicalProcess(GO:"keratinocyte differentiation")
proteinAbundance(MGI:Trp63) negativeCorrelation biologicalProcess(GO:"keratinocyte differentiation")

SET Evidence = "To further evaluate directly if SOCS-3 is indeed a genuine target of miR-203, we exogenously
expressed miR-203 in mouse keratinocytes by infection with adenovirus
containing miR-203. Figure 1c (lanes 4–6) shows a slight upregulation of SOCS-3
as compared with keratinocytes infected with adenovirus containing scrambled sequence
(lanes 1–3). These data indicate that SOSC-3 is not repressed by miR- 203;
conversely its upregulation is presumably independent of miR-203."

microRNAAbundance(MGI:Mir203) causesNoChange proteinAbundance(MGI:Socs3)

SET Evidence = "As control, Figure 2d also shows p63 mRNA levels in keratinocytes induced to differentiate
by calcium treatment. p63 protein expression was also markedly diminished
in mouse keratinocytes infected with adenovirus containing miR-203 (Figure 2e,
lanes 3–4) compared with mouse keratinocytes infected with adenovirus containing
a scrambled sequence (lanes 1–2). Together, these results indicate that effect
of miR-203 on p63 is direct and is mediated by a specific 30-UTR target site."

microRNAAbundance(MGI:Mir203) directlyDecreases rnaAbundance(MGI:Trp63)

SET Evidence = "Indeed, we have previously shown that the ubiquitin E3 ligase, Itch, contributes to
the reduction in DNp63 protein levels.21"

catalyticActivity(proteinAbundance(MGI:Itch)) directlyIncreases degradation(proteinAbundance(MGI:Trp63))

SET Evidence = "As expected, pre-miR-transfected cells showed reduced cell growth when compared to
cells transfected with scrambled oligonucleotides. In contrast, overexpression
of antagomiR- 203 resulted in an increase in cell growth (Figure 4)."

microRNAAbundance(MGI:Mir203) decreases biologicalProcess(GO:"cell proliferation")

SET Evidence = "This suggests that overexpression of miR-203 triggers cells toward differentiation
by interfering with the proliferative potential of proliferating keratinocytes
through ΔNp63 downregulation. This result is consistent with a requirement for
ΔNp63 in maintaining proliferative potential of epidermal stem cells."

proteinAbundance(MGI:Trp63) increases biologicalProcess(GO:"cell proliferation")

SET Cell = "Embryonic Stem Cells"
SET Evidence = "Embryonic stem cells can recapitulate in vitro the main steps of embryonic epidermal
differentiation upon exogenous addition of bone morphogenic protein (BMP)-4."

proteinAbundance(MGI:Bmp4) increases biologicalProcess(GO:"epidermal cell differentiation")

SET Evidence = "Soon after BMP-4 treatment, the ΔNp63 gene is activated and remains strongly expressed
until the cells undergo terminal epidermal differentiation.28 Using these
experimental conditions, and concomitant with DNp63 mRNA upregulation, we observed
that miR-203 expression is downregulated (Figure 5c)."

proteinAbundance(MGI:Bmp4) increases rnaAbundance(MGI:Trp63)
proteinAbundance(MGI:Bmp4) decreases rnaAbundance(MGI:Mir203)

SET Disease = {"Head and Neck Neoplasms","Carcinoma, Squamous Cell"}
SET Evidence = "Besides the epidermis and other stratified squamous epithelia, ΔNp63 is commonly overexpressed
in up to 80% of primary head and neck squamous cell carcinomas (HNSCCs).29"
SET Species = "9606"

proteinAbundance(HGNC:TP63) positiveCorrelation pathology(MESHD:"Carcinoma, Squamous Cell")
proteinAbundance(HGNC:TP63) positiveCorrelation pathology(MESHD:"Head and Neck Neoplasms")

SET Evidence = "Recently, it has been shown that ΔNp63a is also overexpressed in HNSCC cell lines
(including JHU-012) and in these cells, it acts as a crucial survival factor by
suppressing p73-dependent apoptosis.29,32–34 Knockdown of ΔNp63 induces the proapoptotic
bcl-2-family members Puma and Noxa, and both their induction and cell
death are p53-independent, but require transactivating isoforms of p73. The inhibition
of p73-dependent transcription by DNp63a involves both direct promoter binding
and physical sequestration of p73 by protein–protein interaction.29,34–35"

proteinAbundance(HGNC:TP63) decreases biologicalProcess(GO:"apoptotic process")
proteinAbundance(HGNC:TP63) decreases (proteinAbundance(HGNC:TP73) increases biologicalProcess(GO:"apoptotic process"))
proteinAbundance(HGNC:TP63) decreases proteinAbundance(HGNC:BBC3)
proteinAbundance(HGNC:TP63) decreases proteinAbundance(HGNC:PMAIP1)
transcriptionalActivity(proteinAbundance(HGNC:TP73)) increases proteinAbundance(HGNC:BBC3)
transcriptionalActivity(proteinAbundance(HGNC:TP73)) increases proteinAbundance(HGNC:PMAIP1)
proteinAbundance(HGNC:TP63) directlyDecreases transcriptionalActivity(proteinAbundance(HGNC:TP73))

SET Cell = "Cell Line, Tumor"
SET Evidence = "As shown in Figure 6a, ΔNp63 expression was already decreased in JHU-012 cells 12
h after UVC treatment. Simultaneously, with DNp63 downregulation, miR-203 was significantly
upregulated as evaluated by real-time PCR (Figure 6b)."

biologicalProcess(GO:"response to UV-C") decreases proteinAbundance(HGNC:TP63)
biologicalProcess(GO:"response to UV-C") increases rnaAbundance(HGNC:MIR203)

SET Evidence = "To verify that the observed effect on apoptosis and cell cycle is, at least in part,
mediated by miR-203, we infected JHU-012 cells with adenoviruses containing
miR-203 or scrambled sequence. ΔNp63 protein expression was markedly diminished
(about 50%) in JHU-012 cells infected with adenovirus containing miR-203 as compared
with cells infected with adenovirus containing scrambled sequence (Figure 7a).
In addition, we observed a significant increase of cell death (from 5 to 17%,
Figure 7b), an increased number of cells in G1 and a reduction in the proportion
of cells in G2 (Figure 7c)."

microRNAAbundance(HGNC:MIR203) decreases proteinAbundance(HGNC:TP63)
microRNAAbundance(HGNC:MIR203) increases biologicalProcess(GO:"apoptotic process")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 26"

SET Disease = "Neoplasms"
SET CardiovascularSystem = "Blood Vessels"
SET TextLocation = "Abstract"
SET Evidence = "intravital microscopy failed to demonstrate that targeting of VEGFR-2 (by the tyrosine
kinase inhibitor SU5416) induces significant regression of experimental tumor
blood vessels."
SET Citation = {"PubMed","The FASEB journal : official publication of the Federation of American Societies for Experimental Biology","14657001","2004-01-04","Erber R|Thurnher A|Katsen AD|Groth G|Kerger H|Hammes HP|Menger MD|Ullrich A|Vajkoczy P",""}
SET Species = "10090"

abundance(SCHEM:"SU 5416") directlyDecreases kinaseActivity(proteinAbundance(MGI:Kdr))

SET Cell = "Pericytes"
SET Evidence = "this resistance of tumor blood vessels to VEGFR-2 targeting is conferred by pericytes
that stabilize blood vessels and provide endothelial cell survival signals
via the Ang-1/Tie2 pathway."

proteinAbundance(MGI:Angpt1) directlyIncreases kinaseActivity(proteinAbundance(MGI:Tek))
kinaseActivity(proteinAbundance(MGI:Tek)) increases biologicalProcess(GO:"blood vessel development")

SET Evidence = "targeting VEGFR-2 plus the platelet- derived growth factor receptor (PDGFR)-β system
(PDGFR- β) signaling (by SU6668) rapidly forced 40% of tumor blood vessels into
regression, rendering these tumors hypoxic as shown by phosphorescence quenching."

abundance(SCHEM:"SU 6668") directlyDecreases kinaseActivity(proteinAbundance(MGI:Pdgfrb))
compositeAbundance(abundance(SCHEM:"SU 5416"),abundance(SCHEM:"SU 6668")) increases biologicalProcess(MESHPP:"Cell Hypoxia")
compositeAbundance(abundance(SCHEM:"SU 5416"),abundance(SCHEM:"SU 6668")) increases biologicalProcess(GO:"blood vessel development")

SET Cell = "Endothelial Cells"
SET Evidence = "VEGFR-2 plus PDGFR-β targeting enforced tumor blood vessel regression by inducing
endothelial cell apoptosis."

compositeAbundance(abundance(SCHEM:"SU 5416"),abundance(SCHEM:"SU 6668")) increases biologicalProcess(GO:"apoptotic process")

SET TextLocation = "Results"
SET Evidence = "Whereas expression of the VEGF and FGF systems remained largely unchanged, expression
of PDGFR-β and Tie2 were nearly doubled and expression of Ang-1 was increased
by nine fold in SU5416- treated tumors (Fig. 3A-C)."

abundance(SCHEM:"SU 5416") increases rnaAbundance(MGI:Pdgfrb)
abundance(SCHEM:"SU 5416") increases rnaAbundance(MGI:Tek)
abundance(SCHEM:"SU 5416") increases rnaAbundance(MGI:Angpt1)

SET Cell = "Pericytes"
SET Evidence = "the increased expression of PDGFR- β and Tie2 was clearly attributable to pericytes
and endothelial cells (i.e., cells of mouse origin), respectively."

abundance(SCHEM:"SU 5416") increases rnaAbundance(MGI:Pdgfrb)

SET Cell = "Endothelial Cells"

abundance(SCHEM:"SU 5416") increases rnaAbundance(MGI:Tek)

SET IntegumentarySystem = "Skin"
SET Evidence = "However, by none of these means we could detect significant Ang-1 mRNA levels in normal
skin, neither in control nor in treated tissue."

abundance(SCHEM:"SU 5416") causesNoChange rnaAbundance(MGI:Angpt1)

SET Disease = "Hyperplasia"
SET Evidence = "tumor blood vessels in SU6668-treated tumors presented with endothelial hyperplasia
and an increased number of luminal folds (Fig. 5C and D; compare with Fig. 2D)."

abundance(SCHEM:"SU 6668") increases pathology(MESHD:Hyperplasia)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 27"

SET CardiovascularSystem = "Carotid Arteries"
SET TextLocation = "Results"
SET Evidence = "In situ hybridization of injured and control carotid arteries also revealed marked
downregulation of miR-143 and miR-145 expression in the thickened vascular wall,
coincident with decreased expression of the differentiation marker, smooth muscle
α-actin (Sm- α actin) (Supplementary Fig. 4a)."
SET Citation = {"PubMed","Nature","19578358","2009-08-05","Cordes KR|Sheehy NT|White MP|Berry EC|Morton SU|Muth AN|Lee TH|Miano JM|Ivey KN|Srivastava D",""}
SET Species = "10090"

pathology(SDIS:"tissue damage") decreases microRNAAbundance(MGI:Mir143)
pathology(SDIS:"tissue damage") decreases microRNAAbundance(MGI:Mir145)
microRNAAbundance(MGI:Mir143) positiveCorrelation rnaAbundance(MGI:Acta2)
microRNAAbundance(MGI:Mir145) positiveCorrelation rnaAbundance(MGI:Acta2)

SET CardiovascularSystem = "Heart"
SET Evidence = "miR-143 and miR-145 expression was also decreased in hearts of Nkx2.5 mutant mouse
embryos in a dose-dependent fashion (Fig. 2h)."

proteinAbundance(MGI:"Nkx2-5") increases microRNAAbundance(MGI:Mir143)
proteinAbundance(MGI:"Nkx2-5") increases rnaAbundance(MGI:Mir145)

SET CardiovascularSystem = "Carotid Arteries"
SET Evidence = "lentiviral-mediated introduction of miR-145 into ligated mouse carotid arteries in
vivo increased expression of markers of VSMC differentiation (e.g., Calponin and
Sm-α-actin), as well as Myocd, compared to control-infected injured carotid arteries
(Supplementary Fig. 7)."

microRNAAbundance(MGI:Mir145) increases proteinAbundance(MGI:Cnn1)
rnaAbundance(MGI:Mir145) increases proteinAbundance(MGI:Acta2)
rnaAbundance(MGI:Mir145) increases proteinAbundance(MGI:Myocd)

SET Cell = "Embryoid Bodies"
SET Evidence = "miR-143 and miR-145 were each expressed at lower levels in SRF-null embryoid bodies
(EBs) compared to wildtype EBs derived from the respective ES cells (Fig. 2g)"

proteinAbundance(MGI:Srf) increases microRNAAbundance(MGI:Mir143)
proteinAbundance(MGI:Srf) increases rnaAbundance(MGI:Mir145)

SET Cell = "COS Cells"
SET Evidence = "Nkx2.5 could also independently activate this enhancer (miR-143/145 enhancer), and
the combination of SRF, Myocd, and Nkx2.5, which also interacts with SRF26, had
additive effects on luciferase activity. Mutation of each binding site progressively
decreased luciferase activity (Fig. 2f)."
SET Species = "9606"

transcriptionalActivity(proteinAbundance(HGNC:"NKX2-5")) directlyIncreases microRNAAbundance(HGNC:MIR145)
transcriptionalActivity(proteinAbundance(HGNC:SRF)) directlyIncreases microRNAAbundance(HGNC:MIR145)
transcriptionalActivity(proteinAbundance(HGNC:MYOCD)) directlyIncreases microRNAAbundance(HGNC:MIR145)
transcriptionalActivity(proteinAbundance(HGNC:"NKX2-5")) directlyIncreases microRNAAbundance(HGNC:MIR143)
transcriptionalActivity(proteinAbundance(HGNC:SRF)) directlyIncreases microRNAAbundance(HGNC:MIR143)
transcriptionalActivity(proteinAbundance(HGNC:MYOCD)) directlyIncreases microRNAAbundance(HGNC:MIR143)
compositeAbundance(proteinAbundance(HGNC:"NKX2-5"),proteinAbundance(HGNC:SRF),proteinAbundance(HGNC:MYOCD)) directlyIncreases microRNAAbundance(HGNC:MIR145)
compositeAbundance(proteinAbundance(HGNC:"NKX2-5"),proteinAbundance(HGNC:SRF),proteinAbundance(HGNC:MYOCD)) directlyIncreases microRNAAbundance(HGNC:MIR143)

SET CardiovascularSystem = "Muscle, Smooth, Vascular"
SET Evidence = "These findings suggest that miR-145 may promote VSMC differentiation by directly repressing
numerous transcription factors that promote the proliferative state while
stabilizing factors that promote the differentiated state of VSMCs (Fig. 5)."
SET Species = "10090"

microRNAAbundance(MGI:Mir145) increases biologicalProcess(GO:"cardiac vascular smooth muscle cell differentiation")

SET Evidence = "introduction of miR-145, but not miR-143, with the luciferase vector in Cos cells
resulted in relief of the repression and an ~150-fold increase in luciferase activity
compared to the CMV-luciferase- Myocd 3' UTR-luciferase vector alone (Fig.
4d)."
SET Species = "9606"

microRNAAbundance(HGNC:MIR145) increases proteinAbundance(HGNC:MYOCD)
microRNAAbundance(HGNC:MIR143) causesNoChange proteinAbundance(HGNC:MYOCD)

SET Evidence = "In the presence of the Elk-1 3' UTR, miR-143 repressed luciferase activity; this repression
was diminished upon mutation of one of the two miR-143 binding sites
(Fig. 4a)."

microRNAAbundance(HGNC:MIR143) directlyDecreases proteinAbundance(HGNC:ELK1)

SET Evidence = "SRF weakly activated the miR-143/145 enhancer upstream of a luciferase reporter, but
co-transfection of Myocd synergistically and robustly activated luciferase activity
in Cos cells (Fig. 2f)."

compositeAbundance(proteinAbundance(HGNC:SRF),proteinAbundance(HGNC:MYOCD)) increases microRNAAbundance(HGNC:MIR145)
compositeAbundance(proteinAbundance(HGNC:SRF),proteinAbundance(HGNC:MYOCD)) increases microRNAAbundance(HGNC:MIR143)

SET Evidence = "The miR-145 binding site in the 3' UTR of Klf4 specifically mediated miR-145- dependent
repression in luciferase assays (Fig. 4e and Supplementary Fig. 6c)."

microRNAAbundance(HGNC:MIR145) directlyDecreases proteinAbundance(HGNC:KLF4)

SET Disease = "Atherosclerosis"
SET CardiovascularSystem = "Blood Vessels"
SET TextLocation = "Abstract"
SET Evidence = "miR-145 and miR-143 were direct transcriptional targets of serum response factor,
myocardin and Nkx2-5 (NK2 transcription factor related, locus 5) and were downregulated
in injured or atherosclerotic vessels containing proliferating, less differentiated
smooth muscle cells"

microRNAAbundance(MGI:Mir145) negativeCorrelation pathology(MESHD:Atherosclerosis)
microRNAAbundance(MGI:Mir143) negativeCorrelation pathology(MESHD:Atherosclerosis)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 28"

SET CellLine = "293"
SET TextLocation = "Abstract"
SET Evidence = "In human embryonic kidney 293 cells, IL-1β induces IκB kinase β (IKKβ) activation,
IκBα degradation, NF-κB transactivation, and weak Akt activation."
SET Citation = {"PubMed","The Journal of biological chemistry","11976320","2002-05-25","Chen BC|Wu WT|Ho FM|Lin WW",""}
SET Species = "9606"

proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IKBKB))
proteinAbundance(HGNC:IL1B) increases degradation(proteinAbundance(HGNC:NFKBIA))
proteinAbundance(HGNC:IL1B) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET Evidence = "However, IL-1β-induced NF-κB activity is attenuated by increased intracellular calcium
in response to ionomycin, UTP, or thapsigargin or by overexpression of CaMKKc
and/or Akt. Ionomycin and CaMKKc overexpression increases Akt phosphorylation
on Thr308 and enzyme activity. Under these conditions or upon overexpression of
wild type Akt, IL-1β-induced IKKβ activity is diminished. Furthermore, a dominant
negative mutant of Akt abolishes IKKβ inhibition by CaMKKc and ionomycin, suggesting
that Akt acts as a mediator of CaMKK signaling to inhibit IL-1β-induced
IKK activity at an upstream target site."

abundance(SCHEM:Ionomycin) increases abundance(CHEBI:"calcium(2+)")
abundance(CHEBI:UTP) increases abundance(CHEBI:"calcium(2+)")
abundance(CHEBI:thapsigargin) increases abundance(CHEBI:"calcium(2+)")
abundance(CHEBI:"calcium(2+)") decreases (proteinAbundance(HGNC:IL1B) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))
kinaseActivity(proteinAbundance(PFH:"CAMK Family")) decreases (proteinAbundance(HGNC:IL1B) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))) //Do not have a CAMKK Family (CAMKK1 and CAMKK2)
proteinAbundance(PFH:"AKT Family") decreases (proteinAbundance(HGNC:IL1B) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))
kinaseActivity(proteinAbundance(PFH:"CAMK Family")) increases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308)) //CAMKKc is constitutively active CAMKK
kinaseActivity(proteinAbundance(PFH:"CAMK Family")) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
abundance(SCHEM:Ionomycin) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
abundance(SCHEM:Ionomycin) increases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))
abundance(SCHEM:Ionomycin) decreases (proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IKBKB)))
kinaseActivity(proteinAbundance(PFH:"CAMK Family")) decreases (proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IKBKB)))
kinaseActivity(proteinAbundance(PFH:"AKT Family")) decreases (proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IKBKB)))

SET Evidence = "CaMKKc and Akt overexpression decreases IRAK1-mediated NF-κB activity and its association
with MyD88 in response to IL-1β stimulation. Furthermore, CaMKKc and Akt
overexpression increases IRAK1 phosphorylation at Thr100, and point mutation of
this site abrogates the inhibitory effect of Akt on IRAK1-mediated NF-κB activation."

proteinAbundance(HGNC:IRAK1) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
kinaseActivity(proteinAbundance(PFH:"CAMK Family")) decreases (proteinAbundance(HGNC:IRAK1) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))
proteinAbundance(PFH:"AKT Family") decreases (proteinAbundance(HGNC:IRAK1) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))
kinaseActivity(proteinAbundance(PFH:"CAMK Family")) increases proteinAbundance(HGNC:IRAK1,proteinModification(P,T,100))
proteinAbundance(PFH:"AKT Family") increases proteinAbundance(HGNC:IRAK1,proteinModification(P,T,100))
proteinAbundance(HGNC:IRAK1,proteinModification(P,T,100)) directlyDecreases (proteinAbundance(HGNC:IRAK1) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))

SET TextLocation = "Results"
SET Evidence = "In cells transfected with negative mutants of IKKα, IKKβ, and NIK, IL-1β-induced κB
luciferase activity were inhibited by 32 ± 7%, 70 ± 11%, and 33 ± 8%, respectively
(Fig. 1D). Compared with the distinct selectivity for IL-1β action, IKKα and
IKKβ mutants reduced the NIK-induced κB response to a similar extent (Fig. 1D)."

kinaseActivity(proteinAbundance(HGNC:IKBKB)) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
kinaseActivity(proteinAbundance(HGNC:CHUK)) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")) //IKK alpha = CHUK
kinaseActivity(proteinAbundance(HGNC:MAP3K14)) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))

SET Evidence = "Probing of immunoblots with antibodies specific for phosphorylated Akt showed that
10 ng/ml of IL-1β slightly increased Akt Thr308 and Ser473 phosphorylation within
60 min (Fig.2). Using histone H2B as an Akt substrate, a slight increase in
Akt kinase activity was noted within the same time interval as Akt phosphorylation
(Fig. 2)."

proteinAbundance(HGNC:IL1B) increases proteinAbundance(PFH:"AKT Family",proteinModification(P,T,308))
proteinAbundance(HGNC:IL1B) increases proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473))
proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET Evidence = "A shows that IL-1β at 10 ng/ml increased IRAK1 activity, which reached a maximum after
10 min and was sustained for at least 90 min."

proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IRAK1)) //IRAK1 is a kinase

SET Evidence = "IL-1β-induced IRAK1 activity was inhibited by treatment with ionomycin or overexpression
of CaMKKc and Akt."

kinaseActivity(proteinAbundance(PFH:"CAMK Family")) decreases (proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IRAK1)))
proteinAbundance(PFH:"AKT Family") decreases (proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IRAK1)))
abundance(SCHEM:Ionomycin) decreases (proteinAbundance(HGNC:IL1B) increases kinaseActivity(proteinAbundance(HGNC:IRAK1)))

SET Evidence = "In support of previous findings, kinase-dead IRAK1 (K239A) transfection efficiently
triggered κB luciferase activity at a level equivalent to that of wild type IRAK1,
and this activity was similarly reduced by CaMKKc and Akt (Fig. 9C). These
results suggest that the inhibition of IRAK1-dependent signaling by Akt is unrelated
to the kinase activity of IRAK1."

kinaseActivity(proteinAbundance(HGNC:IRAK1)) causesNoChange transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))

SET Evidence = "These results confirm that IRAK1 and Akt can interact in vivo, particularly following
Akt activation."

complexAbundance(proteinAbundance(PFH:"AKT Family"),proteinAbundance(HGNC:IRAK1))

SET Evidence = "Upon stimulation with 10 ng/ml IL-1β for 15 or 30 min, IRAK1 co-immunoprecipitation
with MyD88 was enhanced, whereas it was reduced by the overexpression of Akt
and CaMKKc (Fig.10,C and D)."

proteinAbundance(HGNC:IL1B) increases complexAbundance(proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:MYD88))
proteinAbundance(PFH:"AKT Family") decreases complexAbundance(proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:MYD88))
kinaseActivity(proteinAbundance(PFH:"CAMK Family")) decreases complexAbundance(proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:MYD88))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 29"

SET TextLocation = "Abstract"
SET Evidence = "From yeast two-hybrid experiments we are able to show that the SR3-SR4 domains of
α-actinin 2 are required to bind the COOH-terminal region of the FATZ as does γ-filamin/ABP-L.
Furthermore, by using a glutathione S-transferase overlay assay
we find that FATZ also binds telethonin"
SET Citation = {"PubMed","The Journal of biological chemistry","10984498","","Faulkner G|Pallavicini A|Comelli A|Salamon M|Bortoletto G|Ievolella C|Trevisan S|Kojic' S|Dalla Vecchia F|Laveder P|Valle G|Lanfranchi G",""}

complexAbundance(proteinAbundance(HGNC:MYOZ1),proteinAbundance(HGNC:ACTN2))
complexAbundance(proteinAbundance(HGNC:MYOZ1),proteinAbundance(HGNC:FLNC))
complexAbundance(proteinAbundance(HGNC:MYOZ1),proteinAbundance(HGNC:TCAP))

SET Cell = "Muscle Cells"
SET Evidence = "The level of FATZ protein in muscle cells increases during differentiation, being
clearly detectable before the onset of myosin"

proteinAbundance(HGNC:MYOZ1) positiveCorrelation biologicalProcess(GO:"cell differentiation")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 30"

SET TextLocation = "Abstract"
SET Evidence = "The tumor necrosis factor α receptor (TNFR1) activates downstream effectors that include
the mitogen-activated protein kinase kinase 7 (MKK7)/c-Jun-NH2-kinase (JNK)/activator
protein 1 (AP1) cascade. Here, we report that JNK is activated in
a majority of spontaneous human squamous cell carcinomas (SCC)."
SET Citation = {"PubMed","Cancer research","17440097","","Zhang JY|Adams AE|Ridky TW|Tao S|Khavari PA",""}
SET Species = "9606"

molecularActivity(proteinAbundance(HGNC:TNFRSF1A)) increases kinaseActivity(proteinAbundance(HGNC:MAP2K7))
molecularActivity(proteinAbundance(HGNC:TNFRSF1A)) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
molecularActivity(proteinAbundance(HGNC:TNFRSF1A)) increases transcriptionalActivity(complexAbundance(NCH:"AP-1 Complex"))
kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")) positiveCorrelation pathology(MESHD:"Carcinoma, Squamous Cell")

SET TextLocation = "Results"
SET Evidence = "To study the frequency of JNK induction in human SCC, we probed tissue microarrays
of spontaneous human SCC samples (n=52) with antibodies directed against the phosphorylated
active forms of JNK. Eighty-one percent of SCCs examined exhibited
either strong or moderately strong induction of phosphorylated JNK (pJNK) over
normal tissues (Fig. 1A)."

kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")) positiveCorrelation pathology(MESHD:"Carcinoma, Squamous Cell")

SET Evidence = "To address this, we first studied the effect of a JNK-specific inhibitor, SP600125
(30), which has been shown to inhibit JNK function and epidermal hyperplasia in
epidermis expressing IκBα or deficient in relA (16)."

abundance(SCHEM:SP600125) directlyDecreases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET Evidence = "Ras-driven epidermal neoplasias generated on the surface of immunodeficient SCID mice
were treated topically with DMSO vehicle or SP600125 daily for 5 weeks. DMSO
and untreated control tissues displayed typical findings of neoplasia, including
invasion and disruption of the BMZ, as visualized by type VII collagen staining
(Fig. 2A). In contrast, tissues treated with SP600125 lacked invasive neoplasia
and retained sharp delineation of the BMZ, with a humanspecific desmoglein-3
antibody confirming the human origin of these tissues (Fig. 2A)."

gtpBoundActivity(proteinAbundance(HGNC:HRAS)) increases pathology(MESHD:Neoplasms)
abundance(SCHEM:SP600125) decreases (gtpBoundActivity(proteinAbundance(HGNC:HRAS)) increases pathology(MESHD:Neoplasms))

SET Evidence = "To investigate whether JNK/AP1 dependency is a general process common to other SCC
cell types, we expressed DNc-Jun in spontaneous human SCC cell lines, A431 and
SCC25, and found that DNc-Jun significantly inhibited their s.c. tumor growth as
well (Fig. 2B–C). Furthermore, retroviral-mediated RNA interference knockdown
of MKK7, the upstream activator of JNK, also prevented s.c. tumor growth of A431,
SCC25, and primary keratinocytes transformed by Ras and IκBα (Fig. 2B–D)."

transcriptionalActivity(proteinAbundance(HGNC:JUN)) increases pathology(MESHD:"Carcinoma, Squamous Cell")
kinaseActivity(proteinAbundance(HGNC:MAP2K7)) increases pathology(MESHD:"Carcinoma, Squamous Cell")
transcriptionalActivity(proteinAbundance(HGNC:JUN)) increases pathology(SDIS:"tumor growth")
kinaseActivity(proteinAbundance(HGNC:MAPK7)) increases pathology(SDIS:"tumor growth")

SET Evidence = "We next asked whether components of the JNK cascade could directly promote human epidermal
neoplasia. We expressed either active MKK7 or c-Jun in primary keratinocytes
and examined their capacity to promote tumorigenesis in combination with
Ras in the absence of IκBα. First, we confirmed induction of AP1-dependent gene
reporter activity by MKK7 in vitro (Supplementary Fig. S4). Surface skin grafts
were then regenerated with primary keratinocytes expressing MKK7 and Ras; these
developed into clinical tumors resembling SCC (Fig. 3A). Dermal invasion, one of
the hallmarks of spontaneous human SCC, is apparent in tumors induced by MKK7 and
Ras as revealed by both histologic appearance and BMZ disruption (Fig. 3B–C).
MKK7 and Ras-induced neoplasia depends on intact AP1 function as concurrent expression
of DNc-Jun prevents tumorigenesis (Fig. 3A–C)."

proteinAbundance(HGNC:MAP2K7) increases pathology(MESHD:"Carcinoma, Squamous Cell")
proteinAbundance(HGNC:JUN) increases pathology(MESHD:"Carcinoma, Squamous Cell")
compositeAbundance(proteinAbundance(HGNC:HRAS),proteinAbundance(HGNC:MAP2K7)) increases pathology(MESHD:"Carcinoma, Squamous Cell")

SET Evidence = "Of interest, although Ras by itself activates AP1, coexpression of Ras with MKK7 induces
significantly higher levels of AP1 activity in primary human keratinocytes
than either one alone (Supplementary Fig. S5), indicating that Ras and MKK7 act
in synergy to induce downstream signaling."

kinaseActivity(proteinAbundance(HGNC:MAP2K7)) increases transcriptionalActivity(complexAbundance(NCH:"AP-1 Complex"))
gtpBoundActivity(proteinAbundance(HGNC:HRAS)) increases transcriptionalActivity(complexAbundance(NCH:"AP-1 Complex"))
compositeAbundance(proteinAbundance(HGNC:HRAS),proteinAbundance(HGNC:MAP2K7)) increases transcriptionalActivity(complexAbundance(NCH:"AP-1 Complex"))

SET Cell = "Keratinocytes"
SET Evidence = "Oncogenic Ras alone induces growth arrest in primary human keratinocytes in the G1
phase of the cell cycle (19,31)."

proteinAbundance(HGNC:HRAS,substitution(G,12,V)) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")

SET Evidence = "MKK7 bypassed cell cycle G1 arrest induced by Ras, as shown by flow cytometry (Fig.
4B). Thus, MKK7 promotes epidermal cell proliferation and rescues Ras-induced
cell cycle arrest."

kinaseActivity(proteinAbundance(HGNC:MAP2K7)) decreases (gtpBoundActivity(proteinAbundance(HGNC:HRAS)) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle"))

SET Evidence = "CDK4 is a cyclin-dependent kinase promoting G1 progression previously shown to be
posttranscriptionally down-regulated by Ras, a finding whose functional importance
has been confirmed because CDK4 can bypass Ras-induced growth arrest (31). CDK4
protein was also restored to near-normal levels by MKK7."

kinaseActivity(proteinAbundance(HGNC:CDK4)) increases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")
gtpBoundActivity(proteinAbundance(HGNC:HRAS)) decreases proteinAbundance(HGNC:CDK4)
kinaseActivity(proteinAbundance(HGNC:CDK4)) decreases (proteinAbundance(HGNC:HRAS,substitution(G,12,V)) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle"))

SET Evidence = "In support of this, TNFR1 has recently been implicated in murine epidermal tumorigenesis.
Genetic deletion of Tnfr1 diminished occurrence of neoplasia in mice induced
by both NF-κB blockade and chemical carcinogenesis (33,34)."

proteinAbundance(HGNC:TNFRSF1A) increases pathology(MESHD:Neoplasms)

SET Evidence = "Moreover, recent findings showed that epidermal NF-κB blockade relieves constitutive
repression of JNK activity by the NF-κB RelA subunit and that TNFR1 is required
both for the JNK induction as well as the epidermal hyperplasia that occurs
in this setting (16,17)."

proteinAbundance(HGNC:RELA) decreases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET Evidence = "In contrast, tissues treated with TNFR1 antibody, although hyperplastic, retained
BMZ structure and proper desmoglein-3 expression, indicating intact tissue polarity
(Fig. 5A and B). Blockade of TNFR1 signaling was accompanied by the absence
of detectable pJNK in the tissues treated by the TNFR1 antibody (Supplementary
Fig. S7). In addition, TNFR1 blockade reduced the mitotic index and limited mitotic
cells to the basal layer, whereas proliferating cells were widespread and abundant
in the control tumor tissue (Fig. 5C and D). These findings indicate that
antagonizing TNFR1 function prevents Ras-driven tumorigenesis."

molecularActivity(proteinAbundance(HGNC:TNFRSF1A)) increases pathology(MESHD:Neoplasms)

SET Evidence = "In agreement with this, antibody-mediated TNFR1 blockade significantly inhibited s.c.
tumor growth of three independent SCC tumor lines, A431, SCC25, and CAL27 (Supplementary
Fig. S8A). To determine if TNFR1 action in this context is tumor cell
intrinsic, we used retroviral-mediated RNA interference to decrease TNFR1 expression.
Reduced levels of TNFR1, as confirmed by immunoblotting, significantly
inhibited s.c. growth of Ras-driven tumors and SCC lines (Supplementary Fig. S8B)."

molecularActivity(proteinAbundance(HGNC:TNFRSF1A)) increases pathology(MESHD:"Carcinoma, Squamous Cell")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 31"

SET RespiratorySystem = "Lung"
SET Evidence = "Based on these observations, a mouse model of lung adenocarcinoma has been generated
in which nasal instillation of Ad-Cre to the lungs of K-Ras+/LSL-G12D  conditional
mutant mice (Figure 1a) results in the expression of oncogenic K-RasG12D
and the development of lesions that resemble human tumors (Jackson et al., 2001)."
SET Citation = {"PubMed","Oncogene","19151761","2009-02-19","Ho VM|Schaffer BE|Karnezis AN|Park KS|Sage J",""}
SET Species = "10090"

proteinAbundance(MGI:Kras,substitution(G,12,D)) increases pathology(MESHD:Neoplasms)

SET TextLocation = "Results"
SET Evidence = "The RB tumor suppressor is inactivated in a broad range of human tumors (Classon and
Harlow, 2002; Sherr and McCormick, 2002), including pediatric retinoblastomas
and ~90% of human small cell lung carcinomas (SCLCs)."
SET Species = "9606"

proteinAbundance(HGNC:RB1) negativeCorrelation pathology(MESHD:"Small Cell Lung Carcinoma")
proteinAbundance(HGNC:RB1) negativeCorrelation pathology(MESHD:Retinoblastoma)

SET Evidence = "For instance, RB is rarely found mutated in lung adeno-carcinomas whereas p16INK4α,
an upstream activator of the pRb protein and the two related proteins p107 and
p130, is frequently inactivated in this tumor type (Wistuba et al., 2001)."

proteinAbundance(SPAC:P42771) negativeCorrelation pathology(MESHD:Adenocarcinoma)

SET Evidence = "In addition, loss of function of the pRb family member p130 may be part of tumor progression
in several types of human cancers, including lung adenocarcinomas (Claudio
et al., 2000; Cinti et al., 2005), but a causal role for loss of p130 in
lung cancer progression also remains to be determined."

proteinAbundance(HGNC:RBL2) negativeCorrelation pathology(MESHD:Adenocarcinoma)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 32"

SET CellLine = "IMR-90"
SET Cell = "Fibroblasts"
SET RespiratorySystem = "Lung"
SET TextLocation = "Abstract"
SET Evidence = "inhibition of fibroblast proliferation was mediated exclusively by activation of Epac-1.
PGE2 and Epac-1 inhibited cell proliferation through activation of the small
GTPase Rap1, since decreasing Rap1 activity by transfection with Rap1GAP or
the dominant-negative Rap1N17 prevented, and transfection with the constitutively
active Rap1V12 mimicked, the anti-proliferative effects of PGE2"
SET Citation = {"PubMed","American journal of respiratory cell and molecular biology","18421013","2008-05-17","Huang SK|Wettlaufer SH|Chung J|Peters-Golden M",""}
SET Species = "9606"

abundance(CHEBI:"prostaglandin E2") increases molecularActivity(proteinAbundance(HGNC:RAPGEF3))
molecularActivity(proteinAbundance(HGNC:RAPGEF3)) increases gtpBoundActivity(proteinAbundance(HGNC:RAP1A))
gtpBoundActivity(proteinAbundance(HGNC:RAP1A)) decreases biologicalProcess(MESHPP:"Cell Proliferation")

SET TextLocation = "Results"
SET Evidence = "Work in our laboratory (13) and others (14) has shown that the inhibitory actions
of PGE2 in lung fibroblasts are a result of increases in cAMP, mediated through
the Gas-coupled EP2 receptor;"

abundance(CHEBI:"prostaglandin E2") directlyIncreases molecularActivity(proteinAbundance(HGNC:PTGER2))
molecularActivity(proteinAbundance(HGNC:PTGER2)) increases abundance(CHEBI:"3',5'-cyclic AMP")
abundance(CHEBI:"3',5'-cyclic AMP") decreases biologicalProcess(MESHPP:"Cell Proliferation")

SET Evidence = "To determine which cAMP effector-PKA or Epac-is capable of inhibiting collagen expression
and proliferation, fibroblasts were treated with varying concentrations
of the selective PKA agonist 6-bnz-cAMP or the selective Epac agonist 8-pCPT-2'-ο-Me-cAMP."

abundance(SCHEM:"N(6)-Benzoyl-cyclic amp") directlyIncreases kinaseActivity(proteinAbundance(PFH:"PRKA Family"))
abundance(SCHEM:"8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate") directlyIncreases molecularActivity(proteinAbundance(HGNC:RAPGEF3))

SET Evidence = "the Epac agonist elicited a dose-dependent decrease in proliferation but had no effect
on collagen expression (Figure 1D)"

abundance(SCHEM:"8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate") decreases biologicalProcess(MESHPP:"Cell Proliferation")
abundance(SCHEM:"8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate") causesNoChange proteinAbundance(PFH:"COL1 Family")

SET Evidence = "cells expressing PKACα exhibited a reduction in collagen expression, but not in proliferation
(Figure 2A)"

proteinAbundance(HGNC:PRKACA) causesNoChange biologicalProcess(MESHPP:"Cell Proliferation")
proteinAbundance(HGNC:PRKACA) decreases proteinAbundance(PFH:"COL1 Family")

SET Evidence = "We found that both PGE2 and the Epac agonist stimulated Rap1 activity, as measured
by the RalGDS pulldown of active GTP-loaded Rap1, whereas the PKA agonist actually
had an inhibitory effect on Rap1 activity (Figure 4A)."

abundance(CHEBI:"prostaglandin E2") increases gtpBoundActivity(proteinAbundance(HGNC:RAP1A))
abundance(SCHEM:"8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate") increases gtpBoundActivity(proteinAbundance(HGNC:RAP1A))
abundance(SCHEM:"N(6)-Benzoyl-cyclic amp") decreases gtpBoundActivity(proteinAbundance(HGNC:RAP1A))

SET Evidence = "PGE2 and the PKA agonist, but not the Epac agonist, inhibited PKC-δ phosphorylation
(Figure 5A)"

abundance(CHEBI:"prostaglandin E2") decreases proteinAbundance(HGNC:PRKCD,proteinModification(P))
abundance(SCHEM:"N(6)-Benzoyl-cyclic amp") decreases proteinAbundance(HGNC:PRKCD,proteinModification(P))

SET Evidence = "Cells transfected with the catalytic subunit of PKA also showed diminished PKC-δ phosphorylation
(Figure 5B)."

proteinAbundance(HGNC:PRKACA) decreases proteinAbundance(HGNC:PRKCD,proteinModification(P))

SET Evidence = "Inhibition with the specific PKC-δ inhibitor rottlerin resulted in decreased collagen
expression (Figure 5C)"

abundance(SCHEM:Rottlerin) directlyDecreases kinaseActivity(proteinAbundance(HGNC:PRKCD))
abundance(SCHEM:Rottlerin) decreases proteinAbundance(PFH:"COL1 Family")

SET Evidence = "The PKA agonist dose-dependently inhibited collagen expression but had no effect on
proliferation (Figure 1C)"

abundance(SCHEM:"N(6)-Benzoyl-cyclic amp") decreases kinaseActivity(proteinAbundance(PFH:"COL1 Family"))
abundance(SCHEM:"N(6)-Benzoyl-cyclic amp") causesNoChange biologicalProcess(MESHPP:"Cell Proliferation")

SET Evidence = "In keeping with the agonist data, cells expressing PKACα exhibited a reduction in
collagen expression, but not in proliferation (Figure 2A)"

proteinAbundance(HGNC:PRKACA) decreases proteinAbundance(PFH:"COL1 Family")
proteinAbundance(HGNC:PRKACA) causesNoChange biologicalProcess(MESHPP:"Cell Proliferation")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 33"

SET TextLocation = "Abstract"
SET Evidence = "Rin1 is a Rab5 guanine nucleotide exchange factor that plays an important role in
Ras-activated endocytosis and growth factor receptor trafficking in fibroblasts."
SET Citation = {"PubMed","The Journal of biological chemistry","19570984","2009-08-01","Tomshine JC|Severson SR|Wigle DA|Sun Z|Beleford DA|Shridhar V|Horazdovsky BF",""}
SET Species = "9606"

molecularActivity(proteinAbundance(HGNC:RIN1)) directlyDecreases gtpBoundActivity(proteinAbundance(HGNC:RAB5A))

SET CellLine = "A549"
SET Evidence = "Rin1 depletion from A549 cells resulted in a decrease in cell proliferation that was
correlated to a decrease in epidermal growth factor receptor (EGFR) signaling.
Expression of wild type Rin1 but not the Rab5 guanine nucleotide exchange factor-deficient
Rin1 (Rin1Δ) complemented the Rin1 depletion effects, and overexpression
of Rin1Δ had a dominant negative effect on cell proliferation."

molecularActivity(proteinAbundance(HGNC:RIN1)) increases biologicalProcess(GO:"cell proliferation")

SET Evidence = "Rin1 depletion stabilized the cell surface levels of EGFR, suggesting that internalization
was necessary for robust signaling in A549 cells. In support of this conclusion,
introduction of either dominant negative Rab5 or dominant negative dynamin
decreased A549 proliferation and EGFR signaling."

proteinAbundance(HGNC:RIN1) increases cellSurfaceExpression(proteinAbundance(HGNC:EGFR))
gtpBoundActivity(proteinAbundance(PFH:"DNM Family")) increases (proteinAbundance(HGNC:EGF) increases biologicalProcess(GO:"cell proliferation"))

SET TextLocation = "Results"
SET Evidence = "To test whether the cell proliferation defect observed with Rin1 depletion was because
of altered EGFR signaling, A549 cells were transfected with control or Rin1-specific
morpholinos, serum-starved, and then stimulated with EGF. The levels
of phosphorylated ERK1/2 (pERK) were used to assess EGF signaling (Fig. 2C). Depletion
of Rin1 from A549 cells resulted in at least a 2-fold decrease in pERK levels
(Fig. 2, C and D), but not total ERK levels (supplemental Fig. 2), indicating
that the decrease in cell proliferation correlated with a decrease in EGF signaling."

proteinAbundance(HGNC:RIN1) increases kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family"))

SET Evidence = "Rin1 depletion resulted in a decrease in cell proliferation as measured by the percent
change in proliferation between 24 and 72 h (Fig. 3). This decrease in cell
proliferation was not because of any initial morpholino toxicity because 24 h
after electroporation cells receiving control or Rin1 targeting morpholinos showed
no difference in proliferation (supplemental Fig. 3). These data confirmed a
participatory role of Rin1 in EGF-mediated cell proliferation."

proteinAbundance(HGNC:RIN1) increases (proteinAbundance(HGNC:EGF) increases biologicalProcess(GO:"cell proliferation"))

SET Evidence = "However, Rin1Δ expression did not complement Rin1 knockdown defects but instead caused
further inhibition of cell proliferation (Fig. 4E). These results suggest
that a functional Vps9 domain is critical for Rin1 activity in EGFR-mediated cell
proliferation. To verify that the Rin1 Vps9 domain was important for A549 cell
proliferation, Rin1Δ or wild type Rin1 expression constructs were transfected into
A549 cells and assayed for colony formation (Fig. 5, A and B). Only Rin1Δ expression
but not wild type Rin1 expression resulted in decreased cell proliferation.
These results indicated that Rin1 lacking a functional Vps9 domain acted as
a dominant negative, suggesting that the trafficking roles of Rin1 were mediating
EGFR proliferative signaling in A549 cells."

molecularActivity(proteinAbundance(HGNC:RIN1)) increases (kinaseActivity(proteinAbundance(HGNC:EGFR)) increases biologicalProcess(GO:"cell proliferation"))

SET Evidence = "After 10 min of EGF treatment, EGFR levels dropped ~2-fold in cells transfected with
the control morpholino (Fig. 6, A and B), whereas cells depleted of Rin1 showed
very little receptor loss following EGF stimulation."

proteinAbundance(HGNC:RIN1) increases degradation(proteinAbundance(HGNC:EGFR))

SET Evidence = "To confirm that EGFR internalization was critical for potentiating EGFR signaling,
a GFP-tagged dominant negative dynamin (dn-dynamin) K44A expression construct
was transiently transfected into A549 cells, and the impact of its expression on
EGF-stimulated signaling was determined (Fig. 7A). The expression of dn-dynamin
(Fig. 7B) resulted in a ~2-fold decrease in ERK1/2 activation in response to EGF
stimulation (Fig. 7, A and C); this observation supports the conclusion that internalization
of EGFR is critical for proper signaling in A549 cells."

gtpBoundActivity(proteinAbundance(PFH:"DNM Family")) increases kinaseActivity(proteinAbundance(HGNC:EGFR))
gtpBoundActivity(proteinAbundance(PFH:"DNM Family")) increases biologicalProcess(GO:"epidermal growth factor receptor signaling pathway")
gtpBoundActivity(proteinAbundance(PFH:"DNM Family")) increases (biologicalProcess(GO:"receptor internalization") increases biologicalProcess(GO:"epidermal growth factor receptor signaling pathway"))
gtpBoundActivity(proteinAbundance(PFH:"DNM Family")) increases translocation(proteinAbundance(HGNC:EGFR),MESHCL:"Cell Membrane",MESHCL:Cytoplasm)

SET Evidence = "To test the role of Rab5 in these processes, A549 cells were transfected with a GFP-tagged
dominant negative Rab5 S34N (GFP-dnRab5) expression construct (Fig. 7A).
Similar to the results with Rin1 depletion, expression of GFP-dnRab5 resulted
in a ~2-fold decrease in pERK levels when compared with control cells expressing
GFP alone."

gtpBoundActivity(proteinAbundance(HGNC:RAB5A)) increases kinaseActivity(proteinAbundance(PFH:"MAPK Erk1/3 Family"))

SET Evidence = "Finally, to confirm that dnRab5 and dn-dynamin expression impacted cell proliferation
in a manner similar to Rin1 depletion, A549 cells transiently transfected with
expression constructs encoding GFP-dnRab5, GFP-dn-dynamin, or GFP alone were
tested for their ability to form colonies (Fig. 8). Cells transfected with GFP-dnRab5
or GFP-dn-dynamin expression constructs showed decreased cell proliferation,
supporting the conclusion that proper EGFR internalization and Rab5-mediated
endosomal trafficking of EGFR are critical for potentiating proliferative signaling
in A549 cells."

gtpBoundActivity(proteinAbundance(PFH:"DNM Family")) increases (proteinAbundance(HGNC:EGF) increases biologicalProcess(GO:"cell proliferation"))
gtpBoundActivity(proteinAbundance(HGNC:RAB5A)) increases (proteinAbundance(HGNC:EGF) increases biologicalProcess(GO:"cell proliferation"))
gtpBoundActivity(proteinAbundance(HGNC:RAB5A)) increases translocation(proteinAbundance(HGNC:EGFR),MESHCL:"Cell Membrane",MESHCL:Cytoplasm)

SET Disease = "Carcinoma, Non-Small-Cell Lung"
SET Evidence = "Gene expression from 186 human lung tumors with associated clinical information were
surveyed for statistically significant variations in RIN1 mRNA levels (34).
Of three Rin1 probe sets on the Affymetrix U95 array, one probe set (1777_at) was
significantly up-regulated in adenocarcinoma, bronchioalveolar carcinoma, metastatic
adenocarcinoma, and carcinoid and squamous cell carcinoma compared with normal
lung (Fig. 9). The other two probe sets demonstrated statistically significant
up-regulation in both squamous cell carcinoma and metastatic adenocarcinoma
of the lung."

rnaAbundance(HGNC:RIN1) positiveCorrelation pathology(MESHD:Adenocarcinoma)
rnaAbundance(HGNC:RIN1) positiveCorrelation pathology(MESHD:"Carcinoma, Squamous Cell")
rnaAbundance(HGNC:RIN1) positiveCorrelation pathology(MESHD:"Adenocarcinoma, Bronchiolo-Alveolar")
rnaAbundance(HGNC:RIN1) positiveCorrelation pathology(MESHD:"Carcinoid Tumor")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 34"

SET TextLocation = "Results"
SET Evidence = "In human pancreatic islets, specific insulin biosynthesis, i.e. after normalization
to total protein biosynthesis, increased by 2-fold (P < 0.01) upon stimulation
with glucose and by 2.3-fold (P < 0.01) upon stimulation with insulin (Fig.1)"
SET Citation = {"PubMed","Endocrinology","15001544","2004-04-04","Andreozzi F|D'Alessandris C|Federici M|Laratta E|Del Guerra S|Del Prato S|Marchetti P|Lauro R|Perticone F|Sesti G",""}
SET Species = "9606"
SET EndocrineSystem = "Islets of Langerhans"

abundance(CHEBI:glucose) increases proteinAbundance(HGNC:INS)

SET Evidence = "Insulin biosynthesis in human pancreatic islets exposed to glucosamine was reduced
by 39% upon glucose stimulation (P < 0.01) and by 24% upon insulin stimulation
(P < 0.01) as compared with untreated control human islets."

abundance(CHEBI:glucosamine) decreases (abundance(CHEBI:glucose) increases proteinAbundance(HGNC:INS))

SET CellLine = "RIN-m"
SET Evidence = "in control RIN β-cells, specific insulin biosynthesis increased by 1.9-fold (P < 0.001)
upon stimulation with glucose and by 2.0-fold (P < 0.001) upon stimulation
with insulin (Fig.2). Insulin biosynthesis in RIN β-cells exposed to glucosamine
was reduced by 40% upon glucose stimulation (P < 0.001) and by 45% upon insulin
stimulation (P < 0.01) as compared with untreated control β-cells."
SET Species = "10116"

abundance(CHEBI:glucosamine) decreases (abundance(CHEBI:glucose) increases proteinAbundance(HGNC:INS))

SET DigestiveSystem = "Islets of Langerhans"
SET Evidence = "we combined the stimulation with glucose or insulin with the cotreatment with inhibitors
of the insulin receptor tyrosine kinase [hydroxy-2-naphthalenylmethylphosphonic
acid trisacetoxymethyl ester (HNMPA)], PI 3-kinase (wortmannin and LY294002),
and mTOR (rapamycin). As shown in Figs. 1 and 2, HNMPA, wortmannin, LY294002,
and rapamycin inhibited both glucose- and insulin-stimulated insulin biosynthesis
in both human pancreatic islets and RIN β-cells."
SET Species = "9606"

kinaseActivity(proteinAbundance(HGNC:INSR)) increases (abundance(CHEBI:glucose) increases proteinAbundance(HGNC:INS))
kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) increases (abundance(CHEBI:glucose) increases proteinAbundance(HGNC:INS))
kinaseActivity(proteinAbundance(HGNC:MTOR)) increases (abundance(CHEBI:glucose) increases proteinAbundance(HGNC:INS))
abundance(CHEBI:wortmannin) directlyDecreases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))
abundance(CHEBI:rapamycin) directlyDecreases kinaseActivity(proteinAbundance(HGNC:MTOR))

SET Evidence = "As shown in Fig. 3A, exposure of the cells to high glucose concentrations resulted
in a 47% reduction of insulin-stimulated tyrosine phosphorylation of IRS-1 as
compared with control RIN β-cells."
SET Species = "10116"

abundance(CHEBI:glucose) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Irs1,proteinModification(P,Y)))

SET Evidence = "insulin-stimulated PI 3-kinase activity associated with IRS-1 was reduced by 36% in
RIN β-cells exposed to high glucose concentrations as compared with control RIN
β-cells (Fig. 3B)."

abundance(CHEBI:glucose) decreases (proteinAbundance(PFR:"Ins Family") increases kinaseActivity(complexAbundance(NCR:"p85/p110 PI3Kinase Complex")))

SET Evidence = "exposure of the cells to glucosamine resulted in a 38% reduction of insulin-stimulated
tyrosine phosphorylation of IRS-1 as compared with control RIN β-cells."

abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Irs1,proteinModification(P,Y)))

SET Evidence = "Insulin-stimulated PI 3-kinase activity associated with IRS-1 was reduced by 40% in
RIN β-cells exposed to glucosamine as compared with control RIN β-cells (Fig.
3B)"

abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases kinaseActivity(complexAbundance(NCR:"p85/p110 PI3Kinase Complex")))

SET Evidence = "As shown in Fig. 4, insulin-stimulated Tyr608 and Tyr628 phosphorylation of IRS-1
was decreased by 30 and 46%, respectively, in RIN β-cells exposed to glucosamine
as compared with control RIN β-cells."

abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Irs1,proteinModification(P,Y,608)))
abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Irs1,proteinModification(P,Y,628)))

SET Evidence = "Exposure of cells to glucosamine also resulted in a 39% reduction of insulin-stimulated
tyrosine phosphorylation of IRS-2 as compared with control RIN β-cells (Fig.
5A)."

abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Irs2,proteinModification(P,Y)))

SET Evidence = "To determine whether alterations in insulin-stimulated PI 3-kinase activation induced
by exposure of RIN β-cells to glucosamine affected Akt phosphorylation, lysates
from insulin-treated RIN cells were immunoblotted with phospho-specific anti-Ser473
antibody. Insulin-induced Ser473 Akt phosphorylation was reduced by 37%
(Fig. 6)."

abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Akt1,proteinModification(P,S,473)))

SET Evidence = "As shown in Fig. 7A, insulin-stimulated phosphorylation of mTOR at Ser2248 was decreased
by 30%, whereas phosphorylation of tuberin at Thr1462 was decreased by 36%
in RIN β-cells exposed to glucosamine as compared with control RIN β-cells (Fig.
7B)."

abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Mtor,proteinModification(P,S,2448)))
abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Tsc2,proteinModification(P,S,1462)))

SET Evidence = "As shown in Fig. 8A, insulin-stimulated p70S6 kinase Thr389  phosphorylation was decreased
by 50% in RIN β-cells exposed to glucosamine as compared with control
RIN β-cells, whereas expression of p70S6 kinase did not differ between glucosamine-treated
and -untreated RIN β-cells as detected by immunoblotting."

abundance(CHEBI:glucosamine) decreases (proteinAbundance(PFR:"Ins Family") increases proteinAbundance(RGD:Rps6kb2,proteinModification(P,T,389)))

SET Evidence = "As shown in Fig. 9, A–C, exposure of RIN β-cells to high glucose resulted in an increased
phosphorylation of both JNK and the transcription factor c-Jun, a physiological
substrate of JNK as well as the ERK-1 and -2 members of MAPK family."

abundance(CHEBI:glucose) increases proteinAbundance(PFR:"Mapk JNK Family",proteinModification(P))
proteinAbundance(PFR:"Mapk JNK Family",proteinModification(P)) directlyIncreases kinaseActivity(proteinAbundance(PFR:"Mapk JNK Family"))
kinaseActivity(proteinAbundance(PFR:"Mapk JNK Family")) directlyIncreases proteinAbundance(RGD:Jun,proteinModification(P))

SET Evidence = "exposure of RIN β-cells to high glucose increased phosphorylation of both IRS-1 Ser307
and IRS-1 Ser612 (Fig. 10, A and B)"

abundance(CHEBI:glucose) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,307))
abundance(CHEBI:glucose) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,612))

SET Evidence = "Inhibition of hexosamine biosynthesis by the GFAT inhibitor azaserine reversed the
stimulatory effects of glucose on JNK, c-Jun, and ERK1/2 activation (Fig. 9, A–C)
as well as IRS-1 phosphorylation at Ser307 and Ser612 (Fig. 10, A and B)."

abundance(SCHEM:Azaserine) directlyDecreases catalyticActivity(proteinAbundance(RGD:Gfpt1))
abundance(SCHEM:Azaserine) decreases (abundance(CHEBI:glucose) increases kinaseActivity(proteinAbundance(PFR:"Mapk JNK Family")))
abundance(SCHEM:Azaserine) decreases (abundance(CHEBI:glucose) increases transcriptionalActivity(proteinAbundance(RGD:Jun)))
abundance(SCHEM:Azaserine) decreases (abundance(CHEBI:glucose) increases kinaseActivity(proteinAbundance(RGD:Mapk1)))
abundance(SCHEM:Azaserine) decreases (abundance(CHEBI:glucose) increases kinaseActivity(proteinAbundance(RGD:Mapk3)))

SET Evidence = "exposure of RIN β-cells to glucosamine resulted in an increased phosphorylation of
JNK, c-Jun, and ERK1/2 as compared with control RIN β-cells (Fig. 9, A–C)."

abundance(CHEBI:glucosamine) increases kinaseActivity(proteinAbundance(PFR:"Mapk JNK Family"))
abundance(CHEBI:glucosamine) increases proteinAbundance(RGD:Jun,proteinModification(P))
abundance(CHEBI:glucosamine) increases kinaseActivity(proteinAbundance(RGD:Mapk1))
abundance(CHEBI:glucosamine) increases kinaseActivity(proteinAbundance(RGD:Mapk3))

SET Evidence = "Exposure of RIN β-cells to glucosamine increased phosphorylation of both IRS-1 Ser307
and IRS-1 Ser612, which was reversed by treatment with either a cell-permeable
JNK inhibitor or PD98059, a reversible MAPK kinase (MEK)1 inhibitor, the enzyme
that directly activates ERK1/2, respectively (Fig. 10, A and B)"

abundance(CHEBI:glucosamine) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,307))
abundance(CHEBI:glucosamine) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,612))
kinaseActivity(proteinAbundance(PFR:"Mapk JNK Family")) increases (abundance(CHEBI:glucosamine) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,307)))
kinaseActivity(proteinAbundance(PFR:"Mapk JNK Family")) increases (abundance(CHEBI:glucosamine) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,612)))
kinaseActivity(proteinAbundance(RGD:Map2k1)) increases (abundance(CHEBI:glucosamine) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,307)))
kinaseActivity(proteinAbundance(RGD:Map2k1)) increases (abundance(CHEBI:glucosamine) increases proteinAbundance(RGD:Irs1,proteinModification(P,S,612)))
abundance(SCHEM:"PD 98,059") directlyDecreases kinaseActivity(proteinAbundance(RGD:Map2k1))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 35"

SET TextLocation = "Review"
SET Evidence = "Triggering of the IL-1R or TLR causes the adaptor protein MyD88 to be recruited to
the receptor complex, which in turn promotes association with the IL-1R-associated
kinases IRAK4 and IRAK1. During the formation of this complex, IRAK4 is activated,
leading to the hyperphosphorylation of IRAK-1, which then induces the interaction
of TRAF6 with the complex."
SET Citation = {"PubMed","The Journal of biological chemistry","12893815","2003-08-30","Akira S",""}

molecularActivity(proteinAbundance(HGNC:MYD88)) directlyIncreases complexAbundance(proteinAbundance(HGNC:MYD88),proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:IRAK4))
complexAbundance(proteinAbundance(HGNC:MYD88),proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:IRAK4)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:IRAK4))
kinaseActivity(proteinAbundance(HGNC:IRAK4)) directlyIncreases proteinAbundance(HGNC:IRAK1,proteinModification(P))
proteinAbundance(HGNC:IRAK1,proteinModification(P)) directlyIncreases complexAbundance(proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:TRAF6))

SET CellStructure = "Cell Membrane"
SET Evidence = "The IRAK-4·IRAK-1·TRAF6 complex then interacts at the membrane with another preformed
complex consisting of TAK1, TAB1, and TAB2. This interaction induces phosphorylation
of TAB2 and TAK1, which then translocate together with TRAF6 and TAB1
to the cytosol."

complexAbundance(proteinAbundance(HGNC:IRAK4),proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:TRAF6),proteinAbundance(HGNC:MAP3K7),proteinAbundance(HGNC:TAB1),proteinAbundance(HGNC:TAB2))
complexAbundance(proteinAbundance(HGNC:IRAK4),proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:TRAF6),proteinAbundance(HGNC:MAP3K7),proteinAbundance(HGNC:TAB1),proteinAbundance(HGNC:TAB2)) directlyIncreases proteinAbundance(HGNC:MAP3K7,proteinModification(P))
complexAbundance(proteinAbundance(HGNC:IRAK4),proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:TRAF6),proteinAbundance(HGNC:MAP3K7),proteinAbundance(HGNC:TAB1),proteinAbundance(HGNC:TAB2)) directlyIncreases proteinAbundance(HGNC:TAB2,proteinModification(P))

SET CellStructure = "Cytoplasm"

complexAbundance(proteinAbundance(HGNC:TAB1),proteinAbundance(HGNC:TAB2),proteinAbundance(HGNC:TRAF6),proteinAbundance(HGNC:MAP3K7))

SET Evidence = "TAK1 is subsequently activated in the cytoplasm, leading to the activation of IKK.
Inactive IKK sequesters NF-κB in the cytoplasm, but activation leads to phosphorylation
and degradation of IκB and consequent release of NF-κB. Activation of
TAK1 also results in the activation of MAP kinases and c-Jun NH2-terminal kinase
(JNK)."

kinaseActivity(proteinAbundance(HGNC:MAP3K7)) increases kinaseActivity(complexAbundance(NCH:"IkappaB Kinase Complex"))
kinaseActivity(complexAbundance(NCH:"IkappaB Kinase Complex")) directlyIncreases degradation(proteinAbundance(HGNC:NFKBIA))
kinaseActivity(complexAbundance(NCH:"IkappaB Kinase Complex")) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
kinaseActivity(proteinAbundance(HGNC:MAP3K7)) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET CellLine = "M1"
SET Evidence = "MyD88 was originally isolated as a myeloid differentiation primary response gene that
is rapidly induced upon IL-6-stimulated differentiation of M1 myeloleukemic
cells into macrophages"
SET Species = "9606"

proteinAbundance(HGNC:IL6) increases rnaAbundance(HGNC:MYD88)

SET Evidence = "Although the kinase activity of IRAK-1 increases strongly following IL-1 stimulation,
IRAK-1 kinase activity is not required for its signaling function, because
overexpression of a kinase-defective mutant of IRAK-1 is observed to strongly induce
NF-κB activation in cells otherwise deficient for IRAK-1. Upon stimulation,
IRAK-1 is recruited to the receptor through a homophilic interaction with the DD
of MyD88."

proteinAbundance(PFH:"IL1 Family") increases kinaseActivity(proteinAbundance(HGNC:IRAK1))
proteinAbundance(HGNC:IRAK1) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
proteinAbundance(PFH:"IL1 Family") increases complexAbundance(proteinAbundance(HGNC:MYD88),proteinAbundance(HGNC:IRAK1))

SET Evidence = "MyD88 also binds to IRAK-4 and thereby facilitates IRAK-4 phosphorylation of critical
residue(s) in the kinase activation loop of IRAK-1, triggering IRAK-1's own
kinase activity. Once activated, IRAK-1 likely autophosphorylates residues in its
N terminus. TRAF6 is also recruited to the receptor complex via interaction with
IRAK-1."

proteinAbundance(HGNC:MYD88) directlyIncreases (kinaseActivity(proteinAbundance(HGNC:IRAK4)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:IRAK1)))
complexAbundance(proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:TRAF6))

SET Evidence = "IRAK-1-deficient mice and cell lines showed diminished cytokine production in response
to IL-1 and LPS;"
SET Species = "10090"

proteinAbundance(PFM:"Il1 Family") increases biologicalProcess(GO:"cytokine production")
abundance(SCHEM:Lipopolysaccharide) increases biologicalProcess(GO:"cytokine production")
proteinAbundance(MGI:Irak1) increases (proteinAbundance(PFM:"Il1 Family") increases biologicalProcess(GO:"cytokine production"))
proteinAbundance(MGI:Irak1) increases (abundance(SCHEM:Lipopolysaccharide) increases biologicalProcess(GO:"cytokine production"))

SET Cell = "Macrophages"
SET Evidence = "Data with IRAK-M knock-out mice have revealed that IRAK-M serves as a negative regulator
of IL-1R/TLR signaling (19). IRAK-M-deficient macrophages produced significantly
higher cytokine levels in response to a variety of IL-1R/TLR ligands."

proteinAbundance(MGI:Irak3) decreases biologicalProcess(GO:"toll-like receptor signaling pathway")
proteinAbundance(MGI:Irak3) decreases biologicalProcess(GO:"cytokine production")

SET Evidence = "TRAF6 directly interacts with CD40 and TRANCE-R"

complexAbundance(proteinAbundance(HGNC:TRAF6),proteinAbundance(HGNC:CD40))
complexAbundance(proteinAbundance(HGNC:TRAF6),proteinAbundance(HGNC:TNFRSF11A))

SET Evidence = "Studies using small interfering RNA (siRNA) to inhibit TAK1 expression show that TAK1
is essential for both IL-1- and TNF-α-induced NF-κB activation. Two TAK1-binding
proteins, TAB1 and TAB2, have been identified (24, 25). When ectopically co-expressed,
TAB1 augments the kinase activity of TAK1, indicating that TAB1 functions
as an activator of TAK1."

proteinAbundance(PFH:"IL1 Family") increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
proteinAbundance(HGNC:TNF) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))
proteinAbundance(HGNC:MAP3K7) increases (proteinAbundance(PFH:"IL1 Family") increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))
proteinAbundance(HGNC:MAP3K7) increases (proteinAbundance(HGNC:TNF) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))
proteinAbundance(HGNC:TAB1) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAP3K7))
complexAbundance(proteinAbundance(HGNC:TAB2),proteinAbundance(HGNC:MAP3K7))

SET Evidence = "TAB2 is associated with the cell membrane in unstimulated conditions, but upon stimulation
it translocates to the cytosol, where it functions as an adaptor linking
TAK1 to TRAF6, thereby facilitating TAK1 activation."

complexAbundance(proteinAbundance(HGNC:TAB2),proteinAbundance(HGNC:TRAF6),proteinAbundance(HGNC:MAP3K7))
proteinAbundance(HGNC:TAB2) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAP3K7))

SET Evidence = "It has been shown recently that ubiquitination plays an important role in TAK1 activation
(26, 27). IKK activation by TRAF6 requires a dimeric ubiquitin-conjugating
enzyme complex composed of Ubc13 and Uev1A as well as the TAK1·kinase complex.
TRAF6 can interact through its RING finger domain with Ubc13 in the Ubc13·Uev1A
complex. This Ubc·TRAF6 complex catalyzes the formation of a Lys-63-linked polyubiquitin
chain, which triggers TAK1 activation through a unique proteasome-independent
mechanism."

proteinAbundance(HGNC:TRAF6) increases kinaseActivity(complexAbundance(NCH:"IkappaB Kinase Complex"))
catalyticActivity(complexAbundance(proteinAbundance(HGNC:UBE2N),proteinAbundance(HGNC:UBE2V1),proteinAbundance(HGNC:TRAF6))) increases kinaseActivity(proteinAbundance(HGNC:MAP3K7))

SET Evidence = "Tollip—Tollip (Toll-interacting protein) was originally cloned as a protein interacting
with the IL-1 receptor accessory protein (28). Tollip also associates with
TLR2 and TLR4. In resting cells, Tollip forms a complex with members of the IRAK
family, thereby preventing NF-κB activation. Upon activation Tollip·IRAK-1 complexes
are recruited to the cognate receptor, resulting in the rapid autophosphorylation
of IRAK-1 and its dissociation from the receptor."

complexAbundance(proteinAbundance(HGNC:TOLLIP),proteinAbundance(HGNC:IL1RAP))
complexAbundance(proteinAbundance(HGNC:TOLLIP),proteinAbundance(HGNC:TLR2))
complexAbundance(proteinAbundance(HGNC:TOLLIP),proteinAbundance(HGNC:TLR4))
complexAbundance(proteinAbundance(HGNC:TOLLIP),proteinAbundance(HGNC:IRAK1))
proteinAbundance(HGNC:TOLLIP) decreases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))

SET Evidence = "Pellino 1 is required for IL-1-induced NF-κB activation and IL-8 gene expression (30).
Pellino 2 has also been shown to be involved in IL-1R/TLR signaling pathways
(31). Following IL-1 stimulation, IRAK-1 and Pellino 2 associate to form complexes.
Ectopic expression of a Pellino 2 antisense construct was shown to inhibit
IL-1- and LPS-dependent but not TNF-α-dependent activation of the IL-8 promoter."

proteinAbundance(HGNC:PELI1) increases (proteinAbundance(PFH:"IL1 Family") increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))
proteinAbundance(PFH:"IL1 Family") increases complexAbundance(proteinAbundance(HGNC:IRAK1),proteinAbundance(HGNC:PELI2))
proteinAbundance(HGNC:PELI2) increases (proteinAbundance(PFH:"IL1 Family") increases rnaAbundance(HGNC:IL8))
proteinAbundance(HGNC:PELI2) increases (abundance(SCHEM:Lipopolysaccharide) increases rnaAbundance(HGNC:IL8))

SET Evidence = "TLR2 has been shown to bind directly to the regulatory p85 subunit of the PI 3-kinase
(32)."

complexAbundance(proteinAbundance(HGNC:TLR2),proteinAbundance(PFH:"PIK3R Class IA Family"))

SET Evidence = "LPS stimulation has been shown to result in tyrosine phosphorylation of MyD88 and
formation of a PI 3-kinase·MyD88 complex (33)."

abundance(SCHEM:Lipopolysaccharide) increases complexAbundance(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"),proteinAbundance(HGNC:MYD88))
abundance(SCHEM:Lipopolysaccharide) increases proteinAbundance(HGNC:MYD88,proteinModification(P,Y))

SET Evidence = "it is noteworthy that, compared with other TLR ligands, poly(I-C) stimulation induces
the production of relatively large amounts of type I interferons and interferon-inducible
genes but smaller amounts of inflammatory cytokines such as TNF-α
and IL-6, further suggesting that TLR3 does not utilize the MyD88-dependent pathway
for signaling."

abundance(SCHEM:"Poly I-C") directlyIncreases molecularActivity(proteinAbundance(HGNC:TLR3))
abundance(SCHEM:"Poly I-C") increases biologicalProcess(GO:"type I interferon secretion")

SET Evidence = "Following virus infection, double-stranded RNA, or LPS treatment, IRF-3 undergoes
phosphorylation and translocates from the cytoplasm to the nucleus, resulting in
the transcriptional activation of type I interferons."

biologicalProcess(GO:"response to virus") increases proteinAbundance(HGNC:IRF3,proteinModification(P))
biologicalProcess(GO:"response to virus") increases translocation(proteinAbundance(HGNC:IRF3),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")
translocation(proteinAbundance(HGNC:IRF3),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus") increases biologicalProcess(GO:"type I interferon production")

SET Evidence = "TIRAP was shown to associate with TLR-4 but not with other TLRs. Overexpression of
a dominant-negative form of TIRAP was shown to inhibit LPS-induced NF-κB activation
and dendritic cell maturation. Blockage of TIRAP using a cell-permeable inhibitory
peptide also prevented induction of IP-10 by LPS."

complexAbundance(proteinAbundance(HGNC:TIRAP),proteinAbundance(HGNC:TLR4))
molecularActivity(proteinAbundance(HGNC:TIRAP)) increases (abundance(SCHEM:Lipopolysaccharide) increases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex")))

SET Cell = "Dendritic Cells"

molecularActivity(proteinAbundance(HGNC:TIRAP)) increases (abundance(SCHEM:Lipopolysaccharide) increases biologicalProcess(GO:"dendritic cell differentiation"))
molecularActivity(proteinAbundance(HGNC:TIRAP)) increases (abundance(SCHEM:Lipopolysaccharide) increases proteinAbundance(HGNC:CXCL10))

SET Evidence = "Overexpression of TRIF, but not MyD88 or TIRAP, preferentially activates the IFN-β
promoter. A dominant-negative form (DN) of TRIF, but not MyD88DN or TIRAPDN, blocked
the TLR3-mediated response to poly(I-C),"

proteinAbundance(HGNC:TICAM1) increases rnaAbundance(HGNC:IFNB1)
molecularActivity(proteinAbundance(HGNC:TICAM1)) increases biologicalProcess(GO:"toll-like receptor 3 signaling pathway")
proteinAbundance(HGNC:MYD88) causesNoChange rnaAbundance(HGNC:IFNB1)
proteinAbundance(HGNC:TIRAP) causesNoChange rnaAbundance(HGNC:IFNB1)

SET Evidence = "Interestingly, TRIF-deficient mice abolished the response to LPS in terms of cytokine
production that was considered to be mediated by the MyD88-dependent pathway."

proteinAbundance(MGI:Ticam1) increases (abundance(SCHEM:Lipopolysaccharide) increases biologicalProcess(GO:"cytokine production"))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 36"

SET Tissue = "Mammary Glands, Human"
SET Evidence = "We have observed previously that adhesion of normal HB2 cells to collagen I is accompanied
by a collagen-induced phosphorylation of DDR1.9 The present experiments
show that adhesion to collagen IV also causes a phosphorylation of DDR1 in mammary
epithelial cells (Fig.1b)."
SET Citation = {"PubMed","International journal of cancer. Journal international du cancer","12471617","","Dejmek J|Dib K|Jönsson M|Andersson T",""}
SET Species = "9606"

proteinAbundance(PFH:"COL1 Family") increases proteinAbundance(HGNC:DDR1,proteinModification(P))
proteinAbundance(PFH:"COL4 Family") increases proteinAbundance(HGNC:DDR1,proteinModification(P))

SET TextLocation = "Results"
SET Evidence = "To explore the mechanism(s) involved in the Wnt-5a-dependent effects on collagen-induced
phosphorylation of DDR1 in mammary epithelial cells and on adhesion of such
cells to collagen,9 we first tested the impact of pertussis and cholera toxins
on the collagen-induced phosphorylation of DDR1 in normal HB2 cells. We found
that the phosphorylation was almost abolished by pertussis toxin (Fig. 2a,b), but
was not affected by cholera toxin (Fig. 2c)."

abundance(SCHEM:"Pertussis toxins") decreases (proteinAbundance(PFH:"COL1 Family") increases proteinAbundance(HGNC:DDR1,proteinModification(P)))

SET Evidence = "In accordance with the observed effects on phosphorylation of DDR1in HB2 cells (Fig.
2), we subsequently found that pertussis toxin, but not cholera toxin, impaired
the adhesion of normal HB2 cells to collagen (Fig. 3a,b respectively)."

abundance(SCHEM:"Pertussis toxins") decreases biologicalProcess(GO:"cell-matrix adhesion")
abundance(SCHEM:"Cholera toxin") causesNoChange biologicalProcess(GO:"cell-matrix adhesion")

SET Evidence = "α2β1 integrins have been reported to be the major receptor responsible for attachment
of HB2 cells to collagen.9,24 We found, however, that adhesion of HB2 cells
to collagen was decreased by less than 50% in the presence of an anti-β1 integrin
Ab (Fig. 3a), which indicates that, in addition to engagement of β1 integrins,
at least 1 other mechanism must be involved in adherence of these cells to collagen."

proteinAbundance(HGNC:ITGB1) increases biologicalProcess(GO:"cell-matrix adhesion")

SET CellLine = "MCF7"
SET Evidence = "Furthermore, we tested the effects of pertussis toxin on Wnt-5a-deficient HB2 (Fig.
4a) and MCF-7 mammary tumor (Fig. 4b) cells. As expected, both of these Wnt-5a-deficient
cell lines exhibited significantly less adhesion that reached a maximum
(50–60% of the plated cells) after 90–120 min (Fig. 4), which is nearly half
of the adhesive capacity of Wnt-5a-expressing HB2 cells (Fig. 3)."

proteinAbundance(HGNC:WNT5A) increases biologicalProcess(GO:"cell-matrix adhesion")
abundance(SCHEM:"Pertussis toxins") decreases (proteinAbundance(HGNC:WNT5A) increases biologicalProcess(GO:"cell-matrix adhesion"))

SET Evidence = "We found that treatment with 7.5 μM mastoparan enabled a marked collagen-induced phosphorylation
of DDR1 after only 30 min (Fig. 5a) and a concomitant increase in
adhesion after 60 and 90 min (Fig. 5b). Other investigators have previously reported
that the indicated concentration of mastoparan primarily activates Gi/o-proteins,
whereas a significantly higher concentration is needed to stimulate transducin
and Gs-proteins.27"

abundance(SCHEM:Mastoparan) increases gtpBoundActivity(proteinAbundance(PFH:"GNAI Family"))
abundance(SCHEM:Mastoparan) increases biologicalProcess(GO:"cell-matrix adhesion")
abundance(SCHEM:Mastoparan) increases (proteinAbundance(PFH:"COL1 Family") increases proteinAbundance(HGNC:DDR1,proteinModification(P)))

SET Evidence = "To further ascertain whether such a link exists between Wnt-5a signaling, collagen-induced
DDR1 activation, and the adhesiveness of HB2 cells, we tested the effects
of PP1, a specific inhibitor of Src family tyrosine kinases. We found that PP1
abolished the collagen-induced phosphorylation of DDR1 (Fig. 6a), and that it
also decreased adhesion of normal HB2 cells by about 50% (Fig. 6b)."

abundance(SCHEM:"PP1 tyrosine kinase inhibitor") directlyDecreases kinaseActivity(proteinAbundance(PFH:"SRC Family"))
abundance(SCHEM:"PP1 tyrosine kinase inhibitor") decreases (proteinAbundance(PFH:"COL1 Family") increases proteinAbundance(HGNC:DDR1,proteinModification(P))) //Full text of paper states that type I collagen was used
abundance(SCHEM:"PP1 tyrosine kinase inhibitor") decreases biologicalProcess(GO:"cell-matrix adhesion")

SET Evidence = "Furthermore, we noted that collagen-stimulated DDR1 interacted with the p85 subunit
of PI3K (Fig. 7b), and we also observed that adherence of HB2 cells to collagen
caused tyrosine phosphorylation of the p85 of PI3K (Fig. 7c), a phenomenon associated
with activation of this enzyme. Neither of these events was observed in
cells pretreated with pertussis toxin (Fig. 7a,b,c)."

proteinAbundance(PFH:"COL1 Family") increases complexAbundance(proteinAbundance(PFH:"PIK3R Class IA Family"),proteinAbundance(HGNC:DDR1))
biologicalProcess(GO:"cell-matrix adhesion") increases proteinAbundance(PFH:"PIK3R Class IA Family",proteinModification(P,Y))
proteinAbundance(PFH:"PIK3R Class IA Family",proteinModification(P,Y)) directlyIncreases kinaseActivity(proteinAbundance(PFH:"PIK3C Class IA Family"))
abundance(SCHEM:"Pertussis toxins") decreases (proteinAbundance(PFH:"COL1 Family") increases complexAbundance(proteinAbundance(PFH:"PIK3R Class IA Family"),proteinAbundance(HGNC:DDR1)))
abundance(SCHEM:"Pertussis toxins") decreases (biologicalProcess(GO:"cell-matrix adhesion") increases proteinAbundance(PFH:"PIK3R Class IA Family",proteinModification(P,Y)))

SET TextLocation = "Abstract"
SET Evidence = "Thus, a Gi/o-protein signaling pathway mediates the effect of Wnt-5a expression by
enabling collagen-induced activation of DDR1, which, in parallel with β1 integrins,
regulates adhesion of mammary cells."

proteinAbundance(HGNC:WNT5A) increases (gtpBoundActivity(proteinAbundance(PFH:"GNAI Family")) increases biologicalProcess(GO:"cell-matrix adhesion"))
proteinAbundance(HGNC:WNT5A) increases (gtpBoundActivity(proteinAbundance(PFH:"GNAI Family")) increases kinaseActivity(proteinAbundance(HGNC:DDR1)))
kinaseActivity(proteinAbundance(HGNC:DDR1)) increases biologicalProcess(GO:"cell-matrix adhesion")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 37"

SET Cell = "Endothelial Cells"
SET TextLocation = "Abstract"
SET Evidence = "Tumor necrosis factor α (TNFα) strongly increased the expression of E-selectin in
human umbilical vein endothelial cells (HUVEC). This effect was independent of
the activation of SAPK2/p38 induced by TNFα."
SET Citation = {"PubMed","The Journal of biological chemistry","11448946","2001-08-11","Laferriere J|Houle F|Taher MM|Valerie K|Huot J",""}
SET Species = "9606"

proteinAbundance(HGNC:TNF) increases proteinAbundance(HGNC:SELE)
proteinAbundance(HGNC:TNF) increases kinaseActivity(proteinAbundance(HGNC:MAPK11))

SET Evidence = "Adhesion of HT-29 cells on a monolayer of HUVEC pretreated with TNFα was dependent
on E-selectin expression but was independent of SAPK2/p38 activity of both HUVEC
and tumor cells. The adhesion of HT-29 cells to E-selectin-expressing HUVEC led
to the activation of SAPK2/p38 in the tumor cells as reflected by the increased
phosphorylation of the actin-polymerizing factor HSP27 by mitogen-activated protein
kinase 2/3, a direct target of SAPK2/p38. Moreover, a recombinant E-selectin/Fc
chimera quickly increased the activation of SAPK2/p38 in HT-29 cells. Blocking
the increased activity of SAPK2/p38 of HT-29 cells by SB203580 or by expressing
a dominant negative form of SAPK2/p38 inhibited their transendothelial migration."

proteinAbundance(HGNC:TNF) increases biologicalProcess(GO:"heterotypic cell-cell adhesion")
proteinAbundance(HGNC:SELE) increases biologicalProcess(GO:"heterotypic cell-cell adhesion")

SET Cell = "Tumor Cells, Cultured"

biologicalProcess(GO:"heterotypic cell-cell adhesion") increases proteinAbundance(HGNC:HSPB1,proteinModification(P))
biologicalProcess(GO:"heterotypic cell-cell adhesion") increases kinaseActivity(proteinAbundance(HGNC:MAPK11))
proteinAbundance(HGNC:SELE) increases kinaseActivity(proteinAbundance(HGNC:MAPK11))

SET CellLine = "HT-29"

kinaseActivity(proteinAbundance(HGNC:MAPK11)) increases biologicalProcess(MESHPP:"Transendothelial and Transepithelial Migration")
kinaseActivity(proteinAbundance(HGNC:MAPK11)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAPKAPK2))
abundance(SCHEM:"SB-203580") decreases biologicalProcess(MESHPP:"Transendothelial and Transepithelial Migration")

SET Cell = "Endothelial Cells"
SET TextLocation = "Results"
SET Evidence = "In primary cultures of HUVEC, TNFα induced a strong activation of the expression of
endothelial adhesion proteins that include E-selectin and ICAM (Fig.1, A—D, and
data not shown). This induction was maximal after 4 h and required de novo protein
synthesis being inhibited by cycloheximide (Fig. 1,E and F)."

proteinAbundance(HGNC:TNF) increases proteinAbundance(HGNC:ICAM1)
proteinAbundance(HGNC:TNF) increases proteinAbundance(HGNC:SELE)

SET Evidence = "As illustrated in Fig.2, A–C, the expression of E-selectin correlated with an increased
adhesion of both colon carcinoma HT-29 cells and HL-60 leukemia cells to
a monolayer of HUVEC. After 30 min, the number of HT-29 cells that adhered to HUVEC-expressing
E-selectin, following activation with TNFα, was 5-fold higher than
when adhering to inactivated HUVEC. Similarly, HT-29 cells quickly adhered to
immobilized recombinant human E-selectin/Fc chimera (data not shown). An anti-E-selectin
neutralizing antibody, but not a matched isotype antibody, decreased the
adhesion of both cancer cell types to the activated endothelium (Fig. 2, A–C)."

proteinAbundance(HGNC:TNF) increases biologicalProcess(GO:"heterotypic cell-cell adhesion")
proteinAbundance(HGNC:SELE) increases biologicalProcess(GO:"heterotypic cell-cell adhesion")

SET Evidence = "TNFα also induced in HUVEC, a marked time- and dose-dependent stimulation of SAPK2/p38
that is characterized by an increased activity of MAPKAP K2/3, a direct physiological
target of SAPK2/p38(21)."

proteinAbundance(HGNC:TNF) increases kinaseActivity(proteinAbundance(HGNC:MAPK11))
kinaseActivity(proteinAbundance(HGNC:MAPK11)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAPKAPK2))
kinaseActivity(proteinAbundance(HGNC:MAPK11)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:MAPKAPK3))

SET Evidence = "inhibiting the TNFα-induced increase in SAPK2/p38 activity by SB203580 did not impair
the expression of E-selectin, which suggested that activation of SAPK2/p38
was not required for the expression of this adhesion molecule (Fig. 1,G and H).
Accordingly, blocking the SAPK2/p38 activity of HUVEC with SB203580 did not inhibit
the adhesion of HT-29 cells to HUVEC (Fig. 2A)."

abundance(SCHEM:"SB-203580") directlyDecreases kinaseActivity(proteinAbundance(HGNC:MAPK11))
abundance(SCHEM:"SB-203580") causesNoChange proteinAbundance(HGNC:SELE)
abundance(SCHEM:"SB-203580") causesNoChange biologicalProcess(GO:"heterotypic cell-cell adhesion")

SET Evidence = "However, HT-29 cells migrated across an endothelial layer of HUVEC, and this migration
was enhanced by pretreating HUVEC with TNFα (Fig.4A). This increase in cell
migration was reduced down to control levels by pretreating HUVEC with the anti-E-selectin
antibody indicating the requirement of E-selectin expression and E-selectin-dependent
adhesion for HT-29 cell migration across an endothelial cell
layer (Fig. 4A)."

proteinAbundance(HGNC:TNF) increases biologicalProcess(MESHPP:"Transendothelial and Transepithelial Migration")
proteinAbundance(HGNC:SELE) increases biologicalProcess(MESHPP:"Transendothelial and Transepithelial Migration")

SET Evidence = "Impairing E-selectin-mediated activation of SAPK2p38 and HSP27 phosphorylation of
HT-29 cells with SB203580 (Fig. 4A and data not shown) or by expressing a dominant
negative form of SAPK2/p38 inhibited their migration across activated HUVEC
(Fig.4B)."

proteinAbundance(HGNC:SELE) increases proteinAbundance(HGNC:HSPB1,proteinModification(P))
proteinAbundance(HGNC:SELE) increases kinaseActivity(proteinAbundance(HGNC:MAPK11))
abundance(SCHEM:"SB-203580") decreases biologicalProcess(MESHPP:"Transendothelial and Transepithelial Migration")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 38"

SET Cell = "Endothelial Cells"
SET Evidence = "Impairing E-selectin-mediated activation of SAPK2p38 and HSP27 phosphorylation of
HT-29 cells with SB203580 (Fig. 4A and data not shown) or by expressing a dominant
negative form of SAPK2/p38 inhibited their migration across activated HUVEC
(Fig.4B)."
SET Citation = {"PubMed","The Journal of biological chemistry","10207013","","Rajavashisth TB|Liao JK|Galis ZS|Tripathi S|Laufs U|Tripathi J|Chai NN|Xu XP|Jovinge S|Shah PK|Libby P",""}
SET Species = "9606"

proteinAbundance(HGNC:IL1B) increases rnaAbundance(HGNC:MMP14)
abundance(CHEBI:"oxidised LDL") increases rnaAbundance(HGNC:MMP14)

SET Evidence = "Incubation of medium conditioned by human smooth muscle cells that contained pro-MMP-2,
with plasma membrane extracts prepared from EC treated with TNF-α, interleukin-1β,
or OxLDL, increased the proteolytic conversion of 72-kDa proMMP-2 to new
gelatinolytic bands of 70- and 68-kDa corresponding to the processed active MMP-2
(Fig. 7A). Proteolytic processing of pro-MMP-2 was reduced in membrane extracts
incubated with anti-MT1-MMP antibody (Fig. 7A and B)."

proteinAbundance(HGNC:TNF) increases catalyticActivity(proteinAbundance(HGNC:MMP2))
proteinAbundance(HGNC:IL1B) increases catalyticActivity(proteinAbundance(HGNC:MMP2))
abundance(CHEBI:"oxidised LDL") increases catalyticActivity(proteinAbundance(HGNC:MMP2))
catalyticActivity(proteinAbundance(HGNC:MMP14)) increases catalyticActivity(proteinAbundance(HGNC:MMP2))

SET TextLocation = "Results"
SET Evidence = "Northern analyses and RNase protection assays revealed that exposure of cultured EC
to TNF-α, interleukin-1β, or Ox-LDL results in the accumulation of MT1- MMP mRNA"

proteinAbundance(HGNC:TNF) increases rnaAbundance(HGNC:MMP14)
proteinAbundance(HGNC:IL1A) increases rnaAbundance(HGNC:MMP14)
proteinAbundance(HGNC:IL1B) increases rnaAbundance(HGNC:MMP14)
abundance(CHEBI:"oxidised LDL") increases rnaAbundance(HGNC:MMP14)

SET Evidence = "Stimulation of EC with TNF-α and/or Ox-LDL for 24 h increased the number of MT1-MMP-bearing
cells to about 1.8-fold (Ox-LDL), 1.7-fold (TNF-α), or 2.5-fold (TNF-α
and Ox-LDL together) as compared with unstimulated cells"

abundance(CHEBI:"oxidised LDL") increases cellSurfaceExpression(proteinAbundance(HGNC:MMP14))
proteinAbundance(HGNC:TNF) increases cellSurfaceExpression(proteinAbundance(HGNC:MMP14))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 39"

SET CellLine = "Calu-6"
SET TextLocation = "Results"
SET Evidence = "TSC exposure dramatically increased the tumorigenicity of Calu-6cells (Fig. 1B)."
SET Citation = {"PubMed","Cancer research","19351856","2009-05-07","Hussain M|Rao M|Humphries AE|Hong JA|Liu F|Yang M|Caragacianu D|Schrump DS",""}
SET Species = "9606"

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases pathology(SDIS:"tumor growth")

SET CellLine = "A549"
SET Evidence = "Tumors arising from TSC-treated A549 cells tended to be somewhat larger than those
developing from untreated cells (364 F 333 versus 200 F 329 mg; P = 0.25, two-tailed
t test; data not shown)."

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases biologicalProcess(SDIS:"tumor growth")

SET Evidence = "Interestingly, Dkk-1, encoding a Wnt signaling antagonist frequently silenced by DNA
methylation in cancer cells (20, 26), was down-regulated in a dose-dependent
manner in both cell lines. Quantitative RT-PCR experiments (Fig. 1C) confirmed
that TSC mediated dose-dependent decreases in Dkk-1 mRNA copy numbers in A549 and
Calu-6cells, which exhibited relatively high Dkk-1 expression."

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") decreases rnaAbundance(HGNC:DKK1)

SET CellLine = "Calu-6"

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") decreases rnaAbundance(HGNC:DKK1)

SET CellLine = "A549"
SET Evidence = "Diminished Dkk-1 expression coincided with reduced Dkk-1 protein levels in A549 and
Calu-6 cells following TSC exposure (Fig. 1D)."

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") decreases proteinAbundance(HGNC:DKK1)

SET CellLine = "Calu-6"

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") decreases proteinAbundance(HGNC:DKK1)

SET CellLine = "A549"
SET Evidence = "Interestingly, TSC exposure decreased H4K16Ac and increased H3K27me3 levels within
the Dkk-1 promoter region in both lung cancer lines."

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") decreases complexAbundance(proteinAbundance(PFH:"Histone H4 Family",proteinModification(A,K,16)),geneAbundance(HGNC:DKK1))
abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases complexAbundance(proteinAbundance(PFH:"Histone H3 Family",proteinModification(M,K,27)),geneAbundance(HGNC:DKK1))

SET CellLine = "Calu-6"

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") decreases complexAbundance(proteinAbundance(PFH:"Histone H4 Family",proteinModification(A,K,16)),geneAbundance(HGNC:DKK1))
abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases complexAbundance(proteinAbundance(PFH:"Histone H3 Family",proteinModification(M,K,27)),geneAbundance(HGNC:DKK1))

SET Evidence = "Chromatin immunoprecipitation analysis (Fig. 3B) revealed a dose-dependent increase
in H3K27me3, which coincided with recruitment of EZH2 and SUZ12 (components of
the “initiation” polycomb repressor complex 2 that catalyze H3K27me3), as well
as Bmi1, a member of “maintenance” polycomb repressor complex 1 (27). Additional
analysis confirmed the dose-dependent deacetylation of H4K16, which coincided
with recruitment of SirT1, a class III histone deacetylase that mediates H4K16deacet
ylation (28)."

proteinAbundance(HGNC:EZH2) positiveCorrelation complexAbundance(proteinAbundance(PFH:"Histone H3 Family",proteinModification(M,K,27)),geneAbundance(HGNC:DKK1))
complexAbundance(proteinAbundance(HGNC:EZH2),geneAbundance(HGNC:DKK1))
proteinAbundance(HGNC:SUZ12) positiveCorrelation complexAbundance(proteinAbundance(PFH:"Histone H3 Family",proteinModification(M,K,27)),geneAbundance(HGNC:DKK1))
complexAbundance(proteinAbundance(HGNC:SUZ12),geneAbundance(HGNC:DKK1))
complexAbundance(proteinAbundance(HGNC:BMI1),geneAbundance(HGNC:DKK1))

SET Evidence = "Quantitative RT-PCR analysis showed that knockdown of EZH2 increased Dkk-1 expression
in untreated Calu-6cells and partially abrogated TSC-mediated repression of
Dkk-1 (Fig. 4C)"

proteinAbundance(HGNC:EZH2) directlyDecreases rnaAbundance(HGNC:DKK1)

SET Evidence = "Knockdown of SirT1 also seemed to somewhat increase Dkk-1 expression in untreated
Calu-6cells and partially abrogate TSC-mediated repression of Dkk-1 (Fig. 4C)."

proteinAbundance(HGNC:SIRT1) decreases rnaAbundance(HGNC:DKK1)

SET Evidence = "Western blot analysis (Fig. 5B) revealed that TSC-mediated repression of Dkk-1 coincided
with dose-dependent phosphorylation of LDL receptor related protein 6(LRP-6)
and dishevelled-2 (Dvl-2) indicative of activation of Wnt receptor complex,
as well as JNK, a downstream effector of noncanonical Wnt signaling."

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases proteinAbundance(HGNC:LRP6,proteinModification(P))
abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases proteinAbundance(HGNC:DVL2,proteinModification(P))
abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases molecularActivity(proteinAbundance(PFH:"WNT Family"))
abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET Evidence = "shRNA-mediated knockdown of Dkk-1 enhanced phosphorylation of JNK in Calu-6cells (Fig.
5C), suggesting that activation of JNK in these cells following TSC exposure
was due, at least in part, to activation of Wnt signaling, rather than nonspecific
responses to genotoxic stress."

proteinAbundance(HGNC:DKK1) decreases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET Evidence = "Wnt5a (which encodes a ligand implicated in noncanonical Wnt signaling; ref. 32) was
markedly induced in TSC-treated Calu-6cells as well as Calu-6cells transfected
with shRNA targeting Dkk-1."

abundance(SCHEM:"smoke condensate, cigarette (gas phase)") increases proteinAbundance(HGNC:WNT5A)
proteinAbundance(HGNC:DKK1) decreases proteinAbundance(HGNC:WNT5A)

SET Evidence = "Additional analysis confirmed the dose-dependent deacetylation of H4K16, which coincided
with recruitment of SirT1, a class III histone deacetylase that mediates
H4K16deacet ylation (28)."

proteinAbundance(HGNC:SIRT1) negativeCorrelation complexAbundance(proteinAbundance(PFH:"Histone H4 Family",proteinModification(A,K,16)),geneAbundance(HGNC:DKK1))

SET TextLocation = "Abstract"
SET Evidence = "Knockdown of Dkk-1 recapitulated the dramatic protumorigenic effects of TSC exposure
in Calu-6 cells."

proteinAbundance(HGNC:DKK1) decreases pathology(SDIS:"tumor growth")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 40"

SET Cell = "T-Lymphocytes"
SET TextLocation = "Review"
SET Evidence = "IL-6 is produced by various types of lymphoid and nonlymphoid cells, such as T cells,
B cells, monocytes, fibroblasts, keratinocytes, endothelial cells, mesangial
cells, and several tumor cells [14]. It induces growth of T cells and differentiation
of cytotoxic T cells [15-19] by augmenting the expression of IL-2 receptor
[15] and the production of IL-2 [20]."
SET Citation = {"PubMed","Arthritis research","12110143","2002-06-09","Naka T|Nishimoto N|Kishimoto T",""}

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell growth")

SET Cell = "T-Lymphocytes, Cytotoxic"

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell differentiation")

SET Cell = "T-Lymphocytes"

proteinAbundance(HGNC:IL6) increases rnaAbundance(HGNC:IL2RA)
proteinAbundance(HGNC:IL6) increases proteinAbundance(HGNC:IL2)

SET Cell = "Macrophages"
SET Evidence = "IL-6 also induces differentiation of macrophages [26], megakaryocytes [27-29], and
osteoclasts [30]."

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell differentiation")

SET Cell = "Megakaryocytes"

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell differentiation")

SET Cell = "Osteoclasts"

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell differentiation")

SET Cell = "Hepatocytes"
SET Evidence = "In the acute-phase reaction, this cytokine stimulates hepatocytes to produce acute-phase
proteins such as C-reactive protein (CRP), fibrinogen, α1-antitrypsin, and
serum amyloid A [12,13], and it simultaneously suppresses albumin production
[11]."

proteinAbundance(HGNC:IL6) increases proteinAbundance(HGNC:CRP)
proteinAbundance(HGNC:IL6) increases proteinAbundance(HGNC:SERPINA1)
proteinAbundance(HGNC:IL6) increases complexAbundance(NCH:"Fibrinogen Complex")
proteinAbundance(HGNC:IL6) increases proteinAbundance(HGNC:SAA1)
proteinAbundance(HGNC:IL6) decreases proteinAbundance(HGNC:ALB)

SET Evidence = "It causes leukocytosis and fever when administered in vivo[31] and also acts as a
growth factor for renal mesangial cells [32], epidermal keratinocytes [33,34],
and various types of tumor cells, for example, in plasmacytoma[8], multiple myeloma[35],
and renal cell carcinoma[36]."

proteinAbundance(HGNC:IL6) increases pathology(MESHD:Leukocytosis)
proteinAbundance(HGNC:IL6) increases pathology(MESHD:Fever)

SET Cell = "Mesangial Cells"

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell growth")

SET Cell = "Keratinocytes"

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell growth")

SET Cell = "Tumor Cells, Cultured"
SET Disease = "Neoplasms"

proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"cell growth")

SET Evidence = "We and our colleagues identified the two components of IL-6 receptor (IL-6R), an 80-kDa
IL-6-binding protein (α chain) and a 130-kDa signal transducer known as gp130
(β chain), in 1988 and 1990[37-39], respectively. Although IL-6 cannot directly
bind to gp130, it can bind to IL-6R to generate the high-affinity complex of
IL-6/IL-6R/gp130."

complexAbundance(proteinAbundance(HGNC:IL6),proteinAbundance(HGNC:IL6R),proteinAbundance(HGNC:IL6ST))

SET Evidence = "Our group and others found that JAK1, JAK2, and Tky-2 are activated and are tyrosine-phosphorylated
in response to IL-6, CNTF, LIF, and OSM[14]"

proteinAbundance(HGNC:IL6) increases kinaseActivity(proteinAbundance(HGNC:JAK1))
proteinAbundance(HGNC:CNTF) increases kinaseActivity(proteinAbundance(HGNC:JAK1))
proteinAbundance(HGNC:LIF) increases kinaseActivity(proteinAbundance(HGNC:JAK1))
proteinAbundance(HGNC:OSM) increases kinaseActivity(proteinAbundance(HGNC:JAK1))
proteinAbundance(HGNC:IL6) increases kinaseActivity(proteinAbundance(HGNC:JAK2))
proteinAbundance(HGNC:CNTF) increases kinaseActivity(proteinAbundance(HGNC:JAK2))
proteinAbundance(HGNC:LIF) increases kinaseActivity(proteinAbundance(HGNC:JAK2))
proteinAbundance(HGNC:OSM) increases kinaseActivity(proteinAbundance(HGNC:JAK2))
proteinAbundance(HGNC:IL6) increases kinaseActivity(proteinAbundance(HGNC:TYK2))
proteinAbundance(HGNC:CNTF) increases kinaseActivity(proteinAbundance(HGNC:TYK2))
proteinAbundance(HGNC:LIF) increases kinaseActivity(proteinAbundance(HGNC:TYK2))
proteinAbundance(HGNC:OSM) increases kinaseActivity(proteinAbundance(HGNC:TYK2))

SET Evidence = "IL-6 activates STAT1 and STAT5 in addition to STAT3."

proteinAbundance(HGNC:IL6) increases transcriptionalActivity(proteinAbundance(HGNC:STAT3))
proteinAbundance(HGNC:IL6) increases transcriptionalActivity(proteinAbundance(HGNC:STAT1))
proteinAbundance(HGNC:IL6) increases transcriptionalActivity(proteinAbundance(PFH:"STAT5 Family"))

SET Evidence = "The binding activity of NF-IL-6 is probably induced by IL-6 through the increased
expression of the NF-IL-6 gene rather than through its post-translational modification."

proteinAbundance(HGNC:IL6) increases rnaAbundance(HGNC:CEBPB) //NF-IL-6 = CEBPB

SET CellLine = "M1"
SET Evidence = "It is known that IL-6 induces growth arrest and macrophage differentiation in the
murine myeloid leukemic cell line M1. The essential role of STAT3 in the IL-6-induced
macrophage differentiation of M1 cells was demonstrated by using dominant
negative forms of STAT3 [67], which inhibit both IL-6-induced growth arrest and
macrophage differentiation in M1 transformants. Blocking STAT3 activation inhibits
IL-6-induced repression of c-Myb and c-Myc, but not EGR-1 induction [68], while
IL-6 enhances the growth of M1 cells when STAT3 is suppressed."
SET Species = "10090"

proteinAbundance(HGNC:IL6) decreases biologicalProcess(GO:"cell growth")
proteinAbundance(HGNC:IL6) increases biologicalProcess(GO:"macrophage differentiation")
transcriptionalActivity(proteinAbundance(HGNC:STAT3)) increases biologicalProcess(GO:"macrophage differentiation")
transcriptionalActivity(proteinAbundance(HGNC:STAT3)) decreases biologicalProcess(GO:"cell growth")
proteinAbundance(HGNC:IL6) decreases rnaAbundance(HGNC:MYB)
proteinAbundance(HGNC:IL6) decreases rnaAbundance(HGNC:MYC)
proteinAbundance(HGNC:IL6) increases rnaAbundance(HGNC:EGR1)
transcriptionalActivity(proteinAbundance(HGNC:STAT3)) decreases rnaAbundance(HGNC:MYB)
transcriptionalActivity(proteinAbundance(HGNC:STAT3)) decreases rnaAbundance(HGNC:MYC)

SET Evidence = "Furthermore, nonreceptor tyrosine kinases, such as Btk, Tec, Fes, and Hck[72,73] are
activated through the IL-6 receptor, as well as through a variety of other cytokine
receptors [74], although the biological significance of these signal transduction
pathways remains to be clarified."

molecularActivity(proteinAbundance(HGNC:IL6R)) increases kinaseActivity(proteinAbundance(HGNC:BTK))
molecularActivity(proteinAbundance(HGNC:IL6R)) increases kinaseActivity(proteinAbundance(HGNC:TEC))
molecularActivity(proteinAbundance(HGNC:IL6R)) increases kinaseActivity(proteinAbundance(HGNC:FES))
molecularActivity(proteinAbundance(HGNC:IL6R)) increases kinaseActivity(proteinAbundance(HGNC:HCK))

SET Evidence = "In fact, a recent study reported that knock-in mutation mice lacking SHP-2 signal
showed sustained gp130-induced STAT3 activation; this finding indicates a negative
regulatory role of SHP-2 for STAT3 activation[75] ."

proteinAbundance(MGI:Ptpn11) decreases (molecularActivity(proteinAbundance(MGI:Il6st)) increases transcriptionalActivity(proteinAbundance(MGI:Stat3)))

SET Evidence = "SOCS-1 directly interacts with JAKs, and thus inhibits their catalytic activity. SOCS-3
also inhibits JAK activity (but only partially in comparison with SOCS-1)
although the augmentation of its effect in the presence of receptors suggests that
SOCS-3 inhibits cytokine signaling by binding to the receptor complex."

proteinAbundance(HGNC:SOCS1) directlyDecreases kinaseActivity(proteinAbundance(PFH:"JAK Family"))
proteinAbundance(HGNC:SOCS3) decreases kinaseActivity(proteinAbundance(PFH:"JAK Family"))

SET Evidence = "Overexpression studies have shown that PIAS-1 associates only with activated STAT1
dimers and inhibits their DNA-binding activity, but that no monomeric forms of
STAT1 are present [99]. Similarly, PIAS-3 associates specifically with activated
STAT3 but not with STAT1, resulting in the blocking of all STAT3-mediated gene
transcriptions, and is especially well known as an inhibitor of IL-6 signaling
in M1 cell lines [98]."

proteinAbundance(MGI:Pias1) directlyDecreases transcriptionalActivity(proteinAbundance(MGI:Stat1))
proteinAbundance(MGI:Pias3) directlyDecreases transcriptionalActivity(proteinAbundance(HGNC:STAT3))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 41"

SET Cell = "Endothelial Cells"
SET Evidence = "Vascular endothelial growth factor (VEGF) is one of the key angiogenic growth factors
and stimulates migration, proliferation, and tube formation of ECs primarily
through the VEGF receptor type2 (VEGR2, KDR/Flk1) (76)."
SET Citation = {"PubMed","Antioxidants & redox signaling","17511588","","Ushio-Fukai M",""}
SET Species = "9606"

proteinAbundance(PFH:"VEGF Family") increases kinaseActivity(proteinAbundance(HGNC:KDR))
proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:angiogenesis)
proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell migration")
proteinAbundance(PFH:"VEGF Family") increases biologicalProcess(GO:"cell proliferation")

SET Evidence = "Excess amounts of reactive oxygen species (ROS) such as O2.- and H2O2 have deleterious
effects on cells and contribute to various cardiovascular diseases including
hypertension, heart failure, atherosclerosis, and diabetes (41), while physiological
concentrations of ROS are involved in signaling to mediate cell migration,
growth, and differentiation (32)."

abundance(CHEBI:"reactive oxygen species") increases biologicalProcess(GO:"cell proliferation")
abundance(CHEBI:"reactive oxygen species") increases biologicalProcess(GO:"cell migration")
abundance(CHEBI:"reactive oxygen species") increases biologicalProcess(GO:"cell differentiation")

SET Evidence = "ROS stimulate induction of VEGF, which in turn increases ROS through activation of
NADPH oxidases that are involved in VEGFR2 autophosphorylation, EC migration,
and proliferation (49, 100, 111)."

abundance(CHEBI:"reactive oxygen species") increases proteinAbundance(PFH:"VEGF Family")

SET Evidence = "Nox2 is a critical component of endothelial NADPH oxidase (38), and its expression
and Nox2-dependent ROS production are increased by oxidized LDL, endothelin-1,
angiotensin II, VEGF, and angiopoietin-2 in ECs (99). Nox1 is involved in shear
stressinduced ROS production which is required for monocyte adhesion (93) and stimulates
branching morphogenesis in sinusoidal ECs (55). Nox4 is most abundantly
expressed in ECs, and involved in basal- (2) and Ang II-induced (109) O2- production.
Moreover, p47phox is involved in cytokine, growth factor, or shear stress-stimulated
ROS production in ECs (48, 67, 107)."

abundance(SCHEM:"Oxidized Low Density Lipoprotein") increases proteinAbundance(HGNC:CYBB)
abundance(SCHEM:"Oxidized Low Density Lipoprotein") increases catalyticActivity(proteinAbundance(HGNC:CYBB))
catalyticActivity(proteinAbundance(HGNC:CYBB)) directlyIncreases abundance(CHEBI:"reactive oxygen species")
proteinAbundance(HGNC:EDN1) increases catalyticActivity(proteinAbundance(HGNC:CYBB))
abundance(SCHEM:"Angiotensin ii") increases catalyticActivity(proteinAbundance(HGNC:CYBB))
proteinAbundance(PFH:"VEGF Family") increases catalyticActivity(proteinAbundance(HGNC:CYBB))
proteinAbundance(HGNC:ANGPT2) increases catalyticActivity(proteinAbundance(HGNC:CYBB))
biologicalProcess(GO:"response to fluid shear stress") increases catalyticActivity(proteinAbundance(HGNC:NOX1))
biologicalProcess(GO:"response to fluid shear stress") increases (molecularActivity(proteinAbundance(HGNC:NOX1)) increases abundance(CHEBI:"reactive oxygen species"))
catalyticActivity(proteinAbundance(HGNC:NOX4)) increases abundance(CHEBI:superoxide)
biologicalProcess(GO:"response to fluid shear stress") increases catalyticActivity(proteinAbundance(HGNC:NCF1))

SET Evidence = "After agonist stimulation or during active EC migration, p47phox translocates to the
membrane ruffles through association with WAVE1 and Rac1/PAK1 (107), as well
as to the focal complexes in lamellar protrusions through binding to adaptor TRAF4
and Hic-5, a focal contact scaffold (108)."

complexAbundance(proteinAbundance(HGNC:NCF1),proteinAbundance(HGNC:WASF1))
complexAbundance(proteinAbundance(HGNC:NCF1),proteinAbundance(HGNC:RAC1))
complexAbundance(proteinAbundance(HGNC:NCF1),proteinAbundance(HGNC:TRAF4))
complexAbundance(proteinAbundance(HGNC:NCF1),proteinAbundance(HGNC:TGFB1I1))

SET Evidence = "Exogenous H2O2 stimulates induction of HIF1α and VEGF by various cell types including
ECs, and promote cell proliferation and migration, cytoskeletal reorganization,
and tube formation in ECs (99)."

abundance(CHEBI:"hydrogen peroxide") increases proteinAbundance(HGNC:HIF1A)
abundance(CHEBI:"hydrogen peroxide") increases biologicalProcess(GO:"cell proliferation")
abundance(CHEBI:"hydrogen peroxide") increases biologicalProcess(GO:"cell migration")
abundance(CHEBI:"hydrogen peroxide") increases biologicalProcess(GO:"epithelial tube formation")
abundance(CHEBI:"hydrogen peroxide") increases proteinAbundance(HGNC:VEGFA)

SET Evidence = "VEGF and angiopoietin-1 stimulate ROS production via activation of Nox2-based NADPH
oxidase and oxidase-derived ROS are involved in EC migration and/or proliferation
(43, 49, 100, 111) (Fig. 1). Thus, many of angiogenic responses in ECs are
dependent on ROS."

proteinAbundance(PFH:"VEGF Family") increases (molecularActivity(proteinAbundance(HGNC:CYBB)) increases abundance(CHEBI:"reactive oxygen species"))
proteinAbundance(HGNC:ANGPT2) increases (molecularActivity(proteinAbundance(HGNC:CYBB)) increases abundance(CHEBI:"reactive oxygen species"))

SET Evidence = "The mitogenic and chemotactic effects of VEGF in ECs are mediated mainly through VEGFR2
(76). VEGFR2 is activated through ligandstimulated receptor dimerization
and transphosphorylation (autophosphorylation) of tyrosine residues in the cytoplasmic
kinase domain. At present, tyrosine residues 951 and 996 in the kinase insert
domain, and 1054 and 1059 in the kinase catalytic domain, have been identified
as autophosphorylation sites for VEGFR2 in a bacterial expression system (30).
This event is followed by activation of downstream signaling pathways such as
Src, PI3 kinase, MAP kinases, and Akt, which is essential for VEGF-induced actin
reorganization, cell migration, and proliferation of ECs."

proteinAbundance(PFH:"VEGF Family") directlyIncreases kinaseActivity(proteinAbundance(HGNC:KDR))
kinaseActivity(proteinAbundance(HGNC:KDR)) directlyIncreases proteinAbundance(HGNC:KDR,proteinModification(P,Y,951))
kinaseActivity(proteinAbundance(HGNC:KDR)) directlyIncreases proteinAbundance(HGNC:KDR,proteinModification(P,Y,996))
proteinAbundance(PFH:"VEGF Family") directlyIncreases proteinAbundance(HGNC:KDR,proteinModification(P,Y,1054))
proteinAbundance(PFH:"VEGF Family") directlyIncreases proteinAbundance(HGNC:KDR,proteinModification(P,Y,1059))
kinaseActivity(proteinAbundance(HGNC:KDR)) directlyIncreases kinaseActivity(proteinAbundance(HGNC:SRC))
kinaseActivity(proteinAbundance(HGNC:KDR)) directlyIncreases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))
kinaseActivity(proteinAbundance(HGNC:KDR)) directlyIncreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET Evidence = "Several PTPs, including SHP-1, SHP-2, and LMW-PTP (HCPTPA), inducibly associate with
VEGFR2 after VEGF stimulation (42, 46, 57)."

proteinAbundance(PFH:"VEGF Family") directlyIncreases complexAbundance(proteinAbundance(HGNC:KDR),proteinAbundance(HGNC:PTPN6))
proteinAbundance(PFH:"VEGF Family") directlyIncreases complexAbundance(proteinAbundance(HGNC:KDR),proteinAbundance(HGNC:PTPN11))
proteinAbundance(PFH:"VEGF Family") directlyIncreases complexAbundance(proteinAbundance(HGNC:KDR),proteinAbundance(HGNC:ACP1))

SET Evidence = "HCPTPA overexpression inhibits VEGFinduced VEGFR2 autophosphorylation, EC migration,
and proliferation (46). High cell density-enhanced PTP1 (DEP- 1)/CD148 attenuates
phosphorylation of VEGFR2 in contact-inhibited confluent ECs (40). A small
molecule inhibitor of PTP1B enhances VEGF-induced VEGFR2 autophosphoryla- tion,
migration, and proliferation of EC, as well as neovascularization in a mouse matrigel
model (92). Angiopoietin-1 stimulates association of SHP-2 to the phosphorylated
Tie-2 receptor (47), which in turn inhibits PI3 kinase-dependent signaling
pathways leading to EC migration."

proteinAbundance(HGNC:ACP1) decreases kinaseActivity(proteinAbundance(HGNC:KDR))
phosphataseActivity(proteinAbundance(HGNC:PTPRJ)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:KDR))
proteinAbundance(HGNC:PTPN11) directlyDecreases kinaseActivity(proteinAbundance(HGNC:TEK))

SET Evidence = "TNF-α inhibits VEGF signaling by recruiting SHP-2 to the VEGFR2 in ECs (42)."

proteinAbundance(HGNC:TNF) increases (phosphataseActivity(proteinAbundance(HGNC:PTPN11)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:KDR)))

SET Evidence = "The SHP-2 is oxidatively inactivated by PDGF-induced ROS when it binds to PDGFR (78).
Thus, it is essential to identify the PTPs which are reversibly oxidized and
inactivated after VEGF stimulation in ECs (Fig. 1)."

abundance(CHEBI:"reactive oxygen species") directlyDecreases phosphataseActivity(proteinAbundance(HGNC:PTPN11))

SET Evidence = "VEGF rapidly activates Rac1 and promotes translocation of Rac1 from the cytosol to
the membrane, thereby activating NADPH oxidase in ECs (100). Overexpression of
dominant negative N17Rac1 significantly inhibits VEGF-induced ROS production that
is involved in VEGFR2 activation, EC migration, and proliferation (100)."

proteinAbundance(PFH:"VEGF Family") increases gtpBoundActivity(proteinAbundance(HGNC:RAC1))
gtpBoundActivity(proteinAbundance(HGNC:RAC1)) directlyIncreases catalyticActivity(complexAbundance(NCH:"NADPH Oxidase Complex"))

SET CellStructure = "Caveolae"
SET Evidence = "VEGFR2 is present in endothelial caveolae through association with Cav1 which negatively
regulates receptor activity in basal state (Fig. 1)(61). Dissociation of
VEGFR2 from caveolae/Cav1 seems to be essential for VEGFR2 autophosphorylation
and activation of downstream signaling events(61)."

proteinAbundance(HGNC:CAV1) directlyDecreases kinaseActivity(proteinAbundance(HGNC:KDR))
complexAbundance(proteinAbundance(HGNC:CAV1),proteinAbundance(HGNC:KDR))

SET Evidence = "Cav1 is tyrosine phosphorylated by ROS (14, 17)and by various growth factors(54, 70),
including VEGF(61). We have demonstrated that VEGF promotes the release of
VEGFR2 from caveolae/lipid rafts, which is contemporaneous with the tyrosine phosphorylation
of Cav1(Tyr14) and VEGFR2 and their colocalization at focal complexes,
appearing as small-dot like structures at the edge of lamellipodia (Figs. 1
and 2)(52)."

proteinAbundance(PFH:"VEGF Family") increases proteinAbundance(HGNC:CAV1,proteinModification(P,Y,14))
proteinAbundance(HGNC:CAV1,proteinModification(P,Y,14)) directlyDecreases complexAbundance(proteinAbundance(HGNC:CAV1),proteinAbundance(HGNC:KDR))

SET Evidence = "Phospho-caveolin interacts with Grb7 (63), low molecular weight protein tyrosine phosphatase
(16), and Csk, a negative regulator for Src (13)."

proteinAbundance(HGNC:CAV1,proteinModification(P,Y,14)) directlyIncreases complexAbundance(proteinAbundance(HGNC:CAV1),proteinAbundance(HGNC:GRB7))
proteinAbundance(HGNC:CAV1,proteinModification(P,Y,14)) directlyIncreases complexAbundance(proteinAbundance(HGNC:CAV1),proteinAbundance(HGNC:ACP1))
proteinAbundance(HGNC:CAV1,proteinModification(P,Y,14)) directlyIncreases complexAbundance(proteinAbundance(HGNC:CAV1),proteinAbundance(HGNC:CSK))

SET Evidence = "Of note, overexpression of mutant Cav1 (Y14F) blocks VEGF-stimulated localization
of phospho-VEGFR2 at focal complexes as well as EC migration and proliferation."

proteinAbundance(HGNC:CAV1) decreases biologicalProcess(GO:"cell migration")
proteinAbundance(HGNC:CAV1) decreases biologicalProcess(GO:"cell proliferation")

SET Evidence = "In ECs, VEGF stimulates ARF6 association with Rac1, which is cotemporaneous with Rac1
activation. The dominant negative ARF6 (T27N),inhibits VEGF-stimulated GTP-loading
of Rac1, ROS production, and VEGFR2 autophosphorylation. These results suggest
that ARF6 is an upstream mediator for Rac1, which may contribute to ROS production
that mediates VEGFR2 autophosphorylation in ECs (Fig. 1)."

proteinAbundance(PFH:"VEGF Family") increases gtpBoundActivity(proteinAbundance(HGNC:ARF6))
proteinAbundance(PFH:"VEGF Family") increases complexAbundance(proteinAbundance(HGNC:ARF6),proteinAbundance(HGNC:RAC1))
gtpBoundActivity(proteinAbundance(HGNC:ARF6)) increases gtpBoundActivity(proteinAbundance(HGNC:RAC1))

SET Evidence = "Tyrosine phosphorylation of VE-cadherin is required for reducing cell–cell adhesions
and is mediated through cSrc which is dependent on ROS (69,103)."

proteinAbundance(HGNC:CDH5,proteinModification(P,Y)) directlyDecreases biologicalProcess(GO:"cell-cell adhesion")
kinaseActivity(proteinAbundance(HGNC:SRC)) directlyIncreases proteinAbundance(HGNC:CDH5,proteinModification(P,Y))

SET Evidence = "IQGAP1 captures and stabilizes microtubules by interacting with CLIP-170, a microtubule
plus end binding protein, near the cell cortical regions (83). Activated
Rac1 promotes capture of CLIP-170-capped microtubules in lamellipodia(75)."

complexAbundance(proteinAbundance(HGNC:IQGAP1),proteinAbundance(HGNC:CLIP1))
gtpBoundActivity(proteinAbundance(HGNC:RAC1)) increases complexAbundance(proteinAbundance(HGNC:IQGAP1),proteinAbundance(HGNC:CLIP1))

SET Evidence = "At the leading edge of cells, Rac1 also links the adenomatous polyposis coli (APC)
protein to actin filaments through binding to IQGAP1, thereby regulating polarization
and directional migration by forming a complex with APC and CLIP-170. Of
note, Nox2 also binds to and colocalizes with IQGAP1 at the leading edge in actively
migrating ECs (Fig. 2)(50)."

gtpBoundActivity(proteinAbundance(HGNC:RAC1)) increases complexAbundance(proteinAbundance(HGNC:APC),proteinAbundance(HGNC:IQGAP1))
gtpBoundActivity(proteinAbundance(HGNC:RAC1)) increases complexAbundance(proteinAbundance(HGNC:CLIP1),proteinAbundance(HGNC:APC))
complexAbundance(proteinAbundance(HGNC:CYBB),proteinAbundance(HGNC:IQGAP1))

SET Evidence = "We also demonstrated that VEGF-induced capillary tube formation in three-dimensional
culture in type I collagen gels is impaired in IQGAP1 knocked down ECs."

proteinAbundance(HGNC:IQGAP1) increases biologicalProcess(GO:"epithelial tube formation")

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 42"

SET TextLocation = "Results"
SET Evidence = "The model was appropriate for testing the effects of desaturase inhibition because,
after subplantar injection of carrageenan, an acute and localized inflammatory
response occurs in the footpad, characterized by increased edema and neutrophil
infiltration. Inhibition of edema was obtained with aspirin and indomethacin and
was comparable to that obtained in the rat model."
SET Citation = {"PubMed","Lipids","10419129","","Obukowicz M|Welsch D|Salsgiver W|Martin-Berger C|Chinn K|Duffin K|Raz A|Needleman P",""}
SET Species = "10090"

abundance(CHEBI:"acetylsalicylic acid") decreases pathology(MESHD:Edema)
abundance(CHEBI:indomethacin) decreases pathology(MESHD:Edema)
pathology(MESHD:Edema) subProcessOf biologicalProcess(GO:"inflammatory response")
biologicalProcess(MESHPP:"Neutrophil Infiltration") subProcessOf biologicalProcess(GO:"inflammatory response")

SET TextLocation = "Legend"
SET DigestiveSystem = "Liver"
SET Evidence = "Desaturase activity was determined directly in mouse liver by quantifying the conversion
of 14C-DGLA → 14C-AA (Δ5 desaturase activity) or 14C-LA → 14C-AA (combined
Δ6 desaturase + elongase + Δ5 desaturase activities)."

catalyticActivity(proteinAbundance(MGI:Fads1)) directlyIncreases reaction(reactants(abundance(CHEBI:"all-cis-eicosa-8,11,14-trienoic acid")),products(abundance(CHEBI:"arachidonic acid")))

SET Evidence = "A. SC-26196 inhibited Δ6 desaturase activity and decreased edema.  SC-26196 inhibited
desaturase activity in vivo(ED50 = 20 mpk) and decreased edema dose-dependently
(fig.3). Nearly complete inhibition of the conversion of 14C-LA to 14C-GLA
+14C-DGLA + 14C-AA in mouse liver was obtained with a single 100 mpk i.p. or i.g.
dose (90–100% inhibition)."

catalyticActivity(proteinAbundance(MGI:Fads2)) increases abundance(CHEBI:"arachidonic acid")
catalyticActivity(proteinAbundance(MGI:Fads2)) increases pathology(MESHD:Edema)

SET Evidence = "D. Dietary AA restored edema and MPO activity."

abundance(CHEBI:"arachidonic acid") increases pathology(MESHD:Edema)
abundance(CHEBI:"arachidonic acid") increases catalyticActivity(proteinAbundance(MGI:Mpo))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 43"

SET TextLocation = "Abstract"
SET CellStructure = "Cytoplasm"
SET Evidence = "Phosphorylation of cytoplasmic FOXO at specific sites by JNK initiates translocation
into the nucleus"
SET Citation = {"PubMed","Cell cycle (Georgetown, Tex.)","15917664","2005-08-03","Vogt PK|Jiang H|Aoki M",""}

kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")) directlyIncreases proteinAbundance(PFH:"FOXO Family",proteinModification(P))
proteinAbundance(PFH:"FOXO Family",proteinModification(P)) increases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")

SET Evidence = "Akt-dependent phosphorylation reduces the DNA-binding activity of FOXO, interferes
with binding to the co-activators p300/CBP, and inactivates the FOXO nuclear translocation
signal"

kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyIncreases proteinAbundance(PFH:"FOXO Family",proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyDecreases transcriptionalActivity(proteinAbundance(PFH:"FOXO Family"))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases complexAbundance(proteinAbundance(HGNC:AKT1),proteinAbundance(HGNC:EP300))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases complexAbundance(proteinAbundance(HGNC:AKT1),proteinAbundance(HGNC:CREBBP))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")
proteinAbundance(PFH:"FOXO Family",proteinModification(P)) directlyDecreases transcriptionalActivity(proteinAbundance(PFH:"FOXO Family"))

SET Evidence = "The Akt-phosphorylated FOXO is exported from the nucleus in a CRM1- and 14-3-3-dependent
process"

molecularActivity(proteinAbundance(HGNC:XPO1)) directlyIncreases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)
molecularActivity(proteinAbundance(PFH:"14-3-3 Family")) directlyIncreases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)
kinaseActivity(proteinAbundance(HGNC:AKT1)) increases (molecularActivity(proteinAbundance(HGNC:XPO1)) directlyIncreases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm))
kinaseActivity(proteinAbundance(HGNC:AKT1)) increases (molecularActivity(proteinAbundance(PFH:"14-3-3 Family")) directlyIncreases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm))

SET Evidence = "Akt-phosphorylated FOXO interacts with the ubiquitin ligase Skp2 and is targeted for
proteasomal degradation."

kinaseActivity(proteinAbundance(HGNC:AKT1)) increases complexAbundance(proteinAbundance(HGNC:SKP2),proteinAbundance(PFH:"FOXO Family"))
catalyticActivity(proteinAbundance(HGNC:SKP2)) directlyIncreases degradation(proteinAbundance(PFH:"FOXO Family"))
kinaseActivity(proteinAbundance(HGNC:AKT1)) increases (catalyticActivity(proteinAbundance(HGNC:SKP2)) directlyIncreases degradation(proteinAbundance(PFH:"FOXO Family")))

SET TextLocation = "Review"
SET Evidence = "FOXO proteins intervene in the cell cycle by activating the cyclin-dependent kinase
(CDK) inhibitors p27kip1 and p21cip1."

kinaseActivity(proteinAbundance(PFH:"FOXO Family")) increases proteinAbundance(HGNC:CDKN1A)
kinaseActivity(proteinAbundance(PFH:"FOXO Family")) increases proteinAbundance(HGNC:CDKN1B)

SET Evidence = "They also repress transcription of cyclin D1 and D2, which results in an attenuation
of CDK4 activity and reduced phosphorylation of Rb protein, and hence increased
binding activity of E2F family members to Rb."

transcriptionalActivity(proteinAbundance(PFH:"FOXO Family")) directlyDecreases rnaAbundance(HGNC:CCND1)
transcriptionalActivity(proteinAbundance(PFH:"FOXO Family")) directlyDecreases rnaAbundance(HGNC:CCND2)
proteinAbundance(HGNC:CCND1) directlyIncreases kinaseActivity(proteinAbundance(HGNC:CDK4))
proteinAbundance(HGNC:CCND2) directlyIncreases kinaseActivity(proteinAbundance(HGNC:CDK4))
kinaseActivity(proteinAbundance(HGNC:CDK4)) directlyIncreases proteinAbundance(HGNC:RB1,proteinModification(P))
proteinAbundance(HGNC:RB1,proteinModification(P)) directlyDecreases complexAbundance(proteinAbundance(PFH:"E2F Family"),proteinAbundance(HGNC:RB1))

SET Evidence = "The overall effect of FOXO on cell cycle control is G1 arrest"

transcriptionalActivity(proteinAbundance(PFH:"FOXO Family")) decreases biologicalProcess(GO:"G1/S transition of mitotic cell cycle")

SET Evidence = "Phosphorylation of the N-terminal Akt motif disrupts the interaction of this domain
with the transcriptional co-activators p300/CBP and facilitates binding of FOXO
to a 14-3-3 protein instead"

kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyIncreases complexAbundance(proteinAbundance(PFH:"FOXO Family"),proteinAbundance(PFH:"14-3-3 Family"))

SET Evidence = "Oxidative stress, for instance a low concentration of hydrogen peroxide (H2O2),leads
to an activation of the small GTPase Ral, which in turn is instrumental in the
phosphorylation and activation of the Jun N-terminal kinase JNK."

biologicalProcess(GO:"response to oxidative stress") increases gtpBoundActivity(proteinAbundance(HGNC:RALA))
gtpBoundActivity(proteinAbundance(HGNC:RALA)) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET Evidence = "JNK-induced phosphorylation initiates nuclear import of FOXO proteins and activation
of their transcriptional regulatory potential."

kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")) increases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")
kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")) increases transcriptionalActivity(proteinAbundance(PFH:"FOXO Family"))

SET Evidence = "Nuclear import triggered by oxidative stress results in association of FOXO proteins
with proteins that have histone acetylase activity, such as p300/CBP and p300/CBP-associated
factor (PCAF)."

biologicalProcess(GO:"response to oxidative stress") increases translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus")

SET CellStructure = "Cell Nucleus"

biologicalProcess(GO:"response to oxidative stress") increases complexAbundance(proteinAbundance(PFH:"FOXO Family"),proteinAbundance(HGNC:EP300))
biologicalProcess(GO:"response to oxidative stress") increases complexAbundance(proteinAbundance(PFH:"FOXO Family"),proteinAbundance(HGNC:CREBBP))
biologicalProcess(GO:"response to oxidative stress") increases complexAbundance(proteinAbundance(PFH:"FOXO Family"),proteinAbundance(HGNC:KAT2B))
translocation(proteinAbundance(PFH:"FOXO Family"),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus") increases transcriptionalActivity(proteinAbundance(PFH:"FOXO Family"))

SET TextLocation = {"Review","Review"}
SET Evidence = "acetylation of FOXO appears to reduce transcriptional activity"

proteinAbundance(PFH:"FOXO Family",proteinModification(A)) directlyDecreases transcriptionalActivity(proteinAbundance(PFH:"FOXO Family"))

SET TextLocation = "Review"
SET Evidence = "Acetylated and JNK-phosphorylated nuclear FOXO then recruits SIRT1, a constitutively
nuclear, nicotinamide adenine dinucleotide-dependent protein deacetylase. This
recruitment, like the nuclear import, is dependent on oxidative stress signals."

biologicalProcess(GO:"response to oxidative stress") increases complexAbundance(proteinAbundance(PFH:"FOXO Family"),proteinAbundance(HGNC:SIRT1))

SET Evidence = "For FOXO3a, the critical kinase is IKKβ rather than Akt, and the relevant target residue
is serine 644, attracting an as yet unidentified ubiquitin ligase.16"

kinaseActivity(proteinAbundance(HGNC:IKBKB)) directlyIncreases proteinAbundance(HGNC:FOXO3,proteinModification(P,S,644))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 44"

SET TextLocation = "Abstract"
SET Evidence = "Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective
in a subset of patients with advanced non-small cell lung cancer (NSCLC)."
SET Citation = {"PubMed","Proceedings of the National Academy of Sciences of the United States of America","15731348","2005-03-24","Engelman JA|Jänne PA|Mermel C|Pearlberg J|Mukohara T|Fleet C|Cichowski K|Johnson BE|Cantley LC",""}
SET Species = "9606"

abundance(SCHEM:Gefitinib) directlyDecreases kinaseActivity(proteinAbundance(HGNC:EGFR))

SET Disease = "Carcinoma, Non-Small-Cell Lung"
SET Evidence = "In this study, we observe that gefitinib reduces phospho-Akt levels only in NSCLC
cell lines in which it inhibits growth."

abundance(SCHEM:Gefitinib) decreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
proteinAbundance(PFH:"AKT Family",proteinModification(P,S,473)) directlyIncreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET Evidence = "We observe that PI3K associates with ErbB-3 exclusively in gefitinib-sensitive NSCLC
cell lines. Gefitinib dissociates this complex, thereby linking EGFR inhibition
to decreased Akt activity."

complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
abundance(SCHEM:Gefitinib) decreases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
kinaseActivity(proteinAbundance(HGNC:EGFR)) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "Calu-3"
SET Evidence = "Down-regulation of ErbB-3 by means of short hairpin RNA leads to decreased phospho-Akt
levels in the gefitinib-sensitive NSCLC cell lines, Calu-3 (WT EGFR) and H3255
(L858R EGFR), but has no effect on Akt activation in the gefitinib-resistant
cell lines, A549 and H522."

proteinAbundance(HGNC:ERBB3) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "A549"
SET Cell = "Acrosome"

proteinAbundance(HGNC:ERBB3) causesNoChange kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "NCI-H522"

proteinAbundance(HGNC:ERBB3) causesNoChange proteinAbundance(PFH:"AKT Family",proteinModification(P,T,493))

SET CellLine = "Calu-3"
SET TextLocation = "Results"
SET Evidence = "Therefore, the p85 IPs were probed with anti-ErbB-3 antibodies. In the gefitinib-sensitive
NSCLC cell lines, there is indeed a gefitinib-labile interaction between
p85 and ErbB-3 (Fig. 2A Bottom Right)."

complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
abundance(SCHEM:Gefitinib) decreases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))

SET CellLine = "A-431"

complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
abundance(SCHEM:Gefitinib) decreases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))

SET Evidence = "As shown in Fig. 3A, EGF stimulated an association between p85 and ErbB-3 (also observed
as the 210-kDa PTyr protein). This association was blocked by exposing the
cells to 1 μM gefitinib. Assessment of ErbB-3 immunoprecipitations reveals that
gefitinib leads to a decrease in ErbB-3 tyrosine phosphorylation (Fig. 3B Top)
and the amount of coprecipitated p85 (Fig. 3B Middle)."

proteinAbundance(HGNC:EGF) increases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
abundance(SCHEM:Gefitinib) decreases (proteinAbundance(HGNC:EGF) increases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family")))

SET CellLine = "Calu-3"
SET Evidence = "As shown in Fig. 5, the ErbB-3 shRNA efficiently down-regulated ErbB-3 in both the
Calu-3 and H3255 cells, leading to a marked reduction in phospho-Akt levels and
demonstrating that ErbB-3 couples to the PI3K/Akt pathway in these cells. In contrast,
the amount of phospho-Akt was unchanged in the A549 and H522 cell lines
infected with ErbB-3 shRNA."

proteinAbundance(HGNC:ERBB3) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "A549"

proteinAbundance(HGNC:ERBB3) causesNoChange kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "NCI-H522"

proteinAbundance(HGNC:ERBB3) causesNoChange kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "Calu-3"
SET Evidence = "As shown in Fig. 3A, EGF stimulated an association between p85 and ErbB-3 (also observed
as the 210-kDa PTyr protein). This association was blocked by exposing the
cells to 1 μM gefitinib. Assessment of ErbB-3 immunoprecipitations reveals that
gefitinib leads to a decrease in ErbB-3 tyrosine phosphorylation (Fig. 3B Top)
and the amount of coprecipitated p85 (Fig. 3B Middle)."

proteinAbundance(HGNC:EGF) increases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
abundance(SCHEM:Gefitinib) decreases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
abundance(SCHEM:Gefitinib) decreases proteinAbundance(HGNC:ERBB3,proteinModification(P,Y))

SET Evidence = "As shown in Fig. 3C, phosphorylated Akt levels are dramatically reduced by 0.25 μM
gefitinib. At this concentration, we also observe a reduction in the amount of
ErbB-3 associated with p85 and decreased levels of phosphorylated ErbB-3 and phosphorylated
EGFR. In contrast, phosphorylated ErbB-2 levels are not significantly
reduced until concentrations of 4 μM are used."

abundance(SCHEM:Gefitinib) decreases kinaseActivity(proteinAbundance(PFH:"AKT Family"))
abundance(SCHEM:Gefitinib) decreases complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(PFH:"PIK3R Class IA Family"))
abundance(SCHEM:Gefitinib) decreases kinaseActivity(proteinAbundance(HGNC:EGFR))
abundance(SCHEM:Gefitinib) causesNoChange kinaseActivity(proteinAbundance(HGNC:ERBB2))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 45"

SET TextLocation = "Abstract"
SET Evidence = "Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF
receptor-2 (VEGFR-2)."
SET Citation = {"PubMed","Nature medicine","11329059","","Carmeliet P|Moons L|Luttun A|Vincenti V|Compernolle V|De Mol M|Wu Y|Bono F|Devy L|Beck H|Scholz D|Acker T|DiPalma T|Dewerchin M|Noel A|Stalmans I|Barra A|Blacher S|Vandendriessche T|Ponten A|Eriksson U|Plate KH|Foidart JM|Schaper W|Charnock-Jones DS|Hicklin DJ|Herbert JM|Collen D|Persico MG",""}
SET Species = "10090"

proteinAbundance(MGI:Vegfa) increases biologicalProcess(GO:angiogenesis)
proteinAbundance(MGI:Vegfa) directlyIncreases kinaseActivity(proteinAbundance(MGI:Kdr))
kinaseActivity(proteinAbundance(MGI:Kdr)) increases biologicalProcess(GO:angiogenesis)

SET Evidence = "Both VEGF and PlGF bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VEGFR-1,
which exists as a soluble or a membrane-bound type, is an inert decoy or
a signaling receptor for PlGF during angiogenesis."

complexAbundance(proteinAbundance(MGI:Flt1),proteinAbundance(MGI:Pgf))
complexAbundance(proteinAbundance(MGI:Vegfa),proteinAbundance(MGI:Flt1))

SET Evidence = "However, loss of PlGF impaired angiogenesis, plasma extravasation and collateral growth
during ischemia, inflammation, wound healing and cancer. Transplantation
of wild-type bone marrow rescued the impaired angiogenesis and collateral growth
in Pgf-/- mice, indicating that PlGF might have contributed to vessel growth in
the adult by mobilizing bone-marrow-derived cells."

proteinAbundance(MGI:Pgf) increases biologicalProcess(GO:angiogenesis)

SET Evidence = "The synergism between PlGF and VEGF was specific, as PlGF deficiency impaired the
response to VEGF, but not to bFGF or histamine. VEGFR-1 was activated by PlGF,
given that anti-VEGFR-1 antibodies and a Src-kinase inhibitor blocked the endothelial
response to PlGF or VEGF/PlGF."

proteinAbundance(MGI:Pgf) directlyIncreases kinaseActivity(proteinAbundance(MGI:Flt1))

SET TextLocation = "Results"
SET Evidence = "To examine the role of PlGF in angiogenesis, we inactivated the gene expressing PlGF
(Pgf) in mice. Unexpectedly, the absence of PlGF—even in combination with a
loss of VEGF-B—had a negligible effect on vascular development."

proteinAbundance(MGI:Pgf) causesNoChange biologicalProcess(GO:"vasculature development")

SET Evidence = "VEGF-B is another ligand of VEGFR-1 (ref. 18), but loss of VEGF-B (Vegfb–/–) does
not affect vascular development19."

proteinAbundance(MGI:Vegfb) causesNoChange biologicalProcess(GO:"vasculature development")
complexAbundance(proteinAbundance(MGI:Vegfb),proteinAbundance(MGI:Flt1))

SET UrogenitalSystem = "Corpus Luteum"
SET Evidence = "Fewer vessels developed in corpora lutea at 4.5 days of pregnancy in Pgf–/– mice (vessels/mm2:
910 ± 62 in 6 wildtype mice versus 430 ± 80 in 6 Pgf–/– mice; P <
0.005; Fig. 1e and f), but did not impair reproduction. Thus, loss of PlGF impaired
VEGF-dependent retinal and luteal angiogenesis."

proteinAbundance(MGI:Pgf) increases biologicalProcess(GO:angiogenesis)

SET SenseOrgan = "Retina"

proteinAbundance(MGI:Pgf) increases biologicalProcess(GO:angiogenesis)

SET Disease = "Neoplasms"
SET Evidence = "When both tumor and host expressed PlGF, tumors were large and highly vascularized
(4 ± 1 g; n = 8; Fig. 1g and j). In contrast, when they both lacked PlGF, tumors
remained small and poorly vascularized (1.0 ± 0.3 g; n = 8; Fig. 1h and j),"

proteinAbundance(MGI:Pgf) increases biologicalProcess(GO:angiogenesis)
proteinAbundance(MGI:Pgf) increases pathology(MESHD:"Neovascularization, Pathologic")

SET Disease = "Infarction"
SET CardiovascularSystem = "Coronary Vessels"
SET Evidence = "We analyzed revascularization of myocardial infarcts after ligating the left anterior
descending coronary artery 25. Compared with wild type mice, Pgf–/– infarcts
contained approximately 20% fewer vessels (vessels/mm2: 134 ± 9 in wild-type mice
versus 111 ± 5 in Pgf–/– mice; n = 12 to 24; P < 0.05; Fig. 2f and g)."

proteinAbundance(MGI:Pgf) increases biologicalProcess(GO:angiogenesis)

SET IntegumentarySystem = "Skin"
SET Evidence = "Healing of skin incisions progressed more slowly in Pgf–/–  mice versus wild-type
(Fig. 3a–c)"

proteinAbundance(MGI:Pgf) increases biologicalProcess(MESHPP:"Wound Healing")

SET TextLocation = "Legend"
SET Evidence = "In pathological conditions, PlGF is upregulated and stimulates angiogenesis via displacement
of VEGF from VEGF-R1 to VEGFR2 and via activation of VEGFR-1, of which
a larger fraction is membraneassociated."

proteinAbundance(MGI:Pgf) increases (proteinAbundance(MGI:Vegfa) directlyIncreases kinaseActivity(proteinAbundance(MGI:Kdr)))
proteinAbundance(MGI:Pgf) decreases complexAbundance(proteinAbundance(MGI:Vegfa),proteinAbundance(MGI:Flt1))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 46"

SET TextLocation = "Abstract"
SET Evidence = "In pathological conditions, PlGF is upregulated and stimulates angiogenesis via displacement
of VEGF from VEGF-R1 to VEGFR2 and via activation of VEGFR-1, of which
a larger fraction is membraneassociated."
SET Citation = {"PubMed","The Journal of biological chemistry","15345710","2004-10-01","Laederich MB|Funes-Duran M|Yen L|Ingalla E|Wu X|Carraway KL|Sweeney C",""}

proteinAbundance(HGNC:LRIG1) increases proteinAbundance(HGNC:EGFR,proteinModification(U,K))

SET CellLine = "293T/17"
SET Evidence = "Here we tested whether the related human LRIG1 (also called Lig-1) protein can act
as a negative regulator of EGF receptor and its relatives, ErbB2, ErbB3, and ErbB4.
We observed that in co-transfected 293T cells, LRIG1 forms a complex with
each of the ErbB receptors independent of growth factor binding. We further observed
that co-expression of LRIG1 with EGF receptor suppresses cellular receptor
levels, shortens receptor half-life, and enhances ligand-stimulated receptor ubiquitination."
SET Species = "9606"

complexAbundance(proteinAbundance(HGNC:EGFR),proteinAbundance(HGNC:LRIG1))
complexAbundance(proteinAbundance(HGNC:ERBB2),proteinAbundance(HGNC:LRIG1))
complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(HGNC:LRIG1))
complexAbundance(proteinAbundance(HGNC:ERBB4),proteinAbundance(HGNC:LRIG1))
proteinAbundance(HGNC:LRIG1) decreases proteinAbundance(HGNC:EGFR)
proteinAbundance(HGNC:LRIG1) increases proteinAbundance(HGNC:EGFR,proteinModification(U,K))
proteinAbundance(HGNC:EGFR,proteinModification(U,K)) directlyIncreases degradation(proteinAbundance(HGNC:EGFR))

SET CellLine = "NIH/3T3"
SET Evidence = "Finally, we observed that co-expression of LRIG1 suppresses EGF-stimulated transformation
of NIH3T3 fibroblasts and that the inducible expression of LRIG1 in PC3
prostate tumor cells suppresses EGF- and neuregulin-1-stimulated cell cycle progression."
SET Species = "10090"

proteinAbundance(MGI:Lrig1) decreases (proteinAbundance(MGI:Egf) increases biologicalProcess(GO:"immortalization of host cell"))

SET CellLine = "PC-3"
SET Species = "9606"

proteinAbundance(HGNC:LRIG1) decreases (proteinAbundance(HGNC:EGF) increases biologicalProcess(GO:"cell proliferation"))
proteinAbundance(HGNC:LRIG1) decreases (proteinAbundance(HGNC:NRG1) increases biologicalProcess(GO:"cell proliferation"))

SET CellLine = "293T/17"
SET TextLocation = "Results"
SET Evidence = "We observed that EGFR, ErbB2, ErbB3, and ErbB4 each co-immunoprecipitated with the
145- kDa LRIG1, but co-immunoprecipitation of endogenous insulin receptor was
not observed. These observations indicate that LRIG1 is capable of forming a specific
complex with each of the receptors of the ErbB family."

complexAbundance(proteinAbundance(HGNC:EGFR),proteinAbundance(HGNC:LRIG1))
complexAbundance(proteinAbundance(HGNC:ERBB2),proteinAbundance(HGNC:LRIG1))
complexAbundance(proteinAbundance(HGNC:ERBB3),proteinAbundance(HGNC:LRIG1))
complexAbundance(proteinAbundance(HGNC:ERBB4),proteinAbundance(HGNC:LRIG1))

SET NervousSystem = "Brain"
SET Evidence = "Because previous studies have demonstrated that LRIG1 is prominently expressed in
glial cells of mouse brain (14), we used the co-immunoprecipitation assay to examine
the association of LRIG1 and EGFR in mouse brain lysates. We observed that
EGFR could be specifically co-immunoprecipitated with LRIG1 (Fig. 1B), indicating
that the two proteins are associated in a complex in vivo."
SET Species = "10090"

complexAbundance(proteinAbundance(MGI:Egfr),proteinAbundance(MGI:Lrig1))

SET Evidence = "Interestingly, when lysates from co-transfection experiments were blotted with anti-receptor
antibodies, a loss of EGFR, ErbB2, ErbB3, and ErbB4 was observed in
the presence of LRIG1, but no loss of insulin receptor was observed despite very
efficient transfection of these cells (Fig. 1C, compare lanes 1 and 3 in all panels).
These observations suggest that a functional consequence of LRIG1 interaction
with receptor tyrosine kinases may be suppression of receptor levels to lower
the efficiency of signaling."
SET Species = "9606"

proteinAbundance(HGNC:LRIG1) decreases proteinAbundance(HGNC:EGFR)
proteinAbundance(HGNC:LRIG1) decreases proteinAbundance(HGNC:ERBB2)
proteinAbundance(HGNC:LRIG1) decreases proteinAbundance(HGNC:ERBB3)
proteinAbundance(HGNC:LRIG1) decreases proteinAbundance(HGNC:ERBB4)

SET Evidence = "Consistent with previous reports, we observed that growth factor treatment promoted
the rapid ubiquitination of receptors. Interestingly, for both receptors LRIG1
markedly potentiated the ratio of ubiquitinated receptor to total receptor following
growth factor stimulation."

proteinAbundance(HGNC:LRIG1) increases (proteinAbundance(HGNC:EGF) directlyIncreases proteinAbundance(HGNC:EGFR,proteinModification(U,K)))
proteinAbundance(HGNC:LRIG1) increases (proteinAbundance(HGNC:EGF) directlyIncreases proteinAbundance(HGNC:ERBB4,proteinModification(U,K)))

SET Evidence = "To determine whether LRIG1 expression influences the ubiquitination and degradation
rate of ErbB receptors in the inducible expression system, we focused on the
effect of LRIG1 expression on the properties of EGFR in the PC3-LRIG1 cells. Similar
to the results with transfected 293T cells (Fig. 3), we observed that the induction
of LRIG1 expression markedly augmented the ubiquitination of EGFR in response
to EGF treatment (Fig. 5A). This potentiation of ligand-stimulated EGFR ubiquitination
correlated with a suppression of EGFR tyrosine phosphorylation and
receptor levels after growth factor treatment."

proteinAbundance(HGNC:LRIG1) increases proteinAbundance(HGNC:EGFR,proteinModification(U,K))
proteinAbundance(HGNC:LRIG1) decreases kinaseActivity(proteinAbundance(HGNC:EGFR))

SET CellLine = "PC-3"
SET Evidence = "In the experiment illustrated in Fig. 5B, PC3-LRIG1 cells were treated with and without
tetracycline to induce LRIG1 expression, and a time course of EGF stimulation
of the cells was carried out. Lysates were immunoblotted with anti-phosphotyrosine
and anti-EGFR antibodies. In the presence of LRIG1, EGFR responded less
efficiently to EGF as determined by blotting autophosphorylated receptors with anti-phosphotyrosine.
Interestingly, LRIG1 expression also resulted in an accelerated
loss of EGFR."

proteinAbundance(HGNC:LRIG1) decreases kinaseActivity(proteinAbundance(HGNC:EGFR))
proteinAbundance(HGNC:LRIG1) decreases proteinAbundance(HGNC:EGFR)

SET Evidence = "As shown in Fig. 5C, the presence of LRIG1 accelerated the rate at which EGF receptor
was degraded by cells. Taken together, the results depicted in Fig. 5 suggest
that LRIG1 negatively regulates ErbB receptors by promoting receptor ubiquitination
and increasing the basal and ligand-stimulated rates of receptor degradation."

proteinAbundance(HGNC:LRIG1) increases proteinAbundance(HGNC:EGFR,proteinModification(U,K))

SET CellLine = "NIH/3T3"
SET Evidence = "In the experiment depicted in Fig. 6A, NIH3T3 cells were transfected with control
vector alone, EGF receptor, or EGF receptor together with LRIG1. Cells were treated
without or with EGF, and colonies were counted after 3.5 weeks of growth. Consistent
with numerous previous reports, we observed that EGF stimulated colony
formation in this assay. This effect was completely blocked when LRIG1 was co-expressed,
but LRIG1 expression was not able to suppress transformation induced by
H-Ras (not shown)."
SET Species = "10090"

proteinAbundance(MGI:Lrig1) decreases (proteinAbundance(MGI:Egf) increases biologicalProcess(GO:"immortalization of host cell"))

SET CellLine = "PC-3"
SET Evidence = "Stimulation with EGF or NRG1β resulted in a dramatic shift of cells into S-phase in
the absence of LRIG1 expression. However, the presence of LRIG1 markedly suppressed
these effects."
SET Species = "9606"

proteinAbundance(HGNC:LRIG1) decreases (proteinAbundance(HGNC:EGF) increases biologicalProcess(GO:"cell proliferation"))
proteinAbundance(HGNC:LRIG1) decreases (proteinAbundance(HGNC:NRG1) increases biologicalProcess(GO:"cell proliferation"))

SET Evidence = "Interestingly, other LRR domain-containing proteins have also been demonstrated to
interact with receptor tyrosine kinases. Decorin, a secreted proteoglycan containing
nine LRRs, has been shown to interact with the EGF receptor and ErbB2 to
initially enhance their activities (27, 28). Decorin interaction with receptors
has been suggested to mediate prolonged receptor down-regulation and the inhibition
of cellular growth through enhanced expression of p21waf1 (29)."

proteinAbundance(HGNC:DCN) directlyIncreases kinaseActivity(proteinAbundance(HGNC:EGFR))
proteinAbundance(HGNC:DCN) directlyIncreases kinaseActivity(proteinAbundance(HGNC:ERBB2))
proteinAbundance(HGNC:DCN) decreases proteinAbundance(HGNC:EGFR)
proteinAbundance(HGNC:DCN) decreases proteinAbundance(HGNC:ERBB2)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 47"

SET MuskuloskeletalSystem = "Muscle, Skeletal"
SET TextLocation = "Abstract"
SET Evidence = "The most notable impact on IGF-I signaling was a significant blunting of IGF-I induced
increase in S6K1 phosphorylation by PD-98059 coinfusion (~ 5-fold, P < 0.001
vs. 3-fold, P < 0.01)."
SET Citation = {"PubMed","Journal of applied physiology (Bethesda, Md. : 1985)","12959952","2003-10-05","Haddad F|Adams GR",""}
SET Species = "10116"

abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(RGD:Igf1) increases kinaseActivity(proteinAbundance(PFR:"Rps6kb Family")))

SET Evidence = "Insulin-like growth factor-I (IGF-I) has been shown to stimulate a hypertrophy response
in skeletal muscles in vivo. In vitro studies have delineated two primary
intracellular pathways that appear to mediate the effects of IGF-I in skeletal
muscle: the Ras-ERK pathway and the phosphoinositide-3 kinase pathway."

proteinAbundance(RGD:Igf1) increases biologicalProcess(GO:"skeletal muscle hypertrophy")
gtpBoundActivity(proteinAbundance(PFR:"Ras Family")) increases biologicalProcess(GO:"skeletal muscle hypertrophy")
kinaseActivity(proteinAbundance(PFR:"MAPK Erk1/3 Family")) increases biologicalProcess(GO:"skeletal muscle hypertrophy")
kinaseActivity(complexAbundance(NCR:"p85/p110 PI3Kinase Complex")) increases biologicalProcess(GO:"skeletal muscle hypertrophy")

SET Cell = "Cell Line"
SET Evidence = "In vitro, the Ras pathway appears to regulate the mitogenic effects of IGF-I signaling,
whereas the phosphoinositide-3 kinase pathway is associated with cellular
differentiation."

gtpBoundActivity(proteinAbundance(PFR:"Ras Family")) increases biologicalProcess(GO:"cell proliferation")
kinaseActivity(complexAbundance(NCR:"p85/p110 PI3Kinase Complex")) increases biologicalProcess(GO:"cell differentiation")
proteinAbundance(RGD:Igf1) increases gtpBoundActivity(proteinAbundance(PFR:"Ras Family"))
proteinAbundance(RGD:Igf1) increases kinaseActivity(complexAbundance(NCR:"p85/p110 PI3Kinase Complex"))

SET Evidence = "Our results show that 14 days of coinfusion of MAPK/ERK kinase inhibitor PD-098059
(PD) limited the phosphorylation of ERK and prevented IGF-I induced increases
in protein (18%, P < 0.05 vs. 7%, not significant) or myofibrillar protein (23%,
P < 0.01 vs. 5%, not significant)."

abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(RGD:Igf1) increases biologicalProcess(GO:"skeletal muscle hypertrophy"))
abundance(SCHEM:"PD 98,059") decreases kinaseActivity(proteinAbundance(PFR:"MAPK Erk1/3 Family"))

SET Evidence = "The most notable impact on IGF-I signaling was a significant blunting of IGF-I induced
increase in S6K1 phosphorylation by PD-98059 coinfusion (~ 5-fold, P < 0.001
vs. 3-fold, P < 0.01)."

proteinAbundance(RGD:Igf1) increases proteinAbundance(PFR:"Rps6kb Family",proteinModification(P,T,412))
abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(RGD:Igf1) increases proteinAbundance(PFR:"Rps6kb Family",proteinModification(P,T,412)))
proteinAbundance(RGD:Igf1) increases kinaseActivity(proteinAbundance(PFR:"Rps6kb Family"))
abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(RGD:Igf1) increases kinaseActivity(proteinAbundance(PFR:"Rps6kb Family")))

SET TextLocation = "Results"

rnaAbundance(RGD:Myog) positiveCorrelation biologicalProcess(GO:"muscle cell differentiation")

SET Evidence = "Muscle hypertrophy. Local infusion of IGF-I for 14 days resulted in a 19% increase
in muscle wet weight and an 18% increase in the total protein content of the IGF
but not the IGF+PD plantaris muscles (Fig. 1A, Table 1). Total protein concentration
was unchanged in both treatment groups (Table 1). IGF-I infusion resulted
in a 23% increase in myofibrillar protein content (IGF group) that was completely
blunted by coinfusion of MEK inhibitor PD-098059 (Fig. 1B)."

proteinAbundance(RGD:Igf1) increases biologicalProcess(GO:"skeletal muscle hypertrophy")
abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(RGD:Igf1) increases biologicalProcess(GO:"skeletal muscle hypertrophy"))

SET Evidence = "Mitogenic indicators. The DNA content of the IGF and IGF+PD infused muscles increased
~50% compared with the contralateral muscles (Fig. 2A). The concentration of
DNA was also increased by both treatments (Table 1). Similarly, there was a significant
increase in the expression and/or accumulation of cyclin D1 mRNA in the
IGF and IGF+PD muscles (Fig. 2B)."

proteinAbundance(RGD:Igf1) increases biologicalProcess(GO:"cell proliferation")
proteinAbundance(RGD:Igf1) increases rnaAbundance(RGD:Ccnd1)

SET Evidence = "Myogenic processes. The mRNA for myogenin, a putative marker of myogenic differentiation,
increased significantly in the IGF+PD muscles, whereas this change was
not significant after IGF-I infusion alone (Fig. 3)."

compositeAbundance(proteinAbundance(RGD:Igf1),abundance(SCHEM:"PD 98,059")) increases rnaAbundance(RGD:Myog)
proteinAbundance(RGD:Igf1) causesNoChange rnaAbundance(RGD:Myog)
rnaAbundance(RGD:Myog) positiveCorrelation biologicalProcess(GO:"muscle cell differentiation")

SET Evidence = "Intracellular signaling. Infusion of IGF-I resulted in an approximate fivefold increase
in the phosphorylation of ERKs 1 and 2 (Fig. 4), whereas the total ERK levels
were unchanged vs. contralateral muscles (data not shown). Coinfusion (IGF+PD)
completely blunted the increase in ERK1 phosphorylation and significantly reduced
the increase in ERK2 phosphorylation (Fig. 4B). Similar to ERK2, the phosphorylation
of S6K1 was increased fivefold in the IGF and 2.8-fold in the IGF+PD
muscles (Fig. 5). The infusion protocols did not impact the total amount of S6K1
(data not shown)."

proteinAbundance(RGD:Igf1) increases kinaseActivity(proteinAbundance(PFR:"MAPK Erk1/3 Family"))
abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(RGD:Igf1) increases kinaseActivity(proteinAbundance(PFR:"MAPK Erk1/3 Family")))
proteinAbundance(RGD:Igf1) increases kinaseActivity(proteinAbundance(PFR:"Rps6kb Family"))

SET Evidence = "IGF-I-related mRNA. IGF-I infusion resulted in a 48 and 63% increase in IGFBP-5 mRNA
in the IGF and IGFPD muscles, respectively (Fig. 7A). The mRNA for IGFBP-4 increased
significantly (4-fold) in the IGFPD but not IGF muscles (Fig. 7B)."

proteinAbundance(RGD:Igf1) increases rnaAbundance(RGD:Igfbp5)
compositeAbundance(proteinAbundance(RGD:Igf1),abundance(SCHEM:"PD 98,059")) increases rnaAbundance(RGD:Igfbp5)
compositeAbundance(proteinAbundance(RGD:Igf1),abundance(SCHEM:"PD 98,059")) increases rnaAbundance(RGD:Igfbp4)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 48"

SET CellLine = "NIH/3T3"
SET TextLocation = "Results"
SET Evidence = "Under conditions where activation of neither RAF nor AKT alone was sufficient to induce
DNA synthesis, coactivation of both kinases elicited a strong cooperative
response."
SET Citation = {"PubMed","Molecular and cellular biology","15572689","","Mirza AM|Gysin S|Malek N|Nakayama K|Roberts JM|McMahon M",""}
SET Species = "10090"

compositeAbundance(proteinAbundance(MGI:Raf1),proteinAbundance(MGI:Akt1)) increases biologicalProcess(MESHPP:"DNA Replication")

SET Evidence = "Activation of AKT or RAF alone led to a two- or threefold induction of cyclin D1 expression,
respectively (Fig. 2A). However, coactivation of both signaling pathways
led to a sixfold induction of cyclin D1."

compositeAbundance(proteinAbundance(MGI:Raf1),proteinAbundance(MGI:Akt1)) increases proteinAbundance(MGI:Ccnd1)

SET Evidence = "Strikingly, coactivation of RAF and AKT led to a rapid and profound repression of
p27Kip1 expression that was clearly evident at 6 h and continued up to 24 h (Fig.
2A)."

compositeAbundance(proteinAbundance(MGI:Raf1),proteinAbundance(MGI:Akt1)) decreases proteinAbundance(MGI:Cdkn1b)

SET Evidence = "Consistent with previous observations, activation of AKT alone led to a ~50% reduction
of KIP1 mRNA that was evident after 24 h (38). Activation of RAF alone led
to a ~65% reduction of KIP1 mRNA that was best evident after 24 h."

kinaseActivity(proteinAbundance(MGI:Akt1)) decreases rnaAbundance(MGI:Cdkn1b)
kinaseActivity(proteinAbundance(MGI:Raf1)) decreases rnaAbundance(MGI:Cdkn1b)

SET Evidence = "PDGF stimulation of quiescent NIH 3T3 cells leads to activation of both the PI3'-kinase3→PDK1→AKT
and the RAF→MEK→ERK signaling pathways and repression of p27Kip1
expression (Fig. 3A)."

proteinAbundance(PFM:"Pdgf Family") increases kinaseActivity(proteinAbundance(MGI:Akt1))
proteinAbundance(PFM:"Pdgf Family") increases kinaseActivity(proteinAbundance(PFM:"MAPK Erk1/3 Family"))
proteinAbundance(PFM:"Pdgf Family") decreases proteinAbundance(MGI:Cdkn1b)

SET Evidence = "Consistent with observations described above, PDGF repressed KIP1 mRNA by ~60%."

proteinAbundance(PFM:"Pdgf Family") decreases rnaAbundance(MGI:Cdkn1b)

SET Evidence = "Inhibition of either the PI3'-kinase→PDK1→AKT or the RAF→ MEK→ERK pathway alone partially
inhibited the effects of PDGF on KIP1 mRNA expression."

abundance(SCHEM:"LY 294002") decreases (proteinAbundance(PFM:"Pdgf Family") decreases rnaAbundance(MGI:Cdkn1b))
abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(PFM:"Pdgf Family") decreases rnaAbundance(MGI:Cdkn1b))

SET TextLocation = "Legend"
SET Evidence = "RAF and AKT cooperate to promote cell cycle progression"

compositeAbundance(proteinAbundance(MGI:Raf1),proteinAbundance(MGI:Akt1)) increases biologicalProcess(GO:"cell cycle")

SET TextLocation = "Results"
SET Evidence = "Serum deprivation of parental NIH 3T3 cells leads to elevated p27Kip1 expression and
cell cycle arrest (Fig. 4A)."

biologicalProcess(GO:"cellular response to starvation") increases proteinAbundance(MGI:Cdkn1b)
biologicalProcess(GO:"cellular response to starvation") increases biologicalProcess(GO:"cell cycle arrest")

SET Evidence = "Serum-deprived 3T3:iRAS cells displayed elevated p27Kip1 that was reduced by subsequent
induction of H-RASG12V expression by addition of IPTG (Fig. 4B)."

proteinAbundance(MGI:Hras1,substitution(G,12,V)) decreases (biologicalProcess(GO:"cellular response to starvation") increases proteinAbundance(MGI:Cdkn1b))

SET Evidence = "Pharmacological inhibition of the PI3'-kinase→PDK1→AKT pathway, the RAF→MEK→ERK signaling
pathway, or both pathways together prevented the H-RASG12V-mediated reduction
of p27Kip1 expression. Cumulatively, these data suggest that the level of
p27Kip1 expression in RAS-transformed cells is under the dual control of the PI3'-kinase→PDK1→AKT
and RAF→MEK→ERK pathways."

abundance(SCHEM:"PD 98,059") decreases (proteinAbundance(MGI:Hras1,substitution(G,12,V)) decreases proteinAbundance(MGI:Cdkn1b))
abundance(SCHEM:"LY 294002") decreases (proteinAbundance(MGI:Hras1,substitution(G,12,V)) decreases proteinAbundance(MGI:Cdkn1b))

SET CellLine = "Hs 766T"
SET Disease = "Carcinoma, Pancreatic Ductal"
SET Evidence = "Hs766T cells express activated KRAS and display elevated levels of pERK1/2 and pAKT
(Fig. 4C)."
SET Species = "9606"

gtpBoundActivity(proteinAbundance(HGNC:KRAS)) increases kinaseActivity(proteinAbundance(HGNC:MAPK1))
gtpBoundActivity(proteinAbundance(HGNC:KRAS)) increases kinaseActivity(proteinAbundance(HGNC:MAPK3))
gtpBoundActivity(proteinAbundance(HGNC:KRAS)) increases kinaseActivity(proteinAbundance(HGNC:AKT1))

SET Evidence = "Treatment of Hs766T cells with the PI3'-kinase inhibitor LY294002 led to a selective
decrease in pAKT with little or no effect on pERK1/2."

abundance(SCHEM:"LY 294002") decreases kinaseActivity(proteinAbundance(HGNC:AKT1))
abundance(SCHEM:"LY 294002") causesNoChange kinaseActivity(proteinAbundance(HGNC:MAPK1))
abundance(SCHEM:"LY 294002") causesNoChange kinaseActivity(proteinAbundance(HGNC:MAPK3))

SET Evidence = "By contrast, treatment of the cells with the MEK inhibitor U0126 or CI-1040 led to
a selective decrease in pERK1/2 with little or no effect on pAKT"

abundance(SCHEM:U0126) decreases kinaseActivity(proteinAbundance(HGNC:MAPK1))
abundance(SCHEM:U0126) decreases kinaseActivity(proteinAbundance(HGNC:MAPK3))
abundance(SCHEM:U0126) causesNoChange kinaseActivity(proteinAbundance(HGNC:AKT1))

SET Evidence = "both the PI3'-kinase and the MEK inhibitors led to accumulation of p27Kip1 expression."

abundance(SCHEM:"LY 294002") directlyDecreases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))
abundance(SCHEM:"PD 98,059") decreases kinaseActivity(proteinAbundance(HGNC:MAPK1))
abundance(SCHEM:"PD 98,059") decreases kinaseActivity(proteinAbundance(HGNC:MAPK3))
abundance(SCHEM:"LY 294002") increases proteinAbundance(HGNC:CDKN1B)
abundance(SCHEM:"PD 98,059") increases proteinAbundance(HGNC:CDKN1B)

SET Evidence = "Phosphorylation of p27Kip1 on threonine 187 (T187) by active cdk2 leads to its recognition
by the F-box protein SCFSkp2, thereby promoting p27Kip1 ubiquitination
and destruction by the 26S proteasome (45)."

kinaseActivity(proteinAbundance(HGNC:CDK2)) directlyIncreases proteinAbundance(HGNC:CDKN1B,proteinModification(P,T,187))
proteinAbundance(HGNC:CDKN1B,proteinModification(P,T,187)) directlyIncreases complexAbundance(proteinAbundance(HGNC:SKP2),proteinAbundance(HGNC:CDKN1B))
catalyticActivity(proteinAbundance(HGNC:SKP2)) directlyIncreases proteinAbundance(HGNC:CDKN1B,proteinModification(U))
proteinAbundance(HGNC:CDKN1B,proteinModification(U)) directlyIncreases degradation(proteinAbundance(HGNC:CDKN1B))
proteinAbundance(HGNC:CDKN1B,proteinModification(P,T,187)) directlyIncreases (catalyticActivity(proteinAbundance(HGNC:SKP2)) directlyIncreases degradation(proteinAbundance(HGNC:CDKN1B)))

SET CellLine = "NIH/3T3"
SET Evidence = "Activation of AKT alone had little or no effect on total p21Cip1 expression measured
in whole-cell lysates (Fig. 7A, lanes 1 to 4), whereas activation of RAF alone
led to robust induction of p21Cip1 as reported previously (Fig. 7A, lanes 5 to7,
and 7B)."
SET Species = "10090"

kinaseActivity(proteinAbundance(HGNC:AKT1)) causesNoChange proteinAbundance(HGNC:CDKN1A)
kinaseActivity(proteinAbundance(HGNC:RAF1)) increases proteinAbundance(HGNC:CDKN1A)

SET Evidence = "coactivation of RAF and AKT led to sustained cdk2 activity (lanes 8 to 10), whereas
activation of RAF or AKT alone elicited, at best, only transient activation of
cdk2 (lanes 2 to 7)."

compositeAbundance(proteinAbundance(HGNC:RAF1),proteinAbundance(HGNC:AKT1)) increases kinaseActivity(proteinAbundance(HGNC:CDK2))

SET Evidence = "RAF-induced p21Cip1 was readily detected in complex with cdk2 (lanes 5 to 7)."

kinaseActivity(proteinAbundance(HGNC:RAF1)) increases complexAbundance(proteinAbundance(HGNC:CDKN1A),proteinAbundance(HGNC:CDK2))

SET Evidence = "AKT activation elicits sustained cdk2 activation, not by inhibiting p21Cip1 expression
but by promoting the removal of p21Cip1 from cdk2 complexes."

kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases complexAbundance(proteinAbundance(HGNC:CDK2),proteinAbundance(HGNC:CDKN1A))
complexAbundance(proteinAbundance(HGNC:CDK2),proteinAbundance(HGNC:CDKN1A)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:CDK2))

SET Evidence = "AKT promoted nuclear export of RAF-induced p21Cip1 into a cytoplasmic compartment
as reported previously (Fig. 7C) (65)."

kinaseActivity(proteinAbundance(HGNC:AKT1)) increases translocation(proteinAbundance(HGNC:CDKN1A),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 49"

SET CellLine = "HeLa"
SET TextLocation = "Results"
SET Evidence = "Thus Lys559, which lies within the N-terminal extension of class II HDACs, is required
for sumoylation of HDAC4 in vitro and in vivo and is likely to be the predominant
modification site for SUMO."
SET Citation = {"PubMed","The EMBO journal","12032081","","Kirsh O|Seeler JS|Pichler A|Gast A|Müller S|Miska E|Mathieu M|Harel-Bellan A|Kouzarides T|Melchior F|Dejean A",""}
SET Species = "9606"

proteinAbundance(HGNC:HDAC4,proteinModification(S,K,559))

SET Cell = "COS Cells"
SET Evidence = "COS-7 cells were transiently transfected with expression vectors for SUMO-1 together
with HDAC4 or HDAC4-K559R followed by immunoprecipitation using the anti-HDAC4
antibodies and an assay for histone deacetylase activity (Figure 4B). Although
the two proteins were expressed at a similar level (inset), the HDAC activity
associated with HDAC4-K559R was significantly reduced, to a level barely above that
of endogenous HDAC4 (compare lane 3 with lanes 1 and 2)."

proteinAbundance(HGNC:HDAC4,proteinModification(S,K,559)) directlyIncreases catalyticActivity(proteinAbundance(HGNC:HDAC4))

SET Evidence = "As seen in Figure 4C, both the modified and unmodified HDAC4 species were retained
efficiently by GST–N-CoR, GST–MEF2C and GST–14-3-3ε but not by the GST–PML control."

complexAbundance(proteinAbundance(HGNC:HDAC4),proteinAbundance(HGNC:NCOR1))
complexAbundance(proteinAbundance(HGNC:HDAC4),proteinAbundance(HGNC:MEF2C))
complexAbundance(proteinAbundance(HGNC:HDAC4),proteinAbundance(HGNC:YWHAE))

SET Evidence = "The ability of the sumoylation-deficient HDAC4-K559R mutant to repress transcription
was slightly impaired when compared with that of the wild-type HDAC4 protein
(Figure 4A)."

proteinAbundance(HGNC:HDAC4,proteinModification(S,K,559)) directlyIncreases transcriptionalActivity(proteinAbundance(HGNC:HDAC4))

SET Evidence = "As expected, expression of a construct (HDAC4-ΔNLS) lacking these residues rendered
the protein entirely cytoplasmic, albeit without impairing the protein's ability
to aggregate (Figure 6B). Western blot analysis of cells expressing HDAC4- ΔNLS
demonstrated this protein to be unable to undergo SUMO-1 modification (Figure
6C, lane 3), even upon co-expression of exogenous His-SUMO-1 (Figure 6C, lane
4). This inability, however, is not an intrinsic property of this protein since
modification by SUMO-1 occurs as efficiently as for the full-length HDAC4 protein
using the in vitro assay (Figure 6C, compare lane 8 with lane 6)."

translocation(proteinAbundance(HGNC:HDAC4),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus") directlyIncreases proteinAbundance(HGNC:HDAC4,proteinModification(S,K,559))

SET Evidence = "Consistent with previous observations, transfection of a constitutively active CaMKI
vector in HeLa cells induced nuclear exclusion of HDAC4 in the vast majority
of the cells (Figure 6D)."

kinaseActivity(proteinAbundance(HGNC:CAMK1)) increases translocation(proteinAbundance(HGNC:HDAC4),MESHCL:"Cell Nucleus",MESHCL:Cytoplasm)

SET Evidence = "Moreover RanBP2 functions catalytically as 5 ng of BP2ΔFG were sufficient to promote
modification of a 100-fold molar excess of HDAC4. Thus, RanBP2 plays an E3-like
role in SUMO modification of HDAC4."

catalyticActivity(proteinAbundance(HGNC:RANBP2)) directlyIncreases proteinAbundance(HGNC:HDAC4,proteinModification(S,K,559))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 50"

SET TextLocation = "Abstract"
SET Evidence = "A POSH mutant that is unable to bind Akt2"
SET Citation = {"PubMed","The Journal of biological chemistry","14504284","2003-10-21","Figueroa C|Tarras S|Taylor J|Vojtek AB",""}
SET Species = "9606"

complexAbundance(proteinAbundance(HGNC:SH3RF1),proteinAbundance(HGNC:AKT2))

SET Evidence = "In addition, we show that the association of MLK3 with POSH is increased upon inhibition
of the endogenous phosphatidylinositol 3-kinase/Akt signaling pathway."

kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex")) decreases complexAbundance(proteinAbundance(HGNC:SH3RF1),proteinAbundance(HGNC:MAP3K11))

SET Evidence = "Akt2 binds to a POSH-MLK-MKK-JNK complex and phosphorylates MLK3"

kinaseActivity(proteinAbundance(HGNC:AKT2)) directlyIncreases proteinAbundance(HGNC:MAP3K11,proteinModification(P))

SET Evidence = "phosphorylation of MLK3 by Akt2 results in the disassembly of the JNK complex bound
to POSH and down-regulation of the JNK signaling pathway"

proteinAbundance(HGNC:MAP3K11,proteinModification(P)) directlyDecreases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))

SET CellLine = "293"
SET TextLocation = "Results"
SET Evidence = "This increase in the MLK-POSH complex is accompanied by an increase in phospho-c-Jun,
a measure of JNK pathway activation (Fig. 5B)."

complexAbundance(proteinAbundance(HGNC:MAP3K11),proteinAbundance(HGNC:SH3RF1)) increases proteinAbundance(HGNC:JUN,proteinModification(P))
complexAbundance(proteinAbundance(HGNC:MAP3K11),proteinAbundance(HGNC:SH3RF1)) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family")) directlyIncreases proteinAbundance(HGNC:JUN,proteinModification(P))

SET Evidence = "The association of MLK3 with POSH is substantially increased by LY294002 treatment
(Fig. 5C). Thus, inhibition of endogenous Akt kinases enhances the ability of
POSH to scaffold MLK3."

abundance(SCHEM:"LY 294002") increases complexAbundance(proteinAbundance(HGNC:SH3RF1),proteinAbundance(HGNC:MAP3K11))

SET Evidence = "Introduction of MLK3 into cells alone activates the JNK signaling pathway, as assessed
by Western blot analysis of phospho-c-Jun levels (Fig. 6A)."

proteinAbundance(HGNC:MAP3K11) increases kinaseActivity(proteinAbundance(PFH:"MAPK JNK Family"))
proteinAbundance(HGNC:MAP3K11) increases proteinAbundance(HGNC:JUN,proteinModification(P))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 51"

SET MuskuloskeletalSystem = "Muscle, Skeletal"
SET TextLocation = "Abstract"
SET Evidence = "Transgenic expression of PGC-1α recently has been shown to dramatically increase the
content of type I muscle fibers in skeletal muscle, but the relationship between
PGC-1α expression and the key components in calcium signaling is not clear."
SET Citation = {"PubMed","Proceedings of the National Academy of Sciences of the United States of America","12764228","2003-06-22","Handschin C|Rhee J|Lin J|Tarr PT|Spiegelman BM",""}
SET Species = "10090"

proteinAbundance(MGI:Ppargc1a) increases biologicalProcess(GO:"skeletal muscle adaptation")

SET Evidence = "In this report, we show that the PGC-1α promoter is regulated by both CaMKIV and CnA
activity. CaMKIV activates PGC-1α largely through the binding of cAMP response
element-binding protein to the PGC-1α promoter."

proteinAbundance(MGI:Camk4) increases rnaAbundance(MGI:Ppargc1a)
transcriptionalActivity(proteinAbundance(PFM:"Creb Family")) increases rnaAbundance(MGI:Ppargc1a)

SET Evidence = "Transgenic expression of PGC-1α recently has been shown to dramatically increase the
content of type I muscle fibers in skeletal muscle, but the relationship between
PGC-1α expression and the key components in calcium signaling is not clear."

proteinAbundance(MGI:Ppargc1a) increases biologicalProcess(GO:"muscle cell differentiation")

SET Evidence = "Moreover, we show that a positive feedback loop exists between PGC-1α and members
of the myocyte enhancer factor 2 (MEF2) family of transcription factors. MEF2s
bind to the PGC-1α promoter and activate it, predominantly when coactivated by PGC-1α.
MEF2 activity is stimulated further by CnA signaling."

transcriptionalActivity(proteinAbundance(PFM:"Mef2 Family")) directlyIncreases rnaAbundance(MGI:Ppargc1a)
transcriptionalActivity(proteinAbundance(MGI:Ppargc1a)) directlyIncreases transcriptionalActivity(proteinAbundance(PFM:"Mef2 Family"))
phosphataseActivity(complexAbundance(NCM:"Calcineurin Complex")) increases transcriptionalActivity(proteinAbundance(PFM:"Mef2 Family"))

SET TextLocation = "Results"

transcriptionalActivity(proteinAbundance(MGI:Ppargc1a)) increases rnaAbundance(MGI:Ppargc1a)

SET Evidence = "Promoter fragments that contain either 2 or 6 kb of 5' flanking region of mouse PGC-1α
both are activated at least 3-fold by the expression of constitutively active
CaMKIV (Fig. 1A). In contrast, expression of a constitutively active CnA has
very little effect on reporter gene activity, consistent with the results obtained
previously for PGC-1α mRNA expression in CaMKIV and CnA transgenic mice (11).
However, the combination of CaMKIV and CnA has a powerful effect on the PGC-1α
promoter, increasing transcription by ~7-fold (Fig. 1A)."

transcriptionalActivity(proteinAbundance(MGI:Camk4)) directlyIncreases rnaAbundance(MGI:Ppargc1a)
phosphataseActivity(complexAbundance(NCM:"Calcineurin Complex")) causesNoChange rnaAbundance(MGI:Ppargc1a)
phosphataseActivity(complexAbundance(NCM:"Calcineurin Complex")) increases (transcriptionalActivity(proteinAbundance(MGI:Camk4)) directlyIncreases rnaAbundance(MGI:Ppargc1a))

SET Evidence = "CaMKIV has been shown to phosphorylate and activate many proteins, including CREB.
Because CREB has been shown to be an important activator of PGC-1α gene expression
in the fasted liver (24), we used the dominant-negative ACREB protein to examine
a potential role for CREB in the CaMKIV-mediated control of the PGC-1α promoter.
Although ACREB alone had no effect on the PGC-1α promoter, this protein severely
reduced the activation of the PGC-1α promoter by CaMKIV alone or CaMKIV
in combination with CnA (Fig. 1A)."

proteinAbundance(MGI:Camk4) directlyIncreases transcriptionalActivity(proteinAbundance(MGI:Creb1))

SET DigestiveSystem = "Liver"

transcriptionalActivity(proteinAbundance(MGI:Creb1)) increases rnaAbundance(MGI:Ppargc1a)
transcriptionalActivity(proteinAbundance(MGI:Creb1)) increases rnaAbundance(MGI:Ppargc1a)
transcriptionalActivity(proteinAbundance(MGI:Creb1)) increases (proteinAbundance(MGI:Camk4) directlyIncreases rnaAbundance(MGI:Ppargc1a))

SET Evidence = "As shown in Fig. 1C, mutagenesis of the CRE site abolished induction of the mouse
PGC-1α promoter by forskolin, as expected."

abundance(SCHEM:Colforsin) increases rnaAbundance(MGI:Ppargc1a)

SET Evidence = "Because MEF2 and NFAT transcription factors are known targets of CaMKIV and CnA in
muscle fiber-type determination, we tested the role of these factors in the control
of the PGC-1α promoter."

kinaseActivity(proteinAbundance(MGI:Camk4)) increases transcriptionalActivity(proteinAbundance(PFM:"Mef2 Family"))
kinaseActivity(proteinAbundance(MGI:Camk4)) increases transcriptionalActivity(proteinAbundance(PFM:"Nfat Family"))

SET Evidence = "As shown in Fig. 2A, a coactivation by PGC-1α of both MEF2C and MEF2D, but not NFAT,
was observed on the PGC-1α promoter. These data suggest that PGC-1α might participate
in the activation of its own promoter and that the MEF2 proteins may function
both in the regulation of PGC-1α expression and as downstream targets of
PGC-1α coactivation of other muscle-selective genes."

transcriptionalActivity(proteinAbundance(MGI:Mef2c)) increases rnaAbundance(MGI:Ppargc1a)
transcriptionalActivity(proteinAbundance(MGI:Mef2d)) increases rnaAbundance(MGI:Ppargc1a)

SET Evidence = "As shown in Fig. 2B, CnA is able to substantially increase the activity of MEF2C and
MEF2D on the PGC-1α promoter. The strongest effect was observed when MEF2C or
MEF2D was expressed with both CnA and PGC-1α (Fig. 2B)."

phosphataseActivity(complexAbundance(NCM:"Calcineurin Complex")) increases (transcriptionalActivity(proteinAbundance(MGI:Mef2c)) increases rnaAbundance(MGI:Ppargc1a))
phosphataseActivity(complexAbundance(NCM:"Calcineurin Complex")) increases (transcriptionalActivity(proteinAbundance(MGI:Mef2c)) increases rnaAbundance(MGI:Ppargc1a))

SET Evidence = "We next examined whether mutations of this MEF2 site affects MEF2 activity on the
PGC-1α promoter. The mutated 2-kb promoter (called ΔMEF2; see Fig. 3A) is no longer
able to mediate MEF2C or MEF2D induction alone, when activated by CnA or coactivated
by PGC-1α, suggesting that this site is responsible for the MEF2 action
(Fig. 3B). Moreover, electrophoretic mobility-shift assays revealed binding of
MEF2C to this MEF-binding site but not the mutated ΔMEF site in the PGC-1α promoter
(Fig. 3C). The identity of the MEF2C–DNA complex was confirmed by using an
anti-MEF2 antibody that leads to a supershift of the DNA–protein complex."

transcriptionalActivity(proteinAbundance(MGI:Mef2c)) directlyIncreases rnaAbundance(MGI:Ppargc1a)
transcriptionalActivity(proteinAbundance(MGI:Mef2d)) directlyIncreases rnaAbundance(MGI:Ppargc1a)

SET Evidence = "To confirm that the coactivation of MEF2C by PGC-1α observed in reporter gene assays
(Fig. 3B) was linked to direct binding of these two proteins, we tested whether
PGC-1α directly interacts with MEF2C on this MEF-binding site. Increasing amounts
of PGC-1α protein (amino acids 31–797) decreased the mobility of the complex
containing MEF2C bound to the MEF-binding site, as visualized by a supershift
in electrophoretic mobility-shift assays (Fig. 3D). As a control, PGC-1α protein
that lacks the MEF2C-interaction domain (amino acids 1–180; see ref. 7) was not
able to bind to MEF2C. Inclusion of an MEF2- specific antibody was able to supershift
further the protein–DNA complex containing MEF2C, PGC-1α, and the MEF2-binding
site (Fig. 3E). Neither a shift nor a supershift could be obtained when using
the mutated ΔMEF site. These results indicate that MEF2s bind to the PGC-1α
promoter and that PGC-1α coactivates MEF2 proteins on the PGC-1α promoter by a
direct protein–protein interaction."

transcriptionalActivity(proteinAbundance(MGI:Ppargc1a)) directlyIncreases rnaAbundance(MGI:Ppargc1a)
transcriptionalActivity(complexAbundance(proteinAbundance(MGI:Ppargc1a),proteinAbundance(MGI:Mef2c))) directlyIncreases rnaAbundance(MGI:Ppargc1a)

SET Evidence = "Real-time PCR primers were designed for the PGC-1α  3' untranslated region that allows
for determination of the levels of ectopically expressed and endogenous PGC-1α.
As shown in Fig. 4B and as expected, ectopic PGC-1α is detected only in the
muscle of transgenic mice. Strikingly, a 7-fold elevation of endogenous PGC-1α
mRNA was seen in the transgenic animals as compared with wild-type mice (Fig. 4B).
A robust increase in the transcript levels of cytochrome c and myoglobin also
was observed in the RNA isolated from skeletal muscle of the transgenic mice,
whereas GAPDH transcript levels remained unchanged (Fig. 4B). These results indicate
a regulation of PGC-1α transcription by PGC-1α  protein in an apparent autoregulatory
loop."

transcriptionalActivity(proteinAbundance(MGI:Ppargc1a)) increases rnaAbundance(MGI:Ppargc1a)

SET Evidence = "Expression of myoglobin in C2C12 myotubes also required infection of both PGC-1α and
MEF2C (Fig. 5C)."

compositeAbundance(proteinAbundance(MGI:Ppargc1a),proteinAbundance(MGI:Mef2c)) increases rnaAbundance(MGI:Mb)

SET Evidence = "Troponin I slow is induced after infection with virally encoded MEF2C, and the addition
of PGC-1α  has no further effect (Fig. 5D). In contrast, GLUT4 transcript
levels can be elevated by PGC-1α alone, independent of MEF2C infection, consistent
with previous reports (7) (Fig. 5E)."

proteinAbundance(MGI:Mef2c) increases rnaAbundance(MGI:Tnni1)
proteinAbundance(MGI:Ppargc1a) increases rnaAbundance(MGI:Slc2a4)

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 52"

SET TextLocation = "Abstract"
SET Evidence = "The anaphase-promoting complex (APC) or cyclosome is a ubiquitin ligase that initiates
anaphase and mitotic exit."
SET Citation = {"PubMed","The EMBO journal","14657031","","Kraft C|Herzog F|Gieffers C|Mechtler K|Hagting A|Pines J|Peters JM",""}
SET Species = "9606"

catalyticActivity(complexAbundance(NCH:"Anaphase Promoting Complex")) increases biologicalProcess(GO:anaphase)
catalyticActivity(complexAbundance(NCH:"Anaphase Promoting Complex")) increases biologicalProcess(GO:"exit from mitosis")

SET Evidence = "APC activation is thought to depend on APC phosphorylation and Cdc20 binding."

proteinAbundance(HGNC:CDC20) directlyIncreases catalyticActivity(complexAbundance(NCH:"Anaphase Promoting Complex"))

SET Evidence = "APC phosphorylation by Cdk1, but not by Plk1, is sufficient for increased Cdc20 binding
and APC activation."

kinaseActivity(proteinAbundance(HGNC:CDK1)) directlyIncreases complexAbundance(proteinAbundance(HGNC:CDC20),complexAbundance(NCH:"Anaphase Promoting Complex"))
kinaseActivity(proteinAbundance(HGNC:CDK1)) directlyIncreases catalyticActivity(complexAbundance(NCH:"Anaphase Promoting Complex"))
kinaseActivity(proteinAbundance(HGNC:PLK1)) causesNoChange catalyticActivity(complexAbundance(NCH:"Anaphase Promoting Complex"))
kinaseActivity(proteinAbundance(HGNC:PLK1)) causesNoChange complexAbundance(proteinAbundance(HGNC:CDC20),complexAbundance(NCH:"Anaphase Promoting Complex"))

SET CellLine = "HeLa"
SET TextLocation = "Results"
SET Evidence = "Cdc20 peptides were only found in mitotic APC samples, confirming that Cdc20 associates
with APC in a mitosis-specific manner."

biologicalProcess(GO:mitosis) positiveCorrelation complexAbundance(proteinAbundance(HGNC:CDC20),complexAbundance(NCH:"Anaphase Promoting Complex"))

SET Evidence = "We raised antibodies against two mitosis-specific sites on Cdc27 (phospho-S427 and
phospho-T447) and one each on Apc1 (phospho-S355), Cdc16 (phospho-S558) and Cdc23
(phospho-T556."

biologicalProcess(GO:mitosis) positiveCorrelation proteinAbundance(HGNC:CDC27,proteinModification(P,S,427))
biologicalProcess(GO:mitosis) positiveCorrelation proteinAbundance(HGNC:CDC27,proteinModification(P,T,447))
biologicalProcess(GO:mitosis) positiveCorrelation proteinAbundance(HGNC:ANAPC1,proteinModification(P,S,355))
biologicalProcess(GO:mitosis) positiveCorrelation proteinAbundance(HGNC:CDC16,proteinModification(P,S,558))
biologicalProcess(GO:mitosis) positiveCorrelation proteinAbundance(HGNC:CDC23,proteinModification(P,T,556))

SET Evidence = "Immunopurified S-phase APC was phosphorylated in vitro using Cdk1, Plk1, or both in
the presence of either non-radioactive ATP or [γ-32P]ATP. The latter reactions
were analysed by SDS–PAGE followed by silver staining and phosphorimaging (Figure
3A). Both kinases were able to phosphorylate Apc1, Cdc27, Apc5, Cdc16 and Cdc23."

kinaseActivity(proteinAbundance(HGNC:CDK1)) directlyIncreases proteinAbundance(HGNC:ANAPC1,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:CDK1)) directlyIncreases proteinAbundance(HGNC:CDC27,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:CDK1)) directlyIncreases proteinAbundance(HGNC:ANAPC5,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:CDK1)) directlyIncreases proteinAbundance(HGNC:CDC16,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:CDK1)) directlyIncreases proteinAbundance(HGNC:CDC23,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:PLK1)) directlyIncreases proteinAbundance(HGNC:ANAPC1,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:PLK1)) directlyIncreases proteinAbundance(HGNC:CDC27,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:PLK1)) directlyIncreases proteinAbundance(HGNC:ANAPC5,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:PLK1)) directlyIncreases proteinAbundance(HGNC:CDC16,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:PLK1)) directlyIncreases proteinAbundance(HGNC:CDC23,proteinModification(P))

SET Evidence = "We recently found that HeLa cells depleted of Plk1 by this protocol enter mitosis
but are then delayed in prometaphase by the spindle checkpoint."

proteinAbundance(HGNC:PLK1) decreases biologicalProcess(GO:"response to spindle checkpoint signal")
proteinAbundance(HGNC:PLK1) increases biologicalProcess(GO:"mitotic prometaphase")

SET Evidence = "When APC was isolated from Plk1 RNAi cells or from control cells 10 h after the second
thymidine release, i.e. when control cells were progressing through mitosis
and when most Plk1 RNAi cells were in prometaphase, no difference in the ubiquitination
activities of the APC samples could be detected, further supporting the
notion that APC activation was not compromised in the Plk1 RNAi cells (Figure
7B)."

proteinAbundance(HGNC:PLK1) causesNoChange catalyticActivity(complexAbundance(NCH:"Anaphase Promoting Complex"))

SET Evidence = "These observations indicate that normal Plk1 levels are not essential for APC-mediated
degradation of cyclin A."

proteinAbundance(HGNC:PLK1) causesNoChange degradation(proteinAbundance(PFH:"CCNA Family"))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 53"

SET TextLocation = "Review"
SET Evidence = "Mutations and deletions of tumor suppressor genes, such as p53 or PTEN (phosphatase
and tensin homologue deleted on chromosome 10), are two of the several events
underlying the loss of apoptotic pathways (4)."
SET Citation = {"PubMed","Cancer research","16540633","","Goswami A|Ranganathan P|Rangnekar VM",""}
SET Species = "9606"

proteinAbundance(HGNC:TP53) increases biologicalProcess(GO:"apoptotic process")
proteinAbundance(HGNC:PTEN) increases biologicalProcess(GO:"apoptotic process")

SET Disease = "Neoplasms"
SET Evidence = "The interaction of the cell survival kinase, Akt1 (5), with the prostate apoptosis
response-4 protein, Par-4 (6), results in phosphorylation and silencing of Par-4
(7) and thus offers an intervention target for the selective induction of apoptosis
in cancer cells."

complexAbundance(proteinAbundance(HGNC:AKT1),proteinAbundance(HGNC:PAWR))
kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyIncreases proteinAbundance(HGNC:PAWR,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyDecreases molecularActivity(proteinAbundance(HGNC:PAWR))

SET Evidence = "Akt1 is a key cell survival protein functionally involved in antiapoptosis in various
cancers (8, 9)."

proteinAbundance(HGNC:AKT1) decreases biologicalProcess(GO:"apoptotic process")

SET Evidence = "Akt1 activity is elevated in cancer due to the loss of PTEN tumor suppressor function"

phosphataseActivity(proteinAbundance(HGNC:PTEN)) decreases kinaseActivity(proteinAbundance(HGNC:AKT1))

SET Evidence = "A, Akt1, which is activated by PI3K, plays a central role in cell survival by inactivating
key agonists of apoptosis."

kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases molecularActivity(proteinAbundance(HGNC:CDKN1B))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases molecularActivity(proteinAbundance(HGNC:CDKN1A))
kinaseActivity(proteinAbundance(HGNC:AKT1)) increases catalyticActivity(proteinAbundance(HGNC:MDM2))
catalyticActivity(proteinAbundance(HGNC:MDM2)) decreases transcriptionalActivity(proteinAbundance(HGNC:TP53))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases molecularActivity(proteinAbundance(HGNC:PAWR))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases molecularActivity(proteinAbundance(HGNC:BAD))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases kinaseActivity(proteinAbundance(HGNC:GSK3B))
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases transcriptionalActivity(proteinAbundance(HGNC:FOXO3))

SET CellStructure = "Cytoplasm"
SET Evidence = "Par-4 is ubiquitously expressed in normal tissues and cell types and is found primarily
in the cytoplasm (12–15)."

proteinAbundance(HGNC:PAWR)

SET CellStructure = "Cell Nucleus"
SET Evidence = "Par-4 localizes both to the cytoplasm and the nucleus in many but not all cancer cells
and clinical specimens (6, 13–17)."

proteinAbundance(HGNC:PAWR)

SET Evidence = "inhibition of endogenous Par-4 with antisense oligodeoxynucleotides, a dominant-negative
leucine zipper domain, or RNA interference precludes apoptosis"

molecularActivity(proteinAbundance(HGNC:PAWR)) increases biologicalProcess(GO:"apoptotic process")
proteinAbundance(HGNC:PAWR) increases biologicalProcess(GO:"apoptotic process")

SET Evidence = "Par-4 knockout mice spontaneously develop tumors of the liver, lung, and endometrium,
exhibit prostatic intraepithelial neoplasia (PIN), and show an increased frequency
of estrogen-inducible tumors in the endometrium and BBN-inducible tumors
in the bladder (18)."
SET Species = "10090"

proteinAbundance(HGNC:PAWR) decreases pathology(MESHD:"Liver Neoplasms")
proteinAbundance(HGNC:PAWR) decreases pathology(MESHD:"Lung Neoplasms")
proteinAbundance(HGNC:PAWR) decreases pathology(MESHD:"Endometrial Neoplasms")

SET Disease = "Prostatic Intraepithelial Neoplasia"

proteinAbundance(HGNC:PAWR) decreases pathology(MESHD:"Prostatic Intraepithelial Neoplasia")

SET Evidence = "Par-4 action is not inhibited by Bcl-2 or BclxL overexpression (19)."
SET Species = "9606"

proteinAbundance(HGNC:BCL2) causesNoChange molecularActivity(proteinAbundance(HGNC:PAWR))
proteinAbundance(HGNC:BCL2L1) causesNoChange molecularActivity(proteinAbundance(HGNC:PAWR))

SET Disease = "Prostatic Neoplasms"
SET Evidence = "Importantly, overexpression of Par-4 in prostate cancer xenografts by i.t. injections
of adenoviral Par-4, either in s.c. tumors in nude mice or in orthotopic tumors
in the prostatic milieu (6, 19), results in apoptosis and tumor growth inhibition,"
SET Species = "10090"

proteinAbundance(HGNC:PAWR) increases biologicalProcess(GO:"apoptotic process")
proteinAbundance(HGNC:PAWR) decreases biologicalProcess(SDIS:"tumor growth")

SET Evidence = "Indeed, our recent studies reveal that binding of Akt1 to Par-4 results in both Par-4
phosphorylation and inactivation of its proapoptotic potential (7)."
SET Species = "9606"

complexAbundance(proteinAbundance(HGNC:AKT1),proteinAbundance(HGNC:PAWR))
kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyIncreases proteinAbundance(HGNC:PAWR,proteinModification(P))
kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyDecreases molecularActivity(proteinAbundance(HGNC:PAWR))

SET Evidence = "Both approaches led to the identification of the cell survival kinase, Akt1, as a
Par-4–interacting protein in prostate cancer cell lines (7)."

complexAbundance(proteinAbundance(HGNC:PAWR),proteinAbundance(HGNC:AKT1))

SET Evidence = "Nuclear translocation of Par-4 is essential for the inhibition of NF-κB-dependent
transcriptional activity"

translocation(proteinAbundance(HGNC:PAWR),MESHCL:Cytoplasm,MESHCL:"Cell Nucleus") decreases transcriptionalActivity(complexAbundance(NCH:"Nfkb Complex"))

SET Evidence = "Par-4 partner proteins WT1, ZIPK/DAXX, and THAP"

complexAbundance(proteinAbundance(HGNC:PAWR),proteinAbundance(HGNC:WT1))
complexAbundance(proteinAbundance(HGNC:PAWR),proteinAbundance(HGNC:DAXX))

SET Evidence = "Akt1 binding and phosphorylation of Par-4 results in 14-3-3-mediated cytoplasmic retention
of Par-4 and abrogation of apoptosis."

proteinAbundance(HGNC:PAWR,proteinModification(P)) directlyIncreases complexAbundance(proteinAbundance(PFH:"14-3-3 Family"),proteinAbundance(HGNC:PAWR))

SET CellStructure = "Cytoplasm"

complexAbundance(proteinAbundance(PFH:"14-3-3 Family"),proteinAbundance(HGNC:PAWR))
complexAbundance(proteinAbundance(PFH:"14-3-3 Family"),proteinAbundance(HGNC:PAWR)) directlyDecreases (molecularActivity(proteinAbundance(HGNC:PAWR)) increases biologicalProcess(GO:"apoptotic process"))

SET Evidence = "PTEN induced apoptosis in prostate cancer cells via a mechanism that was inhibited
by blocking endogenous Par-4 expression with RNA interference."

proteinAbundance(HGNC:PAWR) increases (proteinAbundance(HGNC:PTEN) increases biologicalProcess(GO:"apoptotic process"))

SET Disease = "Neoplasms"
SET Evidence = "although phosphorylation of Par-4 at the T155 residue by PKA activates the Par-4 apoptotic
potential in cancer cells, T155 phosphorylation does not induce apoptosis
in the presence of Par-4 phosphorylation by AKT1 and cytoplasmic retention by
14-3-3 proteins."

proteinAbundance(HGNC:PAWR,proteinModification(P,T,163)) directlyIncreases molecularActivity(proteinAbundance(HGNC:PAWR))
molecularActivity(proteinAbundance(HGNC:PAWR)) increases biologicalProcess(GO:"apoptotic process")

SET TextLocation = "Abstract"
SET Evidence = "We recently showed that the cancer-selective proapoptotic protein Par-4 is a key target
for inactivation by PI3K/Akt signaling"

molecularActivity(proteinAbundance(HGNC:PAWR)) increases biologicalProcess(GO:"apoptotic process")
kinaseActivity(proteinAbundance(HGNC:AKT1)) decreases molecularActivity(proteinAbundance(HGNC:PAWR))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 54"

SET TextLocation = "Results"
SET Evidence = "To generate mice that express a constitutively active mutant of Hck (i.e., HckY499F),
we used gene targeting in ES cells to introduce a tyrosine (Y499) to phenylalanine
(F) substitution in exon 13 of the endogenous hck gene."
SET Citation = {"PubMed","The Journal of experimental medicine","12208875","","Ernst M|Inglese M|Scholz GM|Harder KW|Clay FJ|Bozinovski S|Waring P|Darwiche R|Kay T|Sly P|Collins R|Turner D|Hibbs ML|Anderson GP|Dunn AR",""}
SET Species = "10090"

proteinAbundance(MGI:Hck,substitution(Y,499,F)) directlyIncreases kinaseActivity(proteinAbundance(MGI:Hck))

SET RespiratorySystem = "Lung"
SET Evidence = "the lungs of all adult HckF/F mice (3–4 mo and older) showed areas of atelectasis,
inflammatory infiltration into the interstitium and alveoli, and some areas of
enlarged airspaces"

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases pathology(MESHD:"Pulmonary Atelectasis")

SET RespiratorySystem = {"Pulmonary Alveoli","Lung"}

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases pathology(MESHD:Inflammation)

SET RespiratorySystem = "Lung"
SET Evidence = "Eosinophils represented the most prominent cell type within the infiltrates (30 ±
9% of total BAL-F cells in HckF/F mice versus 2 ± 1% in HckY/Y mice)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases pathology(MESHD:"Pulmonary Eosinophilia")

SET Tissue = "Epithelium"
SET Evidence = "The epithelium lining conducting airways was frequently hypertrophic and many epithelial
cells were enlarged due to excessive production and/or accumulation of mucus
material (Fig. 2, c and d)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases pathology(MESHD:Hypertrophy)

SET Evidence = "lungs from HckF/F mice showed areas of mild emphysema, as histologically evident from
alveolar enlargement with the loss of the orderly appearance of the acinus,
and signs of fibrosis characterized by deposition of extracellular matrix in the
alveolar septa (Fig. 2, e and f)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases pathology(MESHD:Emphysema)
proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases pathology(MESHD:"Pulmonary Fibrosis")

SET Evidence = "BAL-F recovered from the lungs of mutant mice revealed elevated levels of IL-5 (70
± 27 pg/ml in HckY/Y versus 17 ± 5 pg/ml in HckY/Y) and eotaxin (37 ± 8 pg/ml
in HckY/Y versus 23 ± 4 pg/ml in HckY/Y), features associated with eosinophilia
(28, 29)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases proteinAbundance(MGI:Il5)
proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases proteinAbundance(MGI:Ccl11)
proteinAbundance(MGI:Il5) positiveCorrelation pathology(MESHD:"Pulmonary Eosinophilia")
proteinAbundance(MGI:Ccl11) positiveCorrelation pathology(MESHD:"Pulmonary Eosinophilia")

SET RespiratorySystem = "Pulmonary Alveoli"
SET Evidence = "Such a pulmonary challenge with LPS elicits a rapid and transient neutrophilic inflammatory
response, followed by macrophage invasion into the alveolar spaces (31)."

abundance(CHEBI:lipopolysaccharide) increases biologicalProcess(GO:"neutrophil activation")
abundance(CHEBI:lipopolysaccharide) increases biologicalProcess(GO:"regulation of macrophage activation")

SET RespiratorySystem = "Lung"
SET Evidence = "By contrast, the number of macrophages and eosinophils in BAL-F from unchallenged
HckF/F mice were profoundly elevated in comparison to those detected in BAL-F from
unchallenged HckY/Y mice, with macrophages accounting for about onethird of
all cells recovered in BAL-F from HckF/F mice"

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases biologicalProcess(GO:"regulation of macrophage activation")

SET Evidence = "analysis of BAL-F from LPS-challenged HckF/F mice, but not from similarly challenged
HckY/Y mice, revealed a rapid and transient increase in levels of the proinflammatory
cytokine TNFα (Fig. 5 c),"

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases (abundance(CHEBI:lipopolysaccharide) increases proteinAbundance(MGI:Tnf))

SET Evidence = "Analysis of BAL-F from LPSchallenged HckF/F mice revealed exaggerated induction of
MMP-2 and MMP-9 activity when compared with that detected in BAL-F from LPS-challenged
HckY/Y mice (Fig. 5 d)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases (abundance(CHEBI:lipopolysaccharide) increases peptidaseActivity(proteinAbundance(MGI:Mmp9)))
proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases (abundance(CHEBI:lipopolysaccharide) increases peptidaseActivity(proteinAbundance(MGI:Mmp2)))

SET HemicAndImmuneSystem = "Macrophages"
SET Evidence = "The increased release of NO into the culture medium of LPSstimulated BMDMs from HckF/F
mice is likely to be explained by the increased expression of inducible nitric
oxide synthetase (iNOS; Fig. 7 c)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases (abundance(CHEBI:lipopolysaccharide) increases abundance(CHEBI:"nitric oxide"))
proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases (abundance(CHEBI:lipopolysaccharide) increases proteinAbundance(MGI:Nos2))

SET HemicAndImmuneSystem = {"Monocytes","Macrophages"}
SET Evidence = "Collectively, these observations suggested that monocytes and macrophages in HckF/F
mice have enhanced phagocytic activity."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases biologicalProcess(GO:phagocytosis)

SET Cell = "Neutrophils"
SET Evidence = "PMNs derived from HckF/F mice had a modestly enhanced migratory capacity when compared
with PMNs from wild-type mice (unpublished data)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases biologicalProcess(GO:"cell migration")

SET HemicAndImmuneSystem = "Macrophages"
SET Evidence = "BMDMs derived from HckF/F mice exhibited an enhanced capacity to migrate when tested
in in vitro \"wound-healing\" assays (unpublished data)."

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases biologicalProcess(GO:"cell migration")

SET Evidence = "PMNs from HckF/F mice released approximately twofold more superoxide in response to
TNFα or fMLP stimulation than did their wild-type counterparts when plated on
fibrinogen-coated microtiter plates"

proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases (proteinAbundance(MGI:Tnf) increases abundance(CHEBI:superoxide))
proteinAbundance(MGI:Hck,substitution(Y,499,F)) increases (abundance(CHEBIID:53490) increases abundance(CHEBI:superoxide))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 55"

SET CellLine = "MCF7"
SET TextLocation = "Abstract"
SET Evidence = "In transiently transfected MCF-7 human breast cancer cells, overexpression of COUP-TFI
inhibited TCDD-activated reporter gene activity from the CYP1A1 promoter.
TCDD inhibited estradiol (E2)-activated reporter gene activity from a consensus
ERE and from the EREs in the pS2 and Fos genes, and COUP-TFI did not block the antiestrogenic
activity of TCDD."
SET Citation = {"PubMed","Archives of biochemistry and biophysics","10620335","","Klinge CM|Kaur K|Swanson HI",""}
SET Species = "9606"

proteinAbundance(HGNC:NR2F1) decreases rnaAbundance(HGNC:CYP1A1)
abundance(CHEBIID:28119) increases rnaAbundance(HGNC:CYP1A1)
proteinAbundance(HGNC:NR2F1) decreases (abundance(CHEBIID:28119) increases rnaAbundance(HGNC:CYP1A1))

SET TextLocation = "Results"
SET Evidence = "Estradiol reportedly blocked TCDD-induced accumulation of CYP1A1 mRNA and AHR-mediated
activation of the CYP1A1 gene promoter in MCF-7 cells (32)."

abundance(SCHEM:Tetrachlorodibenzodioxin) increases rnaAbundance(HGNC:CYP1A1)
transcriptionalActivity(proteinAbundance(HGNC:AHR)) directlyIncreases rnaAbundance(HGNC:CYP1A1)
abundance(SCHEM:Estradiol) decreases (abundance(SCHEM:Tetrachlorodibenzodioxin) increases rnaAbundance(HGNC:CYP1A1))
abundance(SCHEM:Estradiol) decreases (transcriptionalActivity(proteinAbundance(HGNC:AHR)) directlyIncreases rnaAbundance(HGNC:CYP1A1))

SET Evidence = "We examined how TCDD, alone or in combination with E2, affected luciferase reporter
gene expression from the CYP1A1 promoter in MCF-7 cells. As anticipated, TCDD
induced a 3.5-fold induction of luciferase activity (Fig. 7A). E2 stimulated a
2-fold induction of luciferase activity from the CYP1A1 promoter."

abundance(SCHEM:Tetrachlorodibenzodioxin) increases rnaAbundance(HGNC:CYP1A1)
abundance(SCHEM:Estradiol) increases rnaAbundance(HGNC:CYP1A1)

SET Evidence = "Cotransfection with COUP–TFI significantly inhibited TCDD-stimulated luciferase activity
from the CYP1A1 promoter (Fig. 7A). E2 did not relieve the COUP–TFI-mediated
inhibition of TCDD-induced activity. COUP–TFI also inhibited the E2-induced
activity from the CYP1A1 promoter."

proteinAbundance(HGNC:NR2F1) decreases (abundance(SCHEM:Tetrachlorodibenzodioxin) increases rnaAbundance(HGNC:CYP1A1))
proteinAbundance(HGNC:NR2F1) decreases (abundance(SCHEM:Estradiol) increases rnaAbundance(HGNC:CYP1A1))

SET Evidence = "TCDD inhibits E2-induction of pS2, a human breast cancer prognostic marker (47), and
stimulates c-fos expression (48)."

abundance(SCHEM:Tetrachlorodibenzodioxin) decreases (abundance(SCHEM:Estradiol) increases rnaAbundance(HGNC:TFF1))
abundance(SCHEM:Estradiol) increases rnaAbundance(HGNC:TFF1)
abundance(SCHEM:Tetrachlorodibenzodioxin) increases rnaAbundance(HGNC:FOS)

SET Evidence = "Here we tested how expression of COUP–TFI affected TCDD activity from the natural
ERE sequences from the pS2 and c-fos promoters in transiently transfected MCF-7
cells. E2 alone stimulated a 1.6- to 2.1-fold induction in luciferase activity
from the pS2 ERE (Fig. 8A). 4-OHT blocked the E2 activity, indicating the specificity
of the induction by ER. TCDD alone gave a 1.4-fold induction in luciferase
activity. Cotreatment with TCDD suppressed E2-stimulated luciferase activity. COUP–TFI
inhibited both E2- and TCDD-stimulated luciferase activity from pS2."

abundance(CHEBIID:16469) increases rnaAbundance(HGNC:TFF1)
abundance(SCHEM:"4,17beta-Dihydroxy-4-androstene-3-one") decreases (abundance(CHEBIID:16469) increases rnaAbundance(HGNC:TFF1))
abundance(SCHEM:Tetrachlorodibenzodioxin) increases rnaAbundance(HGNC:TFF1)
abundance(SCHEM:Tetrachlorodibenzodioxin) decreases (abundance(CHEBIID:16469) increases rnaAbundance(HGNC:TFF1))
proteinAbundance(HGNC:NR2F1) decreases (abundance(CHEBIID:16469) increases rnaAbundance(HGNC:TFF1))
proteinAbundance(HGNC:NR2F1) decreases (abundance(SCHEM:Tetrachlorodibenzodioxin) increases rnaAbundance(HGNC:TFF1))

SET Evidence = "Although both ERα and AHR/ARNT specifically interact with the regulatory region of
the c-fos gene, only E2 induced reporter activity from the FOS-1211 construct
(Fig. 8B). The FOS-1211 oligomer binds ERa and AHR/ARNT in EMSA (data not shown).
TCDD suppressed the E2-stimulated luciferase activity. COUP–TFI significantly
inhibited E2-stimulated luciferase activity from FOS–1211, but had no effect in
TCDD-treated cells."

transcriptionalActivity(proteinAbundance(HGNC:ESR1)) directlyIncreases rnaAbundance(HGNC:FOS)
complexAbundance(proteinAbundance(HGNC:AHR),proteinAbundance(HGNC:ARNT),geneAbundance(HGNC:FOS))
abundance(SCHEM:Estradiol) increases rnaAbundance(HGNC:FOS)
abundance(SCHEM:Tetrachlorodibenzodioxin) decreases (abundance(SCHEM:Estradiol) increases rnaAbundance(HGNC:FOS))
proteinAbundance(HGNC:NR2F1) decreases (abundance(SCHEM:Estradiol) increases rnaAbundance(HGNC:FOS))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 56"

SET TextLocation = "Abstract"
SET Evidence = "Glycogen synthase kinase 3 (GSK-3) is implicated in multiple biological processes
including metabolism, gene expression, cell fate determination, proliferation,
and survival. GSK-3 activity is inhibited through phosphorylation of serine 21 in
GSK-3α and serine 9 in GSK-3β."
SET Citation = {"PubMed","Proceedings of the National Academy of Sciences of the United States of America","11035810","","Fang X|Yu SX|Lu Y|Bast RC|Woodgett JR|Mills GB",""}

proteinAbundance(PFH:"GSK3 Family") association biologicalProcess(GO:"cell fate determination")
proteinAbundance(PFH:"GSK3 Family") association biologicalProcess(GO:"cell proliferation")

SET Evidence = "GSK-3 activity is inhibited through phosphorylation of serine 21 in GSK-3α and serine
9 in GSK-3β. These serine residues of GSK-3 have been previously identified
as targets of protein kinase B (PKByAkt), a serineythreonine kinase located downstream
of phosphatidylinositol 3-kinase."

proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:GSK3A))
proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9)) directlyDecreases kinaseActivity(proteinAbundance(HGNC:GSK3B))
kinaseActivity(proteinAbundance(PFH:"AKT Family")) directlyIncreases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
kinaseActivity(proteinAbundance(PFH:"AKT Family")) directlyIncreases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))
kinaseActivity(proteinAbundance(PFH:"AKT Family")) directlyDecreases kinaseActivity(proteinAbundance(HGNC:GSK3A))
kinaseActivity(proteinAbundance(PFH:"AKT Family")) directlyDecreases kinaseActivity(proteinAbundance(HGNC:GSK3B))

SET Evidence = "Here, we show that serine 21 in GSK-3α and serine 9 in GSK-3β are also physiological
substrates of cAMP dependent protein kinase A. Protein kinase A physically associates
with, phosphorylates, and inactivates both isoforms of GSK-3."

kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyIncreases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyIncreases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))
kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyDecreases kinaseActivity(proteinAbundance(HGNC:GSK3A))
kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyDecreases kinaseActivity(proteinAbundance(HGNC:GSK3B))

SET CellLine = "Rat1-R12"
SET TextLocation = "Results"
SET Evidence = "In Rat1, NIH 3T3, and HEK293 cells, increases in the intracellular levels of cAMP
stimulate phosphorylation of GSK-3α and -β, as demonstrated by immunoblotting with
GSK-3 phosphorylation-specific antibodies. As shown in Fig. 1, the cell-permeable
cAMP analogue 8-Br-cAMP induced a marked increase in phosphorylation of GSK-3α
and - β at serine 21 and 9, respectively, whereas the structurally related
cGMP analogue 8-Br-cGMP had little effect. Forskolin, which activates adenyl cyclase
thus raising intracellular cAMP levels (15), triggered a similar elevation
in GSK-3 phosphorylation at serine 21 and 9. In Rat1 cells, isoproterenol, which
activates the b-adrenergic receptor stimulating adenylate cyclase and increasing
endogenous cAMP levels (16, 17), also efficiently stimulated GSK-3 phosphorylation
at these serine sites. In NIH 3T3 cells that contain few of the β-adrenergic
receptors, stimulation with other G-protein-coupled receptor agonists, such as
lysophosphatidic acid. also led to GSK-3 phosphorylation (data not shown)"
SET Species = "10116"

abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(SCHEM:"lysophosphatidic acid") increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(SCHEM:"lysophosphatidic acid") increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))
abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "HEK001"
SET Cell = "Cell Line"
SET UrogenitalSystem = "Kidney"
SET Species = "9606"

abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(SCHEM:Isoproterenol) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(SCHEM:"lysophosphatidic acid") increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(SCHEM:"lysophosphatidic acid") increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(SCHEM:Isoproterenol) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(SCHEM:"8-Bromo cyclic adenosine monophosphate") increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(SCHEM:"8-Bromo cyclic adenosine monophosphate") increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(SCHEM:"8-Bromo cyclic adenosine monophosphate") increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(SCHEM:"8-Bromo cyclic adenosine monophosphate") increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "NIH/3T3"
SET Evidence = "PI3K-dependent activation of PKB is an intermediary in the phosphorylation and inactivation
of GSK-3 induced by insulin and other growth factors (10, 12, 14). Insulin
and IGF-1 efficiently activate the PI3K pathway in NIH 3T3 and Rat1 cells,
respectively. GSK-3 phosphorylation induced by insulin and IGF-1 were eliminated
by pretreatment with the PI3K inhibitors wortmannin or LY294002. In contrast,
the effects of 8-Br-cAMP or forskolin on GSK-3 phosphorylation in these cell lines
were not altered by inhibition of PI3K activity with wortmannin or LY294002 (Fig.
2A), excluding the possibility that PKA induces GSK-3 phosphorylation through
activation of PI3K."
SET Species = "10090"

abundance(CHEBIID:50864) increases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))

SET CellLine = "Rat1-R12"
SET Species = "10116"

proteinAbundance(HGNC:IGF1) increases kinaseActivity(complexAbundance(NCH:"p85/p110 PI3Kinase Complex"))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(CHEBIID:50864) increases kinaseActivity(proteinAbundance(HGNC:GSK3A))

SET CellLine = "Rat1-R12"
SET Species = "10116"

proteinAbundance(HGNC:IGF1) increases kinaseActivity(proteinAbundance(HGNC:GSK3A))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(CHEBIID:50864) increases kinaseActivity(proteinAbundance(HGNC:GSK3B))

SET CellLine = "Rat1-R12"
SET Species = "10116"

proteinAbundance(HGNC:IGF1) increases kinaseActivity(proteinAbundance(HGNC:GSK3B))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(CHEBIID:52289) decreases (abundance(CHEBIID:50864) increases kinaseActivity(proteinAbundance(HGNC:GSK3A)))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(CHEBIID:52289) decreases (abundance(CHEBIID:50864) increases kinaseActivity(proteinAbundance(HGNC:GSK3B)))

SET CellLine = "NIH/3T3"
SET Evidence = "To determine whether PKA-induced PKB activation accounts for GSK-3 phosphorylation
after treatment with 8-Br-cAMP, forskolin, or isoproterenol, PKB phosphorylation
at serine 473 and threonine 308, which is crucial for activation of PKB (20),
was assessed. As expected, insulin and IGF-1 strongly stimulated phosphorylation
of PKB at serine 473 in NIH 3T3 or Rat1 cells (Fig. 2B). In contrast, 8-Br-cAMP,
forskolin, and isoproterenol did not significantly alter PKB phosphorylation
at serine 473 (Fig. 2B). Similar results were obtained with a threonine 308 phosphorylation-specific
antibody (data not shown)."
SET Species = "10090"

abundance(CHEBIID:50864) increases proteinAbundance(HGNC:AKT1,proteinModification(P,S,473))
proteinAbundance(HGNC:IGF1) increases proteinAbundance(HGNC:AKT1,proteinModification(P,S,473))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(CHEBIID:50864) increases proteinAbundance(HGNC:AKT1,proteinModification(P,S,473))
proteinAbundance(HGNC:IGF1) increases proteinAbundance(HGNC:AKT1,proteinModification(P,S,473))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(CHEBIID:50864) increases proteinAbundance(HGNC:AKT1,proteinModification(P,T,308))
proteinAbundance(HGNC:IGF1) increases proteinAbundance(HGNC:AKT1,proteinModification(P,T,308))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(CHEBIID:50864) increases proteinAbundance(HGNC:AKT1,proteinModification(P,T,308))
proteinAbundance(HGNC:IGF1) increases proteinAbundance(HGNC:AKT1,proteinModification(P,T,308))

SET CellLine = "NIH/3T3"
SET Evidence = "Forskolin increased PKB activity weakly in Rat1 and NIH 3T3 cells. A slightly stronger
stimulation of PKB activity was seen in Rat1 cells treated with isoproterenol.
However, activation of PKB by forskolin or isoproterenol was much less than
that induced by IGF-1 or insulin (Fig. 2C)."
SET Species = "10090"

abundance(CHEBI:forskolin) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(CHEBI:forskolin) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "NIH/3T3"
SET Species = "10090"

abundance(SCHEM:Isoproterenol) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(SCHEM:Isoproterenol) increases kinaseActivity(proteinAbundance(PFH:"AKT Family"))

SET CellLine = "NIH/3T3"
SET Evidence = "As demonstrated in Fig. 2C, however, 8-Br-cAMP, forskolin, or isoproterenol stimulated
phosphorylation of GSK-3α more efficiently than IGF-1 or insulin and increased
phosphorylation of GSK-3β to levels comparable to those induced by IGF-1 or
insulin."
SET Species = "10090"

abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))
abundance(SCHEM:Isoproterenol) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(SCHEM:Isoproterenol) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "Rat1-R12"
SET Species = "10116"

abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(CHEBI:forskolin) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))
abundance(SCHEM:Isoproterenol) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
abundance(SCHEM:Isoproterenol) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET CellLine = "NIH/3T3"
SET Evidence = "To determine whether the association between GSK-3 and PKAc is regulated by cAMP levels,
GSK-3β was immunoprecipitated from HEK293 and NIH 3T3 cells treated with
or without forskolin. The level of PKAc in GSK-3β immunoprecipitates was markedly
reduced in forskolintreated cells compared with that in unstimulated cells (Fig.
3C), suggesting that dissociation of the GSK-3β-PKAc complex occurs after PKA
activation or GSK-3 phosphorylation."
SET Species = "10090"

abundance(CHEBI:forskolin) decreases complexAbundance(proteinAbundance(HGNC:GSK3B),proteinAbundance(HGNC:PRKACA))

SET Cell = "HEK293 Cells"
SET Species = "9606"

abundance(CHEBI:forskolin) decreases complexAbundance(proteinAbundance(HGNC:GSK3B),proteinAbundance(HGNC:PRKACA))

SET Evidence = "Transfection of PKAc, but not empty vector, enhanced phosphorylation of cotransfected
GSK-3α and -β at serine 21 and 9 in HEK293 cells (Fig. 4A)."

proteinAbundance(HGNC:PRKACA) increases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21))
proteinAbundance(HGNC:PRKACA) increases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9))

SET Evidence = "Consistent with this in vivo activity, PKAc enzyme efficiently phosphorylated GSK-3α
and -β at serine 21 and 9 in vitro (Fig. 4B), which was blocked by addition
of the PKA peptide inhibitor (PKI) (26). Similar results were obtained when immunoprecipitated
GSK- 3α, immunoprecipitatedHA-GSK-3β, purified GSK-3α, or recombinant
GSK-3β was used as substrate (Fig. 4B)."

kinaseActivity(proteinAbundance(HGNC:PRKACA)) directlyIncreases proteinAbundance(HGNC:GSK3A,proteinModification(P,S,21)) //in vitro
kinaseActivity(proteinAbundance(HGNC:PRKACA)) directlyIncreases proteinAbundance(HGNC:GSK3B,proteinModification(P,S,9)) //in vitro

SET Evidence = "These in vivo and in vitro observations establish that PKA can directly phosphorylate
and inactivate GSK-3."

proteinAbundance(HGNC:PRKACA) directlyDecreases kinaseActivity(proteinAbundance(PFH:"GSK3 Family"))
proteinAbundance(HGNC:PRKACA) directlyDecreases kinaseActivity(proteinAbundance(PFH:"GSK3 Family"))
proteinAbundance(HGNC:PRKACA) decreases kinaseActivity(proteinAbundance(PFH:"GSK3 Family")) //in vitro
proteinAbundance(HGNC:PRKACA) directlyDecreases kinaseActivity(proteinAbundance(PFH:"GSK3 Family")) //in vitro

SET Evidence = "BAD was originally demonstrated to be phosphorylated at serine 136 by PKB (32, 33).
However, BAD can also be inactivated through phosphorylation of serine 112 by
Rsk, which is located downstream of mitogen-activated protein kinases (MAPKyErk)
(34–36), or alternatively by mitochondriaanchored PKA (37). Additionally, Rsk
can phosphorylate CREB at the same serine 133 site as PKA, leading to the expression
of cAMP-responsive genes (34)."
SET Species = "10090"

kinaseActivity(proteinAbundance(PFH:"AKT Family")) directlyIncreases proteinAbundance(HGNC:BAD,proteinModification(P,S,136)) //mouse S136 not present in human, possibly S134
kinaseActivity(proteinAbundance(PFH:"AKT Family")) directlyDecreases molecularActivity(proteinAbundance(HGNC:BAD))
kinaseActivity(proteinAbundance(PFH:"RPS6KA Family")) directlyIncreases proteinAbundance(HGNC:BAD,proteinModification(P,S,112))
kinaseActivity(proteinAbundance(PFH:"RPS6KA Family")) directlyDecreases molecularActivity(proteinAbundance(HGNC:BAD))
kinaseActivity(proteinAbundance(PFH:"RPS6KA Family")) directlyIncreases proteinAbundance(HGNC:CREB1,proteinModification(P,S,133))
kinaseActivity(proteinAbundance(PFH:"PRKA Family")) directlyIncreases proteinAbundance(HGNC:CREB1,proteinModification(P,S,133))

UNSET STATEMENT_GROUP

SET STATEMENT_GROUP = "Group 57"

SET CardiovascularSystem = "Blood Vessels"
SET TextLocation = "Review"
SET Evidence = "VEGF is the most critical driver of vascular formation, as it is required to initiate
the formation of immature vessels by vasculogenesis or angiogenic sprouting."
SET Citation = {"PubMed","Journal of cellular physiology","12891700","","Michiels C",""}

proteinAbundance(HGNC:VEGFA) increases biologicalProcess(GO:vasculogenesis)

SET Evidence = "Ang1 and ephrinB2 are subsequently required for further remodeling and maturation
of this initially immature vasculature notably as endothelial cells integrate with
supporting cells such as smooth muscle cells and pericytes."

proteinAbundance(HGNC:ANGPT1) increases biologicalProcess(GO:"vasculature development")
proteinAbundance(HGNC:EFNB2) increases biologicalProcess(GO:"vasculature development")

SET Cell = "Endothelial Cells"
SET Evidence = "VEGF was initially defined, characterized, and purified for its ability to induce
vascular leak and permeability as well as for its ability to promote endothelial
cell proliferation (Ferrara, 1999)."

proteinAbundance(HGNC:VEGFA) increases biologicalProcess(MESHPP:"Cell Proliferation")

SET HemicAndImmuneSystem = "Endothelium, Lymphatic"
SET Evidence = "VEGFR3 is largely restricted to lymphatic endothelium while VEGFR1 and R2 are expressed
by vascular endothelium."

proteinAbundance(HGNC:FLT4)

SET CardiovascularSystem = "Endothelium, Vascular"

proteinAbundance(HGNC:KDR)
proteinAbundance(HGNC:FLT1)

SET Evidence = "VEGFR2 is the main receptor able to induce endothelial cell proliferation as well
as migratory and sprouting activity and to help promote endothelial cells to form
tubule-like structures"

proteinAbundance(HGNC:KDR) increases biologicalProcess(MESHPP:"Cell Proliferation")
proteinAbundance(HGNC:KDR) increases biologicalProcess(GO:"cell migration")
proteinAbundance(HGNC:KDR) increases biologicalProcess(GO:"sprouting angiogenesis")

SET CardiovascularSystem = "Blood Vessels"
SET Evidence = "Failure of vasculogenesis is also observed in Flk-1 deficient mice (Shalaby et al.,
1995)."
SET Species = "10090"

proteinAbundance(MGI:Kdr) increases biologicalProcess(GO:vasculogenesis)

SET Evidence = "Ang1 would rather have a permissive role by optimizing the manner by which endothelial
cells interact with each other and integrate with supporting cells and matrix."

proteinAbundance(HGNC:ANGPT1) increases biologicalProcess(GO:"cell-cell adhesion")
proteinAbundance(HGNC:ANGPT1) increases biologicalProcess(GO:"cell-matrix adhesion")

SET Evidence = "In a normal adult vessel, Ang1 is associated with Tie2 to keep the vessels in a stable
state."

complexAbundance(proteinAbundance(HGNC:ANGPT1),proteinAbundance(HGNC:TEK))

SET Evidence = "Ang2 bound to the same Tie2 receptor as did Ang1, it could not activate it. Instead,
Ang2 provided the first example of a naturally occurring antagonist for a tyrosine
receptor."

proteinAbundance(HGNC:ANGPT2) directlyDecreases (proteinAbundance(HGNC:ANGPT1) directlyIncreases kinaseActivity(proteinAbundance(HGNC:TEK)))

SET Evidence = "recent knockout studies have suggested key role for ephrin B2 and it EphB4 receptor
during vascular development mainly in early angiogenic remodeling (Gerety et
al., 1999)."

complexAbundance(proteinAbundance(HGNC:EFNB2),proteinAbundance(HGNC:EPHB4)) increases biologicalProcess(GO:"vasculature development")
complexAbundance(proteinAbundance(HGNC:EFNB2),proteinAbundance(HGNC:EPHB4)) increases biologicalProcess(GO:"blood vessel remodeling")

SET Evidence = "Stimuli like histamine, atrial natriuretic factor, or thrombin, induce a rapid and
short-lived increase in vascular permeability while others like cytokines or VEGF
induce a sustained response."

abundance(CHEBI:histamine) increases biologicalProcess(GO:"regulation of vascular permeability")
abundance(SCHEM:"Atrial natriuretic factor") increases biologicalProcess(GO:"regulation of vascular permeability")
proteinAbundance(HGNC:F2) increases biologicalProcess(GO:"regulation of vascular permeability")
proteinAbundance(HGNC:VEGFA) increases biologicalProcess(GO:"regulation of vascular permeability")

SET Evidence = "The major antiplatelet agents secreted by endothelial cells are prostacyclin (PGI2)
and nitric oxide (NO) (Cines et al., 1998)."

abundance(CHEBI:"prostaglandin I2") decreases biologicalProcess(GO:"blood coagulation")
abundance(CHEBI:"nitric oxide") decreases biologicalProcess(GO:"blood coagulation")

SET Cell = "Blood Platelets"
SET Evidence = "The major antiplatelet agents secreted by endothelial cells are prostacyclin (PGI2)
and nitric oxide (NO) (Cines et al., 1998). Both synergistically increasecAMPcontent
in platelets, hence preventing their aggregation (de Graaf et al., 1992)."

compositeAbundance(abundance(CHEBI:"prostaglandin I2"),abundance(CHEBI:"nitric oxide")) increases abundance(CHEBI:"3',5'-cyclic AMP")
abundance(CHEBI:"3',5'-cyclic AMP") decreases biologicalProcess(GO:"platelet aggregation")
compositeAbundance(abundance(CHEBI:"prostaglandin I2"),abundance(CHEBI:"nitric oxide")) decreases biologicalProcess(GO:"platelet aggregation")

SET Cell = "Endothelial Cells"
SET Evidence = "PGI2 and NO are constitutively released by endothelial cells but their synthesis is
increased in response to a similar range of agonists, notably molecules involved
in the coagulation process (e.g., bradykinine and thrombin)"

proteinAbundance(HGNC:F2) increases cellSecretion(abundance(CHEBI:"prostaglandin I2"))
proteinAbundance(HGNC:F2) increases cellSecretion(abundance(CHEBI:"nitric oxide"))
abundance(CHEBI:bradykinin) increases cellSecretion(abundance(CHEBI:"prostaglandin I2"))
abundance(CHEBI:bradykinin) increases cellSecretion(abundance(CHEBI:"nitric oxide"))

SET Evidence = "The protein C/protein S pathway is initiated when thrombin interacts with the endothelial
cell receptor thrombomodulin, facilitating activation of protein C (Sadler,
1997)."

proteinAbundance(HGNC:F2) directlyIncreases molecularActivity(proteinAbundance(HGNC:THBD))
molecularActivity(proteinAbundance(HGNC:THBD)) increases molecularActivity(proteinAbundance(HGNC:PROC))

SET HemicAndImmuneSystem = "Blood"
SET Evidence = "Activated protein C inactivates two cofactors essential for blood coagulation: factors
VIIIa and Va."

molecularActivity(proteinAbundance(HGNC:PROC)) decreases molecularActivity(proteinAbundance(HGNC:F8))
molecularActivity(proteinAbundance(HGNC:PROC)) decreases molecularActivity(proteinAbundance(HGNC:F5))
molecularActivity(proteinAbundance(HGNC:F8)) increases biologicalProcess(GO:"blood coagulation")
molecularActivity(proteinAbundance(HGNC:F5)) increases biologicalProcess(GO:"blood coagulation")

SET Evidence = "To be effective, protein C must form a complex with protein S, which is synthesized
by endothelial cells (Stern et al., 1991; Esmon, 2000)."

complexAbundance(proteinAbundance(HGNC:PROC),proteinAbundance(HGNC:PROS1))
proteinAbundance(HGNC:PROS1) directlyIncreases molecularActivity(proteinAbundance(HGNC:PROC))

SET Cell = "Blood Platelets"
SET Evidence = "Complex formation between thrombin and thrombomodulin also prevents thrombin from
being able to clot fibrinogen or to activate platelets (Esmon, 1995)."

molecularActivity(proteinAbundance(HGNC:F2)) increases biologicalProcess(GO:"platelet activation")
complexAbundance(proteinAbundance(HGNC:F2),proteinAbundance(HGNC:THBD)) directlyDecreases molecularActivity(proteinAbundance(HGNC:F2))

SET Cell = "Endothelial Cells"
SET Evidence = "It must be noted that the natural inhibitor of t-PA, plasminogen activator inhibitor
type 1 (PAI-1) is also constitutively secreted by endothelial cells."

molecularActivity(proteinAbundance(HGNC:SERPINE1)) directlyDecreases peptidaseActivity(proteinAbundance(HGNC:PLAT))

SET Evidence = "The second is the von Willebrand factor (vWF) of which endothelial cells are the major
source (Denis, 2002). vWF is constitutively secreted into the plasma and the
subendothelial matrix. It is also stored in high amount in Weibel–Palade bodies,
which can be mobilized rapidly in response to agonists like thrombin (van Mourik
et al., 2002)."

proteinAbundance(HGNC:F2) increases cellSecretion(proteinAbundance(HGNC:VWF))

SET Evidence = "vWF binds and stabilizes coagulation factor VIII and is a specific factor required
for the binding of platelets to exposed extracellular matrix components when the
vessel wall is damaged (Ruggeri and Preissner, 1999)."

complexAbundance(proteinAbundance(HGNC:VWF),proteinAbundance(HGNC:F8))
proteinAbundance(HGNC:VWF) directlyDecreases degradation(proteinAbundance(HGNC:F8))

SET Cell = "Blood Platelets"

proteinAbundance(HGNC:VWF) increases biologicalProcess(GO:"cell-matrix adhesion")

SET Cell = "Endothelial Cells"
SET Evidence = "However, when exposed to thrombin, cytokines, or LPS, endothelial cells synthesize
and express tissue factor at their surface (Nawroth et al., 1986; Mackman, 1997)."

proteinAbundance(HGNC:F2) increases cellSurfaceExpression(proteinAbundance(HGNC:F3))
abundance(CHEBI:lipopolysaccharide) increases cellSurfaceExpression(proteinAbundance(HGNC:F3))

SET Evidence = "Thrombin is the main effector protease of the coagulation cascade. Factor Xa, activated
by factor VIIa and tissue factor, converts prothrombin to active thrombin."

peptidaseActivity(proteinAbundance(HGNC:F2)) increases biologicalProcess(GO:"blood coagulation")
complexAbundance(proteinAbundance(HGNC:F3),proteinAbundance(HGNC:F7)) increases peptidaseActivity(proteinAbundance(HGNC:F10))
peptidaseActivity(proteinAbundance(HGNC:F10)) increases peptidaseActivity(proteinAbundance(HGNC:F2))

SET CellStructure = "Cell Membrane"
SET Evidence = "In endothelial cells, thrombin causes vWF release, the appearance of P-selectin at
the plasma membrane, production of PAF and chemokines."

proteinAbundance(HGNC:F2) increases proteinAbundance(HGNC:SELP)

SET Evidence = "PAR-1, the one present at the surface of endothelial cells, is activated when thrombin
cleaves its amino-terminal extracellular domain (exodomain) at a specific
site."

peptidaseActivity(proteinAbundance(HGNC:F2)) directlyIncreases molecularActivity(proteinAbundance(HGNC:F2R))

SET Evidence = "The NO generation by endothelial cells is constitutive but may be enhanced by a wide
variety of compounds, including acetylcholine, angiotensin II, bradykinin, histamine,
adenine nucleotides, arachidonic acid"

abundance(CHEBI:acetylcholine) increases abundance(CHEBI:"nitric oxide")
abundance(CHEBI:"angiotensin II") increases abundance(CHEBI:"nitric oxide")
abundance(CHEBI:bradykinin) increases abundance(CHEBI:"nitric oxide")
abundance(CHEBI:histamine) increases abundance(CHEBI:"nitric oxide")
abundance(CHEBI:"arachidonic acid") increases abundance(CHEBI:"nitric oxide")

SET Evidence = "It is synthesized from oxygen and L-arginine by NO synthase (NOS)."

catalyticActivity(proteinAbundance(PFH:"NOS Family")) increases reaction(reactants(abundance(CHEBI:dioxygen),abundance(CHEBI:"L-arginine")),products(abundance(CHEBI:"nitric oxide")))

SET CardiovascularSystem = "Muscle, Smooth, Vascular"
SET Evidence = "EDRF diffuses to the vascular smooth muscle cells where it stimulates soluble guanylate
cyclase, resulting in an increased formation of cyclic GMP and subsequent
relaxation (Fig. 2A) (Denninger and Marletta, 1999)."

abundance(CHEBI:"nitric oxide") increases catalyticActivity(proteinAbundance(PFH:"GUCY Family"))
catalyticActivity(proteinAbundance(PFH:"GUCY Family")) increases abundance(CHEBI:"3',5'-cyclic GMP")
abundance(CHEBI:"3',5'-cyclic GMP") increases biologicalProcess(GO:"relaxation of vascular smooth muscle")

SET TextLocation = {"Review","Review"}
SET Evidence = "infusion of a NOS inhibitor, like L-NMMA, increases the resting blood pressure (Fleming
et al., 1996)."

abundance(CHEBIID:28229) directlyDecreases catalyticActivity(proteinAbundance(PFH:"NOS Family"))
abundance(CHEBIID:28229) increases biologicalProcess(MESHPP:"Blood Pressure")

SET TextLocation = "Review"
SET Evidence = "Endothelium generates PGI2, which relaxes the underlying smooth muscle cells through
activation of adenylate cyclase and subsequent generation of cAMP."

abundance(CHEBI:"prostaglandin I2") increases catalyticActivity(proteinAbundance(PFH:"ADCY Family"))
catalyticActivity(proteinAbundance(PFH:"ADCY Family")) directlyIncreases abundance(CHEBI:"3',5'-cyclic AMP")
abundance(CHEBI:"3',5'-cyclic AMP") increases biologicalProcess(GO:"relaxation of vascular smooth muscle")

SET Evidence = "Endothelial cells constitutively release PGI2 (Moncada et al., 1976) which appears
to be involved in the regulation of resting vascular tone, in addition to EDRF.
It is released in higher amount in response to ligand binding on the cell surface
such as thrombin, arachidonic acid, histamine, serotonin"

proteinAbundance(HGNC:F2) increases cellSecretion(abundance(CHEBI:"prostaglandin I2"))
abundance(CHEBI:"arachidonic acid") increases cellSecretion(abundance(CHEBI:"prostaglandin I2"))
abundance(CHEBI:histamine) increases cellSecretion(abundance(CHEBI:"prostaglandin I2"))
abundance(CHEBI:serotonin) increases cellSecretion(abundance(CHEBI:"prostaglandin I2"))

SET Evidence = "The endothelinA (ETA) receptor is situated on the vascular smooth muscle cells and
has a high affinity for ET-1 and ET-2 but not for ET-3."

proteinAbundance(HGNC:EDN1) directlyIncreases molecularActivity(proteinAbundance(HGNC:EDNRA))
proteinAbundance(HGNC:EDN2) directlyIncreases molecularActivity(proteinAbundance(HGNC:EDNRA))
proteinAbundance(HGNC:EDN3) causesNoChange molecularActivity(proteinAbundance(HGNC:EDNRA))

SET Evidence = "the endothelinB (ETB) receptor is situated on the endothelial cells and has a similar
affinity for the three endothelin isoforms."

proteinAbundance(HGNC:EDN1) directlyIncreases molecularActivity(proteinAbundance(HGNC:EDNRB))
proteinAbundance(HGNC:EDN2) directlyIncreases molecularActivity(proteinAbundance(HGNC:EDNRB))
proteinAbundance(HGNC:EDN3) directlyIncreases molecularActivity(proteinAbundance(HGNC:EDNRB))

SET Evidence = "Binding to ETA receptor stimulated phospholipase C initiating in turn events leading
eventually to smooth muscle cell contraction (Kedzierski and Yanagisawa, 2001)."

molecularActivity(proteinAbundance(HGNC:EDNRA)) increases catalyticActivity(proteinAbundance(PFH:"PLC Family"))
catalyticActivity(proteinAbundance(PFH:"PLC Family")) decreases biologicalProcess(GO:"relaxation of vascular smooth muscle")

SET Evidence = "The result of ET binding to ETB receptor on endothelial cells is the release of EDRF/
PGI2, which opposes the vasoconstricting action of ET."

molecularActivity(proteinAbundance(HGNC:EDNRB)) increases cellSecretion(abundance(CHEBI:"prostaglandin I2"))

SET Evidence = "Vasoconstricting agents like ET-1 also exert mitogenic activity on smooth muscle cells
(Alberts et al., 1994) while EDRF and PGI2 inhibit smooth muscle cell proliferation"

proteinAbundance(HGNC:EDN1) increases biologicalProcess(MESHPP:"Cell Proliferation")
abundance(CHEBI:"nitric oxide") decreases biologicalProcess(MESHPP:"Cell Proliferation")
abundance(CHEBI:"prostaglandin I2") decreases biologicalProcess(MESHPP:"Cell Proliferation")

SET Evidence = "Endothelial (eNOS) and neuronal (nNOS) isoforms are constitutively expressed and are
activated by calmodulin/calcium."

proteinAbundance(HGNC:CALM1) increases catalyticActivity(proteinAbundance(HGNC:NOS1))
proteinAbundance(HGNC:CALM1) increases catalyticActivity(proteinAbundance(HGNC:NOS3))

SET Evidence = "Receptor-mediated agonist stimulation (e.g., bradykinin, acetylcholine, thrombin,
histamine,...) leads to rapid enzyme activation by depalmitoylation, binding to
calmodulin/calcium, displacement displacement of caveolin and release from the
plasma membrane(Govers and Rabelink, 2001; Marletta, 2001)."

abundance(CHEBI:bradykinin) increases catalyticActivity(proteinAbundance(HGNC:NOS3))
abundance(CHEBI:acetylcholine) increases catalyticActivity(proteinAbundance(HGNC:NOS3))
proteinAbundance(HGNC:F2) increases catalyticActivity(proteinAbundance(HGNC:NOS3))
abundance(CHEBI:histamine) increases catalyticActivity(proteinAbundance(HGNC:NOS3))

SET Evidence = "eNOS activity is also regulated at the transcriptional level: VEGF, insulin, bFGF
increase eNOS expression while hypoxia and oxidized LDL decrease it (Sase and Michel,
1997)."

proteinAbundance(HGNC:VEGFA) increases rnaAbundance(HGNC:NOS3)
proteinAbundance(HGNC:INS) increases rnaAbundance(HGNC:NOS3)
proteinAbundance(HGNC:FGF2) increases rnaAbundance(HGNC:NOS3)
biologicalProcess(GO:"response to hypoxia") decreases rnaAbundance(HGNC:NOS3)
abundance(CHEBI:"oxidised LDL") decreases rnaAbundance(HGNC:NOS3)

SET Evidence = "Shear stress causes rapid eNOS activation and upregulates eNOS gene expression by
transcription activation of the eNOS promoter (Xiao et al., 1997)."

biologicalProcess(GO:"cellular response to fluid shear stress") increases rnaAbundance(HGNC:NOS3)

SET Evidence = "the induced adherence in inflammatory situation requires induction of L-selectin ligand
and/or of E- and P-selectins on the endothelial surface. E-selectin is transcriptionally
induced by cytokines such as IL-1, TNF-α, or by LPS (Klein et al.,
1995; Scholz et al., 1996)."

proteinAbundance(PFH:"IL1 Family") increases rnaAbundance(HGNC:SELE)
proteinAbundance(HGNC:TNF) increases rnaAbundance(HGNC:SELE)
abundance(CHEBI:lipopolysaccharide) increases rnaAbundance(HGNC:SELE)

SET Evidence = "In contrast, P-selectin is stored in the membrane of storage granules, the Weibel–
Palade bodies, in endothelial cells (McEver et al., 1989). Fusion of these granules
with the plasma membrane is rapidly stimulated by proinflammatory mediators
such as histamine and thrombin."

abundance(CHEBI:histamine) increases translocation(proteinAbundance(HGNC:SELP),MESHCL:"Cytoplasmic Granules",MESHCL:"Cell Membrane")
proteinAbundance(HGNC:F2) increases translocation(proteinAbundance(HGNC:SELP),MESHCL:"Cytoplasmic Granules",MESHCL:"Cell Membrane")

SET Evidence = "L-selectin (constitutive rolling on endothelial cells) and P- and/or E-selectins (inflammatory
mediatorinduced capture) work cooperatively to initiate leukocyte
migration."

compositeAbundance(proteinAbundance(HGNC:SELL),proteinAbundance(HGNC:SELP),proteinAbundance(HGNC:SELE)) increases biologicalProcess(GO:"leukocyte migration")

SET Cell = "Neutrophils"
SET Evidence = "Preformed Mac-1 is stored in granules in neutrophils and can be rapidly mobilized
to the neutrophil surface after exposure to degranulation stimuli such as the bacterial
peptide fMLP or to cytokines (Altieri and Edgington, 1988). However, it
is not yet competent for ligand binding. The ligand binding site lies on an extracellular
region of the α subunit called the I domain, that is inaccessible to
potential ligands unless integrins are activated. Integrin activation involves a
conformational change such that the I domain is exposed (Oxvig et al., 1999). This
change may be induced by phosphorylation of the cytoplasmic tail of the β subunit
(Buyon et al., 1997), possibly through a pathway involving the small GTP-binding
protein Rho, but this is still unclear."

abundance(CHEBIID:53490) increases cellSurfaceExpression(complexAbundance(proteinAbundance(HGNC:ITGAM),proteinAbundance(HGNC:ITGB2)))
proteinAbundance(HGNC:ITGB2,proteinModification(P)) directlyIncreases molecularActivity(complexAbundance(proteinAbundance(HGNC:ITGAM),proteinAbundance(HGNC:ITGB2)))

SET HemicAndImmuneSystem = "Leukocytes"
SET Evidence = "Migration of all leukocytes depends mainly on β2 integrins (Mac-1 and LFA-1) and on
ICAM-1, their ligand on endothelial cells."

complexAbundance(proteinAbundance(HGNC:ITGAM),proteinAbundance(HGNC:ITGB2),proteinAbundance(HGNC:ICAM1)) increases biologicalProcess(GO:"leukocyte migration")
complexAbundance(proteinAbundance(HGNC:ITGAL),proteinAbundance(HGNC:ITGB2),proteinAbundance(HGNC:ICAM1)) increases biologicalProcess(GO:"leukocyte migration")

SET Evidence = "Specific increased expression of glycolytic enzymes, glucose tranporter GLUT-1, VEGF,
tyrosine hydroxylase, transferrin, and erythropoietin is observed, all proteins
involved in the adaptative response of cells to hypoxia."

biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:SLC2A1)
biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:TH)
biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:TF)
biologicalProcess(GO:"response to hypoxia") increases proteinAbundance(HGNC:EPO)

SET Cell = "Endothelial Cells"
SET Evidence = "Numerous molecules stimulate endothelial proliferation and migration, including VEGF,
Ang1, and bFGF."

proteinAbundance(HGNC:VEGFA) increases biologicalProcess(MESHPP:"Cell Proliferation")
proteinAbundance(HGNC:VEGFA) increases biologicalProcess(GO:"cell migration")
proteinAbundance(HGNC:ANGPT1) increases biologicalProcess(MESHPP:"Cell Proliferation")
proteinAbundance(HGNC:ANGPT1) increases biologicalProcess(GO:"cell migration")
proteinAbundance(HGNC:FGF2) increases biologicalProcess(MESHPP:"Cell Proliferation")
proteinAbundance(HGNC:FGF2) increases biologicalProcess(GO:"cell migration")

UNSET STATEMENT_GROUP

